<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Bras Nefrol</journal-id><journal-id journal-id-type="iso-abbrev">J Bras Nefrol</journal-id><journal-id journal-id-type="publisher-id">jbn</journal-id><journal-title-group><journal-title>Jornal Brasileiro de Nefrologia</journal-title></journal-title-group><issn pub-type="ppub">0101-2800</issn><issn pub-type="epub">2175-8239</issn><publisher><publisher-name>Sociedade Brasileira de Nefrologia</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40009791</article-id><article-id pub-id-type="pmc">PMC11864789</article-id>
<article-id pub-id-type="other">05001</article-id><article-id pub-id-type="doi">10.1590/2175-8239-JBN-2024-0033en</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brazilian Society of Nephrology</subject></subj-group></article-categories><title-group><article-title>I Brazilian guideline on hypertension in dialysis of the Brazilian Society of Nephrology</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9490-7997</contrib-id><name><surname>Rodrigues</surname><given-names>Cibele Isaac Saad</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role>design and general coordination of the guidelines</role><role>chapter coordination</role><role>writing</role><role>critical review of the manuscript</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4176-9572</contrib-id><name><surname>Ferreira-Filho</surname><given-names>Sebasti&#x000e3;o Rodrigues</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role>design and general coordination of the guidelines</role><role>chapter coordination</role><role>critical review of the manuscript</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7368-4704</contrib-id><name><surname>Moura</surname><given-names>Ana Fl&#x000e1;via de Souza</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role>chapter coordination</role><role>critical review of the manuscript</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7333-8884</contrib-id><name><surname>Poli-de-Figueiredo</surname><given-names>Carlos Eduardo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><role>chapter coordination</role><role>critical review of the manuscript</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7587-0604</contrib-id><name><surname>da Silva</surname><given-names>Dirceu Reis</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><role>chapter coordination</role><role>critical review of the manuscript</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8803-1300</contrib-id><name><surname>Polacchini</surname><given-names>Fernanda Salom&#x000e3;o Gorayeb</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><role>chapter coordination</role><role>critical review of the manuscript</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9404-9707</contrib-id><name><surname>de Almeida</surname><given-names>Fernando Ant&#x000f4;nio</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role>chapter coordination</role><role>critical review of the manuscript</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2566-0016</contrib-id><name><surname>Pinheiro</surname><given-names>Maria Eliete</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref><role>chapter coordination</role><role>critical review of the manuscript</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9719-3176</contrib-id><name><surname>Bezerra</surname><given-names>Rodrigo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref><role>chapter coordination</role><role>critical review of the manuscript</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7778-2907</contrib-id><name><surname>de Paula</surname><given-names>Rog&#x000e9;rio Baumgratz</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref><role>chapter coordination</role><role>critical review of the manuscript</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1525-2991</contrib-id><name><surname>Peixoto</surname><given-names>Aldo Jos&#x000e9;</given-names></name><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8555-8649</contrib-id><name><surname>Figueiredo</surname><given-names>Ana Elizabeth Prado Lima</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9983-4720</contrib-id><name><surname>Feitosa</surname><given-names>Audes Di&#x000f3;genes Magalh&#x000e3;es</given-names></name><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3056-3077</contrib-id><name><surname>Machado</surname><given-names>Carlos Alberto</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff14" ref-type="aff">
<sup>14</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8523-760X</contrib-id><name><surname>Amodeo</surname><given-names>Celso</given-names></name><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1564-121X</contrib-id><name><surname>Mion</surname><given-names>D&#x000e9;cio</given-names><suffix>Junior</suffix></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff16" ref-type="aff">
<sup>16</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3853-7842</contrib-id><name><surname>Muxfeldt</surname><given-names>Elizabeth Silaid</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff17" ref-type="aff">
<sup>17</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3370-9326</contrib-id><name><surname>da Silva</surname><given-names>Giovanio Vieira</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff16" ref-type="aff">
<sup>16</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1339-3731</contrib-id><name><surname>Moura-Neto</surname><given-names>Jos&#x000e9; Andrade</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0508-9887</contrib-id><name><surname>Pazeli</surname><given-names>Jos&#x000e9; Muniz</given-names><suffix>J&#x000fa;nior</suffix></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff18" ref-type="aff">
<sup>18</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1390-8651</contrib-id><name><surname>Lotaif</surname><given-names>Leda Daud</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff15" ref-type="aff">
<sup>15</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2081-6846</contrib-id><name><surname>Drager</surname><given-names>Luciano F.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff16" ref-type="aff">
<sup>16</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1435-7994</contrib-id><name><surname>Mart&#x000ed;n</surname><given-names>Luis Cuadrado</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff19" ref-type="aff">
<sup>19</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4865-6442</contrib-id><name><surname>Bortolotto</surname><given-names>Luiz Aparecido</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff16" ref-type="aff">
<sup>16</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3651-9923</contrib-id><name><surname>Bastos</surname><given-names>Marcus Gomes</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8171-3920</contrib-id><name><surname>Malachias</surname><given-names>Marcus Vin&#x000ed;cius Bol&#x000ed;var</given-names></name><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff20" ref-type="aff">
<sup>20</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-0747-5051</contrib-id><name><surname>Moreira</surname><given-names>Marcos Vin&#x000ed;cius Paiva Cavalcanti</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9645-5303</contrib-id><name><surname>Canziani</surname><given-names>Maria Eugenia Fernandes</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff21" ref-type="aff">
<sup>21</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1582-7268</contrib-id><name><surname>Miranda</surname><given-names>Roberto Dischinger</given-names></name><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff21" ref-type="aff">
<sup>21</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9787-4393</contrib-id><name><surname>Franco</surname><given-names>Roberto Jorge da Silva</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff19" ref-type="aff">
<sup>19</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0255-6710</contrib-id><name><surname>Pecoits</surname><given-names>Roberto</given-names><suffix>Filho</suffix></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff22" ref-type="aff">
<sup>22</sup>
</xref><xref rid="aff23" ref-type="aff">
<sup>23</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5704-5248</contrib-id><name><surname>Mulinari</surname><given-names>Rogerio Andrade</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff24" ref-type="aff">
<sup>24</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2212-041X</contrib-id><name><surname>Elias</surname><given-names>Rosilene Motta</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff16" ref-type="aff">
<sup>16</sup>
</xref><xref rid="aff25" ref-type="aff">
<sup>25</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1265-1930</contrib-id><name><surname>Barroso</surname><given-names>Weimar Kunz Sebba</given-names></name><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff26" ref-type="aff">
<sup>26</sup>
</xref><role>writing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0003-5102</contrib-id><name><surname>Nadruz</surname><given-names>Wilson</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff27" ref-type="aff">
<sup>27</sup>
</xref><role>writing</role></contrib></contrib-group><aff id="aff1">
<label>1</label>Brazilian Society of Nephrology, S&#x000e3;o Paulo, SP, Brazil.</aff><aff id="aff2">
<label>2</label>Brazilian Society of Hypertension, S&#x000e3;o Paulo, SP, Brazil.</aff><aff id="aff3">
<label>3</label>Pontif&#x000ed;cia Universidade Cat&#x000f3;lica de S&#x000e3;o Paulo, Sorocaba, SP, Brazil.</aff><aff id="aff4">
<label>4</label>Universidade Federal de Uberl&#x000e2;ndia, Uberl&#x000e2;ndia, MG, Brazil.</aff><aff id="aff5">
<label>5</label>Escola Bahiana de Medicina e Sa&#x000fa;de P&#x000fa;blica, Salvador, BA, Brazil.</aff><aff id="aff6">
<label>6</label>Pontif&#x000ed;cia Universidade Cat&#x000f3;lica do Rio Grande do Sul, Porto Alegre, RS, Brazil.</aff><aff id="aff7">
<label>7</label>Hospital de Cl&#x000ed;nicas de Porto Alegre, Porto Alegre, RS, Brazil.</aff><aff id="aff8">
<label>8</label>Hospital de Base de S&#x000e3;o Jos&#x000e9; do Rio Preto, S&#x000e3;o Jos&#x000e9; do Rio Preto, SP, Brazil.</aff><aff id="aff9">
<label>9</label>Universidade Federal de Alagoas, Alagoas, AL, Brazil.</aff><aff id="aff10">
<label>10</label>Universidade Federal de Pernambuco, Recife, PE, Brazil.</aff><aff id="aff11">
<label>11</label>Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil.</aff><aff id="aff12">
<label>12</label>Yale University, Yale School of Medicine, New Haven, United States.</aff><aff id="aff13">
<label>13</label>Brazilian Society of Cardiology, S&#x000e3;o Paulo, SP, Brazil.</aff><aff id="aff14">
<label>14</label>Secretaria Municipal de Sa&#x000fa;de de Campos do Jord&#x000e3;o, Campos do Jord&#x000e3;o, SP, Brazil.</aff><aff id="aff15">
<label>15</label>Hospital do Cora&#x000e7;&#x000e3;o da Associa&#x000e7;&#x000e3;o Beneficente S&#x000ed;ria de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, Brazil.</aff><aff id="aff16">
<label>16</label>Universidade de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, Brazil.</aff><aff id="aff17">
<label>17</label>Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</aff><aff id="aff18">
<label>18</label>Faculdade de Medicina de Barbacena, Barbacena, MG, Brazil.</aff><aff id="aff19">
<label>19</label>Universidade Estadual Paulista, Botucatu, SP, Brazil.</aff><aff id="aff20">
<label>20</label>Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas de Minas Gerais, Belo Horizonte, MG, Brazil.</aff><aff id="aff21">
<label>21</label>Universidade Federal de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, Brazil.</aff><aff id="aff22">
<label>22</label>Pontif&#x000ed;cia Universidade Cat&#x000f3;lica do Paran&#x000e1;, Curitiba, PR, Brazil.</aff><aff id="aff23">
<label>23</label>Arbor Research Collaborative for Health, Ann Arbor, United States.</aff><aff id="aff24">
<label>24</label>Universidade Federal do Paran&#x000e1;, Curitiba, PR, Brazil.</aff><aff id="aff25">
<label>25</label>Universidade Nove de Julho, S&#x000e3;o Paulo, SP, Brazil.</aff><aff id="aff26">
<label>26</label>Universidade Federal de Goi&#x000e1;s, Goiania, GO, Brazil.</aff><aff id="aff27">
<label>27</label>Universidade Estadual de Campinas, Campinas, SP, Brazil.</aff><author-notes><corresp id="c001">
<bold>Correspondence to:</bold> Cibele Isaac Saad Rodrigues. Email: <email>cibele.sr@gmail.com</email>
</corresp><fn fn-type="other" id="FN1"><label>*</label><p>
<bold>Implementation:</bold> Brazilian Society of Nephrology, Department of Hypertension and Department of Dialysis</p></fn><fn fn-type="other" id="FN2"><label>*</label><p>
<bold>General coordinators:</bold> Cibele Isaac Saad Rodrigues and Sebasti&#x000e3;o Rodrigues Ferreira-Filho</p></fn><fn fn-type="other" id="FN3"><label>*</label><p>
<bold>Chapter coordinators:</bold> Cibele Isaac Saad Rodrigues, Sebasti&#x000e3;o Rodrigues Ferreira-Filho, Ana Fl&#x000e1;via Moura, Carlos Eduardo Poli de Figueiredo, Dirceu Reis da Silva, Fernanda Salom&#x000e3;o Gorayeb Polacchini, Fernando Ant&#x000f4;nio de Almeida, Maria Eliete Pinheiro, Rodrigo Bezerra, Rog&#x000e9;rio Baumgratz de Paula.</p></fn><fn fn-type="COI-statement"><p>
<bold>Conflict of Interest</bold>
</p><p>
<table-wrap position="float" id="d67e764"><table frame="box" rules="all" cellpadding="5" cellspacing="5"><tbody><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>Declaration of potential conflicts of interest by the authors/collaborators of the Brazilian Guidelines of Arterial Hypertension</bold>
</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>Relationship of the Guideline&#x02019;s author/collaborator with the pharmaceutical industry in the past 3 years</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Guideline Member</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Relationship with pharmaceutical industry</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aldo Jos&#x000e9; Peixoto</td><td align="left" valign="top" rowspan="1" colspan="1">Receives personal or institutional support from the industry: all grants were institutional (all from research in which I served as Principal Investigator) and all were directed to Yale University (New Haven, CT, USA) by the following pharmaceutical or medical device companies: Bayer, Boehringer-Ingelheim, Lundbeck, Reata, Vascular Dynamics.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ana Elizabeth Prado Lima Figueiredo</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ana Fl&#x000e1;via de Souza Moura</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Audes Di&#x000f3;genes Magalh&#x000e3;es Feitosa</td><td align="left" valign="top" rowspan="1" colspan="1">Is a member of the advisory or steering board of the pharmaceutical or medical device industry.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Carlos Eduardo Poli-de-Figueiredo</td><td align="left" valign="top" rowspan="1" colspan="1">Participated in regulatory committees for industry-sponsored scientific studies (HD Fit: not related to this Guideline).<break/>Received personal or institutional support from the industry (Mayo Clinic PucRS).<break/>Authored scientific manuscripts for industry-sponsored journals (HD Fit).</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Carlos Alberto Machado</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Celso Amodeo</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cibele Isaac Saad Rodrigues</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">D&#x000e9;cio Mion Junior</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dirceu Reis da Silva</td><td align="left" valign="top" rowspan="1" colspan="1">Is a member of the advisory or steering board of the pharmaceutical or medical device industry.<break/>Received personal or institutional support from the industry.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Elizabeth Silaid Muxfeldt</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fernanda Salom&#x000e3;o Gorayeb Polacchini</td><td align="left" valign="top" rowspan="1" colspan="1">Received personal or institutional support from the industry.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fernando Ant&#x000f4;nio de Almeida</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Giovanio Vieira da Silva</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Jos&#x000e9; Andrade Moura-Neto</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Jos&#x000e9; Muniz Pazeli J&#x000fa;nior</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Leda Daud Lotaif</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Luciano Drager</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Luis Cuadrado Martin</td><td align="left" valign="top" rowspan="1" colspan="1">Received personal or institutional support from the industry.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Luiz Aparecido Bortolotto</td><td align="left" valign="top" rowspan="1" colspan="1">Authored scientific manuscripts for industry-sponsored journals.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marcus Gomes Bastos</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marcus Vin&#x000ed;cius Bol&#x000ed;var Malachias</td><td align="left" valign="top" rowspan="1" colspan="1">Speaker at industry-sponsored events or activities related to the positioning in question. <break/>Authored scientific manuscripts for industry-sponsored journals.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marcus Vinicius P. Cavalcanti Moreira</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Maria Eliete Pinheiro</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Maria Eugenia Fernandes Canziani</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Roberto Jorge da Silva Franco</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Roberto Dischinger Miranda</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Roberto Pecoits Filho</td><td align="left" valign="top" rowspan="1" colspan="1">Is a member of the advisory or steering board of the pharmaceutical or medical device industry. <break/>Participated in regulatory committees for industry-sponsored scientific studies.<break/>Received personal or institutional support from the industry. <break/>Authored scientific manuscripts for industry-sponsored journals.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rodrigo Bezerra</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rog&#x000e9;rio Baumgratz de Paula</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rogerio Andrade Mulinari</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rosilene Motta Elias</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sebasti&#x000e3;o Rodrigues Ferreira-Filho</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weimar Kunz Sebba Barroso</td><td align="left" valign="top" rowspan="1" colspan="1">Participated in clinical and/or experimental studies subsidized by the pharmaceutical or medical device industry related to the guideline in question.<break/>Speaker at industry-sponsored events or activities related to the positioning in question. <break/>Is a member of the advisory or steering board of the pharmaceutical or medical device industry.<break/>Participated in regulatory committees for industry-sponsored scientific studies. <break/>Received personal or institutional support from the industry. <break/>Authored scientific manuscripts in industry-sponsored journals.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wilson Nadruz</td><td align="left" valign="top" rowspan="1" colspan="1">Nothing to declare.</td></tr></tbody></table></table-wrap>
</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>24</day><month>2</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><season>Jan-Mar</season><year>2025</year></pub-date><volume>47</volume><issue>1</issue><elocation-id>e20240033</elocation-id><history><date date-type="received"><day>19</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>01</day><month>8</month><year>2024</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><title>Abstract</title><p>Hypertension in dialysis patients (HTND) has a high prevalence, affecting at least 80% or more of patients, and its management in the nephrology practice is heterogeneous and often empirical. Knowing how to define, understand the pathophysiology, diagnose, monitor and treat with lifestyle changes, and adjust antihypertensive drugs to achieve the recommended blood pressure (BP) target - to reduce morbidity and mortality - requires specific knowl&#x000ad;edge and approaches within the contexts of hemodialysis (HD) and peritoneal dialysis (PD). This document is the first guideline of the Brazilian Society of Nephrology, developed by the departments of Hypertension and Dialysis. It aims to guide physicians who provide care in dialysis centers on how to manage patients with HTND, in a comprehensive and individualized manner, based on the critical appraisal of the best available scientific evidence. When such evidence is scarce or unavailable, the opinion of specialists should be recommended. The different topics covered include HTND definition (pre-HD BP &#x02265; 140/90 mmHg and post-HD BP &#x02265; 130/80 mmHg), epidemiology, and pathophysiology; diagnosis of HTND preferably with BP measurements outside the dialysis setting (BP &#x02265; 130/80 mmHg); complementary assessment; blood pressure targets; non-pharmacological treatment; use of the most appropriate antihypertensive medications; special situations; and complications of HTND, predominantly cardiovascular ones.</p></abstract><kwd-group><title>Keywords:</title><kwd>Hypertension</kwd><kwd>Kidney Dialysis</kwd><kwd>Peritoneal Dialysis</kwd><kwd>Risk Factors; Pharmacological Treatment</kwd><kwd>Clinical Practice Guidelines as Topic</kwd><kwd>Chronic Kidney Failure</kwd><kwd>Renal Hypertension</kwd><kwd>Blood Pressure Determination</kwd><kwd>Chronic Kidney Insufficiency</kwd></kwd-group><counts><fig-count count="14"/><table-count count="24"/><ref-count count="309"/></counts></article-meta></front><body><sec><title>Grade of Recommendations and Levels of Evidence<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>
</title><p>The recommendations were stratified into Classes or Grades I, IIa, IIb, or III and levels of evidence, described as follows:</p><sec><title>Classes (Degrees) of Recommendation</title><p>Class I &#x02013; Conditions for which there is conclusive evidence, or if not, general agreement that a given treatment or procedure is safe/beneficial and useful/effective;</p><p>Class II &#x02013; Conditions for which there is conflicting evidence and/or differing opinions about the safety and benefit/efficacy of the given treatment or procedure;</p><p>Class IIA &#x02013; The majority of evidence/opinion is in favor of the given treatment or procedure. The majority approves;</p><p>Class IIB &#x02013; Safety and benefit/efficacy is less well established, with no predominance of opinion;</p><p>Class III &#x02013; Conditions for which there is evidence and/or consensus that the procedure or treatment is not useful/effective and in some cases may even be harmful.</p></sec><sec><title>Levels of Evidence</title><p>Level A &#x02013; Data from multiple welldesigned, concordant randomized controlled trials and/or robust metaanalysis of randomized clinical studies;</p><p>Level B &#x02013; Data from a less robust meta-analysis, from a single randomized study or from large non-randomized (observational) studies;</p><p>Level C &#x02013; Data from the consensus of expert opinions and/or small studies, retrospective trials, and registries.</p></sec></sec><sec sec-type="intro"><title>Introduction</title><p>The primary objective of this publication is to provide nephrologists caring for chronic kidney disease patients on dialysis with the best available scientific evidence on the different aspects of HTN, from its pathophysiology to treatment. This is an unprecedented document in Portuguese language, designed to be useful to nephrologists in their daily clinical practice.</p><p>The SBN departments involved in this initiative aim for the recommendations and suggestions expressed here to have national repercussions, contributing to a better approach and treatment for individuals requiring dialysis therapies, with consequent benefits in reducing CV and renal morbidity and mortality.</p><p>It is a fact that even the prestigious KDIGO (Kidney Diseases Improving Global Outcomes), in its guidelines on HTN in CKD, did not postulate recommendations for stage 5D. This is likely due to the lack of randomized controlled trials, and systematic reviews and meta-analyses in this population that could support recommendations with high levels of confidence and quality.</p><p>Currently in Brazil, according to the 2022 Census of the Brazilian Society of Nephrology, there are 872 dialysis centers, with an estimated prevalence of 153,831 patients in stage 5D, with 91% on HD. HTN is identified as the direct cause responsible for CKD 5D in approximately 34% of cases, and it is present as a comorbidity in over 80% of patients in dialysis programs. This means that there is a major problem to be tackled, with a potential therapeutic inertia (TI) that could be responsible for worse morbidity and mortality outcomes<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>.</p></sec><sec><title>Definition, Epidemiology, and Pathophysiology of Hypertension in Dialysis Patients</title><sec><title>Definition/Epidemiology</title><p>HTND is defined based on observations previously established for the general population, with thresholds for determining normotension or hypertension varying across different guidelines<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>. Measuring BP in dialysis patients thus poses a challenge to standardization. Ideally, BP should be based on home interdialytic assessments with HBPM or ABPM, following the recommended standardization<sup>
<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>
</sup>.</p><p>In epidemiological terms, HTN occurs in more than 80% of dialysis patients, and is often poorly controlled<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup>.</p><p>Key messages:</p><list list-type="bullet"><list-item><p>IDH has an estimated prevalence of 5% to 15% and is correlated with hospitalizations and mortality<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup> (Class I/Level B);</p></list-item><list-item><p>Many studies show the presence of reverse epidemiology, with J or U-shaped curves<sup>
<xref rid="B8" ref-type="bibr">8</xref>
</sup> (Class I/Level B).</p></list-item></list><p>For the diagnosis of HTN, it is recommended:</p><list list-type="bullet"><list-item><p>HBPM: mean &#x02265; 130/80 mmHg, considering the day of installation and additional 6 consecutive days (see protocol in Chapter 3);</p></list-item><list-item><p>ABPM in HD: mean &#x02265; 130/80 mmHg in 44h (see protocol in Chapter 3);</p></list-item><list-item><p>ABPM in PD: mean &#x02265; 130/80 mmHg in 24h (see protocol in Chapter 3);</p></list-item><list-item><p>HBPM/ABPM unavailable: measurements taken on a non-dialysis day, midweek for HD, or at the office for PD;</p></list-item><list-item><p>IDH is defined as an increase &#x02265; 10 mmHg in SBP during or immediately after HD in 4 out of 6 sessions. Motivates further evaluation<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup>.</p></list-item></list><p>Key messages:</p><list list-type="bullet"><list-item><p>Pre-, intra- and post-HD BP measurements are inaccurate for diagnosis, but useful for diagnosing IDH and for hemodynamic control<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup> (Class I/Level B).</p></list-item><list-item><p>The diagnostic threshold for pre-HD is &#x0003e; 140/90 mmHg, and post-HD &#x0003e; 130/80 mmHg<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup> (Class I/Level B).</p></list-item></list></sec><sec><title>Pathophysiology of Htnd</title><p>The pathophysiology of HTND is complex and multifactorial, encompassing both general and CKD-specific factors<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup> (<xref rid="F01" ref-type="fig">Figure 1</xref>). However, most patients with CKD 5D have HTN and DM as their main causes. This means they represent a population with HTN that may precede the onset of dialysis therapy by decades. Additionally, patients with CKD of other etiologies also present with HTN, often secondary to the baseline kidney disease.</p><fig position="float" id="F01"><label>Figure 1</label><caption><title>Pathophysiology of hypertension in patients undergoing dialysis treatment.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf01" position="float"/><attrib>Abbreviations &#x02013; CKD Grade 5D: chronic kidney disease stage 5 on dialysis; OSA: obstructive sleep apnea; Na+: sodium; RRT: renal replacement therapy; RAAS: renin-angiotensin-aldosterone system; SNS: sympathetic nervous system; EPO: recombinant human erythropoietin.</attrib></fig><sec><title>Relationship between volume overload and hypertension in CKD</title><p>The role of hypervolemia in HTND could be evidenced by the reduction in BP associated with intensified UF. In a study, daily, long-term HD resulted in BP control in about 90% of patients<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup>, with a dissociation observed between achieving the estimated DW and BP control, verified weeks or months after reaching euvolemia. This phenomenon, known as the &#x0201c;lag phenomenon&#x0201d;, appears to be related to the additional removal of salt as UF is intensified<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup>. Similar results have been observed in Turkey<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup>. Common strategies in these studies included restricting salt in the diet and extended dialysis sessions. A randomized study, in which UF intensification was achieved without extending the HD session length, confirmed a significant improvement in BP control in patients who reached the estimated DW, compared to those in the control group<sup>
<xref rid="B14" ref-type="bibr">14</xref>
</sup>.</p><p>In PD patients, few studies have assessed the relationship between hypervolemia and HTN<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup>. One of them evaluated PD patients undergoing intensified UF, with a 5% reduction in body weight<sup>
<xref rid="B16" ref-type="bibr">16</xref>
</sup>. After 5 weeks, a reduction in body weight, extracellular water, and inspiratory diameter of the inferior vena cava were observed, along with improved BP control. Hypervolemia appears to play a predominant role in HTN in PD patients.</p><p>In recent decades, a new element has been associated with excess sodium in CKD. In 2003, Titze et al.<sup>
<xref rid="B17" ref-type="bibr">17</xref>
</sup> demonstrated the sodium retention complexed to glycosaminoglycans in the skin and muscles of animal models, therefore without water retention. Non-osmotic sodium accumulation creates a &#x0201c;buffer&#x0201d; system for sodium storage<sup>
<xref rid="B18" ref-type="bibr">18</xref>
</sup>, with macrophage recruitment, induction of the tonicity-responsive enhancer-binding protein (TonEPB) gene expression, and vascular endothelial growth factor C (VEGF-C), which induce hypertrophy of lymphatic vessels, NO release, and vasodilation. However, in situations of excess sodium or impaired sodium excretion, the functioning of this &#x0201c;buffer&#x0201d; system is compromised, leading to increased sodium in the skin and muscles, with immune system activation, inflammation, and fibrosis<sup>
<xref rid="B19" ref-type="bibr">19</xref>
</sup>. Increased subcutaneous sodium content, detectable by magnetic resonance imaging, contributes to HTN and increased CV events in chronic kidney patients<sup>
<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>The role of hypervolemia in HTN in CKD stage 5D could be evidenced by the BP reduction associated with intensified UF (Class I/Level B). In PD patients, it also appears to play a leading role in HTN (Class I/Level C).</p></list-item></list></sec><sec><title>Parameters interfering with BP: sodium/composition of dialysis solution</title><p>Dialysis patients are typically hypervolemic and hypertensive, especially due to exacerbated salt sensitivity, inappropriate activation of the RAAS in response to sodium intake, and decreased natriuresis<sup>
<xref rid="B22" ref-type="bibr">22</xref>
</sup>. The body&#x02019;s sodium pool includes skin and muscle deposits, particularly in diabetics<sup>
<xref rid="B23" ref-type="bibr">23</xref>
</sup>, with partial removal by HD<sup>
<xref rid="B21" ref-type="bibr">21</xref>
</sup>, and impacts on BP control and LVH<sup>
<xref rid="B24" ref-type="bibr">24</xref>
</sup>. When it persists at the end of HD, HTN may translate into residual hypervolemia<sup>
<xref rid="B25" ref-type="bibr">25</xref>
</sup>, as well as in the interdialytic interval<sup>
<xref rid="B26" ref-type="bibr">26</xref>
</sup>.</p><p>Different sodium concentrations in the dialysis solution may be related to volume and BP control<sup>
<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>
</sup> and, if higher than serum concentrations, result in increased IDWG, without correlating with BP variations<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup>. Patients subjected to lower sodium concentrations in the dialysis solution experienced a higher occurrence of intradialytic hypotension<sup>
<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B31" ref-type="bibr">31</xref>
</sup>, reduced IDWG<sup>
<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>
</sup>, lower BP<sup>
<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>
</sup>, and minimized use of antihypertensives<sup>
<xref rid="B29" ref-type="bibr">29</xref>
</sup>, but with no positive effects on the reduction of LVH<sup>
<xref rid="B28" ref-type="bibr">28</xref>
</sup>, hospitalization rates<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup>, and mortality<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup>. An ongoing study aims to evaluate the effect of different dialysate sodium concentrations on CV events and mortality in HD patients (RESOLVE, NCT02823821).</p><p>In addition, pre-HD natremia usually approaches the physiological level of individual adjustment (set point), and it is possible to adopt a dialysis solution sodium concentration similar to this level (isonatremic dialysis), based on sodium removal by convection and avoiding positive balance<sup>
<xref rid="B32" ref-type="bibr">32</xref>
</sup>.</p><p>Key messages:</p><list list-type="bullet"><list-item><p>Caution is advised when increasing or decreasing the sodium of the dialysis solution, since high sodium levels increase the IDWG and, conversely, low sodium levels reduce the IDWG and BP, but increase the risk of intradialytic hypotension (Class I/Level B).</p></list-item><list-item><p>There is no indication to adjust the sodium concentration in the dialysis solution with the aim of reducing hospitalization or mortality (Class I/Level B).</p></list-item></list></sec><sec><title>Ultrafiltration (UF) Rate</title><p>High UF rates are associated with hypotension, but if they are too low, they could perpetuate hypervolemia, the main determinant of HTN<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup>. The relationship between UF and BP reduction is consistent, but in hypertensive patients it may be influenced by other factors involved in the pathophysiology of HTN<sup>
<xref rid="B33" ref-type="bibr">33</xref>
</sup>.</p><p>Essential to avoid hypotension, the maintenance of plasma volume during HD depends on refilling (absorption of interstitial and lymphatic fluids in the microcirculation), which <italic>per se</italic> is independent of whether or not higher UF rates are adopted<sup>
<xref rid="B34" ref-type="bibr">34</xref>
</sup>.</p><p>Counterregulatory compensatory mechanisms to UF are reflex tachycardia and vasoconstriction. Therefore, patients with autonomic and/or ventricular dysfunction may develop intradialytic hypotension even with low UF rates<sup>
<xref rid="B35" ref-type="bibr">35</xref>
</sup>. High UF rates are associated with intradialytic hypotension, reduced RRF, and increased mortality<sup>
<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>,<xref rid="B39" ref-type="bibr">39</xref>
</sup>. The adoption of UF rates &#x0003e; 13 mL/kg/h<sup>
<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>,<xref rid="B39" ref-type="bibr">39</xref>
</sup> seemed to be deleterious overall, and UF rates &#x0003e; 10 mL/kg/h<sup>
<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B39" ref-type="bibr">39</xref>
</sup> are harmful, especially in the presence of ventricular dysfunction<sup>
<xref rid="B35" ref-type="bibr">35</xref>
</sup>. In a HD regimen of 1 to 2 times a week, even lower UF rates (less than 6 mL/Kg/h) appear to be necessary<sup>
<xref rid="B36" ref-type="bibr">36</xref>
</sup>. If RRF remains preserved, the association between high UF rates and mortality is attenuated<sup>
<xref rid="B36" ref-type="bibr">36</xref>
</sup>.</p><p>Hypotension is associated with an accelerated reduction in RRF, mitigating its positive effect on mortality, both in HD and PD<sup>
<xref rid="B40" ref-type="bibr">40</xref>
</sup>. It is recommended to increase either the HD session length or its frequency to avoid UF rates &#x0003e; 13 mL/kg/h while still managing hypervolemia<sup>
<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B41" ref-type="bibr">41</xref>
</sup>. Essentially, these UF rate limits may be adopted, but a set of factors should also be considered, including intradialytic hemodynamics, comorbidities, symptoms, and medication use<sup>
<xref rid="B41" ref-type="bibr">41</xref>
</sup>.</p><p>Key messages:</p><list list-type="bullet"><list-item><p>It is recommended to avoid high UF rates, i.e. &#x0003e; 13 mL/kg/h, as they are associated with increased mortality, intradialytic hypotension, and an accelerated reduction in RRF.</p></list-item><list-item><p>It is recommended that in patients with ventricular dysfunction, the suggested threshold is even lower (up to 10 mL/kg/h) (Class I/Level B).</p></list-item></list></sec><sec><title>Renin-Angiotensin-Aldosterone System (RAAS) activation</title><p>The kidneys can synthesize all components of the RAAS, even in dialysis patients<sup>
<xref rid="B42" ref-type="bibr">42</xref>
</sup>, in whom PRA is inappropriately elevated in relation to hypervolemia. These data are reinforced by the increase in PRA following dialysis sessions, indicating that remaining nephrons may perceive sodium variations and increase RAAS activity. Angiotensin II exerts deleterious effects by stimulating aldosterone production, and sodium retention by causing endothelial damage and stimulating the SNS<sup>
<xref rid="B42" ref-type="bibr">42</xref>,<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B44" ref-type="bibr">44</xref>
</sup>. The administration of lisinopril to HD patients resulted in improved BP control, as assessed by 44-hour ABPM, when compared to the control group<sup>
<xref rid="B45" ref-type="bibr">45</xref>
</sup>.</p><p>In addition to Angiotensin II, the vasculotoxic action of aldosterone has been shown, especially in the presence of salt. This finding suggests that aldosterone may play a permissive role in sodium toxicity in the endothelium, thereby becoming a risk factor for CV complications<sup>
<xref rid="B46" ref-type="bibr">46</xref>
</sup>.</p><p>Accordingly, blockade of mineralocorticoid receptors with spironolactone resulted in improved BP control and reduced CV mortality in HD patients<sup>
<xref rid="B47" ref-type="bibr">47</xref>
</sup>. Thus, aldosterone contributes to the worsening of HTN by exerting genomic and non-genomic effects, inducing inflammation and vascular toxicity in the presence of excess salt.</p><p>Key message:</p><list list-type="bullet"><list-item><p>It is recommended to block RAAS due to its inadequate activation, despite hypervolemia, which significantly contributes to the genesis of HTN and to increased CV risk in CKD patients (Class I/Level B).</p></list-item></list></sec><sec><title>Sympathetic Nervous System (SNS) activation</title><p>Activation of the SNS in CKD is one of the main mechanisms related to the pathophysiology of HTN. Factors responsible for SNS hyperactivity in CKD include reduced bioavailability of NO, ED, uremic toxicity, and inflammation, as well as a high prevalence of OSA<sup>
<xref rid="B48" ref-type="bibr">48</xref>,<xref rid="B49" ref-type="bibr">49</xref>,<xref rid="B50" ref-type="bibr">50</xref>
</sup>.</p><p>Increased plasma norepinephrine concentrations and sympathetic activity, assessed through muscle sympathetic nerve activity (MSNA), highlight the importance of the SNS in the pathophysiology of HTN in CKD. Renal sympathetic afferent nerves innervating the renal arteries, and CNS efferents stimulated by B1 receptors, cause renal arteriolar vasoconstriction and RAAS activation, with a consequent increase in renal vascular resistance and sodium retention<sup>
<xref rid="B51" ref-type="bibr">51</xref>
</sup>. CKD patients exhibit renalase deficiency, an enzyme produced by the kidneys and responsible for metabolizing catecholamines<sup>
<xref rid="B52" ref-type="bibr">52</xref>
</sup>.</p><p>SNS hyperactivity also contributes to CV mortality, being associated with atherosclerotic disease, LVH, and the presence of cardiac arrhythmias, which account for approximately 25% of deaths in dialysis patients<sup>
<xref rid="B53" ref-type="bibr">53</xref>
</sup>. Sympathetic hyperactivity is confirmed by improved BP control following native kidney nephrectomy in patients with CKD stage 5D<sup>
<xref rid="B54" ref-type="bibr">54</xref>
</sup>, and by renal denervation in patients at different CKD stages<sup>
<xref rid="B55" ref-type="bibr">55</xref>
</sup> and on HD<sup>
<xref rid="B56" ref-type="bibr">56</xref>
</sup>. Finally, the administration of BB in dialysis patients reduces CKD progression and mortality<sup>
<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B58" ref-type="bibr">58</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>SNS blockade is recommended for the treatment of HTN, as sympathetic hyperactivity is an important pathophysiological mechanism in HTN and mortality in CKD (Class I/Level A).</p></list-item></list></sec><sec><title>Endothelial dysfunction</title><p>It is reasonable to state that endothelial disfunction associated with HTN in patients on HD or PD precedes the diagnosis of CKD by decades, considering that most CKD patients have DM and/or HTN, or are elderly and present several CV risk factors. A study in rats subjected to 5/6 nephrectomy documented the reduction in endothelial NO synthase activity, resulting in lower NO availability and elevated BP<sup>
<xref rid="B59" ref-type="bibr">59</xref>
</sup>. The reduction in NO supply has been attributed to changes in the metabolism of pteridines, which are aromatic compounds that act as cofactors in various inflammatory and immunological processes<sup>
<xref rid="B60" ref-type="bibr">60</xref>
</sup>. In patients with stage 5D CKD, the reduction in the BH4/BH2 ratio - compounds belonging to the pteridine group - was associated with a reduction in endothelial NO availability, inflammation/ malnutrition processes, and CVD<sup>
<xref rid="B61" ref-type="bibr">61</xref>
</sup>. Also, the oxidative stress present in CKD<sup>
<xref rid="B62" ref-type="bibr">62</xref>
</sup>, and particularly the increased plasma levels of asymmetric dimethylarginine (ADMA), interfere with NO production and are associated with LVH and CV mortality in HD patients<sup>
<xref rid="B63" ref-type="bibr">63</xref>,<xref rid="B64" ref-type="bibr">64</xref>,<xref rid="B65" ref-type="bibr">65</xref>
</sup>. ADMA is an endogenous inhibitor of NO synthesis, which accumulates due to reductions in GFR and intracellular metabolization<sup>
<xref rid="B65" ref-type="bibr">65</xref>
</sup>.</p><p>Patients with stage 5D CKD have elevated ET1 levels, which contribute to the worsening of HTN<sup>
<xref rid="B66" ref-type="bibr">66</xref>
</sup> and play a significant role in the occurrence of IDH<sup>
<xref rid="B67" ref-type="bibr">67</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>Main message: The pre-existing endothelial dysfunction experienced by most CKD patients becomes even more severe as GFR decreases, thus contributing to the pathophysiology of HTN and the occurrence of CV events and death (Class II/Level B).</p></list-item></list></sec><sec><title>Increased Arterial Stiffness (AS)</title><p>AS causes an increase in peripheral and central BP, such as SBP, PP, and LV mass, as well as reductions in DBP and coronary perfusion. AS may also be considered an independent factor for CV mortality and CKD progression.</p><p>The mechanisms involved in AS in patients with CKD are not yet fully defined, but they include arterial calcification, chronic volume overload, mechanical stress due to HTN, chronic microinflammation, sympathetic and RAAS hyperactivity, accumulation of glucose degradation products, lipid peroxidation, and abnormalities in the NO system. Even a mild reduction in GFR is a risk factor for the development of AS. UF in HD is not capable of significantly reversing/decreasing AS<sup>
<xref rid="B68" ref-type="bibr">68</xref>,<xref rid="B69" ref-type="bibr">69</xref>,<xref rid="B70" ref-type="bibr">70</xref>,<xref rid="B71" ref-type="bibr">71</xref>
</sup>.</p><p>AS is multifactorial and some of these are exclusive to CKD: a) high phosphorus levels, which activate genes related to the osteoblast phenotype in smooth muscle cells, leading to arterial calcification<sup>
<xref rid="B72" ref-type="bibr">72</xref>
</sup>; b) protein-energy malnutrition, which is common in CKD and causes an increase in AS<sup>
<xref rid="B73" ref-type="bibr">73</xref>
</sup>; c) elevated ADMA; d) increased FGF 23; e) reduced magnesium<sup>
<xref rid="B74" ref-type="bibr">74</xref>,<xref rid="B75" ref-type="bibr">75</xref>,<xref rid="B76" ref-type="bibr">76</xref>
</sup>. Low serum concentrations of fetuin-A are associated with vascular calcification in CKD<sup>
<xref rid="B77" ref-type="bibr">77</xref>
</sup>.</p></sec><sec><title>Obstructive Sleep Apnea (OSA) in HTND</title><p>OSA is defined as a partial or complete collapse of the upper airways during sleep, causing sleep fragmentation and intermittent hypoxemia. The diagnosis and severity of OSA are based on the apnea-hypopnea index (AHI) obtained through polysomnography or polygraphy: up to 4.9 = no OSA; 5.0 to 14.9 = mild OSA; 15 to 29.9 = moderate OSA; and &#x02265; 30 events per hour = severe OSA<sup>
<xref rid="B78" ref-type="bibr">78</xref>
</sup>.</p><p>OSA is highly prevalent in the dialysis population, affecting 50% to 70% of patients. When associated with HTN, it exhibits pathophysiological mechanisms that are amplified, most notably hypervolemia<sup>
<xref rid="B79" ref-type="bibr">79</xref>,<xref rid="B80" ref-type="bibr">80</xref>
</sup>.</p><p>The clinical picture is poorly specific, with a lower prevalence of snoring and daytime sleepiness reported in CKD 5D<sup>
<xref rid="B81" ref-type="bibr">81</xref>
</sup>. Indication for an objective sleep examination should be considered more liberally in these patients. Severe OSA may be related to resistant and refractory HTN<sup>
<xref rid="B82" ref-type="bibr">82</xref>
</sup>.</p><p>Once moderate or severe OSA has been identified, regardless of BP behavior, treatment should be individualized. The indication for continuous positive airway pressure (CPAP) during sleep may not be the first choice in dialysis patients. To reduce hypervolemia in this subgroup, UF optimization techniques, such as extended nocturnal HD, or PD with cycler machines, have proven effective in small clinical trials<sup>
<xref rid="B78" ref-type="bibr">78</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>The clinical picture of OSA in patients with CKD 5D is poorly specific. The indication for an objective sleep examination (polysomnography or polygraphy) should be considered in a more liberal and individualized manner, as should the use of CPAP (Class IIB/Level C).</p></list-item></list></sec><sec><title>Drugs that interfere with blood pressure control</title><p>Increased BP is a well-recognized complication of EPO therapy in HD patients<sup>
<xref rid="B83" ref-type="bibr">83</xref>
</sup>. Approximately 30% of patients develop HTN or require adjustment of antihypertensive medication after a few weeks or months. The pathophysiology of HTN due to EPO use appears to be independent of its effect on red blood cell mass and viscosity<sup>
<xref rid="B84" ref-type="bibr">84</xref>
</sup>. The most likely mechanisms involve increased production or enhanced response to ET-1, a pronounced increase in BP response to angiotensin II infusion, and hypersensitivity to norepinephrine<sup>
<xref rid="B83" ref-type="bibr">83</xref>
</sup>. There are reports of an association between abnormalities in the circadian rhythm of BP and the use of EPO in ABPM<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>. Preventing EPO-induced hypertension is a clinical challenge with several possible management strategies listed below as recommendations<sup>
<xref rid="B83" ref-type="bibr">83</xref>,<xref rid="B84" ref-type="bibr">84</xref>
</sup>.</p><p>Finally, the use of drugs that notoriously raise BP should be avoided, which are already extensively mentioned in the Brazilian Hypertension Guidelines<xref rid="B4" ref-type="bibr">4</xref>.</p><p>Key messages:</p><p>In EPO-induced HTN refractory to antihypertensive management, the following are recommended:</p><list list-type="bullet"><list-item><p>Attention to dry weight (Class IIA/Level B);</p></list-item><list-item><p>Preference for subcutaneous route of EPO administration (Class IIA/Level B);</p></list-item><list-item><p>Reduce hemoglobin target (Class IIA/Level C);</p></list-item><list-item><p>Start with a low dose of EPO, increase slowly and, in extreme cases, discontinue its use (Class IIA/Level B);</p></list-item><list-item><p>Avoid the use of drugs that notoriously raise BP (Class IIA/Level B).</p></list-item></list></sec><sec><title>Inertia of the care team</title><p>Clinical or therapeutic inertia (TI) refers to the failure of healthcare professionals to initiate, intensify, or discontinue treatments when indicated, including both pharmacological and non-pharmacological measures<sup>
<xref rid="B85" ref-type="bibr">85</xref>
</sup>. TI is observed in around 2/3 of visits with hypertensive patients<sup>
<xref rid="B86" ref-type="bibr">86</xref>
</sup>. Also, in the dialysis literature, there is evidence associated with failure in introducing or intensifying antihypertensive therapy or adjusting volume status. In a retrospective analysis of patients with CKD and uncontrolled HTN, TI appears to have occurred on approximately 44% of occasions, judging by the non-identification of a reason for the failure in medical decision-making<sup>
<xref rid="B87" ref-type="bibr">87</xref>
</sup>.</p><p>Regarding the psychological profile of the physician most prone to TI, the preference for apparent short-term safety through inaction seems to predominate<sup>
<xref rid="B88" ref-type="bibr">88</xref>
</sup>. Coping with this behavior involves the continued encouragement of proactive conduct aimed at achieving therapeutic goals, within a policy of improving quality of care<sup>
<xref rid="B89" ref-type="bibr">89</xref>
</sup>.</p><p>TI is described in various CV prevention scenarios<sup>
<xref rid="B89" ref-type="bibr">89</xref>
</sup>, such as the management of dialysis patients with DM<sup>
<xref rid="B90" ref-type="bibr">90</xref>
</sup> or elderly patients on polypharmacy<sup>
<xref rid="B91" ref-type="bibr">91</xref>
</sup>. Implicating factors include clinical uncertainty regarding BP measurement, poor medication adherence, and diastolic and/or orthostatic hypotension<sup>
<xref rid="B87" ref-type="bibr">87</xref>
</sup>.</p><p>Examining the use of potentially inappropriate medications (centrally-acting alpha-agonists or alpha-blockers), the risk of TI in elderly dialysis patients was higher among black individuals, with polypharmacy, and without functional limitations. However, there was no increase in hospitalizations or mortality in those who maintained these medications<sup>
<xref rid="B87" ref-type="bibr">87</xref>
</sup>.</p><p>Among hypertensive patients, the use of structured medical education and a regular feedback system was successful, with greater control of HTN, but no improvement in CV outcomes<sup>
<xref rid="B92" ref-type="bibr">92</xref>
</sup>.</p><p>Recommendations in the existing literature indicate that patient education and involvement in the management of their CV risks reduce TI<sup>
<xref rid="B88" ref-type="bibr">88</xref>,<xref rid="B93" ref-type="bibr">93</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>To reduce therapeutic inertia, it is recommended that protocols should involve patients, caregivers, physicians, and a multidisciplinary team for achieving clinical goals in the control of HTN (Class I/Level B).</p></list-item></list></sec><sec><title>Poor adherence to antihypertensive treatment</title><p>Adherence can be defined as the extent to which an individual complies with the recommendations of a healthcare provider<sup>
<xref rid="B94" ref-type="bibr">94</xref>
</sup>. Low adherence to treatment is associated with unfavorable clinical outcomes and is common among patients with CKD 5D<sup>
<xref rid="B95" ref-type="bibr">95</xref>
</sup>.</p><p>Regarding BP control in HD or PD, poor adherence could pose a series of difficulties for the management of HTN. The lack of implementation of behavioral measures, such as reducing salt intake and limiting weight gain in the interdialytic period, coupled with a failure to use prescribed antihypertensive drugs - whether due to complex dosing regimens, associated side effects, or, in the specific case of HD patients, the fear of intradialytic hypotension episodes - could hinder the achievement of therapeutic goals.</p><p>As for strategies to improve adherence, studies in this population are scarce. In general, the following strategies are recommended:</p><list list-type="order"><list-item><p>Reduction in salt intake/limitation of interdialytic weight gain (IDWG): structured interventions based on continuous patient education, conducted by a multidisciplinary team, may improve these variables<sup>
<xref rid="B96" ref-type="bibr">96</xref>
</sup>.</p></list-item><list-item><p>Measurement of BP in the interdialytic period, through HBPM, promotes greater adherence to antihypertensive drugs, directly impacting on BP control<sup>
<xref rid="B97" ref-type="bibr">97</xref>
</sup>.</p></list-item><list-item><p>Pharmacological treatment: selection of medications with a lower adverse event profile and better dosing convenience<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup>.</p></list-item><list-item><p>In HD patients, the medication schedule should be adjusted according to the session, without discontinuing antihypertensive drugs, particularly in patients with a tendency to intradialytic hypertension<sup>
<xref rid="B98" ref-type="bibr">98</xref>
</sup>.</p></list-item></list><p>Key messages:</p><p>Strategies to improve adherence to antihypertensive treatment in HD patients include:</p><list list-type="bullet"><list-item><p>Continuous education aimed at limiting salt intake and IDWG (Class IIA/Level B).</p></list-item><list-item><p>Home or outpatient BP measurement during the interdialytic period (Class IIA/Level B).</p></list-item><list-item><p>Use of antihypertensive drugs, preferably in a single daily dose (Class I/Level A).</p></list-item></list></sec></sec></sec><sec><title>Diagnosis of Hypertension in Patients Undergoing Peritoneal Dialysis (PD) and Hemodialysis (HD)</title><p>BP measurements related to the HD session are not sufficient for diagnosing HTN and have poor prognostic value. Observational studies report a U-shaped association between peridialytic BP and mortality. In contrast, BP outside the dialysis unit shows a linear and direct association with mortality<sup>
<xref rid="B99" ref-type="bibr">99</xref>,<xref rid="B100" ref-type="bibr">100</xref>
</sup>. The BP behavior in dialysis patients is directly related to their volume status, so that measurements taken prior to HD overestimate BP, while those taken after HD underestimate it<sup>
<xref rid="B101" ref-type="bibr">101</xref>
</sup>. As opposed to this expected drop in BP during HD, 7&#x02013;30% of these patients experience an increase during this period<sup>
<xref rid="B102" ref-type="bibr">102</xref>
</sup>. This contributes to the variability and inconsistency in BP measurements during the peridialysis period. Conversely, there is growing evidence of the superiority of measurements taken outside the HD unit.</p><sec><title>Blood Pressure Measurement Related to the HD Session</title><p>BP measurement related to the HD session can be assessed using three measures: predialysis BP, intradialytic BP, and postdialysis BP. Determining the number of readings to be taken during the intradialytic period will depend on the nephrologist&#x02019;s clinical judgment. This decision will consider pre-dialysis BP values, a history of intradialytic hypotension or hypertension episodes, the need for elevated ultrafiltration rates, patients undergoing dry weight adjustment, and the patient&#x02019;s general clinical condition.</p><p>Key messages:</p><list list-type="bullet"><list-item><p>BP during the HD session has low prognostic value (Class I/Level B).</p></list-item><list-item><p>It is recommended that during the HD session, BP be measured at least every hour (Class IIA/Level C).</p></list-item><list-item><p>According to the Kidney Disease Outcomes Quality Initiative (KDOQI), in HD patients, HTN should be diagnosed as pre-dialysis BP &#x0003e; 140/90 mmHg, or post-dialysis BP &#x0003e; 130/80 mmHg10 (Class IIA/Level B).</p></list-item></list><p>However, they are taken under circumstances that deviate from those recommended for adequate BP measurement, including: anxiety about starting the treatment, anticipation of pain from the arteriovenous fistula puncture<sup>
<xref rid="B103" ref-type="bibr">103</xref>
</sup>, discontinuation of antihypertensive drugs on the day of HD (in some patients), clearance of antihypertensive drugs, use of erythropoiesis-stimulating agents, white coat and masking effects, pre- or intradialytic diet, validation of oscillometric devices used in HD machines, and a high number of patients being assessed by the same health professional in a short period of time.</p><p>Several studies have been conducted to assess the diagnostic accuracy of peridialytic BP measures, as well as their representativeness of BP in the interdialytic period<sup>
<xref rid="B101" ref-type="bibr">101</xref>,<xref rid="B104" ref-type="bibr">104</xref>,<xref rid="B105" ref-type="bibr">105</xref>
</sup>. The pattern observed in most patients is a tendency towards a reduction in post-dialysis BP in relation to pre-dialysis BP. This can be explained by the hemodynamic response to UF during dialysis, and generally, the magnitude of this reduction is associated with the ultrafiltrate volume. Similarly, studies suggest that IDWG has a direct influence on the elevation of pre-dialysis BP<sup>
<xref rid="B105" ref-type="bibr">105</xref>
</sup>. Performing the correct BP measurement technique in the HD unit is challenging, and for this reason, inadequate technique has already been implicated in the poor performance of pre- and post-HD BP to diagnose and/or assess the prognosis of HTN in these patients. However, a study has demonstrated that, even when properly performed, this type of measure has no prognostic significance<sup>
<xref rid="B104" ref-type="bibr">104</xref>
</sup>. Certain conditions are inherent to the dialysis setting, and performing pre- and post-dialysis BP measurements in a designated location, that preserves the necessary criteria for correct BP measurement, may not be feasible within the logistics of a HD session. Thus, BP measurements during the HD session should not be used for diagnosing HTN or defining adjustments to the patient&#x02019;s antihypertensive regimen<sup>
<xref rid="B101" ref-type="bibr">101</xref>
</sup>.</p><p>Peridialytic BP measurements are imprecise estimates of BP, limiting their ability to provide clear and direct prognostic associations, even when such an association does exist.</p></sec><sec><title>Intradialytic Hypertension (IDH)</title><p>Despite fluid removal through UF, there is a subset of patients who exhibit a rise in BP during and/or after the HD session, compared to pre-HD BP levels. These patients are classified as having IDH<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup>. An increase in SBP &#x02265; 10 mmHg during or after the HD session compared to pre-dialysis levels in 4 out of 6 sessions is commonly used to characterize a patient with IDH<sup>
<xref rid="B106" ref-type="bibr">106</xref>
</sup>. However, Singh et al. reported that any observed increases in SBP are related to a higher risk of fatal CV events<sup>
<xref rid="B107" ref-type="bibr">107</xref>
</sup>.</p><p>It is important to note that IDH is not detected in all HD sessions for the same patient. Conversely, there is a greater correlation between BP values detected within the first 90 minutes of HD and those measured immediately after the session. In Brazil, a single-center analysis showed that 11% of patients experienced an increase in SBP &#x02265; 10 mmHg in more than 50% of HD sessions<sup>
<xref rid="B108" ref-type="bibr">108</xref>
</sup>. The pathophysiological mechanisms that justify this condition include hypervolemia, positive sodium balance, RAAS and SNS hyperactivity, endothelial disfunction, and higher or lower clearance of antihypertensive medications<sup>
<xref rid="B109" ref-type="bibr">109</xref>
</sup>.</p><p>The main mechanisms involved in intradialytic HTN are highlighted in <xref rid="T1" ref-type="table">Chart 1</xref>.</p><table-wrap position="float" id="T1"><label>Chart 1</label><caption><title>Pathophysiological mechanisms of intradialytic hypertension</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypervolemia</td><td align="left" valign="top" rowspan="1" colspan="1">Excess fluid is one of the primary causes of elevated blood pressure in patients with intradialytic hypertension (IDH). The paradoxical rise in blood pressure observed in some patients during ultrafiltration may result from increased cardiac output due to hypervolemia and dilation of the cardiac chambers. This indicates that intensifying ultrafiltration and reducing dry weight could serve as effective treatment strategies for IDH.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Activation of the renin-angiotensin-aldosterone system (RAAS)</td><td align="left" valign="top" rowspan="1" colspan="1">RAAS stimulation is triggered by hypovolemia resulting from ultrafiltration.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sympathetic System Hyperactivity</td><td align="left" valign="top" rowspan="1" colspan="1">Individuals with chronic kidney disease (CKD) typically exhibit sympathetic hyperactivity, which can be alleviated by increasing the frequency of hemodialysis sessions<sup>
<xref rid="B110" ref-type="bibr">110</xref>
</sup>.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sodium Control</td><td align="left" valign="top" rowspan="1" colspan="1">A positive sodium balance is one of the primary mechanisms contributing to extracellular fluid overload and hypertension in dialysis patients. Effective sodium removal can be achieved by adjusting the ultrafiltration rate and the sodium concentration in the dialysate.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Endothelial Dysfunction</td><td align="left" valign="top" rowspan="1" colspan="1">In response to ultrafiltration and both mechanical and hormonal stimuli, endothelial cells synthesize and release humoral factors that play a role in blood pressure homeostasis. Patients with intradialytic hypertension (IDH) exhibit a significant increase in plasma endothelin-1 levels and a decrease in nitric oxide levels compared to controls<sup>
<xref rid="B109" ref-type="bibr">109</xref>
</sup>.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dialysis clearance of antihypertensive medications</td><td align="left" valign="top" rowspan="1" colspan="1">Antihypertensive medications vary in their susceptibility to filtration through the dialyzer membrane.</td></tr></tbody></table><table-wrap-foot><fn id="T1FN1"><p>Abbreviations &#x02013; IDH: intradialytic hypertension; CO: cardiac output; UF: ultrafiltration; DW: dry weight; RAAS: renin angiotensin aldosterone system; CKD: chronic kidney disease; NO: nitric oxide.</p></fn></table-wrap-foot></table-wrap><p>Several strategies have been proposed for the treatment of IDH, such as<sup>
<xref rid="B111" ref-type="bibr">111</xref>
</sup>:</p><list list-type="bullet"><list-item><p>Optimization of antihypertensive treatment: ensuring the use of appropriate medication, aiming for the ideal dry weight, checking adherence to both pharmacological and non-pharmacological treatment, in addition to extending the duration and/or frequency of HD sessions;</p></list-item><list-item><p>Consider the use of BB with alpha-blocker activity (labetalol);</p></list-item><list-item><p>Use short-acting antihypertensives before starting the HD session;</p></list-item><list-item><p>Selection of less dialyzable antihypertensive agents;</p></list-item><list-item><p>Consider reducing sodium concentration of dialysis solution;</p></list-item><list-item><p>Avoid a very high calcium concentration in the dialysis solution;</p></list-item><list-item><p>Consider elevating the temperature of the dialysate. Very cold baths are favorable to the emergence of IDH;</p></list-item><list-item><p>Consider administering erythropoiesis-stimu&#x000ad;lating agents subcutaneously.</p></list-item></list></sec><sec><title>Blood Pressure Measurements Outside the Hemodialysis Unit</title><p>These measurements have proven to be a more accurate parameter for assessing BP changes related to reduced DW, in addition to being more associated with target organ damage and CV events. In these patients, the prevalence of nocturnal HTN (risers) and the non-dipper pattern are usually higher than those in the overall hypertensive population<sup>
<xref rid="B112" ref-type="bibr">112</xref>,<xref rid="B113" ref-type="bibr">113</xref>
</sup>.</p><sec><title>Self-measurement of blood pressure in dialysis patients</title><p>There is no conclusive evidence validating specific protocols (number of measurements and timing) nor normality values for this method<sup>
<xref rid="B114" ref-type="bibr">114</xref>
</sup>. However, SMBP should follow the same recommendations and precautions as office BP measurements.</p><p>Key message:</p><list list-type="bullet"><list-item><p>SMBP is not recommended on a routine basis for the diagnosis and management of HTN in HD or PD patients and should only be used as a screening method (Class I, Level C).</p></list-item></list></sec><sec><title>Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) </title><p>In HD patients, ABPM and HBPM have shown a better correlation with target organ damage, CV events, and death from any cause<sup>
<xref rid="B100" ref-type="bibr">100</xref>,<xref rid="B101" ref-type="bibr">101</xref>,<xref rid="B104" ref-type="bibr">104</xref>
</sup>. Both display a good correlation with each other, as reported in the DRIP study, in which BP changes assessed by HBPM after 4 and 8 weeks of DW adjustment were associated with BP changes assessed by 44-hour ABPM<sup>
<xref rid="B105" ref-type="bibr">105</xref>
</sup>. Another benefit demonstrated in a study with HD patients was the finding that an antihypertensive medication adjustment strategy based on HBPM proved to be more effective in BP control than a strategy based on pre-HD SBP<sup>
<xref rid="B97" ref-type="bibr">97</xref>
</sup>.</p><p>Performing a 44-hour ABPM, fitting the device after a midweek dialysis session (between the second and third sessions of the week) and removing it immediately before the next session, provides prognostic information in HD patients and is the only method capable of assessing BP behavior during sleep. As in the general population, the sleep-wake ratio is a significant predictor of clinical outcomes in dialysis patients. Therefore, the absence of BP dipping during sleep (&#x0003c; 10% of the average nighttime BP in relation to wakefulness) or reverse dipping (elevated nighttime BP in relation to wakefulness), is associated with the risk of overall and CV mortality<sup>
<xref rid="B115" ref-type="bibr">115</xref>,<xref rid="B116" ref-type="bibr">116</xref>
</sup>. However, ABPM is not a practical test to perform and has low acceptance in this population, partly due to the prevalent frequency of sleep disorders and pruritus associated with CKD<sup>
<xref rid="B78" ref-type="bibr">78</xref>,<xref rid="B117" ref-type="bibr">117</xref>
</sup>. Conversely, HBPM, in addition to showing a good correlation with prognosis, is low-cost and better tolerated<sup>
<xref rid="B118" ref-type="bibr">118</xref>
</sup>. The advantages of the methods are listed in <xref rid="T2" ref-type="table">Chart 2</xref>, and the recommended protocols for their implementation are shown in <xref rid="T3" ref-type="table">Charts 3</xref> and <xref rid="T4" ref-type="table">4</xref> (Class IIA/Level C).</p><table-wrap position="float" id="T2"><label>Chart 2</label><caption><title>Advantages of ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM)</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="center" colspan="2" valign="top" rowspan="1">Advantages common to ABPM and HBPM</th></tr></thead><tbody><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Characterization of white-coat hypertension</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Characterization of masked hypertension</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Identification of true resistant hypertension</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Greater adherence to the diagnosis and treatment of hypertension</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Better efficiency in blood pressure control</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Good reproducibility</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Better correlation with target organ damage and cardiovascular events than blood pressure measured at dialysis unit</td></tr><tr style="border-top:solid black 0.1em;border-bottom:solid black 0.1em; border-color: #000000"><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Advantages of ABPM</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Advantages of HBPM</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Regarded as the gold standard for blood pressure assessment.</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Assessment of the highest number of blood pressure measurements over the greatest number of days.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Assessment of blood pressure during sleep and daily activities.</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Involves the patient in their self-care through blood pressure measurement.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Assessment of rapid morning blood pressure elevation.</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Low-cost.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Evaluates 24-hour blood pressure management.</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Well accepted by patients.</td></tr></tbody></table><table-wrap-foot><fn id="T2FN1"><p>Abbreviations &#x02013; ABPM: ambulatory blood pressure monitoring; HBPM: home blood pressure monitoring.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Chart 3</label><caption><title>Protocol for conducting ambulatory blood pressure monitoring (ABPM) in dialysis patients</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1">ABPM</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">In patients undergoing hemodialysis three times a week, 24-hour ambulatory ABPM does not capture blood pressure measurements throughout the interdialytic cycle. For these patients, a 44-hour ABPM is recommended<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup>. It is important to note that the cuff should not be placed on the arm with the arteriovenous fistula (AVF).</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Verification period:</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; 44 hours (if the software does not support the 44-hour protocol, two consecutive 22-hour assessments are recommended). For patients undergoing daily hemodialysis (HD) or peritoneal dialysis (PD), a 24-hour ABPM is recommended.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Number of measurements:</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; At least 48 valid measurements are required during the 44-hour ABPM (32 while awake and 16 during sleep) and <break/>24 valid measurements during the 24-hour ABPM (16 while awake and 8 during sleep).</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Installation day:</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; The device should be installed after the mid-week dialysis session and removed immediately after the following session. For a 44-hour ABPM, it should be removed just before the dialysis session.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>ABPM report:</bold> The report must include the date and time of the start and end of the assessment (indicating the interdialytic period during which it was conducted), the number and percentage of measurements taken versus valid measurements, the average systolic blood pressure (SBP) and diastolic blood pressure (DBP) over 24 hours during wakefulness and during sleep. It should also detail blood pressure behavior during wakefulness and sleep, episodes of hypotension and/or blood pressure peaks, and any correlations between activities, symptoms, and medications. The conclusion should specify whether the blood pressure behavior was considered normal or abnormal (abnormal if the mean SBP &#x02265; 130 mmHg and/or DBP &#x02265; 80 mmHg, as shown in <xref rid="T10" ref-type="table">Table 1</xref>).</td></tr></tbody></table><table-wrap-foot><fn id="T3FN1"><p>Abbreviations &#x02013; ABPM: ambulatory blood pressure monitoring; HD: hemodialysis; BP: blood pressure; h: hours; AVF: arteriovenous fistula; HBPM: home blood pressure monitoring; SBP: systolic blood pressure; DBP: diastolic blood pressure.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T10"><label>Table 1</label><caption><title>Blood pressure values considered abnormal for ambulatory blood pressure monitoring (ABPM) and for home blood pressure monitoring (HBPM)</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" colspan="2" valign="top" rowspan="1">SBP (mmHg)</th><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" colspan="2" valign="top" rowspan="1">DBP (mmHg)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">ABPM 44h</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265;130</td><td align="center" valign="top" rowspan="1" colspan="1">and/or</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265;80</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABPM awake</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265;135</td><td align="center" valign="top" rowspan="1" colspan="1">and/or</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265;85</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABPM sleep</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265;120</td><td align="center" valign="top" rowspan="1" colspan="1">and/or</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265;70</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HBPM</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265;130</td><td align="center" valign="top" rowspan="1" colspan="1">and/or</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265;80</td></tr></tbody></table><table-wrap-foot><fn id="T10FN1"><p>Abbreviations &#x02013; ABPM: arterial blood pressure monitoring; HBPM: home blood pressure monitoring; SBP: systolic blood pressure; DBP: diastolic blood pressure.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Chart 4</label><caption><title>Protocol for home blood pressure monitoring in dialysis patients according to the Brazilian guidelines for blood pressure measurements in- and out-office 2023<sup>
<xref rid="B119" ref-type="bibr">119</xref>
</sup>
</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1">Home Blood Pressure Monitoring - HBPM</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Verification period:</bold> Day of installation + six consecutive days.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Number of measurements:</bold> Ideally, 36 measurements (at least 18 valid measurements), taken every day, covering both morning and evening/night periods.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Day 0 or installation day:</bold> For HD and PD, measurements are taken in the office or in the HD clinic, never on the arm with the AVF. Ideally, three measurements are taken (using the average of the last two for the calculation of white-coat and masked blood pressure effects) and measurements are taken at home at night. Measurements taken on the installation day, either in the office or at home, should be excluded from the calculation of the HBPM average.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HBPM days:</bold> At home, BP measurements are taken for six more days. The patients should take three measurements in the morning and three in the evening or at night. For patients undergoing conventional HD (two or three times weekly), measurements taken on dialysis days should be excluded from the calculation of the HBPM average. In cases of daily HD and PD, all measurements are included in the average calculation.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HBPM report:</bold> It should include the reason for the examination request, the number of days of effective measurements, the time and number of measurements on each day, the quality of the procedure, mean BP (total, daily, and for morning and evening/night periods), whether white-coat or masked blood pressure effects were present, and whether the results were considered normal or abnormal (abnormal if averages are &#x02265; 130 mmHg and/or &#x02265; 80 mmHg).</td></tr></tbody></table><table-wrap-foot><fn id="T4FN1"><p>Abbreviations &#x02013; HBPM: home blood pressure monitoring; HD: hemodialysis; PD: peritoneal dialysis; BP: blood pressure; AVF: arteriovenous fistula.</p></fn></table-wrap-foot></table-wrap><p>Key messages:</p><list list-type="bullet"><list-item><p>Message: Both ABPM and HBPM are preferred over office BP in terms of predicting clinical outcomes with a better correlation with target organ damage, CV events, and death from any cause when compared to peridialytic measures (Class I/Level B).</p></list-item><list-item><p>Both ABPM and HBPM show good correlation with each other in HD and PD (Class I/Level B).</p></list-item><list-item><p>44-hour ABPM is recommended as the gold standard method for diagnosing HTN in HD and PD patients<sup>
<xref rid="B113" ref-type="bibr">113</xref>
</sup> (Class I, Level B).</p></list-item><list-item><p>HBPM (installation day and 6 additional days) is recommended as an alternative when ABPM is unavailable (Class I, Level C).</p></list-item><list-item><p>For PD and daily HD, it is recommended to follow the guidelines for the hypertensive population in general, regarding HBPM and 24-hour ABPM (Class I/Level C).</p></list-item></list><p>Regarding peritoneal dialysis (PD), as it is a home dialysis modality, it is suggested that HBPM should be widely applied. In its latest update, the International Society for Peritoneal Dialysis recommends that, in addition to BP measurement during clinical visits, home BP should also be measured on a weekly basis<sup>
<xref rid="B120" ref-type="bibr">120</xref>
</sup>. However, due to the scarcity of evidence, prospective studies are needed to elucidate the actual prognostic significance of out-of-office BP measurements in PD.</p></sec><sec><title>Phenotypes</title><p>Considering both in-office and out-of-office BP, there are 9 possible types of BP behavior: True Normotension (TN), Controlled Hypertension (CH), Sustained Hypertension (SH), Sustained Uncontrolled Hypertension (SUH), White Coat Hypertension (WCH), White Coat Uncontrolled Hypertension (WCHNC), Masked Hypertension (MH), Masked Uncontrolled Hypertension (MUH), and Nocturnal Hypertension (NH).</p><p>WCH refers to a condition in which BP is abnormal in the office but normal when measured by ABPM or HBPM. MH refers to patients whose BP is normal in the office but abnormal when measured by HBPM or ABPM. In patients taking antihypertensive medication, the term &#x0201c;uncontrolled&#x0201d; should be added. TN is when both in- and out-of-office BP measurements are normal and the patient is not on antihypertensive medication; if they are, it is defined as CH. SH is used when both are abnormal in the absence of antihypertensive drugs. If the patient is taking antihypertensive medication, it is defined as SUH. NH is defined when the average BP measured by ABPM is altered during sleep at 24h or 44h, but normal during wakefulness. The prevalence of phenotypes varies considerably according to the BP measurement method and the definition of HTN. In one of the few studies assessing the prevalence of phenotypes among HD patients, 44-hour ABPM abnormal values &#x02265; 135/85 mmHg and &#x02265; 140/80 mmHg were used for the median pre-HD and post-HD BP of six consecutive midweek sessions. The prevalence rates found can be seen in <xref rid="F02" ref-type="fig">Figure 2</xref>
<sup>
<xref rid="B121" ref-type="bibr">121</xref>
</sup>.</p><fig position="float" id="F02"><label>Figure 2</label><caption><title>Prevalence of hypertension phenotypes in patients with chronic kidney disease on hemodialysis.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf02" position="float"/><attrib>Abbreviations &#x02013; BP: blood pressure; HBPM: home blood pressure monitoring; ABPM: ambulatory blood pressure monitoring.</attrib></fig><p>There is a lack of studies assessing the prognosis of phenotypes in dialysis patients. However, among patients with non-dialysis CKD, the risk of CV morbidity and mortality was not increased in those with WCUH, but it was increased in those with MUH and SUH<sup>
<xref rid="B122" ref-type="bibr">122</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>Message: Further studies are needed to assess HTN phenotypes in the population across all dialysis modalities.</p></list-item></list></sec></sec></sec><sec><title>Complementary Assessments of Hypertension and Cardiovascular Risk in Peritoneal Dialysis (PD) and Hemodialysis (HD)</title><sec><title>Calculating Cardiovascular Risk in Chronic Kidney Disease on Dialysis</title><p>While CKD is a strong independent predictor of CV disease<sup>
<xref rid="B123" ref-type="bibr">123</xref>,<xref rid="B124" ref-type="bibr">124</xref>,<xref rid="B125" ref-type="bibr">125</xref>
</sup>, CV disease itself is the leading cause of death in chronic nephropathy patients, highlighting the importance of identifying patients at high risk of CV events and death<sup>
<xref rid="B126" ref-type="bibr">126</xref>,<xref rid="B127" ref-type="bibr">127</xref>
</sup>. In the general population, there are methods capable of predicting the 10-year probability of a CV event, notably the Framingham score and the Atherosclerotic Cardiovascular Disease (ASCVD) risk algorithm, which only consider traditional CV risk factors<sup>
<xref rid="B128" ref-type="bibr">128</xref>,<xref rid="B129" ref-type="bibr">129</xref>
</sup>. In CKD patients, these scores are less accurate, likely due to the existence of non-traditional risk factors related to loss of kidney function and dialysis treatment<sup>
<xref rid="B130" ref-type="bibr">130</xref>&#x02013;<xref rid="B133" ref-type="bibr">133</xref>
</sup>. Consistent with this view, traditional risk factors are predominant in the early stages of CKD, while the non-traditional ones become more relevant as CKD progresses<sup>
<xref rid="B130" ref-type="bibr">130</xref>
</sup>.</p><p>Risk calculation models valuing specific factors for dialysis patients have been proposed<sup>
<xref rid="B131" ref-type="bibr">131</xref>,<xref rid="B132" ref-type="bibr">132</xref>,<xref rid="B133" ref-type="bibr">133</xref>
</sup>. From the analysis of HD patients, assessing the 5-year risk of CV events and death, a predictive score was developed including seven characteristics (age, sex, DM, previous CV disease, type of vascular access at dialysis initiation, monocyte/lymphocyte ratio, and uric acid), resulting in better performance than the Framingham score<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup>. Evaluating Japanese patients on HD (J-DOPPS) over the course of a year, a model was developed including six variables (age, DM, previous CV disease, length of dialysis session, phosphorus, and albumin), also showing better risk discrimination than the Framingham score<sup>
<xref rid="B132" ref-type="bibr">132</xref>
</sup>. A European study of HD patients, followed for up to 2 years and including clinical and laboratory data (age, BMI, smoking, previous CV disease, CKD etiology, pre-dialysis BP, UF, hemoglobin, CRP, albumin, creatinine, and calcium), demonstrated good prediction of overall mortality risk<sup>
<xref rid="B133" ref-type="bibr">133</xref>
</sup>. Altogether, these studies show that adding non-traditional risk factors to predictive models has improved their accuracy in dialysis patients, although the observed death rate remains higher than the predicted one, suggesting that additional risk factors could be included in the construction of a more definitive model<sup>
<xref rid="B131" ref-type="bibr">131</xref>,<xref rid="B132" ref-type="bibr">132</xref>,<xref rid="B133" ref-type="bibr">133</xref>
</sup>. In any case, there is no widely accepted tool available for predicting CV risk in dialysis patients that is both simple and accurate.</p><p>Key messages:</p><list list-type="bullet"><list-item><p>CKD patients should be considered at high CV risk (Class I/Level A).</p></list-item><list-item><p>CV risk assessment of CKD patients may be conducted using risk calculation models for the general population (Class IIA/Level B).</p></list-item><list-item><p>The accuracy of CV risk discrimination in CKD patients is enhanced using specific models that include both traditional and non-traditional risk factors related to CKD and dialysis (Class IIA/Level B).</p></list-item></list></sec><sec><title>Natriuretic Peptides in Chronic Kidney Disease Patients</title><p>Serum natriuretic peptide levels are commonly used in clinical practice for the diagnosis and follow-up of patients with HF<sup>
<xref rid="B134" ref-type="bibr">134</xref>
</sup>. The diagnosis of HF is corroborated by at least one of the following factors: elevations in serum BNP or NT-proBNP concentrations, or objective evidence of pulmonary or systemic congestion of cardiogenic origin<sup>
<xref rid="B134" ref-type="bibr">134</xref>
</sup>.</p><p>These peptides, especially NT-proBNP, appear to predict the risk of CV outcomes and death in individuals at high CV risk<sup>
<xref rid="B135" ref-type="bibr">135</xref>,<xref rid="B136" ref-type="bibr">136</xref>,<xref rid="B137" ref-type="bibr">137</xref>,<xref rid="B138" ref-type="bibr">138</xref>,<xref rid="B139" ref-type="bibr">139</xref>,<xref rid="B140" ref-type="bibr">140</xref>,<xref rid="B141" ref-type="bibr">141</xref>
</sup>, including the potential for using NT-proBNP as an isolated variable that resembles or even surpasses the predictions of multivariate risk models<sup>
<xref rid="B136" ref-type="bibr">136</xref>,<xref rid="B137" ref-type="bibr">137</xref>,<xref rid="B138" ref-type="bibr">138</xref>,<xref rid="B139" ref-type="bibr">139</xref>,<xref rid="B140" ref-type="bibr">140</xref>,<xref rid="B142" ref-type="bibr">142</xref>
</sup>.</p><p>
<xref rid="T5" ref-type="table">Chart 5</xref> illustrates some studies demonstrating the association of NT-proBNP with increased CV risk in the CKD population<sup>
<xref rid="B139" ref-type="bibr">139</xref>,<xref rid="B141" ref-type="bibr">141</xref>,<xref rid="B143" ref-type="bibr">143</xref>,<xref rid="B144" ref-type="bibr">144</xref>,<xref rid="B145" ref-type="bibr">145</xref>,<xref rid="B147" ref-type="bibr">147</xref>
</sup>.</p><table-wrap position="float" id="T5"><label>Chart 5</label><caption><title>Studies in patients with kidney disease evaluating natriuretic peptides as biomarkers of risk of diseases, events, and cardiovascular death</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Study</th><th align="left" valign="top" rowspan="1" colspan="1">Study design</th><th align="left" valign="top" rowspan="1" colspan="1">Kidney disease/other comorbidities</th><th align="left" valign="top" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">TREAT<sup>
<xref rid="B144" ref-type="bibr">144</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Evaluation of the insertion of NT-proBNP and troponin T to a multivariable prediction model</td><td align="left" valign="top" rowspan="1" colspan="1">CKD, with T2DM and anemia</td><td align="left" valign="top" rowspan="1" colspan="1">Increased the predictive ability of CV outcomes by 17.8%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALTITUDE<sup>
<xref rid="B137" ref-type="bibr">137</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Post-hoc analysis of NT-proBNP prediction (single variable) compared to a model with 20 variables</td><td align="left" valign="top" rowspan="1" colspan="1">CKD and/or CV disease</td><td align="left" valign="top" rowspan="1" colspan="1">Predictor of risk of CV events and death, similar to the multivariate model</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CREATE<sup>
<xref rid="B145" ref-type="bibr">145</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">NT-proBNP (single variable)</td><td align="left" valign="top" rowspan="1" colspan="1">CKD (GFR 15-35ml/min) and anemia</td><td align="left" valign="top" rowspan="1" colspan="1">Elevated plasma level as a predictor of risk of CV events and progression of CKD</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Harrison TG et al., 2020<sup>
<xref rid="B141" ref-type="bibr">141</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Meta-analysis with 49 studies, evaluated BNP and NT-proBNP as a marker of risk of CV events and death</td><td align="left" valign="top" rowspan="1" colspan="1">CKD 5D</td><td align="left" valign="top" rowspan="1" colspan="1">Elevated levels of NT-proBNP and BNP were predictors of CV mortality and all-cause death</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Satoh A et al., 2021<sup>
<xref rid="B147" ref-type="bibr">147</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">NT-proBNP with measurement before the first HD of the week</td><td align="left" valign="top" rowspan="1" colspan="1">Patients on HD</td><td align="left" valign="top" rowspan="1" colspan="1">High serum levels were predictors of CV and overall risk of death</td></tr></tbody></table><table-wrap-foot><fn id="T5FN1"><p>Abbreviations &#x02013; DM2: Type 2 diabetes mellitus, CV: cardiovascular, CKD: chronic kidney disease, GFR: Glomerular filtration rate by creatinine clearance, HD: hemodialysis.</p></fn></table-wrap-foot></table-wrap><p>In dialysis patients, NT-proBNP appears to independently predict CV and all-cause mortality<sup>
<xref rid="B141" ref-type="bibr">141</xref>,<xref rid="B147" ref-type="bibr">147</xref>
</sup>, in addition to being a predictive factor for volume overload in HD patients (with or without a decline in LV ejection fraction)<sup>
<xref rid="B147" ref-type="bibr">147</xref>,<xref rid="B148" ref-type="bibr">148</xref>,<xref rid="B149" ref-type="bibr">149</xref>
</sup> and for an increased risk of stroke-related hospitalizations<sup>
<xref rid="B150" ref-type="bibr">150</xref>
</sup>.</p><p>Since renal dysfunction is accompanied by increased concentrations of BNP and NT-proBNP<sup>
<xref rid="B141" ref-type="bibr">141</xref>,<xref rid="B151" ref-type="bibr">151</xref>
</sup>, the strategy of sequential measurements is superior to a single measurement in CKD patients<sup>
<xref rid="B141" ref-type="bibr">141</xref>
</sup>. Thus, in the absence of defined BNP and NT-proBNP cut-off values for dialysis patients, sequential values may better and more dynamically reflect the trajectory of cardiac function and hydration status.</p><p>Key message:</p><list list-type="bullet"><list-item><p>It is recommended to perform serial measure&#x000ad;ments of natriuretic peptides in dialysis patients (preferably NT proBNP), if available, as they may help in the assessment of volume overload, identification and control of HF associated with dialysis CKD, and especially in predicting the risk of CV outcomes and death (Class I/Level B).</p></list-item></list></sec><sec><title>Arterial Stiffness (AS) Assessed by Pulse Wave Velocity (PWV) Measurement</title><p>The degree of AS is a marker of vascular health and aging. One way of estimating it is by measuring arterial PWV, defined as the time taken (m/s) for the pulse wave (generated by systole) to travel between two sites in the arterial system, usually the carotid and femoral arteries. The carotid-femoral (aortic) PWV reflects the viscoelastic properties of the aorta and is considered the gold standard method for assessing AS<sup>
<xref rid="B152" ref-type="bibr">152</xref>
</sup>.</p><p>Elevated aortic PWV indicates increased AS and is associated with a higher risk of CV disease and mortality<sup>
<xref rid="B152" ref-type="bibr">152</xref>
</sup>. Normal values for aortic PWV vary according to age and sex (<xref rid="T11" ref-type="table">Table 2</xref>)<sup>
<xref rid="B153" ref-type="bibr">153</xref>
</sup>.</p><table-wrap position="float" id="T11"><label>Table 2</label><caption><title>Normal pulse wave velocity (PWV) values for men and women according to age group</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" rowspan="2" valign="top" colspan="1">Age group</th><th align="center" colspan="2" valign="top" rowspan="1">PWV (m/s)</th></tr><tr style="border-top:solid black 0.1em;border-bottom:solid black 0.1em; border-color: #000000"><th align="center" valign="top" rowspan="1" colspan="1">Men</th><th align="center" valign="top" rowspan="1" colspan="1">Women</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">20&#x02013;29 years</td><td align="center" valign="top" rowspan="1" colspan="1">6.4</td><td align="center" valign="top" rowspan="1" colspan="1">6.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">30&#x02013;39 years</td><td align="center" valign="top" rowspan="1" colspan="1">6.9</td><td align="center" valign="top" rowspan="1" colspan="1">6.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">40&#x02013;49 years</td><td align="center" valign="top" rowspan="1" colspan="1">7.4</td><td align="center" valign="top" rowspan="1" colspan="1">7.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">50&#x02013;59 years</td><td align="center" valign="top" rowspan="1" colspan="1">8.0</td><td align="center" valign="top" rowspan="1" colspan="1">7.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e; 60 years</td><td align="center" valign="top" rowspan="1" colspan="1">9.2</td><td align="center" valign="top" rowspan="1" colspan="1">8.6</td></tr></tbody></table></table-wrap><p>In HD patients, a greater aortic PWV value predicts higher mortality<sup>
<xref rid="B154" ref-type="bibr">154</xref>
</sup>, and PWV &#x0003e; 10 m/s is an independent predictor of both CV and all-cause mortality<sup>
<xref rid="B155" ref-type="bibr">155</xref>
</sup>. Similarly, accelerated PWV progression (measured at time 0 and every 6 months) may predict CV mortality in patients undergoing HD<sup>
<xref rid="B156" ref-type="bibr">156</xref>
</sup>.</p><p>HD patients appear to have PWV levels that are less sensitive to BP control, reflecting the overlap between traditional CV risk factors and non-traditional factors (related to uremia and dialysis treatment) that are determinants of the greater AS which characterizes this population. Altogether, this may justify the recognition that the lower variation in PWV observed regarding the management of HTN in these individuals was associated with a higher risk of CV events<sup>
<xref rid="B157" ref-type="bibr">157</xref>
</sup>.</p><p>Increased arterial stiffness is relatively common in PD patients. Higher PWV in PD patients is associated with increasing age, the presence of DM and hyperhydration, and has been shown to be a predictor of outcome in these patients<sup>
<xref rid="B158" ref-type="bibr">158</xref>
</sup>.</p><p>In conclusion, the measurement of PWV, considered the gold standard tool for AS, helps calculate CV risk, although further research is needed to establish definitive standards of PWV normality and its role in outcomes within the dialysis population.</p><p>Key message:</p><list list-type="bullet"><list-item><p>Assessment of arterial stiffness using carotid-femoral pulse wave velocity (PWV) is recommended, if available, and on a serial basis, as it potentially predicts CV events as well as mortality in HD and PD (Class I/Level B).</p></list-item></list></sec><sec><title>Bioimpedance as a Diagnostic Method for Body Composition and Volume Status</title><p>Bioimpedance analysis (BIA) assesses body composition by passing an electrical current of different frequencies through the body. It is a diagnostic method used in the context of dialysis patients to estimate the level of hydration and support in BP management<sup>
<xref rid="B159" ref-type="bibr">159</xref>,<xref rid="B160" ref-type="bibr">160</xref>,<xref rid="B161" ref-type="bibr">161</xref>
</sup>.</p><p>In a systematic review with meta-analysis of chronic HD and PD patients, Tabinor et al. suggest that mortality is predicted by a hyperhydration index &#x0003e; 15%, and a phase angle reduced by 1 degree, regardless of comorbidities<sup>
<xref rid="B162" ref-type="bibr">162</xref>
</sup>. In the largest study included, Zoccali et al. demonstrated higher mortality in hyperhydrated patients, regardless of pre-dialysis BP<sup>
<xref rid="B163" ref-type="bibr">163</xref>
</sup>. Other systematic reviews and meta-analyses have focused on showing the impact of using BIA in dialysis patients, and these are summarized in <xref rid="T6" ref-type="table">Chart 6</xref>
<sup>
<xref rid="B161" ref-type="bibr">161</xref>,<xref rid="B164" ref-type="bibr">164</xref>,<xref rid="B165" ref-type="bibr">165</xref>,<xref rid="B166" ref-type="bibr">166</xref>,<xref rid="B167" ref-type="bibr">167</xref>
</sup>.</p><table-wrap position="float" id="T6"><label>Chart 6</label><caption><title>Summary of the main studies demonstrating the impact on the use of bioimpedance in dialysis patients</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Studies</th><th align="left" valign="top" rowspan="1" colspan="1">Study design</th><th align="left" valign="top" rowspan="1" colspan="1">Improved control of hyperhydration</th><th align="left" valign="top" rowspan="1" colspan="1">Improved control of BP</th><th align="left" valign="top" rowspan="1" colspan="1">Other outcomes</th><th align="left" valign="top" rowspan="1" colspan="1">Observations</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Scotland et al., 2018<sup>
<xref rid="B161" ref-type="bibr">161</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Systematic review</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>yes</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">no</td><td align="left" valign="top" rowspan="1" colspan="1">I: no<break/>M: no</td><td align="left" valign="top" rowspan="1" colspan="1">BIA showed no effect on arterial stiffness and was not cost effective</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Covic et al., 2017<sup>
<xref rid="B164" ref-type="bibr">164</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Systematic review and meta-analysis</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>yes</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>yes</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">M: no</td><td align="left" valign="top" rowspan="1" colspan="1">No change in body composition</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Beaubien-<break/>Souligny<break/>et al., 2020<sup>
<xref rid="B168" ref-type="bibr">168</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Systematic review and meta-analysis of randomized studies</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>yes</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>yes</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">LVH: no<break/>ECV: no<break/>
<bold>I: yes</bold>
<break/>M: no</td><td align="left" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yang K et al., 2023<sup>
<xref rid="B166" ref-type="bibr">166</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Meta-analysis of randomized studies</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>yes</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>yes</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>LVH: yes (HD)</bold>
<break/>
<bold>M: yes</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">Reduction of NT Pro-BNP and PWV</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Horowitz et al., 2023<sup>
<xref rid="B167" ref-type="bibr">167</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Systematic review and meta-analysis of randomized studies</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>yes</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>ye</bold>s</td><td align="left" valign="top" rowspan="1" colspan="1">LVH: no<break/>ECV: no<break/>I: no<break/>
<bold>M: yes</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn id="T6FN1"><p>Abbreviations &#x02013; BP: blood pressure; BIA: bioelectrical impedance; LVH: left ventricular hypertrophy; ECV: cardiovascular events; I: hospitalization; M: mortality; PWV: pulse wave velocity.</p></fn></table-wrap-foot></table-wrap><p>It is important to highlight the diversity of parameters derived from the use of BIA to assess the volume status of dialysis patients, with no consensus on a preferred choice among them<sup>
<xref rid="B169" ref-type="bibr">169</xref>,<xref rid="B170" ref-type="bibr">170</xref>
</sup>. Conversely, the literature is more robust in indicating the use of BIA as a support in hypervolemia control rather than as a primary guideline in the conduct of antihypertensive therapy. The use of BIA could impact BP control; however, it is crucial to realize that it should be seen as one of several available alternatives for managing volume status and BP.</p><p>Key message:</p><list list-type="bullet"><list-item><p>BIA is recommended as a complementary method for assessing and managing hyperhydration and BP in HD and PD patients (Class I/Level A).</p></list-item></list></sec><sec><title>Point-of-Care Ultrasound in the Assessment of Volume Status in CKD Patients: Evaluation of Heart, Lungs, and Inferior Vena Cava (IVC)</title><p>Volume status is a fundamental parameter across the entire CKD spectrum, and its clinical assessment has limitations, stimulating the development of more objective volume assessment tools, such as point-of-care ultrasound (POCUS)<sup>
<xref rid="B171" ref-type="bibr">171</xref>
</sup>. POCUS allows for a multi-organ approach, assessing various facets of the patient&#x02019;s volume status.</p><p>The pump-pipes-leaks approach is a proposal for practical and objective assessment of volume status. Insonation of the heart through the parasternal long axis cardiac view enables LV systolic function to be assessed from the variation in its systolic and diastolic volumes, lateral wall and interventricular septum thickness in systole, and amplitude of septal displacement of the anterior mitral valve leaflet (pump)<sup>
<xref rid="B171" ref-type="bibr">171</xref>
</sup>. &#x0201c;Pipes&#x0201d; refers to the assessment of IVC diameter (<xref rid="F03" ref-type="fig">Figure 3A-B</xref>).</p><fig position="float" id="F03"><label>Figure 3</label><caption><title>Point-of-care ultrasound for identifying volume status. Legend: A and B, ultrasound of the inferior vena cava (IVC): A, IVC &#x0003c; 1.7 cm, with a diameter decrease of more than 50% during inspiration, compatible with a euvolemic state; B, plethoric IVC, with a diameter of 2.7 cm and a decrease of less than 50% during inspiration, suggestive of hypervolemia; C, lung ultrasound: B-lines indicating interstitial lung syndrome, as seen in acute pulmonary edema; D, pleural effusion indicated by an anechoic image above the diaphragm; E, ascites, an anechoic image in the hepatorenal space; and F, pericardial effusion indicated by an anechoic image in the pericardial space.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf03" position="float"/></fig><p>A more objective model of volume assessment has been developed using Doppler examination of the hepatic, portal, and renal interlobar veins, known as Venous Excess Ultrasound (VExUS). <xref rid="F04" ref-type="fig">Figure 4</xref> summarizes the Doppler patterns of the hepatic, portal, and renal interlobar veins in the context of mild, moderate, and severe venous congestion. The low quality of evidence available for the use of VExUS in the volume assessment of CKD patients is noteworthy<sup>
<xref rid="B168" ref-type="bibr">168</xref>
</sup>.</p><fig position="float" id="F04"><label>Figure 4</label><caption><title>Doppler patterns of the hepatic, portal and renal interlobar veins in the context of mild, moderate and severe venous congestion.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf04" position="float"/><attrib>Abbreviations &#x02013; IVC: inferior vena cava; a: atrial contraction; S: systole; D: diastole. Note &#x02013; based on Dinh V. POCUS 101 Vexus ultrasound score &#x02013; fluid overload and venous congestion assessment.</attrib></fig><p>Leaks denotes the search for pulmonary congestion through the identification of B-lines (<xref rid="F03" ref-type="fig">Figure 3C</xref>) with high sensitivity, but lower specificity for congestion, as well as pleural effusion (<xref rid="F03" ref-type="fig">Figure 3D</xref>), ascites (<xref rid="F03" ref-type="fig">Figure 3E</xref>), and pericardial effusion (<xref rid="F03" ref-type="fig">Figure 3F</xref>). This allows for the detection of extravascular congestion before the onset of clinical symptoms, thereby adjusting the treatment for dialysis patients<sup>
<xref rid="B172" ref-type="bibr">172</xref>
</sup>.</p><p>In dialysis patients, identifying DW is challenging. If overestimated, DW contributes to persistent volume overload and its consequences; when underestimated, DW may cause intradialytic hypotension and associated complications. In the context of dialysis treatment patients, POCUS can provide valuable information.</p><p>The pump-pipes-leaks strategy enables bedside answers to questions related to the interaction between absolute volume gain, multicompartmental redistribution of extracellular volume, and the multiorgan adverse impact. Further studies are needed to assess its impact on HD patient survival<sup>
<xref rid="B172" ref-type="bibr">172</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>It is recommended to use the pump-pipes-leaks volume estimation tool at the bedside, including the VExUS score, as a potential alternative for assessing the severity of venous congestion in CKD patients (Class II A/Level B).</p></list-item></list></sec></sec><sec><title>Blood Pressure Targets in Peritoneal Dialysis (PD) and Hemodialysis (HD)</title><p>BP targets in dialysis patients, regardless of the modality, remain controversial, and extrapolating BP targets from the general population to this subgroup does not seem the best choice. It has been documented in the literature, through observational studies, that there is a U or J-shaped curve in the BP control of HD and PD patients. However, there may be interpretation biases due to the inclusion of individuals with hypotension, severe CV disease or frailty, contributing to a poor prognosis<sup>
<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B120" ref-type="bibr">120</xref>
</sup>,<sup>
<xref rid="B173" ref-type="bibr">173</xref>,<xref rid="B174" ref-type="bibr">174</xref>
</sup>.</p><p>The CRIC Study (The Chronic Renal Insufficiency Cohort Study), a multicenter prospective cohort study, presented interesting results on the relationship between all-cause mortality and SBP. Among participants who initiated HD (n = 326), a U-shaped association was observed between SBP measured &#x0201c;in the dialysis unit&#x0201d;, presumably before the start of the session, and mortality (HR 1.26 for every 10-mmHg increase), while SBP &#x0201c;outside the dialysis unit&#x0201d; showed a linear association with mortality. These results suggest that the optimal target BP for treatment should be determined by ambulatory BP monitoring (ABPM), which is not always available, well tolerated, or considered cost-effective<sup>
<xref rid="B100" ref-type="bibr">100</xref>,<xref rid="B175" ref-type="bibr">175</xref>
</sup>.</p><p>An American study involving over 17,000 HD patients concluded that those with pre-dialysis SBP &#x0003c; 140 mmHg had significantly higher mortality, especially within the first 3 months after initiating HD<sup>
<xref rid="B176" ref-type="bibr">176</xref>
</sup>. Similar findings related to less unfavorable outcomes with BP control during the interdialytic period were found in a Brazilian center, which included 2,672 HD patients followed for 31 months<sup>
<xref rid="B177" ref-type="bibr">177</xref>
</sup>.</p><p>The best-designed study with the potential to define BP targets was the Blood-Pressure-in-Dialysis (BID), a pilot study that randomized 126 participants to two SBP targets measured in the clinic before the start of the dialysis session: intensive (110&#x02013;140 mmHg) or standard (155&#x02013;165 mmHg), with the primary objective of assessing feasibility and comparative safety over a one-year follow-up period. The study demonstrated the feasibility of the intervention; however, despite the protocol requiring investigators to adjust post-dialysis weight as an initial step towards reaching the target SBP, the intensive SBP goal was only achieved using additional antihypertensive drugs. The authors indicated that there may have been inadequate management of extracellular volume to obtain the dry weight<sup>
<xref rid="B178" ref-type="bibr">178</xref>
</sup>.</p><p>The Kidney Disease Outcomes Quality Initiative (2005) guideline, which has not been updated, arbitrarily recommends a pre-dialysis BP &#x0003c; 140/80 mmHg and post-dialysis BP &#x0003c; 130/80 mmHg in HD patients, primarily based on expert opinion (Class IIA/Level C)<sup>
<xref rid="B179" ref-type="bibr">179</xref>
</sup>.</p><p>Since BP is a biomarker of the &#x0201c;cardiovascular syndrome&#x0201d;, the HTN management should address the prevention and treatment of all its CV complications. In the absence of data from randomized controlled clinical trials in dialysis patients, treatment objectives should be extrapolated from available observational studies and those developed in the general population. Based on this premise, it is reasonable to aim for a pre-dialysis BP &#x02264; 140/90 mmHg or a home BP &#x02264; 130/80 mmHg (Class IIA/Level C). A group of experts participating in a KDIGO initiative that discussed controversies regarding volume and HTN management in dialysis chose not to recommend BP targets for patients on RRT, and defined that general strategies in the management of HTN apply to dialysis patients, such as &#x0201c;Individualizing BP targets and agents according to age, coexisting CV disease, and other comorbidities, in addition to treatment tolerance&#x0201d; and &#x0201c;Inquiring about postural dizziness and checking for orthostatic hypotension&#x0201d;<sup>
<xref rid="B180" ref-type="bibr">180</xref>
</sup>.</p><p>In PD patients, an observational study showed that SBP &#x02264; 110 mmHg was associated with increased mortality, and a protective effect was observed with SBP &#x0003e; 120 mmHg<sup>
<xref rid="B181" ref-type="bibr">181</xref>
</sup>. Thus, based on data from the general population and the CKD population, it is recommended that the target BP be &#x0003c; 140/90 mmHg in PD patients, in agreement with the International Society of Peritoneal Dialysis (ISPD) and other authors (class IIA/Level B)<sup>
<xref rid="B120" ref-type="bibr">120</xref>,<xref rid="B182" ref-type="bibr">182</xref>,<xref rid="B183" ref-type="bibr">183</xref>
</sup>.</p><p>In the absence of evidence from long-term, randomized, controlled clinical trials designed for the specific purpose of defining optimal BP targets in HD and PD, it is recommended that clinical trials be developed comparing different home BP measurement thresholds in relation to clinical outcomes and mortality<sup>
<xref rid="B184" ref-type="bibr">184</xref>,<xref rid="B185" ref-type="bibr">185</xref>,<xref rid="B186" ref-type="bibr">186</xref>,<xref rid="B187" ref-type="bibr">187</xref>,<xref rid="B188" ref-type="bibr">188</xref>
</sup>.</p><p>In <xref rid="T7" ref-type="table">Chart 7</xref>, the recommendations from the major guidelines that cite goals to be achieved in HD patients can be observed.</p><table-wrap position="float" id="T7"><label>chart 7</label><caption><title>Blood pressure targets in hypertension of dialysis patients according to the main Guidelines</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Guidelines</th><th align="left" valign="top" rowspan="1" colspan="1">Blood pressure target (mmHg)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">KDOQI 2005<sup>
<xref rid="B179" ref-type="bibr">179</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Pre-dialysis: &#x0003c;140/90<break/>Post-dialysis: &#x0003c;130/80</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KDOQI 2015 (update)<sup>
<xref rid="B186" ref-type="bibr">186</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Not mentioned, citing lack of data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EURECA-m (ERA &#x02013; EDTA) 2017<sup>
<xref rid="B175" ref-type="bibr">175</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Not mentioned, citing lack of data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Japanese Society for Dialysis Therapy 2012<sup>
<xref rid="B187" ref-type="bibr">187</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Pre-dialysis: &#x0003c;140/90</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Brazilian Hypertension Guidelines 2020<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Pre-dialysis: &#x02264;140/90<break/>Post-dialysis: &#x02264;130/80</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2020 International Society of Hypertension Global Hypertension Practice Guidelines<sup>
<xref rid="B188" ref-type="bibr">188</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">International Society of Peritoneal Dialysis (ISPD) 2015<sup>
<xref rid="B120" ref-type="bibr">120</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Peritoneal dialysis: &#x0003c;140/90 mmHg</td></tr></tbody></table></table-wrap><p>Key messages:</p><list list-type="bullet"><list-item><p>It is recommended that BP targets should be pre-HD: &#x02264; 140/90 mmHg and post-HD &#x02264; 130/80 mmHg (Class IIA/Level B).</p></list-item><list-item><p>It is recommended that the BP target in PD be &#x0003c; 140/90 mmHg (Class IIA/Level B).</p></list-item><list-item><p>It is recommended to prescribe individualized goals for patients on HD and PD, according to age, degree of frailty, tolerance, presence of severe CV disease, and comorbidities (Class IIA/Level B).</p></list-item><list-item><p>Randomized, controlled, and comparative clinical trials of BP targets are recommended for a high-quality evidence-based indication.</p></list-item></list></sec><sec><title>Non-Pharmacological Treatment of HTN in PD and HD</title><sec><title>The Importance of Knowing, Achieving, and Maintaining Dry Weight</title><p>DW represents the state in which there are no signs or symptoms of hypervolemia or hypohydration. For each HD session, a target weight needs to be defined (possibly higher than the DW), considering the volume status, the IDWG, and the tolerated UF rate, to avoid a target weight that is too low (because it could lead to hypotension and accelerate the loss of RRF)<sup>
<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B105" ref-type="bibr">105</xref>
</sup>, or inappropriately high, resulting in HTN and hypervolemia<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup>. Chronic hypervolemia may cause HTN and an increased risk of hospitalization<sup>
<xref rid="B189" ref-type="bibr">189</xref>
</sup> and death<sup>
<xref rid="B163" ref-type="bibr">163</xref>,<xref rid="B190" ref-type="bibr">190</xref>
</sup> (<xref rid="F05" ref-type="fig">Figure 5</xref>). The goal of achieving DW throughout the HD sessions is therefore prioritized, thereby avoiding chronic hypervolemia, even with a higher risk of intradialytic hypotension<sup>
<xref rid="B105" ref-type="bibr">105</xref>
</sup>.</p><fig position="float" id="F05"><label>Figure 5</label><caption><title>Consequences of maintaining hypervolemia.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf05" position="float"/><attrib>Abbreviation &#x02013; UF: ultrafiltration.</attrib></fig><p>The regular application of a DW assessment protocol, preferably using multiple instruments<sup>
<xref rid="B105" ref-type="bibr">105</xref>
</sup>, has been associated with lower mortality, and the use of orthostatic BP measurement has been associated with a lower risk of hospitalization and CV events<sup>
<xref rid="B191" ref-type="bibr">191</xref>
</sup>. Nevertheless, the reliability of clinical signs in accurately estimating blood volume has been questioned<sup>
<xref rid="B192" ref-type="bibr">192</xref>
</sup>.</p><p>In PD, to achieve DW and BP control, priority is given to optimizing urine output with the use of diuretics (in patients with RRF)<sup>
<xref rid="B193" ref-type="bibr">193</xref>
</sup> and peritoneal UF, with appropriate adjustments in glucose load considering the PD prescription and the peritoneal transport rate<sup>
<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B9" ref-type="bibr">9</xref>
</sup>. For these patients, it is recommended to adopt RRF preservation, dietary management, and efforts to limit peritoneal injury.</p><p>The barriers to achieving DW are depicted in <xref rid="F06" ref-type="fig">Figure 6</xref>.</p><fig position="float" id="F06"><label>Figure 6</label><caption><title>Common barriers to achieving dry weight in hemodialysis patients.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf06" position="float"/><attrib>Abbreviations &#x02013; UF: ultrafiltration; HTN: hypertension.</attrib></fig><p>Key messages:</p><list list-type="bullet"><list-item><p>For HTN control, the strategy of gradually adjusting UF to minimal hypovolemia symptoms is recommended, to define and reach DW (Class I/Level B).</p></list-item><list-item><p>It is recommended that DW be assessed regularly and with multiple tools, such as clinical assessment, ultrasound, and bioimpedance (Class I/Level B).</p></list-item><list-item><p>In PD, strategies for preserving RRF and the integrity of the peritoneal membrane are recommended (Class I/Level B).</p></list-item></list></sec><sec><title>Changes in Dialysis Parameters in PD and HD</title><p>There are factors related to dialysis parameters that could interfere with BP, both in HD and PD (<xref rid="F07" ref-type="fig">Figure 7</xref>).</p><fig position="float" id="F07"><label>Figure 7</label><caption><title>Factors related to dialysis modality and the patient that may affect blood pressure control.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf07" position="float"/><attrib>Abbreviations &#x02013; HD: hemodialysis; HDF: online hemodiafiltration; UF: ultrafiltration.</attrib></fig><p>Studies analyzing the sodium concentration in the HD dialysis solution are inconclusive as to its impact on BP and have already been detailed in Chapter 2, item 2.2.2 (Parameters interfering with BP)<sup>
<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B29" ref-type="bibr">29</xref>
</sup>. There is no evidence supporting a reduction in mortality when sodium is individualized<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup>.</p><p>The benefit of sodium profiling used to avoid intradialytic hypotension and reduce sodium intake is controversial<sup>
<xref rid="B103" ref-type="bibr">103</xref>,<xref rid="B191" ref-type="bibr">191</xref>,<xref rid="B194" ref-type="bibr">194</xref>
</sup>. In one study, the use of this profile was associated with positive sodium balance, leading to higher IDWG rates, elevated BP, CV events, and death<sup>
<xref rid="B191" ref-type="bibr">191</xref>
</sup>. Another study showed that the linear profile did not reduce hypotension, although the &#x0201c;stepwise&#x0201d; profile proved effective<sup>
<xref rid="B194" ref-type="bibr">194</xref>
</sup>.</p><p>Methods for adjusting UF include the use of profiling, isolated UF followed by HD (sequential dialysis), or biofeedback devices<sup>
<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B195" ref-type="bibr">195</xref>
</sup>. A study evaluating linear UF profile showed no reduced risk of hypotension, nor differences in troponin levels and LV function<sup>
<xref rid="B196" ref-type="bibr">196</xref>
</sup>. UF biofeedback devices may reduce intradialytic hypotension<sup>
<xref rid="B195" ref-type="bibr">195</xref>
</sup>.</p><p>Reducing the dialysis solution temperature (in different definitions: a decrease in relation to body temperature, fixed at 35.5&#x000ba;C or 36&#x000ba;C, or adjusted using a biofeedback system) has been associated with a reduced intradialytic hypotension<sup>
<xref rid="B197" ref-type="bibr">197</xref>
</sup> and CV mortality<sup>
<xref rid="B191" ref-type="bibr">191</xref>
</sup>, in addition to being well tolerated<sup>
<xref rid="B197" ref-type="bibr">197</xref>
</sup>. An ongoing study (MY TEMP, NCT02628366) will assess cooling dialysis solution in relation to hospitalization and death outcomes due to CV events.</p><p>In PD, the suggested maneuvers for HTN control include<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup>: optimization of urine output with diuretics (in patients with RRF)<sup>
<xref rid="B193" ref-type="bibr">193</xref>
</sup>; reducing intraperitoneal residence time (of glucose-based solutions) in high transporters; glucose-based solutions with higher tonicity (less preferred due to peritoneal and systemic impact); icodextrin solution (increased UF without higher glycemic load)<sup>
<xref rid="B198" ref-type="bibr">198</xref>
</sup>, low-sodium dialysate, as it reduces HTN, without altering adequacy)<sup>
<xref rid="B193" ref-type="bibr">193</xref>
</sup>, and solutions with greater biocompatibility, neutral pH or lower content of glucose degradation products for preservation of the peritoneum and RRF<sup>
<xref rid="B198" ref-type="bibr">198</xref>,<xref rid="B199" ref-type="bibr">199</xref>,<xref rid="B200" ref-type="bibr">200</xref>
</sup>.</p><p>Key messages:</p><list list-type="bullet"><list-item><p>Caution is recommended when adjusting the sodium concentration in dialysis solution for the purposes of BP and volume control (Class I/Level B).</p></list-item><list-item><p>Caution is recommended in the use of sodium profiling to avoid intradialytic hypotension due to the risk of positive balance and its associated harms (Class I/Level B).</p></list-item><list-item><p>It is not recommended that the use of linear UF profile be used to prevent episodes of intradialytic hypotension (Class I/Level B).</p></list-item><list-item><p>Cooling dialysis solution is recommended to prevent intradialytic hypotension (Class I/Level A).</p></list-item><list-item><p>For HTN control in PD, preservation of RRF and peritoneal membrane is recommended (Class I/Level B).</p></list-item></list></sec><sec><title>Changes in Hemodialysis Modality (HDF, Daily HD)</title><p>Alternatives to conventional HD include intensive regimens (with increased frequency and/or length, such as in short daily HD and long daytime or nocturnal HD), and the use of convection (HDF), which may be performed in HD centers or at home. Daily HD is understood in the literature as any regimen of 5 to 7 times a week<sup>
<xref rid="B201" ref-type="bibr">201</xref>,<xref rid="B202" ref-type="bibr">202</xref>,<xref rid="B203" ref-type="bibr">203</xref>,<xref rid="B204" ref-type="bibr">204</xref>,<xref rid="B205" ref-type="bibr">205</xref>
</sup>.</p><p>The use of daily HD allows for a reduction in: BP<sup>
<xref rid="B201" ref-type="bibr">201</xref>,<xref rid="B202" ref-type="bibr">202</xref>,<xref rid="B203" ref-type="bibr">203</xref>
</sup>, the amount of antihypertensive drugs<sup>
<xref rid="B203" ref-type="bibr">203</xref>
</sup>, LVH<sup>
<xref rid="B202" ref-type="bibr">202</xref>
</sup>, tissue inhibitors of metalloproteinase<sup>
<xref rid="B202" ref-type="bibr">202</xref>
</sup>, and phosphorus, which in turn is associated with a reduction in FGF23<sup>
<xref rid="B202" ref-type="bibr">202</xref>
</sup>. A multicenter study of short daily HD in a home environment confirmed a reduction in the number of antihypertensive medications<sup>
<xref rid="B204" ref-type="bibr">204</xref>
</sup>. Intensive HD may also result in reduced hospitalizations (compared to conventional HD) and mortality (compared to conventional HD or PD)<sup>
<xref rid="B205" ref-type="bibr">205</xref>
</sup>.</p><p>Some studies have shown that nocturnal HD reduced SBP<sup>
<xref rid="B202" ref-type="bibr">202</xref>,<xref rid="B206" ref-type="bibr">206</xref>,<xref rid="B207" ref-type="bibr">207</xref>
</sup>, the number of antihypertensive drugs<sup>
<xref rid="B207" ref-type="bibr">207</xref>
</sup>, and LVH<sup>
<xref rid="B202" ref-type="bibr">202</xref>,<xref rid="B207" ref-type="bibr">207</xref>
</sup>, while also improving anemia<sup>
<xref rid="B206" ref-type="bibr">206</xref>
</sup> and hyperphosphatemia<sup>
<xref rid="B202" ref-type="bibr">202</xref>,<xref rid="B206" ref-type="bibr">206</xref>,<xref rid="B207" ref-type="bibr">207</xref>
</sup>.</p><p>High-volume online hemodiafiltration (HDF) provides a lower risk of death from any cause, in contrast to high-flow HD<sup>
<xref rid="B208" ref-type="bibr">208</xref>
</sup>. A study evaluating peridialytic BP parameters showed no benefit of HDF over conventional HD<sup>
<xref rid="B209" ref-type="bibr">209</xref>
</sup>. In another study, HDF reduced CV mortality and episodes of hypotension<sup>
<xref rid="B210" ref-type="bibr">210</xref>
</sup>. To reduce intradialytic hypotension, the intermittent use of ultrapure dialysate infusions has been beneficial for the elderly and those with high IDWG<sup>
<xref rid="B211" ref-type="bibr">211</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>It is recommended, whenever available, to use intensive HD regimens (daily and/or long) with benefits in reducing BP (Class I/Level A), antihypertensive medication (Class I/Level A), and left ventricular mass (Class I, Level B).</p></list-item></list></sec><sec><title>Dietary and Water Intake Recommendations for Hypertensive Patients on PD and HD, Especially to Prevent Interdialytic Weight Gain (IDWG)</title><p>It is recommended that dietary sodium intake for the hypertensive population (non-dialysis) should be up to 2 g/day, corresponding to 5.0 g/day of salt<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup>. In individuals on dialysis, who are typically salt-sensitive, there is a greater impact of salt restriction on BP, suggesting a dietary intake of up to 1.5 g of sodium or 3.6 g of salt<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup>. Compared to antihypertensive treatment, dietary sodium restriction associated with more intensive UF resulted in a reduction in IDWH, LVH, antihypertensive load, and episodes of intradialytic hypotension<sup>
<xref rid="B212" ref-type="bibr">212</xref>
</sup>.</p><p>A meta-analysis identified that reducing salt intake by at least 1 g was associated with a reduction in BP<sup>
<xref rid="B213" ref-type="bibr">213</xref>
</sup>. Conversely, high sodium intake was related to an increased risk of hypervolemia and death, but with no association with BP<sup>
<xref rid="B214" ref-type="bibr">214</xref>
</sup>.</p><p>In addition, hyperglycemia could increase thirst and salt intake, leading to an increase in IDWG and BP<sup>
<xref rid="B215" ref-type="bibr">215</xref>
</sup>. In dialysis patients, the Mediterranean diet appears to improve myocardial remodeling<sup>
<xref rid="B216" ref-type="bibr">216</xref>
</sup>, but has not been able to reduce mortality, similar to the DASH (Dietary Approaches to Stop Hypertension) and vegetarian diets<sup>
<xref rid="B217" ref-type="bibr">217</xref>
</sup>. In turn, polyphenol-rich diets have improved diastolic BP in the dialysis population<sup>
<xref rid="B218" ref-type="bibr">218</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>Dietary sodium restriction of 1.5 to 2.0g/day is recommended for dialysis patients to reduce BP and IDWG (Class I/Level B).</p></list-item></list></sec><sec><title>Physical Exercise for Hypertensive Patients on Pd and Hd</title><p>Studies examining the effect of physical exercise on BP in dialysis patients have yielded divergent results. A meta-analysis did not identify an effect of physical training on BP<sup>
<xref rid="B219" ref-type="bibr">219</xref>
</sup>. However, in another meta-analysis consisting of 78 randomized studies with 3,326 participants, it was possible to highlight a greater reduction in DBP with combined aerobic and resistance exercises, involving patient-tolerated loads on the lower and upper limbs without AVF<sup>
<xref rid="B220" ref-type="bibr">220</xref>
</sup>. On the other hand, improvements are documented in parameters associated with CV outcomes, target organ damage, quality of life and cognitive function<sup>
<xref rid="B219" ref-type="bibr">219</xref>,<xref rid="B220" ref-type="bibr">220</xref>
</sup>. As for the types of physical exercise, evidence shows benefits from both aerobic and resistance exercises. Regarding the location, intradialytic or home-based exercises may be used<sup>
<xref rid="B221" ref-type="bibr">221</xref>
</sup>.</p><p>Key messages:</p><list list-type="bullet"><list-item><p>It is recommended to encourage aerobic activity for a minimum of 30 minutes, at least 5 times a week, for both PD and HD patients (Class IIA/Level B).</p></list-item><list-item><p>It is recommended that supervised resistance training should also be prescribed (Class IIA/Level B).</p></list-item><list-item><p>It is recommended that physical activity be performed, either during dialysis sessions or in the interdialytic interval, outside of the dialysis setting (Class IIA/Level B).</p></list-item><list-item><p>It is recommended that, whenever possible, physical exercises be supervised by physical educators and/or physiotherapists in the units (Class IIA/Level C).</p></list-item></list></sec><sec><title>Other Lifestyle Changes (Spirituality, Stress Management, etc.)</title><p>Spirituality and religiosity are potentially important tools for dialysis patients, positively related to doctor-patient interaction, quality of life and life expectancy, coping with the disease, treatment and its consequences. They should therefore be considered by physicians<sup>
<xref rid="B222" ref-type="bibr">222</xref>
</sup>.</p><p>Spirituality may be understood as the pursuit of meaning and purpose in life, as well as the transcendence of the self. This experience may develop through religiosity and/or belief in God, family, naturalism, rationalism, humanism, and the arts, for example<sup>
<xref rid="B222" ref-type="bibr">222</xref>
</sup>. Religiosity, in turn, implies the human relationship with a transcendent being<sup>
<xref rid="B222" ref-type="bibr">222</xref>
</sup>.</p><p>These concepts correspond to a psychological construction in coping with chronic diseases, converting a personally challenging situation into a meaningful experience<sup>
<xref rid="B223" ref-type="bibr">223</xref>
</sup>. Strong religious beliefs among individuals on dialysis have been correlated with attenuated perceptions of the disease burden and an enhanced sense of social support<sup>
<xref rid="B223" ref-type="bibr">223</xref>,<xref rid="B224" ref-type="bibr">224</xref>
</sup>.</p><p>Adherence to dialysis is influenced by religious faith, age, and education: (a) Muslims have the desire to live and are less likely to discontinue dialysis<sup>
<xref rid="B215" ref-type="bibr">215</xref>,<xref rid="B223" ref-type="bibr">223</xref>
</sup>; (b) Christians with both extrinsic religiosity (religious behavior) and intrinsic religiosity (strong beliefs and commitments) show greater adherence<sup>
<xref rid="B223" ref-type="bibr">223</xref>
</sup>; (c) older age and longer dialysis vintage correlated with better adherence<sup>
<xref rid="B223" ref-type="bibr">223</xref>,<xref rid="B225" ref-type="bibr">225</xref>
</sup>; (d) patient counseling and education provide better results, increased adherence, and a potential reduction in healthcare-related costs<sup>
<xref rid="B223" ref-type="bibr">223</xref>
</sup>.</p><p>In some dialysis centers, social workers and psychologists have supported and encouraged non-formal religious activities (religious literature, prayer, discussion groups) as positive coping methods<sup>
<xref rid="B223" ref-type="bibr">223</xref>,<xref rid="B226" ref-type="bibr">226</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>It is recommended to respect and encourage religiosity and spirituality as a means of improving adherence and coping with dialytic CKD, involving the multidisciplinary team (Class I/Level B).</p></list-item></list></sec></sec><sec><title>Pharmacological Treatment of HTN in PD and HD</title><p>There is an apparent paradox regarding the use of antihypertensive drugs and BP control in dialysis patients, since the greater the number of medications, the greater the likelihood that BP is not controlled, suggesting that the combined use of different antihypertensive drugs may hinder the achievement of the target dry weight<sup>
<xref rid="B227" ref-type="bibr">227</xref>
</sup>. Antihypertensive medications should be used, if necessary, after volume control, preferably those assessed in RCTs. However, these studies are not widely available and have a limited number of participants, making it difficult to generalize guidelines for the use of antihypertensive drugs in dialytic CKD. The frequent CV impairment and the presence of comorbidities in dialysis patients make the combination of factors so diverse and unique that some guidelines recommend an individualized approach regarding the classes of drugs to be used<sup>
<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B48" ref-type="bibr">48</xref>
</sup>.</p><p>The use of antihypertensive medication in dialysis patients provides benefits, reducing overall and CV morbidity and mortality<sup>
<xref rid="B228" ref-type="bibr">228</xref>,<xref rid="B229" ref-type="bibr">229</xref>
</sup>. All classes of antihypertensives could be used for BP control in dialysis patients, if risks and benefits are considered<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup>.</p><sec><title>Diuretics</title><p>The use of these drugs is not supported for HD or PD patients without residual diuresis (&#x0003c; 100 mL/day). In PD patients, diuretics may improve volume status and minimize the need for solutions containing a higher glucose concentration, although the International Society of Peritoneal Dialysis Guidelines do not recommend their use<sup>
<xref rid="B120" ref-type="bibr">120</xref>
</sup>. In HD patients, diuretics could help reduce IDWG, resulting in reduced UF rates and fewer intradialytic hypotension episodes<sup>
<xref rid="B230" ref-type="bibr">230</xref>,<xref rid="B231" ref-type="bibr">231</xref>
</sup>.</p><p>In a prospective cohort study involving <sup>
<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B219" ref-type="bibr">219</xref>
</sup> patients who continued using loop diuretics after the initiation of HD compared to <sup>
<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B78" ref-type="bibr">78</xref>
</sup> controls who did not, lower rates of hospitalization, intradialytic hypotension, and IDWG were observed, with no significant difference in BP or mortality rate within the first year of dialysis. In the USA, the most used diuretic in HD patients is furosemide, at doses of 20 to &#x02265; 320 mg/day<sup>
<xref rid="B232" ref-type="bibr">232</xref>
</sup>.</p><p>A prospective observational study followed 16,420 HD patients across three continents and observed that the use of diuretics (&#x0003e; 90% loop diuretics) in the first 3 months of HD was higher in Japan (47.8%) and Europe (45.1%) compared to the United States (26.4%), with a progressive decline over this period<sup>
<xref rid="B233" ref-type="bibr">233</xref>
</sup>. In this study, diuretic use was associated with lower IDWG and a lower probability of hyperkalemia. Patients with RRF undergoing diuretic therapy were nearly twice as likely to maintain residual diuresis after one year of follow-up compared to those not using diuretics. Patients receiving diuretics also had a lower risk of overall mortality (&#x02013;7%; p = 0.12) and CV mortality (&#x02013;14%; p = 0.03)<sup>
<xref rid="B233" ref-type="bibr">233</xref>
</sup>.</p><p>No studies were found evaluating the use of thiazide or thiazide-like diuretics as monotherapy in PD or HD patients. A study with high-dose triple diuretic therapy (furosemide 1000 mg/day, hydrochlorothiazide 100 mg/day, and spironolactone 50 mg/day) in 51 PD patients demonstrated increased diuresis and improved volume control compared to furosemide alone<sup>
<xref rid="B234" ref-type="bibr">234</xref>
</sup>.</p><p>A meta-analysis including <sup>
<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B226" ref-type="bibr">226</xref>
</sup> HD patients revealed a potential benefit in reducing intradialytic hypotension, CV and all-cause mortality<sup>
<xref rid="B231" ref-type="bibr">231</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>The use of loop diuretics is recommended in HD and PD patients if residual diuresis is present (Class I/Level B).</p></list-item></list></sec><sec><title>Renin-Angiotensin-Aldosterone System (RAAS Inhibitors</title><p>RAAS inhibitors, including ACE inhibitors and ARBs are the most used antihypertensive medications in CKD at its different stages. A meta-analysis of randomized clinical trials evaluating the antihypertensive effect of different classes of drugs compared to placebo or to each other found that ACE inhibitors/ARBs modestly reduced BP when compared to placebo (&#x02013;4.3 mmHg in SBP), as expected for the hypervolemic state typical of CKD in the dialysis phase<sup>
<xref rid="B235" ref-type="bibr">235</xref>
</sup>. When compared to placebo, mineralocorticoid receptor antagonists (MRAs) are the most powerful in reducing BP (&#x02013;10.8 mmHg), followed by BB (&#x02013;8.7 mmHg) and CCB (&#x02013;4.6 mmHg)<sup>
<xref rid="B235" ref-type="bibr">235</xref>
</sup>.</p><p>In dialysis patients, the use of ACE inhibitors or ARBs is associated with a reduction in left ventricular mass index, morbid events - especially HF - and CV mortality<sup>
<xref rid="B236" ref-type="bibr">236</xref>,<xref rid="B237" ref-type="bibr">237</xref>,<xref rid="B238" ref-type="bibr">238</xref>
</sup>. Furthermore, there is evidence that the renal protection provided by these classes of drugs continues at this stage of the disease, as their use is associated with the maintenance of renal function or residual diuresis, which allows for better volume control and reduces the risk of intradialytic hypotension<sup>
<xref rid="B239" ref-type="bibr">239</xref>,<xref rid="B240" ref-type="bibr">240</xref>
</sup>. In PD patients, the use of ACE inhibitors/ARBs is preferably associated with preservation of the peritoneal membrane, with a reduction in fibrosis and maintenance of peritoneal clearance and UF<sup>
<xref rid="B241" ref-type="bibr">241</xref>,<xref rid="B242" ref-type="bibr">242</xref>
</sup>. The risk of hyperkalemia is plausible but controversial, as it is not observed in all studies<sup>
<xref rid="B243" ref-type="bibr">243</xref>,<xref rid="B244" ref-type="bibr">244</xref>,<xref rid="B245" ref-type="bibr">245</xref>
</sup>.</p><p>Key messages:</p><list list-type="bullet"><list-item><p>The use of ACE inhibitors or ARBs in HD and PD patients is recommended as antihypertensive agents due to their pleiotropic effects: reduction of LVH, HF, reduction of peritoneal fibrosis in PD, and CV mortality (Class I/Level B).</p></list-item><list-item><p>Monitoring serum potassium levels is recommended, although the risk of hyperkalemia is controversial and not always observed (Class IIA/Level B).</p></list-item></list></sec><sec><title>Beta-Blockers (BB)</title><p>In dialytic CKD, BB are recommended as the preferred medication. Two RCTs have demonstrated the efficacy and CV protection provided by BB in a subpopulation of dialysis patients. The first, a placebo-controlled RCT, showed that carvedilol used in 114 HD patients with HF (dilated cardiomyopathy and reduced ejection fraction) resulted in clinical improvement, a reduction (&#x02013;49%) in overall and CV mortality (&#x02013;68, 0%) and in hospitalizations due to HF (&#x02013;81%)<sup>
<xref rid="B58" ref-type="bibr">58</xref>
</sup>. The second study aimed to compare the effect of reducing LVH with atenolol or lisinopril (administered following HD sessions) in HD patients with BP &#x02265; 140/90 mmHg and LVH. However, it was halted early because the interim results were so beneficial in favor of atenolol that it would have been unethical to continue the study<sup>
<xref rid="B246" ref-type="bibr">246</xref>
</sup>. Although with a limited number of participants, 100 in each group, the study has become a reference. The rates of severe CV events and hospitalizations were at least halved in the atenolol-randomized group when compared to lisinopril<sup>
<xref rid="B246" ref-type="bibr">246</xref>
</sup>. The 44-hour ABPM was consistently lower in the group receiving atenolol, even though participants in the lisinopril group had received more antihypertensive medication and reduced their dry weight by an additional 3 kilos during follow-up, indicating the superiority of atenolol over lisinopril<sup>
<xref rid="B246" ref-type="bibr">246</xref>
</sup>. Other studies with BB (carvedilol, bisoprolol, and atenolol) have shown similar results regarding BP reduction, on average &#x02013;8.7 mmHg in SBP<sup>
<xref rid="B235" ref-type="bibr">235</xref>
</sup>.</p><p>There is controversy in the literature regarding the dialyzable BB (atenolol, bisoprolol, metoprolol, nadolol) and the non-dialyzable ones (carvedilol, nebivolol, propranolol, pindolol)<sup>
<xref rid="B247" ref-type="bibr">247</xref>
</sup>. Some studies present objective data and suggest that dialyzable BB are superior to the non-dialyzable ones, as they show a reduction in major CV events (stroke, AMI, and CHF), and in both CV and overall mortality, when compared<sup>
<xref rid="B248" ref-type="bibr">248</xref>,<xref rid="B249" ref-type="bibr">249</xref>
</sup>. There is also a meta-analysis of observational studies that found no differences in the CV protective effects between dialyzable and non-dialyzable BB in individuals undergoing HD<sup>
<xref rid="B250" ref-type="bibr">250</xref>
</sup>. All studies that have evaluated possible differences in CV protection between dialyzable and non-dialyzable BB are observational, either retrospective or prospective cohorts, and based on drug prescription data.</p><p>Regardless of the BB, an important question arises: &#x0201c;Could its association with other antihypertensive drugs have an additional beneficial effect?&#x0201d; At least one observational study has evaluated this aspect in HD patients who developed HF after the initiation of dialysis and started using BB, ACE inhibitors/ARBs, or both<sup>
<xref rid="B251" ref-type="bibr">251</xref>
</sup>. In the 5-year mortality follow-up, patients who used only BB were considered a reference for those who used only ACEI/ARBs, those who used both BB and ACEI/ARBs, and for those using any other drugs. Compared to the reference (use of BB alone), mortality for those using only ACE inhibitors/ARBs was similar (+8%; not statistically significant). For those who used a combination of BB and ACE inhibitors/ARBs, mortality was lower (&#x02013;33%; p &#x0003c; 0.001), while for those who used neither BB nor ACE inhibitors/ARBs, mortality was higher (+74%; p &#x0003c; 0.001)<sup>
<xref rid="B251" ref-type="bibr">251</xref>
</sup>.</p><p>Key messages:</p><list list-type="bullet"><list-item><p>Beta-blockers are recommended as preferred drugs for HD and PD patients, unless contraindicated (Class I/Level B).</p></list-item><list-item><p>Preferential use of atenolol is recommended, unless contraindicated (Class I/Level B).</p></list-item><list-item><p>There is insufficient evidence on the preferential use of dialyzable <italic>vs.</italic> non-dialyzable BB (Class IIB/Level B).</p></list-item></list></sec><sec><title>Calcium Channel Blockers (CCB)</title><p>There are few studies evaluating CCB in the treatment of HTN and the prevention of CV complications in dialysis patients. A meta-analysis of randomized studies<sup>
<xref rid="B235" ref-type="bibr">235</xref>
</sup> found only 3 studies with CCB compared to placebo (nitrendipine, diltiazem, and anlodipine), in which, on average, the hypotensive effect was similar to that of ACE inhibitors (&#x02013;4.6 mmHg in systolic BP). The most robust RCT included 251 patients and compared anlodipine <italic>vs.</italic> placebo. It demonstrated a mean reduction of &#x02013;10 mmHg in SBP, a non-significant reduction in overall mortality (primary outcome; RR = 0.62), and a significant reduction (RR = 0.53, p = 0.03) in secondary outcomes (AMI, stroke, myocardial revascularization, and peripheral artery disease requiring revascularization or amputation)<sup>
<xref rid="B252" ref-type="bibr">252</xref>
</sup>. It was observed that the hypotensive effect of nitrendipine was more pronounced in patients with higher IDWG<sup>
<xref rid="B253" ref-type="bibr">253</xref>
</sup>.</p><p>A systematic review with meta-analysis identified 13 randomized or quasi-randomized studies involving the use of CCB in dialysis patients<sup>
<xref rid="B254" ref-type="bibr">254</xref>
</sup>. Although the number of patients included in this analysis was large (1,459), the diversity of the studies and the low level of confidence limited the conclusions<sup>
<xref rid="B254" ref-type="bibr">254</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>The use of CCB in HD and PD patients is recommended, as they maintain their antihypertensive and CV-protective effects, even in the presence of hypervolemia (Class I/Level B).</p></list-item></list></sec><sec><title>Mineralocorticoid Receptor Antagonists (MRA)</title><p>A meta-analysis including 1,133 HD patients in 11 studies on MRA (10 with spironolactone and 1 with eplerenone) observed a greater hypotensive effect when compared to placebo (&#x02013;10.8 mmHg in SBP) and higher drug discontinuation rates, although with no additional risk of hyperkalemia<sup>
<xref rid="B235" ref-type="bibr">235</xref>
</sup>.</p><p>Another meta-analysis, which included 1,309 HD patients, in 14 RCTs involving the use of MRAs (13 with spironolactone) <italic>vs.</italic> placebo or no treatment, demonstrated a significant reduction in non-fatal CV events (&#x02013;49%), a reduction in overall mortality (&#x02013;56%) and CV mortality (&#x02013;59%), without causing statistically significant hyperkalemia<sup>
<xref rid="B255" ref-type="bibr">255</xref>
</sup>.</p><p>A meta-analysis including 829 dialysis patients from 9 RCTs on MRA observed a significant reduction in overall mortality (&#x02013;60%) and CV mortality (&#x02013;66%). However, a 3-fold increase in the risk of hyperkalemia and up to a 5-fold increase in the risk of gynecomastia were observed<sup>
<xref rid="B256" ref-type="bibr">256</xref>
</sup>. In the available meta-analyses, although hyperkalemia may pose a risk, it does not appear to mitigate the beneficial effect on CV and overall mortality<sup>
<xref rid="B255" ref-type="bibr">255</xref>,<xref rid="B256" ref-type="bibr">256</xref>
</sup>.</p><p>Two large ongoing RCTs could provide more reliable data on the efficacy and safety of spironolactone use in dialytic CKD. The Aldosterone Antagonist Chronic Hemodialysis Interventional Survival Trial (ALCHEMIST), which has already recruited 825 HD patients and is due to be completed in 2024, evaluates the effects of spironolactone on clinical outcomes of interest. The Aldosterone Blockade for Health Improvement Evaluation in ESKD Trial (ACHIEVE) plans to enroll 2,750 dialysis patients and compare the effects of spironolactone in relation to CV death or hospitalization.</p><p>It is worth noting that the existing studies predominantly use spironolactone, with a higher risk of gynecomastia, and a low and controversial risk of hyperkalemia (Class I/Level B). To date, there has been no RCT using selective non-steroidal MRAs in HD or PD.</p><p>Key message:</p><list list-type="bullet"><list-item><p>The use of MRAs in HD patients is recommended, given their good antihypertensive effect and their capacity to reduce CV and overall morbidity and mortality (Class I/Level A). For PD patients, the number of studies and the evidence are weak (Class IIB/Level B).</p></list-item></list></sec><sec><title>Other Classes of Antihypertensives</title><sec><title>Centrally acting sympatholytics</title><p>There are no studies involving methyldopa, and a systematic review with meta-analysis concluded that there is no evidence to support the chronic use of clonidine in HD. In addition, its use is associated with a significant side effect profile<sup>
<xref rid="B257" ref-type="bibr">257</xref>
</sup>.</p></sec><sec><title>Direct-acting vasodilators</title><p>There have been no studies of direct-acting vasodilators such as hydralazine and minoxidil in the dialysis population. Hydralazine has been used in association to isosorbide in HD patients with HF with reduced ejection fraction, but not as an antihypertensive agent<sup>
<xref rid="B258" ref-type="bibr">258</xref>,<xref rid="B259" ref-type="bibr">259</xref>
</sup>.</p><p>However, sympatholytics and direct vasodilator agents are used empirically in dialytic CKD, particularly in resistant and refractory HTN. A study conducted in 210 dialysis clinics in the United States found that in the first 6 months of dialysis, sympatholytics are used by 19% of patients, while vasodilators are used by 4% to 10%<sup>
<xref rid="B260" ref-type="bibr">260</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>It is recommended that centrally acting sympatholytics and direct vasodilators be used as the 5th or 6th antihypertensive medication in dialysis patients, or if there are contraindications to the other antihypertensive drugs (Class IIA/Level C).</p></list-item></list></sec></sec><sec><title>Renal and Hemodialysis Clearance of Antihypertensive Drugs</title><p>The need for dose adjustment or post-dialysis replacement of the prescribed antihypertensive medication is a recurring concern for nephrologists when monitoring HD patients. <xref rid="T8" ref-type="table">Chart 8</xref> shows a summary of antihypertensive drugs available in Brazil that are either renally cleared or more extensively dialyzable, and therefore may require adjustment. Antihypertensives not mentioned do not require adjustment or post-HD replacement<sup>
<xref rid="B261" ref-type="bibr">261</xref>
</sup>.</p><table-wrap position="float" id="T8"><label>Chart 8</label><caption><title>Main antihypertensive drugs available in Brazil. Dose adjustment in chronic kidney disease and rate of removal by dialysis<xref rid="T8FN2" ref-type="table-fn">*</xref>
</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Drug class and medications</th><th align="left" valign="top" rowspan="1" colspan="1">Drug adjustment in CKD</th><th align="left" valign="top" rowspan="1" colspan="1">Dialysis removal</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>ACE Inhibitors</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Captopril</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>GFR &#x0003c; 10 mL/min:</bold> administer 50% of the dose every 24 hours</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> administer an extra dose after HD<break/>
<bold>PD:</bold> insignificant removal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Enalapril</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>GFR &#x02264; 30 mL/min:</bold> 2.5 mg every 24 hours. Increase progressively according to BP</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> clearance rate 20% - 50%. Extra dose of 2.5 mg after HD<break/>
<bold>PD:</bold> adjust to 25% of the usual dose</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Benazepril</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>GFR &#x02264; 30 mL/min:</bold> 5 mg every 24h. Increase progressively according to BP</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> adjust the dose to 25% - 50% of the usual dose. No extra dose post-HD<break/>
<bold>PD:</bold> adjust the dose to 25% to 50% of the usual dose</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Lisinopril</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>GFR 10-30 mL/min:</bold> 2.5 mg - 5mg every 24 hours. Increase progressively according to BP<break/>
<bold>GFR &#x0003c; 10 mL/min:</bold> consider replacing with another medication (high risk of AE).</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> 50% clearance rate. The use of 10 mg after HD (3 times/week) is recommended, increasing the dose progressively according to BP<break/>
<bold>PD:</bold> 2.5 mg every 24 hours. Increase progressively according to BP</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Ramipril</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>GFR &#x02264;40 mL/min:</bold> 25% of the usual dose.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> insignificant removal<break/>
<bold>PD:</bold> insignificant removal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Perindopril</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>GFR &#x0003c;30 mL/min:</bold> not recommended</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> post-HD use, if so<break/>
<bold>PD:</bold> not recommended</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Beta-blockers</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Atenolol</bold>
<break/>
<bold>Bisoprolol</bold>
<break/>
<bold>Metoprolol</bold>
<break/>
<bold>Nadolol</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>GFR &#x0003e;30 mL/min:</bold> no need for dose adjustment<break/>
<bold>GFR 10-30mL/min:</bold> half ofdaily dose<break/>
<bold>GFR &#x0003c;10mL/min:</bold> &#x000bc; of daily dose</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> removal rate 25% to 50%. Use of dose after HD.<break/>
<bold>PD:</bold> insignificant removal. Use &#x000bc; of daily dose</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Propranolol</bold>
<break/>
<bold>Pindolol</bold>
<break/>
<bold>Carvedilol</bold>
<break/>
<bold>Nebivolol</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">No need for dose adjustment</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> insignificant removal<break/>
<bold>PD:</bold> insignificant removal</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>Sympatholytic drugs</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Alpha-methyldopa</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>GFR &#x0003c;10 mL/min:</bold> Administer every 12 to 24 hours</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> removal rate of up to 60%. Use one dose after HD.<break/>
<bold>PD:</bold> Administer every 12 to 24 hours.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Clonidine</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>GFR &#x0003c; 30 mL/min:</bold> start with a low dose and increase slowly according to BP and EA</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> insignificant removal<break/>
<bold>PD:</bold> insignificant removal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>ARB</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Angiotensin Receptors Blockers</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">No need for dose adjustment</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> insignificant removal<break/>
<bold>PD:</bold> insignificant removal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>CCB</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Calcium Channel Blockers</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">No need for dose adjustment</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> insignificant removal<break/>
<bold>PD:</bold> insignificant removal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Diuretics</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Loop Diuretics</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">No need for dose adjustment</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> insignificant removal<break/>
<bold>PD:</bold> insignificant removal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Alpha-blockers</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Alpha-blockers</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">No need for dose adjustment</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> insignificant removal<break/>
<bold>PD:</bold> insignificant removal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Vasodilators</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Direct Vasodilators</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">No need for dose adjustment</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> insignificant removal<break/>
<bold>PD:</bold> insignificant removal</td></tr></tbody></table><table-wrap-foot><fn id="T8FN1"><p>Abbreviations &#x02013; ACE: angiotensin-converting enzymes; GFR: glomerular filtration rate; CKD: chronic kidney disease; HD: hemodialysis; PD: peritoneal dialysis; AE: adverse effects; ARB: dos angiotensin receptors blockers; CCB: calcium channel blockers. Notes &#x02013;</p></fn><fn id="T8FN2"><p>*Chart adapted from reference<sup>
<xref rid="B261" ref-type="bibr">261</xref>
</sup>. Information for dose adjustment and removal during dialysis based on UpToDate 2021 recommendations for each drug listed.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Timing of Administration or Suspension of Predialysis Drug Dosing</title><p>Intradialytic hypotension is always a risk for HD patients, particularly if there is excessive IDWG or use of drugs that block defense mechanisms in the event of transient hypovolemia during HD (sympatholytics, BB, and ACE inhibitors/ARBs). It is therefore tempting to reduce the dose or refrain from administering some medication(s) on the day of HD or in the hours prior to it. There is a single cluster-randomized study, conducted in five centers that maintained antihypertensive medication (65 participants) and five centers that discontinued medication on the day of HD (n = 66)<sup>
<xref rid="B98" ref-type="bibr">98</xref>
</sup>. In both groups, the medication used in a single daily dose was maintained as a bedtime dose. The study revealed that there was no reduced risk of intradialytic hypotension nor was there a higher frequency of reaching the estimated dry weight in the group where medication was discontinued on the day of HD. However, there was a higher risk of pre-dialysis hypertension (SBP &#x0003e; 160 mmHg)<sup>
<xref rid="B98" ref-type="bibr">98</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>There is no evidence of benefits in suspending or reducing the dose of antihypertensive medication on the day of HD (Class III/Level B).</p></list-item></list></sec><sec><title>Combination Therapy</title><p>The classes of antihypertensive drugs with the most appropriate profile, considering the effect on BP, the reduction in CV complications, and safety, would be: BB, followed by CCBs and ACE inhibitors/ARBs, and finally MRA. However, this is not the reality in clinical practice. Most patients start their dialysis treatment using BB, ACE inhibitors/ARB, and CCB<sup>
<xref rid="B260" ref-type="bibr">260</xref>
</sup>. Thus, the most reasonable initial strategy should be to control hypervolemia, reaching the estimated DW, avoiding the combination of antihypertensives, and (re)introducing them according to the characteristics of each patient, in the order suggested above. Other antihypertensive drugs could be added, if necessary, only after euvolemia has been reached.</p></sec></sec><sec><title>Special Situations of Hypertension in Dialysis</title><sec><title>Hypertension in Pregnant Women on DP and HD</title><p>The prevalence of pregnancies in women on dialysis is estimated at 1% to 7%, being more frequent in HD patients than in those on PD<sup>
<xref rid="B262" ref-type="bibr">262</xref>,<xref rid="B263" ref-type="bibr">263</xref>
</sup>. Chronic hypertension in early pregnancy is an important factor for maternal complications, but it is not associated with neonatal complications (1/5 = 20.0% <italic>vs.</italic> 2/9 = 22.2%, with no chronic hypertension)<sup>
<xref rid="B262" ref-type="bibr">262</xref>,<xref rid="B263" ref-type="bibr">263</xref>
</sup>. Recently, an increase in the number of pregnancies in women with CKD has been observed, possibly due to improvements in HTN management and a reduction in complications such as polyhydramnios<sup>
<xref rid="B264" ref-type="bibr">264</xref>
</sup>.</p><p>The most common maternal complications in women with CKD, whether dialytic or not, during pregnancy are hypertensive disorders. Identifying the difference between preeclampsia and decompensation of CKD may be challenging. HTN in these patients can be related to fluid overload, and its management with UF could lead to target organ hypoperfusion, including the placenta<sup>
<xref rid="B262" ref-type="bibr">262</xref>
</sup>. There are no randomized clinical trials establishing the optimal BP for pregnant women with CKD on dialysis<sup>
<xref rid="B265" ref-type="bibr">265</xref>
</sup>. Available studies typically follow the HTN management recommendations from the major obstetric guidelines<sup>
<xref rid="B263" ref-type="bibr">263</xref>,<xref rid="B264" ref-type="bibr">264</xref>,<xref rid="B265" ref-type="bibr">265</xref>,<xref rid="B266" ref-type="bibr">266</xref>
</sup>. In addition, strict BP control is necessary, with a target pressure &#x0003c; 140/90 mmHg or a DBP &#x0003c; 85 mmHg, according to the CHIPS study<sup>
<xref rid="B267" ref-type="bibr">267</xref>
</sup>.</p><p>Pregnancy in dialysis patients shows better outcomes when dialysis time and dose are intensified, based on serum urea levels (below 50&#x02013;70 mg/dL)<sup>
<xref rid="B265" ref-type="bibr">265</xref>
</sup>. A systematic review highlighted a higher risk of pregnancy complications in women with CKD, including preeclampsia (odds ratio [OR] 10.4, 95% CI 6.3&#x02013;17.1), preterm birth (OR 5.7, 95% CI 3.3&#x02013;10.0), intrauterine growth restriction or low birth weight (OR 4.9, 95% CI 3.0&#x02013;7.8), caesarean sections (OR 2.7, 95% CI 2.0&#x02013;3.5), and pregnancy failures [including stillbirth and fetal and neonatal death] (OR 1.8, 95% CI 1.0&#x02013;3.1), compared to healthy women in the control group<sup>
<xref rid="B264" ref-type="bibr">264</xref>
</sup>.</p><p>The live birth rate on dialysis has improved significantly over the decades, from 25% in 1960 to over 75% currently. However, 53.4% of babies are still born prematurely, and 65% have a low birth weight, i.e. less than 2.5 kilos<sup>
<xref rid="B268" ref-type="bibr">268</xref>
</sup>. A review that analyzed 10 articles revealed that most pregnant women on HD follow therapeutic regimens ranging from 15 to 40 hours a week (in daily or four-times-a-week regimens), urea target below 60 mg/dL, and creatinine target of 6 mg/dL. The same review demonstrated that most patients use a dialysate flow rate of 500 mL/min, while blood flow and the type of dialyzer varied considerably<sup>
<xref rid="B269" ref-type="bibr">269</xref>
</sup>. Another systematic review identified an overall live birth rate of 82%, with a positive relationship between the number of hours on dialysis and better outcomes, including a reduced risk of preterm birth before 37 weeks of gestation and small-for-gestational-age newborns below the tenth percentile<sup>
<xref rid="B270" ref-type="bibr">270</xref>
</sup>.</p><p>Key messages:</p><list list-type="bullet"><list-item><p>HTN management in pregnant women on PD or HD should be conducted in accordance with the guidelines established for BP control in the general population.</p></list-item><list-item><p>Increased dialysis time and dose are related to better maternal and fetal outcomes (Class I/Level 2A).</p></list-item></list></sec><sec><title>Resistant (RHT) and Refractory Hypertension (RFHT) in Peritoneal Dialysis and Hemodialysis Patients</title><p>According to the main Guidelines, resistant hypertension (RHT) is characterized by a lack of BP control (usually BP &#x0003c; 140/90 mmHg) for more than 3 months, even with the use of three antihypertensive drugs, preferably a thiazide diuretic, a RAAS inhibitor, and a CCB, or the use of four BP-controlling drugs<sup>
<xref rid="B271" ref-type="bibr">271</xref>
</sup>. RfHT, in turn, occurs when BP remains outside the therapeutic target for more than 6 months, even with the use of five or more drugs, including a MRA (spironolactone) and a long-acting thiazide diuretic (chlorthalidone)<sup>
<xref rid="B272" ref-type="bibr">272</xref>,<xref rid="B273" ref-type="bibr">273</xref>
</sup>.</p><p>To diagnose these conditions, it is important to assess treatment adherence and confirm uncontrolled BP using ABPM or HBPM, according to the protocols discussed in Chapter 3.</p><p>Although the pathophysiological mechanism of RHT is directly related to volume overload, which is worsened in the presence of CKD 5D, clinical practice shows that many patients, upon initiating dialysis treatment, still have elevated BP values, despite adequate UF. Studies report a prevalence of RHT ranging from 18%<sup>
<xref rid="B274" ref-type="bibr">274</xref>
</sup> to 24%<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup>.</p><p>For better control of RHT and RfHT, it is important to ensure adequate volume control, achieving optimal DW, as well as individualized prescription of sodium in the dialysis fluid, appropriate dialysis length, and restriction of salt intake in the interdialytic period<sup>
<xref rid="B274" ref-type="bibr">274</xref>
</sup>.</p><p>Pharmacological treatment for patients undergoing dialysis with RHT or RfHT has some particularities. The use of diuretics is not recommended for patients without RRF, and pharmacological treatment follows the recommendations already described in Chapter 7. A non-randomized intervention study has highlighted the BP response to sacubitril/valsartan in these patients, albeit with a small sample size and short duration<sup>
<xref rid="B275" ref-type="bibr">275</xref>
</sup>.</p><p>The use of spironolactone has been shown to be poorly effective for BP control, but it has a positive effect on reducing overall mortality and the incidence of CV events<sup>
<xref rid="B276" ref-type="bibr">276</xref>
</sup>.</p><p>In more challenging cases of BP control in RHT or RfHT patients, once the options of other antihypertensive classes have been exhausted, direct vasodilators such as hydralazine or minoxidil may be considered as therapeutic options<sup>
<xref rid="B277" ref-type="bibr">277</xref>
</sup>. Furthermore, the use of renal denervation in RHT on dialysis has been proposed, although this approach remains a matter of debate. Recent studies, such as RCTs, have shown a favorable short- and long-term BP response in patients undergoing this intervention<sup>
<xref rid="B278" ref-type="bibr">278</xref>,<xref rid="B279" ref-type="bibr">279</xref>
</sup>. The pharmacological treatment follows the recommendations established in Chapter 7.</p><p>Key messages:</p><list list-type="bullet"><list-item><p>It is recommended that, for the diagnosis of true RHT and RfHT, adherence to treatment should be checked and confirmed, preferably by ABPM or HBPM (Class I/Level A).</p></list-item><list-item><p>Renal denervation may be a therapeutic option in selected patients (Class 2B/Level C).</p></list-item></list></sec><sec><title>Systolic Hypertension in the Elderly Undergoing Dialysis</title><p>Isolated systolic arterial hypertension (SHTN) is highly prevalent in elderly patients due to the impaired elasticity of the thoracic great vessels. Conversely, it is known that SHTN, with or without elevated diastolic levels, assessed during the interdialytic period by ABPM or HBPM, is diagnosed in more than 70% of CKD 5D patients<sup>
<xref rid="B280" ref-type="bibr">280</xref>
</sup>. Thus, elderly patients initiating dialysis treatment, like all other subpopulations, may experience accelerated vascular damage, characteristic of CKD 5D patients<sup>
<xref rid="B281" ref-type="bibr">281</xref>
</sup>.</p><p>Elderly patients on dialysis may present with SHTN, even after reaching their DW. In such cases, it is necessary to consider the possibility that increases in systolic levels are the result of central vascular stiffness<sup>
<xref rid="B274" ref-type="bibr">274</xref>
</sup>. The so-called pseudo hypertension should be included in the differential diagnosis of these patients<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup>. It is not uncommon to prescribe gradual fluid removal through UF to normalize BP in these conditions. However, it is important to consider that elderly individuals with pseudo hypertension may develop intravascular hypovolemia with severe CV consequences. Additionally, it is important to consider that elderly hypertensive patients on dialysis may also have secondary hypertension (see item 8.5) and other HTN phenotypes, such as WCH and MH (see item 3.4.3), and that clinical investigations should be conducted as minimally invasively as possible.</p><p>The lack of RCTs on the harmful effects of SHTN in dialysis patients leads to all recommendations being based on expert opinions. The situation becomes more complex when it comes to suggestions for the elderly undergoing dialysis therapy.</p></sec><sec><title>Arterial Hypertension in Hemodialysis Associated with High-Flow Arteriovenous Fistula</title><p>The hemodynamic effects of the creation of an arteriovenous fistula (AVF)<sup>
<xref rid="B282" ref-type="bibr">282</xref>
</sup> have been studied in patients requiring HD. Before creating an AVF, it is crucial to perform a comprehensive cardiac function assessment, with an emphasis on the RV, complemented by information on the LV. Together, a detailed CV evaluation, electrocardiogram and transthoracic echocardiogram enable cardiac functions and structures to be assessed prior to AVF. Furthermore, it is essential to perform a thorough assessment to establish the optimal diameter of the arteriovenous anastomosis, ensuring that the consequent flow reduction manages to lower BP, with benefits outweighing the risk of volume overload and increased pressure on the RV.</p><p>Significant hemodynamic changes occur due to the redistribution of fluids from the high-pressure, low-capacitance arterial system to a low-pressure, high-capacitance system, resulting in reduced peripheral resistance, an increased RV preload and LV afterload<sup>
<xref rid="B283" ref-type="bibr">283</xref>
</sup>. Clinical studies have shown that SBP and DBP decrease in the short and long term after the creation of an AVF, but increase following its ligation<sup>
<xref rid="B284" ref-type="bibr">284</xref>,<xref rid="B285" ref-type="bibr">285</xref>,<xref rid="B286" ref-type="bibr">286</xref>
</sup>. Scholz et al.<sup>
<xref rid="B283" ref-type="bibr">283</xref>
</sup>, in a meta-analysis, confirmed these findings.</p><p>It is essential to assess the hemodynamic and cardiac effects of an AVF and its possible complications, such as right heart failure caused by increased venous return, RV overload, and LV remodeling. Additionally, side effects such as venous stenosis, increased pulmonary BP, and right ventricular dysfunction may occur due to the increased venous flow<sup>
<xref rid="B284" ref-type="bibr">284</xref>,<xref rid="B285" ref-type="bibr">285</xref>,<xref rid="B286" ref-type="bibr">286</xref>
</sup>. These alterations may lead to the need for AVF closure in symptomatic patients<sup>
<xref rid="B287" ref-type="bibr">287</xref>
</sup>. It is crucial to consider the long-term effects of this artificially increased volume load on the right heart. Reddy et al.<sup>
<xref rid="B288" ref-type="bibr">288</xref>
</sup> have demonstrated that the creation of an AVF resulted in significant right heart dilatation and deterioration in right ventricular function, consequently leading to heart failure in over 40% of patients. Conversely, the creation of an AVF may lead to a modest reduction in the left ventricular size and mass, as well as slowing CKD progression in some cases<sup>
<xref rid="B288" ref-type="bibr">288</xref>
</sup>.</p></sec><sec><title>Secondary Hypertension in Dialysis</title><p>Dialysis patients who meet the established criteria for RHT/RfHT (see item 8.2) are candidates to be assessed for possible underlying causes, in addition to the CKD condition itself, which could alone justify the difficulty in BP management<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup>. Patients with secondary endocrine or non-endocrine causes are rarely identified, and the use of medications that may lead to uncontrolled BP - such as nonsteroidal anti-inflammatory drugs, recombinant human erythropoietin, and corticosteroids - should be particularly noted<sup>
<xref rid="B84" ref-type="bibr">84</xref>
</sup>. Another non-endocrine cause highly prevalent among chronic kidney disease patients, including over 50% of those on HD and PD, is OSA, which should be recognized and treated<sup>
<xref rid="B78" ref-type="bibr">78</xref>,<xref rid="B289" ref-type="bibr">289</xref>,<xref rid="B290" ref-type="bibr">290</xref>
</sup>. All possible etiologies should be considered and investigated in clinically and laboratory-selected patients, after achieving the appropriate dry weight.</p></sec><sec><title>Complications of HTN in Dialysis Patients</title><p>The complications of HTN in dialysis patients are eminently CV and fall within the spectrum of target organ damage due to HTN in patients with normal renal function (<xref rid="T9" ref-type="table">Chart 9</xref>). However, due to multiple other CV injury mechanisms in CKD, such as systemic inflammation, endothelial dysfunction, arterial calcification, hyperparathyroidism, anemia, salt overload, and the presence of AVF, it is difficult to demonstrate an independent relationship between HTN and CV complications in dialytic CKD. There are very few studies reporting improvement in these complications with the treatment of HTN, which is a limiting factor for conclusions.</p><table-wrap position="float" id="T9"><label>Chart 9</label><caption><title>Cardiovascular complications of arterial hypertension in dialysis chronic kidney disease</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Left ventricular hypertrophy</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Heart failure</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Coronary heart disease</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sudden cardiac death</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Atrial fibrillation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stroke</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peripheral arterial obstructive disease (including carotid territory)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aortic aneurysms (thoracic, abdominal)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Occlusion of the central retinal artery or central retinal vein</td></tr></tbody></table></table-wrap><p>The most important association is that with clinically manifest CV outcomes such as HF, CAD, sudden cardiac death, and stroke. The relationship between HTN and CV events in dialytic CKD is complex. Studies indicate a U-shaped association between the BP obtained in the dialysis unit and CV events, both coronary and cerebral<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>, as well as with ambulatory BP measurements in PD<sup>
<xref rid="B291" ref-type="bibr">291</xref>
</sup>. Events occur at the highest rates in patients with pre-dialysis SBP below 110&#x02013;120 mmHg. The lowest incidence of events is seen at SBP values between 140&#x02013;160 mmHg, and there is a slight but significant increase above these levels. There are two possible explanations, supported by evidence, for this paradox. One explanation refers to the method of BP measurement, particularly that measured outside the dialysis unit, as some studies suggest that the use of ABPM instead of peridialytic BP converts the U-shaped relationship into a linear one, more similar to what is observed in hypertensive patients with no kidney disease<sup>
<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B5" ref-type="bibr">5</xref>
</sup>,<sup>
<xref rid="B99" ref-type="bibr">99</xref>,<xref rid="B292" ref-type="bibr">292</xref>,<xref rid="B293" ref-type="bibr">293</xref>
</sup>. Similarly, in PD, the absence of a linear relationship between BP and CV outcomes becomes positive when based on SBP values obtained with ABPM<sup>
<xref rid="B294" ref-type="bibr">294</xref>
</sup>. The other explanation is related to the coexistence of cardiac dysfunction in patients with lower BP. A study showed that in patients assessed by ABPM, an analysis excluding patients with HF or AF transformed a U-shaped relationship into a positive linear relationship between BP and outcomes<sup>
<xref rid="B295" ref-type="bibr">295</xref>
</sup>.</p><p>LVH is a common complication of HTN that often precedes the onset of HF and predisposes to arrhythmias that lead to sudden cardiac death. Despite the presence of various other factors in the genesis of LVH in dialysis, HTN is an independent causal factor in several studies<sup>
<xref rid="B296" ref-type="bibr">296</xref>
</sup>. A recent study showed that LVH in HD patients progressively increased with a pre-dialysis SBP rise (1.9&#x000d7; between 131&#x02013;139 mmHg, 7.7&#x000d7; between 140&#x02013;149 mmHg, and 12.9&#x000d7; if &#x0003e; 150 mmHg)<sup>
<xref rid="B297" ref-type="bibr">297</xref>
</sup>. Unfortunately, it is not clear whether lowering BP results in improved LVH in dialysis patients. In the BID (BP in Dialysis) study, there were no differences in LV mass between patients randomized to intensive BP control (SBP 115&#x02013;140 mmHg) <italic>vs.</italic> the control group (SBP 155&#x02013;165 mmHg) after one year of follow-up<sup>
<xref rid="B178" ref-type="bibr">178</xref>
</sup>. Conversely, salt restriction and prolonged dialysis, two interventions that result in better BP control, provide regression of LVH in dialysis patients<sup>
<xref rid="B298" ref-type="bibr">298</xref>
</sup>. ARBs and ACE inhibitors lead to LVH regression in HD and PD patients<sup>
<xref rid="B299" ref-type="bibr">299</xref>
</sup>, which is not the case with aldosterone receptor blockers<sup>
<xref rid="B300" ref-type="bibr">300</xref>
</sup>. It is not defined whether this effect is mediated by BP reduction or by other mechanisms.</p><p>Atrial Fibrillation (AF) has an average prevalence of 11.6% and an average annual incidence of 2.7% in dialytic CKD<sup>
<xref rid="B301" ref-type="bibr">301</xref>
</sup>. While the relationship between HTN and AF is strong in patients without CKD, this association in dialysis is not consistent across publications. Among the largest studies evaluating the issue, there was an approximately 22% increase in the risk of chronic AF in hypertensive patients in a USRDS study<sup>
<xref rid="B302" ref-type="bibr">302</xref>
</sup>, while two studies from other databases (Medicare/Medicaid and DOPPS)<sup>
<xref rid="B303" ref-type="bibr">303</xref>,<xref rid="B304" ref-type="bibr">304</xref>
</sup> demonstrated a decreased risk of AF in the presence of HTN, both in a binary manner (21% reduction)<sup>
<xref rid="B304" ref-type="bibr">304</xref>
</sup> and linearly (6% reduction for every 10 mmHg increase in pre-HD SBP)<sup>
<xref rid="B303" ref-type="bibr">303</xref>
</sup>. There are no studies analyzing the impact of HTN treatment on the incidence of AF in dialysis patients.</p><p>PAD is common in patients with CKD. The relationship between HTN and PAD in dialysis patients is inconsistent. In the CRIC study, HTN was not a risk factor for PAD<sup>
<xref rid="B305" ref-type="bibr">305</xref>
</sup>. On the other hand, the DOPPS study showed a significant relationship between HTN and the prevalence of PAD in HD patients<sup>
<xref rid="B306" ref-type="bibr">306</xref>
</sup>. There is no evidence that the treatment of HTN has any impact on the onset or regression of PAD in CKD. By extrapolation, it makes sense for patients with aortic aneurysms to be managed with impulse control (reduction in both BP and HR).</p><p>Retinal vein occlusion (central artery, central vein) is a complication associated with several risk factors, including HTN. Central retinal artery occlusion is 4.5-fold more frequent in dialytic CKD than in patients with normal renal function. Similarly, central retinal vein occlusion, a more common entity than central artery occlusion, occurs 2.6 times more frequently in dialysis patients<sup>
<xref rid="B307" ref-type="bibr">307</xref>
</sup>. In retrospective studies with multivariate analysis, HTN is independently associated with both complications<sup>
<xref rid="B308" ref-type="bibr">308</xref>,<xref rid="B309" ref-type="bibr">309</xref>
</sup>.</p><p>Key message:</p><list list-type="bullet"><list-item><p>To reduce the risk of CV complications in hypertensive dialysis patients, it is recommended to avoid pre-dialysis SBP &#x0003c; 120 or &#x0003e; 160 mmHg (Class IIA/Level B).</p></list-item></list></sec></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The diagnosis and management of HTN in dialytic CKD are even more complex than for the general population. Different pathophysiological determinants are involved in CKD 5D hypertension, with sodium and volume overload playing a major role. Technologies for this analysis must prove to be both safe and feasible.</p><p>There is greater variability in the circadian rhythm of BP, and 44-hour ABPM appears to provide the most accurate diagnostic and prognostic information. However, HBPM is better tolerated and may be a useful substitute in resource-limited settings. RCTs should be conducted in the long-term using these diagnostic and follow-up tools to determine their importance and significance in outcomes.</p><p>Both intradialytic and off-dialysis hyper- and hypotension are harmful and should be avoided.</p><p>Non-pharmacological interventions, such as dietary sodium restriction, prolonged dialysis vintage, and changing dialysis prescription to improve sodium diffusion, may help in the management of HTN, and have an impact on symptoms, quality of life, and CV complications.</p><p>When dry weight is achieved and it is not sufficient for HTN control, antihypertensive pharmacotherapy is recommended. Although meta-analyses reveal a survival benefit from therapy, no study has fully demonstrated the benefit of one class of antihypertensive drugs over another. Large head-to-head comparative RCTs are needed to elucidate the optimal pharmacological treatment for HTN in dialysis, a gap to be filled by researchers worldwide.</p><p>Treatment and BP targets should be individualized, considering best practices, cost/benefit, dialysis medication clearance, age, frailty, vulnerability, comorbidities, polypharmacy, as well as the patient&#x02019;s priorities and preferences.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ABPM:</term><def><p>ambulatory blood pressure monitoring</p></def></def-item><def-item><term>ACEI:</term><def><p>angiotensin-converting enzyme inhibitors</p></def></def-item><def-item><term>ADMA:</term><def><p>asymmetric dimethylarginine</p></def></def-item><def-item><term>AF:</term><def><p>atrial fibrillation</p></def></def-item><def-item><term>AMI:</term><def><p>acute myocardial infarction</p></def></def-item><def-item><term>ARBs:</term><def><p>angiotensin II receptor blockers</p></def></def-item><def-item><term>AS:</term><def><p>arterial stiffness</p></def></def-item><def-item><term>BB:</term><def><p>beta-blockers</p></def></def-item><def-item><term>BIA:</term><def><p>Bioimpedance analysis</p></def></def-item><def-item><term>BMI:</term><def><p>body mass index</p></def></def-item><def-item><term>BNP:</term><def><p>B-type natriuretic peptide</p></def></def-item><def-item><term>BP:</term><def><p>blood pressure</p></def></def-item><def-item><term>BSN:</term><def><p>Brazilian Society of Nephrology</p></def></def-item><def-item><term>CAD:</term><def><p>coronary artery disease</p></def></def-item><def-item><term>CAP:</term><def><p>central arterial pressure</p></def></def-item><def-item><term>CCB:</term><def><p>calcium channel blockers</p></def></def-item><def-item><term>CH:</term><def><p>controlled hypertension</p></def></def-item><def-item><term>CKD:</term><def><p>chronic kidney disease</p></def></def-item><def-item><term>CKD 5D:</term><def><p>chronic kidney disease with dialysis patient</p></def></def-item><def-item><term>CNS:</term><def><p>central nervous system</p></def></def-item><def-item><term>CO:</term><def><p>cardiac output</p></def></def-item><def-item><term>CV:</term><def><p>cardiovascular</p></def></def-item><def-item><term>CVA:</term><def><p>cerebrovascular accident</p></def></def-item><def-item><term>CVD:</term><def><p>cardiovascular disease</p></def></def-item><def-item><term>DBP:</term><def><p>diastolic blood pressure</p></def></def-item><def-item><term>DM:</term><def><p>
<italic>diabetes mellitus</italic>
</p></def></def-item><def-item><term>DW:</term><def><p>dry weight</p></def></def-item><def-item><term>ED:</term><def><p>endothelial dysfunction</p></def></def-item><def-item><term>EPO:</term><def><p>human recombinant erythropoietin</p></def></def-item><def-item><term>ET1:</term><def><p>endothelin</p></def></def-item><def-item><term>GFR:</term><def><p>glomerular filtration rate</p></def></def-item><def-item><term>HBPM:</term><def><p>home blood pressure monitoring</p></def></def-item><def-item><term>HD:</term><def><p>hemodialysis</p></def></def-item><def-item><term>HDF:</term><def><p>high-volume online hemodiafiltration</p></def></def-item><def-item><term>HF:</term><def><p>heart failure</p></def></def-item><def-item><term>HTN:</term><def><p>hypertension</p></def></def-item><def-item><term>IDH:</term><def><p>intradialytic hypertension</p></def></def-item><def-item><term>IDWG:</term><def><p>interdialytic weight gain</p></def></def-item><def-item><term>KDIGO:</term><def><p>KIDNEY DISEASES IMPROVING GLOBAL OUTCOMES</p></def></def-item><def-item><term>LV:</term><def><p>left ventricle</p></def></def-item><def-item><term>LVH:</term><def><p>left ventricular hypertrophy</p></def></def-item><def-item><term>MH:</term><def><p>masked hypertension</p></def></def-item><def-item><term>MRA:</term><def><p>mineralocorticoid receptor antagonists</p></def></def-item><def-item><term>MUH:</term><def><p>masked uncontrolled hypertension</p></def></def-item><def-item><term>NH:</term><def><p>nocturnal hypertension</p></def></def-item><def-item><term>NO:</term><def><p>nitric oxide</p></def></def-item><def-item><term>NT-proBNP:</term><def><p>N-terminal pro-B-type natriuretic peptide</p></def></def-item><def-item><term>OSA:</term><def><p>obstructive sleep apnea syndrome</p></def></def-item><def-item><term>PD:</term><def><p>peritoneal dialysis</p></def></def-item><def-item><term>POAD:</term><def><p>peripheral obstructive artery disease</p></def></def-item><def-item><term>PP:</term><def><p>pulse pressure</p></def></def-item><def-item><term>PRA:</term><def><p>plasma renin activity</p></def></def-item><def-item><term>RAAS:</term><def><p>renin-angiotensin-aldosterone system</p></def></def-item><def-item><term>RCT:</term><def><p>randomized controlled trials</p></def></def-item><def-item><term>RRF:</term><def><p>residual renal function</p></def></def-item><def-item><term>RRT:</term><def><p>renal replacement therapy</p></def></def-item><def-item><term>RV:</term><def><p>right ventricle</p></def></def-item><def-item><term>SBP:</term><def><p>systolic blood pressure</p></def></def-item><def-item><term>SH:</term><def><p>sustained hypertension</p></def></def-item><def-item><term>SHTN:</term><def><p>systolic hypertension</p></def></def-item><def-item><term>SMBP:</term><def><p>self-measured blood pressure</p></def></def-item><def-item><term>SNS:</term><def><p>sympathetic nervous system</p></def></def-item><def-item><term>SUH:</term><def><p>sustained uncontrolled hypertension</p></def></def-item><def-item><term>SVR:</term><def><p>systemic vascular resistance</p></def></def-item><def-item><term>TI:</term><def><p>therapeutic inertia</p></def></def-item><def-item><term>TN:</term><def><p>true normotension</p></def></def-item><def-item><term>UF:</term><def><p>ultrafiltration</p></def></def-item><def-item><term>WCH:</term><def><p>white coat hypertension</p></def></def-item><def-item><term>WCUH:</term><def><p>white coat uncontrolled hypertension</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="B1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Sociedade Brasileira de Cardiologia</collab>
</person-group><source>Classes de recomenda&#x000e7;&#x000e3;o e n&#x000ed;veis de evid&#x000ea;ncia. Recomenda&#x000e7;&#x000f5;es para a elabora&#x000e7;&#x000e3;o de diretrizes, posicionamentos e atualiza&#x000e7;&#x000f5;es</source><publisher-loc>S&#x000e3;o Paulo</publisher-loc><publisher-name>Sociedade Brasileira de Cardiologia</publisher-name><year>2019</year><date-in-citation content-type="access-date">[cited 2024 Aug 6]</date-in-citation><comment>Available from: <ext-link xlink:href="http://publicacoes.cardiol.br/2014/diretrizes/pdf/Recomendacoes-para-Elaboracao-de-Diretrizes-SBC-2019-PDF.pdf" ext-link-type="uri">http://publicacoes.cardiol.br/2014/diretrizes/pdf/Recomendacoes-para-Elaboracao-de-Diretrizes-SBC-2019-PDF.pdf</ext-link>.</comment></element-citation></ref><ref id="B2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nerbass</surname><given-names>FB</given-names></name>
<name><surname>Lima</surname><given-names>HDN</given-names></name>
<name><surname>Moura</surname><given-names>JA</given-names><suffix>Neto</suffix></name>
<name><surname>Lugon</surname><given-names>JR</given-names></name>
<name><surname>Sesso</surname><given-names>R</given-names></name>
</person-group><article-title>Brazilian Dialysis Survey 2022</article-title><source>J Bras Nefrol</source><year>2024</year><comment>04-06</comment><volume>46</volume><issue>2</issue><fpage>e20230062</fpage><pub-id pub-id-type="doi">10.1590/2175-8239-JBN-2023-0062en</pub-id><!--<pub-id pub-id-type="pmcid">PMC11210532</pub-id>--><pub-id pub-id-type="pmid">38078834</pub-id>
</element-citation></ref><ref id="B3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bansal</surname><given-names>N</given-names></name>
<name><surname>Artinian</surname><given-names>NT</given-names></name>
<name><surname>Bakris</surname><given-names>G</given-names></name>
<name><surname>Chang</surname><given-names>T</given-names></name>
<name><surname>Cohen</surname><given-names>J</given-names></name>
<name><surname>Flythe</surname><given-names>J</given-names></name>
<etal/>
</person-group><article-title>Hypertension in patients treated with in-center maintenance hemodialysis: current evidence and future opportunities: a scientific statement from the American Heart Association</article-title><source>Hypertension</source><year>2023</year><volume>80</volume><issue>6</issue><fpage>e112</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1161/HYP.0000000000000230</pub-id><pub-id pub-id-type="pmid">37092336</pub-id>
</element-citation></ref><ref id="B4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barroso</surname><given-names>WKS</given-names></name>
<name><surname>Rodrigues</surname><given-names>CIS</given-names></name>
<name><surname>Bortolotto</surname><given-names>LA</given-names></name>
<name><surname>Mota-Gomes</surname><given-names>MA</given-names></name>
<name><surname>Brandao</surname><given-names>AA</given-names></name>
<name><surname>Feitosa</surname><given-names>ADM</given-names></name>
<etal/>
</person-group><article-title>Brazilian Guidelines of Hypertension - 2020</article-title><source>Arq Bras Cardiol</source><year>2021</year><volume>116</volume><issue>3</issue><fpage>516</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.36660/abc.20201238</pub-id><pub-id pub-id-type="pmid">33909761</pub-id>
</element-citation></ref><ref id="B5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarafidis</surname><given-names>PA</given-names></name>
<name><surname>Persu</surname><given-names>A</given-names></name>
<name><surname>Agarwal</surname><given-names>R</given-names></name>
<name><surname>Burnier</surname><given-names>M</given-names></name>
<name><surname>de Leeuw</surname><given-names>P</given-names></name>
<name><surname>Ferro</surname><given-names>CJ</given-names></name>
<etal/>
</person-group><article-title>Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)</article-title><source>Nephrol Dial Transplant</source><year>2017</year><volume>32</volume><issue>4</issue><fpage>620</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfw433</pub-id><pub-id pub-id-type="pmid">28340239</pub-id>
</element-citation></ref><ref id="B6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mallamaci</surname><given-names>F</given-names></name>
<name><surname>Torino</surname><given-names>C</given-names></name>
<name><surname>Sarafidis</surname><given-names>P</given-names></name>
<name><surname>Ekart</surname><given-names>R</given-names></name>
<name><surname>Loutradis</surname><given-names>C</given-names></name>
<name><surname>Siamopoulos</surname><given-names>K</given-names></name>
<etal/>
</person-group><article-title>Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study</article-title><source>J Hypertens</source><year>2020</year><volume>38</volume><issue>9</issue><fpage>1849</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000002448</pub-id><pub-id pub-id-type="pmid">32649620</pub-id>
</element-citation></ref><ref id="B7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Georgianos</surname><given-names>PI</given-names></name>
<name><surname>Sarafidis</surname><given-names>PA</given-names></name>
<name><surname>Zoccali</surname><given-names>C</given-names></name>
</person-group><article-title>Intradialysis hypertension in end-stage renal disease patients: clinical epidemiology, pathogenesis, and treatment</article-title><source>Hypertension</source><year>2015</year><volume>66</volume><issue>3</issue><fpage>456</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.115.05858</pub-id><pub-id pub-id-type="pmid">26150436</pub-id>
</element-citation></ref><ref id="B8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foley</surname><given-names>RN</given-names></name>
<name><surname>Herzog</surname><given-names>CA</given-names></name>
<name><surname>Collins</surname><given-names>AJ</given-names></name>
</person-group><article-title>United States Renal Data System. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study</article-title><source>Kidney Int</source><year>2002</year><volume>62</volume><issue>5</issue><fpage>1784</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2002.00636.x</pub-id><pub-id pub-id-type="pmid">12371980</pub-id>
</element-citation></ref><ref id="B9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Flythe</surname><given-names>JE</given-names></name>
<name><surname>Chang</surname><given-names>TI</given-names></name>
<name><surname>Gallagher</surname><given-names>MP</given-names></name>
<name><surname>Lindley</surname><given-names>E</given-names></name>
<name><surname>Madero</surname><given-names>M</given-names></name>
<name><surname>Sarafidis</surname><given-names>PA</given-names></name>
<etal/>
</person-group><article-title>Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference</article-title><source>Kidney Int</source><year>2020</year><volume>97</volume><issue>5</issue><fpage>861</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2020.01.046</pub-id><pub-id pub-id-type="pmid">32278617</pub-id>
</element-citation></ref><ref id="B10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>Kidney Disease Outcomes Quality Initiative (K/DOQI)</collab>
</person-group><article-title>K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease</article-title><source>Am J Kidney Dis</source><year>2004</year><volume>43</volume><issue>5, Suppl 1</issue><fpage>S1</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">15114537</pub-id>
</element-citation></ref><ref id="B11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chazot</surname><given-names>C</given-names></name>
<name><surname>Charra</surname><given-names>B</given-names></name>
<name><surname>Laurent</surname><given-names>G</given-names></name>
<name><surname>Didier</surname><given-names>C</given-names></name>
<name><surname>Vo Van</surname><given-names>C</given-names></name>
<name><surname>Terrat</surname><given-names>JC</given-names></name>
<etal/>
</person-group><article-title>Interdialysis blood pressure control by long haemodialysis sessions</article-title><source>Nephrol Dial Transplant</source><year>1995</year><volume>10</volume><issue>6</issue><fpage>831</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7566612</pub-id>
</element-citation></ref><ref id="B12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Charra</surname><given-names>B</given-names></name>
<name><surname>Bergstrom</surname><given-names>J</given-names></name>
<name><surname>Scribner</surname><given-names>BH</given-names></name>
</person-group><article-title>Blood pressure control in dialysis patients: importance of the lag phenomenon</article-title><source>Am J Kidney Dis</source><year>1998</year><volume>32</volume><issue>5</issue><fpage>720</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/S0272-6386(98)70147-7</pub-id><pub-id pub-id-type="pmid">9820439</pub-id>
</element-citation></ref><ref id="B13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ozkahya</surname><given-names>M</given-names></name>
<name><surname>Ok</surname><given-names>E</given-names></name>
<name><surname>Toz</surname><given-names>H</given-names></name>
<name><surname>Asci</surname><given-names>G</given-names></name>
<name><surname>Duman</surname><given-names>S</given-names></name>
<name><surname>Basci</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Long-term survival rates in haemodialysis patients treated with strict volume control</article-title><source>Nephrol Dial Transplant</source><year>2006</year><volume>21</volume><issue>12</issue><fpage>3506</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfl487</pub-id><pub-id pub-id-type="pmid">17000733</pub-id>
</element-citation></ref><ref id="B14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>R.</given-names></name>
</person-group><article-title>Volume-associated ambulatory blood pressure patterns in hemodialysis patients</article-title><source>Hypertension</source><year>2009</year><volume>54</volume><issue>2</issue><fpage>241</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.109.136366</pub-id><pub-id pub-id-type="pmid">19528362</pub-id>
</element-citation></ref><ref id="B15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Biesen</surname><given-names>W</given-names></name>
<name><surname>Williams</surname><given-names>JD</given-names></name>
<name><surname>Covic</surname><given-names>AC</given-names></name>
<name><surname>Fan</surname><given-names>S</given-names></name>
<name><surname>Claes</surname><given-names>K</given-names></name>
<name><surname>Lichodziejewska-Niemierko</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Fluid status in peritoneal dialysis patients: the European Body Composition Monitoring (EuroBCM) study cohort</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>2</issue><fpage>e17148</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0017148</pub-id><pub-id pub-id-type="pmid">21390320</pub-id>
</element-citation></ref><ref id="B16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Castro</surname><given-names>JR</given-names><suffix>Jr</suffix></name>
<name><surname>Fernandes</surname><given-names>N</given-names></name>
<name><surname>Lacet</surname><given-names>TB</given-names></name>
<name><surname>Maia</surname><given-names>FS</given-names></name>
<name><surname>Bonato</surname><given-names>GR</given-names></name>
<name><surname>Nogueira</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Total body water reduction in subjects with chronic kidney disease on peritoneal dialysis is associated with a better hypertension control</article-title><source>J Bras Nefrol</source><year>2014</year><volume>36</volume><issue>4</issue><fpage>482</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.5935/0101-2800.20140069</pub-id><pub-id pub-id-type="pmid">25517277</pub-id>
</element-citation></ref><ref id="B17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Titze</surname><given-names>J</given-names></name>
<name><surname>Shakibaei</surname><given-names>M</given-names></name>
<name><surname>Schafflhuber</surname><given-names>M</given-names></name>
<name><surname>Schulze-Tanzil</surname><given-names>G</given-names></name>
<name><surname>Porst</surname><given-names>M</given-names></name>
<name><surname>Schwind</surname><given-names>KH</given-names></name>
<etal/>
</person-group><article-title>Glycosaminoglycan polymerization may enable osmotically inactive Na+ storage in the skin</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2004</year><volume>287</volume><issue>1</issue><fpage>H203</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.01237.2003</pub-id><pub-id pub-id-type="pmid">14975935</pub-id>
</element-citation></ref><ref id="B18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Titze</surname><given-names>J.</given-names></name>
</person-group><article-title>Sodium balance is not just a renal affair</article-title><source>Curr Opin Nephrol Hypertens</source><year>2014</year><volume>23</volume><issue>2</issue><fpage>101</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1097/01.mnh.0000441151.55320.c3</pub-id><pub-id pub-id-type="pmid">24401786</pub-id>
</element-citation></ref><ref id="B19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Selvarajah</surname><given-names>V</given-names></name>
<name><surname>Connolly</surname><given-names>K</given-names></name>
<name><surname>McEniery</surname><given-names>C</given-names></name>
<name><surname>Wilkinson</surname><given-names>I.</given-names></name>
</person-group><article-title>Skin sodium and hypertension: a paradigm shift?</article-title><source>Curr Hypertens Rep</source><year>2018</year><volume>20</volume><issue>11</issue><fpage>94</fpage><pub-id pub-id-type="doi">10.1007/s11906-018-0892-9</pub-id><pub-id pub-id-type="pmid">30215153</pub-id>
</element-citation></ref><ref id="B20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dahlmann</surname><given-names>A</given-names></name>
<name><surname>Dorfelt</surname><given-names>K</given-names></name>
<name><surname>Eicher</surname><given-names>F</given-names></name>
<name><surname>Linz</surname><given-names>P</given-names></name>
<name><surname>Kopp</surname><given-names>C</given-names></name>
<name><surname>Mossinger</surname><given-names>I</given-names></name>
<etal/>
</person-group><article-title>Magnetic resonance-determined sodium removal from tissue stores in hemodialysis patients</article-title><source>Kidney Int</source><year>2015</year><volume>87</volume><issue>2</issue><fpage>434</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1038/ki.2014.269</pub-id><pub-id pub-id-type="pmid">25100048</pub-id>
</element-citation></ref><ref id="B21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salerno</surname><given-names>FR</given-names></name>
<name><surname>Akbari</surname><given-names>A</given-names></name>
<name><surname>Lemoine</surname><given-names>S</given-names></name>
<name><surname>Filler</surname><given-names>G</given-names></name>
<name><surname>Scholl</surname><given-names>TJ</given-names></name>
<name><surname>McIntyre</surname><given-names>CW</given-names></name>
</person-group><article-title>Outcomes and predictors of skin sodium concentration in dialysis patients</article-title><source>Clin Kidney J</source><year>2022</year><volume>15</volume><issue>6</issue><fpage>1129</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1093/ckj/sfac021</pub-id><pub-id pub-id-type="pmid">35664280</pub-id>
</element-citation></ref><ref id="B22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balafa</surname><given-names>O</given-names></name>
<name><surname>Kalaitzidis</surname><given-names>RG</given-names></name>
</person-group><article-title>Salt sensitivity and hypertension</article-title><source>J Hum Hypertens</source><year>2021</year><volume>35</volume><issue>3</issue><fpage>184-92</fpage><pub-id pub-id-type="doi">10.1038/s41371-020-00407-1</pub-id><pub-id pub-id-type="pmid">32862203</pub-id>
</element-citation></ref><ref id="B23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kopp</surname><given-names>C</given-names></name>
<name><surname>Linz</surname><given-names>P</given-names></name>
<name><surname>Maier</surname><given-names>C</given-names></name>
<name><surname>Wabel</surname><given-names>P</given-names></name>
<name><surname>Hammon</surname><given-names>M</given-names></name>
<name><surname>Nagel</surname><given-names>AM</given-names></name>
<etal/>
</person-group><article-title>Elevated tissue sodium deposition in patients with type 2 diabetes on hemodialysis detected by (23)Na magnetic resonance imaging</article-title><source>Kidney Int</source><year>2018</year><volume>93</volume><issue>5</issue><fpage>1191</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2017.11.021</pub-id><pub-id pub-id-type="pmid">29455909</pub-id>
</element-citation></ref><ref id="B24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schneider</surname><given-names>MP</given-names></name>
<name><surname>Raff</surname><given-names>U</given-names></name>
<name><surname>Kopp</surname><given-names>C</given-names></name>
<name><surname>Scheppach</surname><given-names>JB</given-names></name>
<name><surname>Toncar</surname><given-names>S</given-names></name>
<name><surname>Wanner</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD</article-title><source>J Am Soc Nephrol</source><year>2017</year><volume>28</volume><issue>6</issue><fpage>1867</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1681/ASN.2016060662</pub-id><pub-id pub-id-type="pmid">28154199</pub-id>
</element-citation></ref><ref id="B25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nongnuch</surname><given-names>A</given-names></name>
<name><surname>Campbell</surname><given-names>N</given-names></name>
<name><surname>Stern</surname><given-names>E</given-names></name>
<name><surname>El-Kateb</surname><given-names>S</given-names></name>
<name><surname>Fuentes</surname><given-names>L</given-names></name>
<name><surname>Davenport</surname><given-names>A</given-names></name>
</person-group><article-title>Increased postdialysis systolic blood pressure is associated with extracellular overhydration in hemodialysis outpatients</article-title><source>Kidney Int</source><year>2015</year><volume>87</volume><issue>2</issue><fpage>452</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/ki.2014.276</pub-id><pub-id pub-id-type="pmid">25075771</pub-id>
</element-citation></ref><ref id="B26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koutroumbas</surname><given-names>G</given-names></name>
<name><surname>Georgianos</surname><given-names>PI</given-names></name>
<name><surname>Sarafidis</surname><given-names>PA</given-names></name>
<name><surname>Protogerou</surname><given-names>A</given-names></name>
<name><surname>Karpetas</surname><given-names>A</given-names></name>
<name><surname>Vakianis</surname><given-names>P</given-names></name>
<etal/>
</person-group><article-title>Ambulatory aortic blood pressure, wave reflections and pulse wave velocity are elevated during the third in comparison to the second interdialytic day of the long interval in chronic haemodialysis patients</article-title><source>Nephrol Dial Transplant</source><year>2015</year><volume>30</volume><issue>12</issue><fpage>2046</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfv090</pub-id><pub-id pub-id-type="pmid">25920919</pub-id>
</element-citation></ref><ref id="B27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Basile</surname><given-names>C</given-names></name>
<name><surname>Pisano</surname><given-names>A</given-names></name>
<name><surname>Lisi</surname><given-names>P</given-names></name>
<name><surname>Rossi</surname><given-names>L</given-names></name>
<name><surname>Lomonte</surname><given-names>C</given-names></name>
<name><surname>Bolignano</surname><given-names>D</given-names></name>
</person-group><article-title>High versus low dialysate sodium concentration in chronic haemodialysis patients: a systematic review of 23 studies</article-title><source>Nephrol Dial Transplant</source><year>2016</year><volume>31</volume><issue>4</issue><fpage>548</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfv084</pub-id><pub-id pub-id-type="pmid">25843783</pub-id>
</element-citation></ref><ref id="B28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>MR</given-names></name>
<name><surname>Vandal</surname><given-names>AC</given-names></name>
<name><surname>de Zoysa</surname><given-names>JR</given-names></name>
<name><surname>Gabriel</surname><given-names>RS</given-names></name>
<name><surname>Haloob</surname><given-names>IA</given-names></name>
<name><surname>Hood</surname><given-names>CJ</given-names></name>
<etal/>
</person-group><article-title>Effect of low-sodium versus conventional sodium dialysate on left ventricular mass in home and self-care satellite facility hemodialysis patients: a randomized clinical trial</article-title><source>J Am Soc Nephrol</source><year>2020</year><volume>31</volume><issue>5</issue><fpage>1078</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1681/ASN.2019090877</pub-id><pub-id pub-id-type="pmid">32188697</pub-id>
</element-citation></ref><ref id="B29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dunlop</surname><given-names>JL</given-names></name>
<name><surname>Vandal</surname><given-names>AC</given-names></name>
<name><surname>Marshall</surname><given-names>MR</given-names></name>
</person-group><article-title>Low dialysate sodium levels for chronic haemodialysis</article-title><source>Cochrane Database Syst Rev</source><year>2019</year><volume>1</volume><issue>1</issue><fpage>CD011204</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD011204.pub2</pub-id><pub-id pub-id-type="pmid">30646428</pub-id>
</element-citation></ref><ref id="B30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Radhakrishnan</surname><given-names>RC</given-names></name>
<name><surname>Varughese</surname><given-names>S</given-names></name>
<name><surname>Chandran</surname><given-names>A</given-names></name>
<name><surname>Jacob</surname><given-names>S</given-names></name>
<name><surname>David</surname><given-names>VG</given-names></name>
<name><surname>Alexander</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Effects of individualized dialysate sodium prescription in hemodialysis - results from a prospective interventional trial</article-title><source>Indian J Nephrol</source><year>2020</year><volume>30</volume><issue>1</issue><fpage>3</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4103/ijn.IJN_391_18</pub-id><pub-id pub-id-type="pmid">32015592</pub-id>
</element-citation></ref><ref id="B31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geng</surname><given-names>X</given-names></name>
<name><surname>Song</surname><given-names>Y</given-names></name>
<name><surname>Hou</surname><given-names>B</given-names></name>
<name><surname>Ma</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
</person-group><article-title>The efficacy and safety of low dialysate sodium levels for patients with maintenance haemodialysis: A systematic review and meta-analysis</article-title><source>Int J Surg</source><year>2020</year><volume>79</volume><fpage>332</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2020.05.027</pub-id><pub-id pub-id-type="pmid">32447003</pub-id>
</element-citation></ref><ref id="B32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>SF</given-names></name>
<name><surname>Peixoto</surname><given-names>AJ</given-names></name>
</person-group><article-title>Sodium balance in maintenance hemodialysis</article-title><source>Semin Dial</source><year>2010</year><volume>23</volume><issue>6</issue><fpage>549</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/j.1525-139X.2010.00794.x</pub-id><pub-id pub-id-type="pmid">21175831</pub-id>
</element-citation></ref><ref id="B33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grekas</surname><given-names>D</given-names></name>
<name><surname>Bamichas</surname><given-names>G</given-names></name>
<name><surname>Bacharaki</surname><given-names>D</given-names></name>
<name><surname>Goutzaridis</surname><given-names>N</given-names></name>
<name><surname>Kasimatis</surname><given-names>E</given-names></name>
<name><surname>Tourkantonis</surname><given-names>A</given-names></name>
</person-group><article-title>Hypertension in chronic hemodialysis patients: current view on pathophysiology and treatment</article-title><source>Clin Nephrol</source><year>2000</year><volume>53</volume><issue>3</issue><fpage>164</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10749293</pub-id>
</element-citation></ref><ref id="B34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitsides</surname><given-names>N</given-names></name>
<name><surname>Pietribiasi</surname><given-names>M</given-names></name>
<name><surname>Waniewski</surname><given-names>J</given-names></name>
<name><surname>Brenchley</surname><given-names>P</given-names></name>
<name><surname>Mitra</surname><given-names>S</given-names></name>
</person-group><article-title>Transcapillary refilling rate and its determinants during haemodialysis with standard and high ultrafiltration rates</article-title><source>Am J Nephrol</source><year>2019</year><volume>50</volume><issue>2</issue><fpage>133</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1159/000501407</pub-id><pub-id pub-id-type="pmid">31288231</pub-id>
</element-citation></ref><ref id="B35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Flythe</surname><given-names>JE</given-names></name>
<name><surname>Kimmel</surname><given-names>SE</given-names></name>
<name><surname>Brunelli</surname><given-names>SM</given-names></name>
</person-group><article-title>Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality</article-title><source>Kidney Int</source><year>2011</year><volume>79</volume><issue>2</issue><fpage>250</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/ki.2010.383</pub-id><pub-id pub-id-type="pmid">20927040</pub-id>
</element-citation></ref><ref id="B36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>YJ</given-names></name>
<name><surname>Okuda</surname><given-names>Y</given-names></name>
<name><surname>Sy</surname><given-names>J</given-names></name>
<name><surname>Lee</surname><given-names>YK</given-names></name>
<name><surname>Obi</surname><given-names>Y</given-names></name>
<name><surname>Cho</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Ultrafiltration rate, residual kidney function, and survival among patients treated with reduced-frequency hemodialysis</article-title><source>Am J Kidney Dis</source><year>2020</year><volume>75</volume><issue>3</issue><fpage>342</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2019.08.019</pub-id><pub-id pub-id-type="pmid">31813665</pub-id>
</element-citation></ref><ref id="B37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Assimon</surname><given-names>MM</given-names></name>
<name><surname>Wenger</surname><given-names>JB</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Flythe</surname><given-names>JE</given-names></name>
</person-group><article-title>Ultrafiltration rate and mortality in maintenance hemodialysis patients</article-title><source>Am J Kidney Dis</source><year>2016</year><volume>68</volume><issue>6</issue><fpage>911</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2016.06.020</pub-id><pub-id pub-id-type="pmid">27575009</pub-id>
</element-citation></ref><ref id="B38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Movilli</surname><given-names>E</given-names></name>
<name><surname>Gaggia</surname><given-names>P</given-names></name>
<name><surname>Zubani</surname><given-names>R</given-names></name>
<name><surname>Camerini</surname><given-names>C</given-names></name>
<name><surname>Vizzardi</surname><given-names>V</given-names></name>
<name><surname>Parrinello</surname><given-names>G</given-names></name>
<etal/>
</person-group><article-title>Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study.</article-title><source>Nephrol Dial Transplant</source><year>2007</year><volume>22</volume><issue>12</issue><fpage>3547</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfm466</pub-id><pub-id pub-id-type="pmid">17890254</pub-id>
</element-citation></ref><ref id="B39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saran</surname><given-names>R</given-names></name>
<name><surname>Bragg-Gresham</surname><given-names>JL</given-names></name>
<name><surname>Levin</surname><given-names>NW</given-names></name>
<name><surname>Twardowski</surname><given-names>ZJ</given-names></name>
<name><surname>Wizemann</surname><given-names>V</given-names></name>
<name><surname>Saito</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS</article-title><source>Kidney Int</source><year>2006</year><volume>69</volume><issue>7</issue><fpage>1222</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5000186</pub-id><pub-id pub-id-type="pmid">16609686</pub-id>
</element-citation></ref><ref id="B40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>MJ</given-names></name>
<name><surname>Park</surname><given-names>JT</given-names></name>
<name><surname>Park</surname><given-names>KS</given-names></name>
<name><surname>Kwon</surname><given-names>YE</given-names></name>
<name><surname>Oh</surname><given-names>HJ</given-names></name>
<name><surname>Yoo</surname><given-names>TH</given-names></name>
<etal/>
</person-group><article-title>Prognostic value of residual urine volume, GFR by 24-hour urine collection, and eGFR in patients receiving dialysis</article-title><source>Clin J Am Soc Nephrol</source><year>2017</year><volume>12</volume><issue>3</issue><fpage>426</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.2215/CJN.05520516</pub-id><pub-id pub-id-type="pmid">28228465</pub-id>
</element-citation></ref><ref id="B41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Flythe</surname><given-names>JE</given-names></name>
<name><surname>Assimon</surname><given-names>MM</given-names></name>
<name><surname>Overman</surname><given-names>RA</given-names></name>
</person-group><article-title>Target weight achievement and ultrafiltration rate thresholds: potential patient implications</article-title><source>BMC Nephrol</source><year>2017</year><volume>18</volume><issue>1</issue><fpage>185</fpage><pub-id pub-id-type="doi">10.1186/s12882-017-0595-5</pub-id><pub-id pub-id-type="pmid">28578687</pub-id>
</element-citation></ref><ref id="B42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malik</surname><given-names>U</given-names></name>
<name><surname>Raizada</surname><given-names>V</given-names></name>
</person-group><article-title>Some aspects of the renin-angiotensin-system in hemodialysis patients</article-title><source>kidney blood press res</source><year>2015</year><volume>40</volume><issue>6</issue><fpage>614</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1159/000368537</pub-id><pub-id pub-id-type="pmid">26618349</pub-id>
</element-citation></ref><ref id="B43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>AH</given-names></name>
<name><surname>Knudsen</surname><given-names>F</given-names></name>
<name><surname>Kristensen</surname><given-names>SD</given-names></name>
</person-group><article-title>Serum angiotensin-converting enzyme increases during hemodialysis. Evidence for injury of the pulmonary vascular endothelium?</article-title><source>Nephron J</source><year>1985</year><volume>40</volume><issue>1</issue><fpage>100</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1159/000183438</pub-id><pub-id pub-id-type="pmid">2987714</pub-id>
</element-citation></ref><ref id="B44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koo</surname><given-names>WS</given-names></name>
<name><surname>Lee</surname><given-names>YJ</given-names></name>
<name><surname>Kim</surname><given-names>HS</given-names></name>
<name><surname>Kim</surname><given-names>SY</given-names></name>
<name><surname>Choi</surname><given-names>EJ</given-names></name>
<name><surname>Chang</surname><given-names>YS</given-names></name>
<etal/>
</person-group><article-title>Changes of plasma angiotensin-converting enzyme activity during hemodialysis</article-title><source>Korean J Intern Med (Korean Assoc Intern Med)</source><year>1987</year><volume>2</volume><issue>1</issue><fpage>62</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.3904/kjim.1987.2.1.62</pub-id><pub-id pub-id-type="pmid">2856479</pub-id>
</element-citation></ref><ref id="B45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>R</given-names></name>
<name><surname>Lewis</surname><given-names>R</given-names></name>
<name><surname>Davis</surname><given-names>JL</given-names></name>
<name><surname>Becker</surname><given-names>B</given-names></name>
</person-group><article-title>Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses</article-title><source>Am J Kidney Dis</source><year>2001</year><volume>38</volume><issue>6</issue><fpage>1245</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1053/ajkd.2001.29221</pub-id><pub-id pub-id-type="pmid">11728957</pub-id>
</element-citation></ref><ref id="B46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rocha</surname><given-names>R</given-names></name>
<name><surname>Stier</surname><given-names>CT</given-names><suffix>Jr</suffix></name>
</person-group><article-title>Pathophysiological effects of aldosterone in cardiovascular tissues</article-title><source>Trends Endocrinol Metab</source><year>2001</year><volume>12</volume><issue>7</issue><fpage>308</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/S1043-2760(01)00432-5</pub-id><pub-id pub-id-type="pmid">11504670</pub-id>
</element-citation></ref><ref id="B47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsumoto</surname><given-names>Y</given-names></name>
<name><surname>Mori</surname><given-names>Y</given-names></name>
<name><surname>Kageyama</surname><given-names>S</given-names></name>
<name><surname>Arihara</surname><given-names>K</given-names></name>
<name><surname>Sugiyama</surname><given-names>T</given-names></name>
<name><surname>Ohmura</surname><given-names>H</given-names></name>
<etal/>
</person-group><article-title>Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>63</volume><issue>6</issue><fpage>528</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2013.09.056</pub-id><pub-id pub-id-type="pmid">24184249</pub-id>
</element-citation></ref><ref id="B48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarafidis</surname><given-names>PA</given-names></name>
<name><surname>Persu</surname><given-names>A</given-names></name>
<name><surname>Agarwal</surname><given-names>R</given-names></name>
<name><surname>Burnier</surname><given-names>M</given-names></name>
<name><surname>de Leeuw</surname><given-names>P</given-names></name>
<name><surname>Ferro</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)</article-title><source>J Hypertens</source><year>2017</year><volume>35</volume><issue>4</issue><fpage>657</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000001283</pub-id><pub-id pub-id-type="pmid">28157814</pub-id>
</element-citation></ref><ref id="B49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Underwood</surname><given-names>CF</given-names></name>
<name><surname>Hildreth</surname><given-names>CM</given-names></name>
<name><surname>Wyse</surname><given-names>BF</given-names></name>
<name><surname>Boyd</surname><given-names>R</given-names></name>
<name><surname>Goodchild</surname><given-names>AK</given-names></name>
<name><surname>Phillips</surname><given-names>JK</given-names></name>
</person-group><article-title>Uraemia: an unrecognized driver of central neurohumoral dysfunction in chronic kidney disease?</article-title><source>Acta Physiol (Oxf)</source><year>2017</year><volume>219</volume><issue>1</issue><fpage>305</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1111/apha.12727</pub-id><pub-id pub-id-type="pmid">27247097</pub-id>
</element-citation></ref><ref id="B50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abuyassin</surname><given-names>B</given-names></name>
<name><surname>Sharma</surname><given-names>K</given-names></name>
<name><surname>Ayas</surname><given-names>NT</given-names></name>
<name><surname>Laher</surname><given-names>I</given-names></name>
</person-group><article-title>Obstructive sleep apnea and kidney disease: a potential bidirectional relationship?</article-title><source>J Clin Sleep Med</source><year>2015</year><volume>11</volume><issue>8</issue><fpage>915</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.5664/jcsm.4946</pub-id><pub-id pub-id-type="pmid">25845900</pub-id>
</element-citation></ref><ref id="B51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grassi</surname><given-names>G</given-names></name>
<name><surname>Biffi</surname><given-names>A</given-names></name>
<name><surname>Seravalle</surname><given-names>G</given-names></name>
<name><surname>Bertoli</surname><given-names>S</given-names></name>
<name><surname>Airoldi</surname><given-names>F</given-names></name>
<name><surname>Corrao</surname><given-names>G</given-names></name>
<etal/>
</person-group><article-title>Sympathetic nerve traffic overactivity in chronic kidney disease: a systematic review and meta-analysis</article-title><source>J Hypertens</source><year>2021</year><volume>39</volume><issue>3</issue><fpage>408</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000002661</pub-id><pub-id pub-id-type="pmid">33031182</pub-id>
</element-citation></ref><ref id="B52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malyszko</surname><given-names>J</given-names></name>
<name><surname>Malyszko</surname><given-names>JS</given-names></name>
<name><surname>Rysz</surname><given-names>J</given-names></name>
<name><surname>Mysliwiec</surname><given-names>M</given-names></name>
<name><surname>Tesar</surname><given-names>V</given-names></name>
<name><surname>Levin-Iaina</surname><given-names>N</given-names></name>
<etal/>
</person-group><article-title>Renalase, hypertension, and kidney - the discussion continues</article-title><source>Angiology</source><year>2013</year><volume>64</volume><issue>3</issue><fpage>181</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1177/0003319712459212</pub-id><pub-id pub-id-type="pmid">22969162</pub-id>
</element-citation></ref><ref id="B53"><label>53.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>US Renal Data System.</collab>
</person-group><source>USRDS 2006 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006 Google Scholar.[A1] [RB2]</source><comment>Dispon&#x000ed;vel em: <ext-link xlink:href="https://ghdx.healthdata.org/record/united-states-renal-data-system-annual-data-report-2006" ext-link-type="uri">https://ghdx.healthdata.org/record/united-states-renal-data-system-annual-data-report-2006</ext-link>
</comment></element-citation></ref><ref id="B54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Converse</surname><given-names>RL</given-names><suffix>Jr</suffix></name>
<name><surname>Jacobsen</surname><given-names>TN</given-names></name>
<name><surname>Toto</surname><given-names>RD</given-names></name>
<name><surname>Jost</surname><given-names>CM</given-names></name>
<name><surname>Cosentino</surname><given-names>F</given-names></name>
<name><surname>Fouad-Tarazi</surname><given-names>F</given-names></name>
<etal/>
</person-group><article-title>Sympathetic overactivity in patients with chronic renal failure</article-title><source>N Engl J Med</source><year>1992</year><volume>327</volume><issue>27</issue><fpage>1912</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1056/NEJM199212313272704</pub-id><pub-id pub-id-type="pmid">1454086</pub-id>
</element-citation></ref><ref id="B55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ott</surname><given-names>C</given-names></name>
<name><surname>Mahfoud</surname><given-names>F</given-names></name>
<name><surname>Mancia</surname><given-names>G</given-names></name>
<name><surname>Narkiewicz</surname><given-names>K</given-names></name>
<name><surname>Ruilope</surname><given-names>LM</given-names></name>
<name><surname>Fahy</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years</article-title><source>Nephrol Dial Transplant</source><year>2022</year><volume>37</volume><issue>2</issue><fpage>304</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfab154</pub-id><pub-id pub-id-type="pmid">34109413</pub-id>
</element-citation></ref><ref id="B56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papademetriou</surname><given-names>V</given-names></name>
<name><surname>Doumas</surname><given-names>M</given-names></name>
<name><surname>Anyfanti</surname><given-names>P</given-names></name>
<name><surname>Faselis</surname><given-names>C</given-names></name>
<name><surname>Kokkinos</surname><given-names>P</given-names></name>
<name><surname>Tsioufis</surname><given-names>C</given-names></name>
</person-group><article-title>Renal nerve ablation for hypertensive patients with chronic kidney disease</article-title><source>Curr Vasc Pharmacol</source><year>2014</year><volume>12</volume><issue>1</issue><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.2174/15701611113119990143</pub-id><pub-id pub-id-type="pmid">23905594</pub-id>
</element-citation></ref><ref id="B57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bakris</surname><given-names>GL</given-names></name>
<name><surname>Hart</surname><given-names>P</given-names></name>
<name><surname>Ritz</surname><given-names>E</given-names></name>
</person-group><article-title>Beta blockers in the management of chronic kidney disease</article-title><source>Kidney Int</source><year>2006</year><volume>70</volume><issue>11</issue><fpage>1905</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5001835</pub-id><pub-id pub-id-type="pmid">17021610</pub-id>
</element-citation></ref><ref id="B58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cice</surname><given-names>G</given-names></name>
<name><surname>Ferrara</surname><given-names>L</given-names></name>
<name><surname>D&#x02019;Andrea</surname><given-names>A</given-names></name>
<name><surname>D&#x02019;Isa</surname><given-names>S</given-names></name>
<name><surname>Di Benedetto</surname><given-names>A</given-names></name>
<name><surname>Cittadini</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>41</volume><issue>9</issue><fpage>1438</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(03)00241-9</pub-id><pub-id pub-id-type="pmid">12742278</pub-id>
</element-citation></ref><ref id="B59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vaziri</surname><given-names>ND</given-names></name>
<name><surname>Ni</surname><given-names>Z</given-names></name>
<name><surname>Wang</surname><given-names>XQ</given-names></name>
<name><surname>Oveisi</surname><given-names>F</given-names></name>
<name><surname>Zhou</surname><given-names>XJ</given-names></name>
</person-group><article-title>Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH</article-title><source>Am J Physiol</source><year>1998</year><volume>274</volume><issue>4</issue><fpage>F642</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.1998.274.4.F642</pub-id><pub-id pub-id-type="pmid">9575886</pub-id>
</element-citation></ref><ref id="B60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carmona-Martinez</surname><given-names>V</given-names></name>
<name><surname>Ruiz-Alcaraz</surname><given-names>AJ</given-names></name>
<name><surname>Vera</surname><given-names>M</given-names></name>
<name><surname>Guirado</surname><given-names>A</given-names></name>
<name><surname>Martinez-Esparza</surname><given-names>M</given-names></name>
<name><surname>Garcia-Penarrubia</surname><given-names>P</given-names></name>
</person-group><article-title>Therapeutic potential of pteridine derivatives: a comprehensive review</article-title><source>Med Res Rev</source><year>2019</year><volume>39</volume><issue>2</issue><fpage>461</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1002/med.21529</pub-id><pub-id pub-id-type="pmid">30341778</pub-id>
</element-citation></ref><ref id="B61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yokoyama</surname><given-names>K</given-names></name>
<name><surname>Tajima</surname><given-names>M</given-names></name>
<name><surname>Yoshida</surname><given-names>H</given-names></name>
<name><surname>Nakayama</surname><given-names>M</given-names></name>
<name><surname>Tokutome</surname><given-names>G</given-names></name>
<name><surname>Sakagami</surname><given-names>H</given-names></name>
<etal/>
</person-group><article-title>Plasma pteridine concentrations in patients with chronic renal failure</article-title><source>Nephrol Dial Transplant</source><year>2002</year><volume>17</volume><issue>6</issue><fpage>1032</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/ndt/17.6.1032</pub-id><pub-id pub-id-type="pmid">12032193</pub-id>
</element-citation></ref><ref id="B62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schnackenberg</surname><given-names>CG</given-names></name>
</person-group><article-title>Oxygen radicals in cardiovascular-renal disease</article-title><source>Curr Opin Pharmacol</source><year>2002</year><volume>2</volume><issue>2</issue><fpage>121</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/S1471-4892(02)00133-9</pub-id><pub-id pub-id-type="pmid">11950621</pub-id>
</element-citation></ref><ref id="B63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vallance</surname><given-names>P</given-names></name>
<name><surname>Leone</surname><given-names>A</given-names></name>
<name><surname>Calver</surname><given-names>A</given-names></name>
<name><surname>Collier</surname><given-names>J</given-names></name>
<name><surname>Moncada</surname><given-names>S</given-names></name>
</person-group><article-title>Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure</article-title><source>Lancet</source><year>1992</year><volume>339</volume><issue>8793</issue><fpage>572</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(92)90865-Z</pub-id><pub-id pub-id-type="pmid">1347093</pub-id>
</element-citation></ref><ref id="B64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000f6;ger</surname><given-names>RH</given-names></name>
<name><surname>Zoccali</surname><given-names>C</given-names></name>
</person-group><article-title>ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease</article-title><source>Atheroscler Suppl</source><year>2003</year><volume>4</volume><issue>4</issue><fpage>23</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S1567-5688(03)00030-8</pub-id><pub-id pub-id-type="pmid">14664899</pub-id>
</element-citation></ref><ref id="B65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zoccali</surname><given-names>C</given-names></name>
<name><surname>Bode-Boger</surname><given-names>S</given-names></name>
<name><surname>Mallamaci</surname><given-names>F</given-names></name>
<name><surname>Benedetto</surname><given-names>F</given-names></name>
<name><surname>Tripepi</surname><given-names>G</given-names></name>
<name><surname>Malatino</surname><given-names>L</given-names></name>
<etal/>
</person-group><article-title>Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study</article-title><source>Lancet</source><year>2001</year><volume>358</volume><issue>9299</issue><fpage>2113</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(01)07217-8</pub-id><pub-id pub-id-type="pmid">11784625</pub-id>
</element-citation></ref><ref id="B66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shichiri</surname><given-names>M</given-names></name>
<name><surname>Hirata</surname><given-names>Y</given-names></name>
<name><surname>Ando</surname><given-names>K</given-names></name>
<name><surname>Emori</surname><given-names>T</given-names></name>
<name><surname>Ohta</surname><given-names>K</given-names></name>
<name><surname>Kimoto</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Plasma endothelin levels in hypertension and chronic renal failure</article-title><source>Hypertension</source><year>1990</year><volume>15</volume><issue>5</issue><fpage>493</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.15.5.493</pub-id><pub-id pub-id-type="pmid">2185151</pub-id>
</element-citation></ref><ref id="B67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Buren</surname><given-names>PN</given-names></name>
</person-group><article-title>Pathophysiology and implications of intradialytic hypertension</article-title><source>Curr Opin Nephrol Hypertens</source><year>2017</year><volume>26</volume><issue>4</issue><fpage>303</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1097/MNH.0000000000000334</pub-id><pub-id pub-id-type="pmid">28399019</pub-id>
</element-citation></ref><ref id="B68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cabrera-Fischer</surname><given-names>E</given-names></name>
<name><surname>Zocalo</surname><given-names>Y</given-names></name>
<name><surname>Wray</surname><given-names>S</given-names></name>
<name><surname>Bia</surname><given-names>D</given-names></name>
</person-group><article-title>Arterial stiffness in haemodialyzed patients: findings and controversies</article-title><source>Curr Hypertens Rev</source><year>2018</year><volume>14</volume><issue>2</issue><fpage>100</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.2174/1573402114666180413115431</pub-id><pub-id pub-id-type="pmid">29651958</pub-id>
</element-citation></ref><ref id="B69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Lindholm</surname><given-names>B</given-names></name>
</person-group><article-title>Cardiovascular Risk Prediction in Chronic Kidney Disease</article-title><source>Am J Nephrol</source><year>2022</year><volume>53</volume><issue>10</issue><fpage>730</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1159/000528560</pub-id><pub-id pub-id-type="pmid">36481730</pub-id>
</element-citation></ref><ref id="B70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagarajarao</surname><given-names>HS</given-names></name>
<name><surname>Musani</surname><given-names>SK</given-names></name>
<name><surname>Cobb</surname><given-names>KE</given-names></name>
<name><surname>Pollard</surname><given-names>JD</given-names></name>
<name><surname>Cooper</surname><given-names>LL</given-names></name>
<name><surname>Anugu</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Kidney function and aortic stiffness, pulsatility, and endothelial function in African Americans: The Jackson Heart Study</article-title><source>Kidney Med</source><year>2021</year><volume>3</volume><issue>5</issue><fpage>702</fpage><lpage>711 e1</lpage><pub-id pub-id-type="doi">10.1016/j.xkme.2021.03.018</pub-id><pub-id pub-id-type="pmid">34693252</pub-id>
</element-citation></ref><ref id="B71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kanbay</surname><given-names>M</given-names></name>
<name><surname>Afsar</surname><given-names>B</given-names></name>
<name><surname>Gusbeth-Tatomir</surname><given-names>P</given-names></name>
<name><surname>Covic</surname><given-names>A</given-names></name>
</person-group><article-title>Arterial stiffness in dialysis patients: where are we now?</article-title><source>Int Urol Nephrol</source><year>2010</year><volume>42</volume><issue>3</issue><fpage>741</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1007/s11255-009-9675-1</pub-id><pub-id pub-id-type="pmid">19924558</pub-id>
</element-citation></ref><ref id="B72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laucyte-Cibulskiene</surname><given-names>A</given-names></name>
<name><surname>Petraviciute</surname><given-names>M</given-names></name>
<name><surname>Gudynaite</surname><given-names>M</given-names></name>
<name><surname>Gumbys</surname><given-names>L</given-names></name>
<name><surname>Valanciene</surname><given-names>D</given-names></name>
<name><surname>Galiauskiene</surname><given-names>K</given-names></name>
<etal/>
</person-group><article-title>Mismatch between stiffness in elastic and muscular arteries as a predictor of vascular calcification in dialysis patients</article-title><source>Aging Clin Exp Res</source><year>2018</year><volume>30</volume><issue>4</issue><fpage>375</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s40520-017-0787-7</pub-id><pub-id pub-id-type="pmid">28660595</pub-id>
</element-citation></ref><ref id="B73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gu</surname><given-names>Y</given-names></name>
<name><surname>Cheng</surname><given-names>LT</given-names></name>
<name><surname>Chen</surname><given-names>HM</given-names></name>
<name><surname>Sun</surname><given-names>XY</given-names></name>
<name><surname>Tang</surname><given-names>LJ</given-names></name>
<name><surname>Guo</surname><given-names>LJ</given-names></name>
<etal/>
</person-group><article-title>Strong association between nutritional markers and arterial stiffness in continuous ambulatory peritoneal dialysis patients</article-title><source>Blood Purif</source><year>2008</year><volume>26</volume><issue>4</issue><fpage>340</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1159/000132465</pub-id><pub-id pub-id-type="pmid">18483453</pub-id>
</element-citation></ref><ref id="B74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soveri</surname><given-names>I</given-names></name>
<name><surname>Lind</surname><given-names>L</given-names></name>
<name><surname>Wikstrom</surname><given-names>B</given-names></name>
<name><surname>Zilmer</surname><given-names>M</given-names></name>
<name><surname>Zilmer</surname><given-names>K</given-names></name>
<name><surname>Fellstrom</surname><given-names>B</given-names></name>
</person-group><article-title>Improvement in central arterial pressure waveform during hemodialysis is related to a reduction in asymmetric dimethylarginine (ADMA) levels</article-title><source>Nephron Clin Pract</source><year>2007</year><volume>106</volume><issue>4</issue><fpage>c180</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1159/000104429</pub-id><pub-id pub-id-type="pmid">17596727</pub-id>
</element-citation></ref><ref id="B75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guti&#x000e9;rrez</surname><given-names>OM</given-names></name>
<name><surname>Mannstadt</surname><given-names>M</given-names></name>
<name><surname>Isakova</surname><given-names>T</given-names></name>
<name><surname>Rauh-Hain</surname><given-names>JA</given-names></name>
<name><surname>Tamez</surname><given-names>H</given-names></name>
<name><surname>Shah</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><issue>6</issue><fpage>584</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0706130</pub-id><pub-id pub-id-type="pmid">18687639</pub-id>
</element-citation></ref><ref id="B76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turgut</surname><given-names>F</given-names></name>
<name><surname>Kanbay</surname><given-names>M</given-names></name>
<name><surname>Metin</surname><given-names>MR</given-names></name>
<name><surname>Uz</surname><given-names>E</given-names></name>
<name><surname>Akcay</surname><given-names>A</given-names></name>
<name><surname>Covic</surname><given-names>A</given-names></name>
</person-group><article-title>Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis</article-title><source>Int Urol Nephrol</source><year>2008</year><volume>40</volume><issue>4</issue><fpage>1075</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s11255-008-9410-3</pub-id><pub-id pub-id-type="pmid">18568412</pub-id>
</element-citation></ref><ref id="B77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>MM</given-names></name>
<name><surname>Smith</surname><given-names>ER</given-names></name>
<name><surname>Holt</surname><given-names>SG</given-names></name>
</person-group><article-title>The role of fetuin-A in mineral trafficking and deposition</article-title><source>Bonekey Rep</source><year>2015</year><volume>4</volume><fpage>672</fpage><pub-id pub-id-type="doi">10.1038/bonekey.2015.39</pub-id><pub-id pub-id-type="pmid">25987986</pub-id>
</element-citation></ref><ref id="B78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>CH</given-names></name>
<name><surname>Lurie</surname><given-names>RC</given-names></name>
<name><surname>Lyons</surname><given-names>OD</given-names></name>
</person-group><article-title>Sleep apnea and chronic kidney disease: a state-of-the-art review</article-title><source>Chest</source><year>2020</year><volume>157</volume><issue>3</issue><fpage>673</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2019.09.004</pub-id><pub-id pub-id-type="pmid">31542452</pub-id>
</element-citation></ref><ref id="B79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aziz</surname><given-names>F</given-names></name>
<name><surname>Chaudhary</surname><given-names>K</given-names></name>
</person-group><article-title>The Triad of sleep apnea, hypertension, and chronic kidney disease: a spectrum of common pathology</article-title><source>Cardiorenal Med</source><year>2016</year><volume>7</volume><issue>1</issue><fpage>74</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1159/000450796</pub-id><pub-id pub-id-type="pmid">27994605</pub-id>
</element-citation></ref><ref id="B80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nicholl</surname><given-names>DDM</given-names></name>
<name><surname>Ahmed</surname><given-names>SB</given-names></name>
<name><surname>Loewen</surname><given-names>AHS</given-names></name>
<name><surname>Hemmelgarn</surname><given-names>BR</given-names></name>
<name><surname>Sola</surname><given-names>DY</given-names></name>
<name><surname>Beecroft</surname><given-names>JM</given-names></name>
<etal/>
</person-group><article-title>Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia</article-title><source>Chest</source><year>2012</year><volume>141</volume><issue>6</issue><fpage>1422</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1378/chest.11-1809</pub-id><pub-id pub-id-type="pmid">22222188</pub-id>
</element-citation></ref><ref id="B81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beecroft</surname><given-names>JM</given-names></name>
<name><surname>Pierratos</surname><given-names>A</given-names></name>
<name><surname>Hanly</surname><given-names>PJ</given-names></name>
</person-group><article-title>Clinical presentation of obstructive sleep apnea in patients with end-stage renal disease</article-title><source>J Clin Sleep Med</source><year>2009</year><volume>5</volume><issue>2</issue><fpage>115</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.5664/jcsm.27438</pub-id><pub-id pub-id-type="pmid">19968043</pub-id>
</element-citation></ref><ref id="B82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oscullo</surname><given-names>G</given-names></name>
<name><surname>Gomez-Olivas</surname><given-names>JD</given-names></name>
<name><surname>Martinez-Garcia</surname><given-names>MA</given-names></name>
</person-group><article-title>Refractory hypertension and obstructive sleep apnea: a novel relationship</article-title><source>Sleep Breath</source><year>2023</year><volume>27</volume><issue>6</issue><fpage>2079-81</fpage><pub-id pub-id-type="doi">10.1007/s11325-023-02864-7</pub-id><pub-id pub-id-type="pmid">37392325</pub-id>
</element-citation></ref><ref id="B83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>R</given-names></name>
<name><surname>Flynn</surname><given-names>J</given-names></name>
<name><surname>Pogue</surname><given-names>V</given-names></name>
<name><surname>Rahman</surname><given-names>M</given-names></name>
<name><surname>Reisin</surname><given-names>E</given-names></name>
<name><surname>Weir</surname><given-names>MR</given-names></name>
</person-group><article-title>Assessment and management of hypertension in patients on dialysis</article-title><source>J Am Soc Nephrol</source><year>2014</year><volume>25</volume><issue>8</issue><fpage>1630</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1681/ASN.2013060601</pub-id><pub-id pub-id-type="pmid">24700870</pub-id>
</element-citation></ref><ref id="B84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brar</surname><given-names>SK</given-names></name>
<name><surname>Perveen</surname><given-names>S</given-names></name>
<name><surname>Chaudhry</surname><given-names>MR</given-names></name>
<name><surname>AlBabtain</surname><given-names>S</given-names></name>
<name><surname>Amreen</surname><given-names>S</given-names></name>
<name><surname>Khan</surname><given-names>S</given-names></name>
</person-group><article-title>Erythropoietin-induced hypertension: a review of pathogenesis, treatment, and role of blood viscosity</article-title><source>Cureus</source><year>2021</year><volume>13</volume><issue>1</issue><fpage>e12804</fpage><pub-id pub-id-type="doi">10.7759/cureus.12804</pub-id><pub-id pub-id-type="pmid">33628672</pub-id>
</element-citation></ref><ref id="B85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Phillips</surname><given-names>LS</given-names></name>
<name><surname>Branch</surname><given-names>WT</given-names><suffix>Jr</suffix></name>
<name><surname>Cook</surname><given-names>CB</given-names></name>
<name><surname>Doyle</surname><given-names>JP</given-names></name>
<name><surname>El-Kebbi</surname><given-names>IM</given-names></name>
<name><surname>Gallina</surname><given-names>DL</given-names></name>
<etal/>
</person-group><article-title>Clinical inertia</article-title><source>Ann Intern Med</source><year>2001</year><volume>135</volume><issue>9</issue><fpage>825</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-135-9-200111060-00012</pub-id><pub-id pub-id-type="pmid">11694107</pub-id>
</element-citation></ref><ref id="B86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Viera</surname><given-names>AJ</given-names></name>
<name><surname>Schmid</surname><given-names>D</given-names></name>
<name><surname>Bostrom</surname><given-names>S</given-names></name>
<name><surname>Yow</surname><given-names>A</given-names></name>
<name><surname>Lawrence</surname><given-names>W</given-names></name>
<name><surname>DuBard</surname><given-names>CA</given-names></name>
</person-group><article-title>Level of blood pressure above goal and clinical inertia in a Medicaid population</article-title><source>J Am Soc Hypertens</source><year>2010</year><volume>4</volume><issue>5</issue><fpage>244</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.jash.2010.07.003</pub-id><pub-id pub-id-type="pmid">20728422</pub-id>
</element-citation></ref><ref id="B87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Desai</surname><given-names>N</given-names></name>
<name><surname>Madhavankutty Saraswathy</surname><given-names>V</given-names></name>
<name><surname>Hunter</surname><given-names>K</given-names></name>
<name><surname>McFadden</surname><given-names>C</given-names></name>
</person-group><article-title>Prevalence of true therapeutic inertia in blood pressure control in an academic chronic kidney disease clinic</article-title><source>J Clin Hypertens (Greenwich)</source><year>2013</year><volume>15</volume><issue>6</issue><fpage>375</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/jch.12095</pub-id><pub-id pub-id-type="pmid">23730985</pub-id>
</element-citation></ref><ref id="B88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pathak</surname><given-names>A</given-names></name>
<name><surname>Poulter</surname><given-names>NR</given-names></name>
<name><surname>Kavanagh</surname><given-names>M</given-names></name>
<name><surname>Kreutz</surname><given-names>R</given-names></name>
<name><surname>Burnier</surname><given-names>M</given-names></name>
</person-group><article-title>Improving the management of hypertension by tackling awareness, adherence, and clinical inertia: a symposium report</article-title><source>Am J Cardiovasc Drugs</source><year>2022</year><volume>22</volume><issue>3</issue><fpage>251</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1007/s40256-021-00505-6</pub-id><pub-id pub-id-type="pmid">34751917</pub-id>
</element-citation></ref><ref id="B89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lebeau</surname><given-names>JP</given-names></name>
<name><surname>Cadwallader</surname><given-names>JS</given-names></name>
<name><surname>Vaillant-Roussel</surname><given-names>H</given-names></name>
<name><surname>Pouchain</surname><given-names>D</given-names></name>
<name><surname>Yaouanc</surname><given-names>V</given-names></name>
<name><surname>Aubin-Auger</surname><given-names>I</given-names></name>
<etal/>
</person-group><article-title>General practitioners&#x02019; justifications for therapeutic inertia in cardiovascular prevention: an empirically grounded typology</article-title><source>BMJ Open</source><year>2016</year><volume>6</volume><issue>5</issue><fpage>e010639</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2015-010639</pub-id><pub-id pub-id-type="pmid">27178974</pub-id>
</element-citation></ref><ref id="B90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clemens</surname><given-names>KK</given-names></name>
<name><surname>Ouedraogo</surname><given-names>AM</given-names></name>
<name><surname>Garg</surname><given-names>AX</given-names></name>
<name><surname>Silver</surname><given-names>SA</given-names></name>
<name><surname>Nash</surname><given-names>DM</given-names></name>
</person-group><article-title>Opportunities to improve diabetes care in the hemodialysis unit: a cohort study in Ontario, Canada</article-title><source>Kidney360</source><year>2021</year><volume>2</volume><issue>4</issue><fpage>653</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.34067/KID.0007082020</pub-id><pub-id pub-id-type="pmid">35373046</pub-id>
</element-citation></ref><ref id="B91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hall</surname><given-names>RK</given-names></name>
<name><surname>Morton</surname><given-names>S</given-names></name>
<name><surname>Wilson</surname><given-names>J</given-names></name>
<name><surname>Ephraim</surname><given-names>PL</given-names></name>
<name><surname>Boulware</surname><given-names>LE</given-names></name>
<name><surname>St Peter</surname><given-names>WL</given-names></name>
<etal/>
</person-group><article-title>Risks associated with continuation of potentially inappropriate antihypertensive medications in older adults receiving hemodialysis</article-title><source>BMC Nephrol</source><year>2021</year><volume>22</volume><issue>1</issue><fpage>232</fpage><pub-id pub-id-type="doi">10.1186/s12882-021-02438-3</pub-id><pub-id pub-id-type="pmid">34147085</pub-id>
</element-citation></ref><ref id="B92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>L&#x000fc;ders</surname><given-names>S</given-names></name>
<name><surname>Schrader</surname><given-names>J</given-names></name>
<name><surname>Schmieder</surname><given-names>RE</given-names></name>
<name><surname>Smolka</surname><given-names>W</given-names></name>
<name><surname>Wegscheider</surname><given-names>K</given-names></name>
<name><surname>Bestehorn</surname><given-names>K</given-names></name>
</person-group><article-title>Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial</article-title><source>Eur J Cardiovasc Prev Rehabil</source><year>2010</year><volume>17</volume><issue>3</issue><fpage>271</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/HJR.0b013e328330be62</pub-id><pub-id pub-id-type="pmid">19901841</pub-id>
</element-citation></ref><ref id="B93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kohok</surname><given-names>DD</given-names></name>
<name><surname>Shah</surname><given-names>S</given-names></name>
<name><surname>Kumar</surname><given-names>R</given-names></name>
<name><surname>Venuto</surname><given-names>L</given-names></name>
<name><surname>Gudleski</surname><given-names>G</given-names></name>
<name><surname>Venuto</surname><given-names>R</given-names></name>
</person-group><article-title>Interventions to reduce clinical inertia in cardiac risk factor management in renal transplant recipients</article-title><source>J Clin Hypertens (Greenwich)</source><year>2014</year><volume>16</volume><issue>2</issue><fpage>127</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/jch.12249</pub-id><pub-id pub-id-type="pmid">24433451</pub-id>
</element-citation></ref><ref id="B94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vrijens</surname><given-names>B</given-names></name>
<name><surname>De Geest</surname><given-names>S</given-names></name>
<name><surname>Hughes</surname><given-names>DA</given-names></name>
<name><surname>Przemyslaw</surname><given-names>K</given-names></name>
<name><surname>Demonceau</surname><given-names>J</given-names></name>
<name><surname>Ruppar</surname><given-names>T</given-names></name>
<etal/>
</person-group><article-title>A new taxonomy for describing and defining adherence to medications</article-title><source>Br J Clin Pharmacol</source><year>2012</year><volume>73</volume><issue>5</issue><fpage>691</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2012.04167.x</pub-id><pub-id pub-id-type="pmid">22486599</pub-id>
</element-citation></ref><ref id="B95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghimire</surname><given-names>S</given-names></name>
<name><surname>Castelino</surname><given-names>RL</given-names></name>
<name><surname>Lioufas</surname><given-names>NM</given-names></name>
<name><surname>Peterson</surname><given-names>GM</given-names></name>
<name><surname>Zaidi</surname><given-names>ST</given-names></name>
</person-group><article-title>Nonadherence to Medication Therapy in Haemodialysis Patients: A Systematic Review</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>12</issue><fpage>e0144119</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0144119</pub-id><pub-id pub-id-type="pmid">26636968</pub-id>
</element-citation></ref><ref id="B96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murali</surname><given-names>KM</given-names></name>
<name><surname>Mullan</surname><given-names>J</given-names></name>
<name><surname>Roodenrys</surname><given-names>S</given-names></name>
<name><surname>Hassan</surname><given-names>HC</given-names></name>
<name><surname>Lambert</surname><given-names>K</given-names></name>
<name><surname>Lonergan</surname><given-names>M</given-names></name>
</person-group><article-title>Strategies to improve dietary, fluid, dialysis or medication adherence in patients with end stage kidney disease on dialysis: a systematic review and meta-analysis of randomized intervention trials</article-title><source>PLoS One</source><year>2019</year><volume>14</volume><issue>1</issue><fpage>e0211479</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0211479</pub-id><pub-id pub-id-type="pmid">30695068</pub-id>
</element-citation></ref><ref id="B97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>da Silva</surname><given-names>GV</given-names></name>
<name><surname>de Barros</surname><given-names>S</given-names></name>
<name><surname>Abensur</surname><given-names>H</given-names></name>
<name><surname>Ortega</surname><given-names>KC</given-names></name>
<name><surname>Mion</surname><given-names>D</given-names><suffix>Jr</suffix></name>
<name><surname>Cochrane Renal Group Prospective Trial Register</surname><given-names>CRG</given-names></name>
</person-group><article-title>Home blood pressure monitoring in blood pressure control among haemodialysis patients: an open randomized clinical trial</article-title><source>Nephrol Dial Transplant</source><year>2009</year><volume>24</volume><issue>12</issue><fpage>3805</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfp332</pub-id><pub-id pub-id-type="pmid">19586971</pub-id>
</element-citation></ref><ref id="B98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>TI</given-names></name>
<name><surname>Tatoian</surname><given-names>ET</given-names></name>
<name><surname>Montez-Rath</surname><given-names>ME</given-names></name>
<name><surname>Chertow</surname><given-names>GM</given-names></name>
</person-group><article-title>Timing of Antihypertensive medications on key outcomes in hemodialysis: a cluster randomized trial</article-title><source>Kidney360</source><year>2021</year><volume>2</volume><issue>11</issue><fpage>1752</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.34067/KID.0001922021</pub-id><pub-id pub-id-type="pmid">35373003</pub-id>
</element-citation></ref><ref id="B99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bansal</surname><given-names>N</given-names></name>
<name><surname>McCulloch</surname><given-names>CE</given-names></name>
<name><surname>Rahman</surname><given-names>M</given-names></name>
<name><surname>Kusek</surname><given-names>JW</given-names></name>
<name><surname>Anderson</surname><given-names>AH</given-names></name>
<name><surname>Xie</surname><given-names>D</given-names></name>
<etal/>
</person-group><article-title>Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: the chronic renal insufficiency cohort study</article-title><source>Hypertension</source><year>2015</year><volume>65</volume><issue>1</issue><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.114.04334</pub-id><pub-id pub-id-type="pmid">25287404</pub-id>
</element-citation></ref><ref id="B100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bansal</surname><given-names>N</given-names></name>
<name><surname>McCulloch</surname><given-names>CE</given-names></name>
<name><surname>Lin</surname><given-names>F</given-names></name>
<name><surname>Alper</surname><given-names>A</given-names></name>
<name><surname>Anderson</surname><given-names>AH</given-names></name>
<name><surname>Cuevas</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Blood pressure and risk of cardiovascular events in patients on chronic hemodialysis: the CRIC Study (Chronic Renal Insufficiency Cohort)</article-title><source>Hypertension</source><year>2017</year><volume>70</volume><issue>2</issue><fpage>435</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.117.09091</pub-id><pub-id pub-id-type="pmid">28674037</pub-id>
</element-citation></ref><ref id="B101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>R</given-names></name>
<name><surname>Peixoto</surname><given-names>AJ</given-names></name>
<name><surname>Santos</surname><given-names>SF</given-names></name>
<name><surname>Zoccali</surname><given-names>C</given-names></name>
</person-group><article-title>Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure</article-title><source>Clin J Am Soc Nephrol</source><year>2006</year><volume>1</volume><issue>3</issue><fpage>389</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.2215/CJN.01891105</pub-id><pub-id pub-id-type="pmid">17699236</pub-id>
</element-citation></ref><ref id="B102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wuerzner</surname><given-names>G</given-names></name>
<name><surname>Pruijm</surname><given-names>M</given-names></name>
<name><surname>Burnier</surname><given-names>M</given-names></name>
</person-group><article-title>Defining intradialytic hypertension: the importance of measuring blood pressure accurately</article-title><source>Nephrol Dial Transplant</source><year>2022</year><volume>37</volume><issue>10</issue><fpage>1783</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfac142</pub-id><pub-id pub-id-type="pmid">35362528</pub-id>
</element-citation></ref><ref id="B103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ebrahimi</surname><given-names>H</given-names></name>
<name><surname>Safavi</surname><given-names>M</given-names></name>
<name><surname>Saeidi</surname><given-names>MH</given-names></name>
<name><surname>Emamian</surname><given-names>MH</given-names></name>
</person-group><article-title>Effects of sodium concentration and dialysate temperature changes on blood pressure in hemodialysis patients: a randomized, triple-blind crossover clinical trial</article-title><source>Ther Apher Dial</source><year>2017</year><volume>21</volume><issue>2</issue><fpage>117</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1111/1744-9987.12506</pub-id><pub-id pub-id-type="pmid">28185407</pub-id>
</element-citation></ref><ref id="B104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alborzi</surname><given-names>P</given-names></name>
<name><surname>Patel</surname><given-names>N</given-names></name>
<name><surname>Agarwal</surname><given-names>R</given-names></name>
</person-group><article-title>Home blood pressures are of greater prognostic value than hemodialysis unit recordings</article-title><source>Clin J Am Soc Nephrol</source><year>2007</year><volume>2</volume><issue>6</issue><fpage>1228</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.2215/CJN.02250507</pub-id><pub-id pub-id-type="pmid">17942773</pub-id>
</element-citation></ref><ref id="B105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>R</given-names></name>
<name><surname>Alborzi</surname><given-names>P</given-names></name>
<name><surname>Satyan</surname><given-names>S</given-names></name>
<name><surname>Light</surname><given-names>RP</given-names></name>
</person-group><article-title>Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial</article-title><source>Hypertension</source><year>2009</year><volume>53</volume><issue>3</issue><fpage>500</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.108.125674</pub-id><pub-id pub-id-type="pmid">19153263</pub-id>
</element-citation></ref><ref id="B106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Buren</surname><given-names>PN</given-names></name>
<name><surname>Inrig</surname><given-names>JK</given-names></name>
</person-group><article-title>Special situations: intradialytic hypertension/chronic hypertension and intradialytic hypotension</article-title><source>Semin Dial</source><year>2017</year><volume>30</volume><issue>6</issue><fpage>545</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1111/sdi.12631</pub-id><pub-id pub-id-type="pmid">28666072</pub-id>
</element-citation></ref><ref id="B107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>AT</given-names></name>
<name><surname>Waikar</surname><given-names>SS</given-names></name>
<name><surname>Mc Causland</surname><given-names>FR</given-names></name>
</person-group><article-title>Association of Different definitions of intradialytic hypertension with long-term mortality in hemodialysis</article-title><source>Hypertension</source><year>2022</year><volume>79</volume><issue>4</issue><fpage>855</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.121.18058</pub-id><pub-id pub-id-type="pmid">35166122</pub-id>
</element-citation></ref><ref id="B108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mattos</surname><given-names>MS</given-names></name>
<name><surname>Lemes</surname><given-names>HP</given-names></name>
<name><surname>Ferreira</surname><given-names>SR</given-names><suffix>Filho</suffix></name>
</person-group><article-title>Correlation between pre- and post-dialysis blood pressure levels in hemodialysis patients with intradialytic hypertension</article-title><source>Int Urol Nephrol</source><year>2016</year><volume>48</volume><issue>12</issue><fpage>2095</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s11255-016-1427-4</pub-id><pub-id pub-id-type="pmid">27671906</pub-id>
</element-citation></ref><ref id="B109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chou</surname><given-names>KJ</given-names></name>
<name><surname>Lee</surname><given-names>PT</given-names></name>
<name><surname>Chen</surname><given-names>CL</given-names></name>
<name><surname>Chiou</surname><given-names>CW</given-names></name>
<name><surname>Hsu</surname><given-names>CY</given-names></name>
<name><surname>Chung</surname><given-names>HM</given-names></name>
<etal/>
</person-group><article-title>Physiological changes during hemodialysis in patients with intradialysis hypertension</article-title><source>Kidney Int</source><year>2006</year><volume>69</volume><issue>10</issue><fpage>1833</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5000266</pub-id><pub-id pub-id-type="pmid">16691262</pub-id>
</element-citation></ref><ref id="B110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zilch</surname><given-names>O</given-names></name>
<name><surname>Vos</surname><given-names>PF</given-names></name>
<name><surname>Oey</surname><given-names>PL</given-names></name>
<name><surname>Cramer</surname><given-names>MJ</given-names></name>
<name><surname>Ligtenberg</surname><given-names>G</given-names></name>
<name><surname>Koomans</surname><given-names>HA</given-names></name>
<etal/>
</person-group><article-title>Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis</article-title><source>J Hypertens</source><year>2007</year><volume>25</volume><issue>6</issue><fpage>1285</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/HJH.0b013e3280f9df85</pub-id><pub-id pub-id-type="pmid">17563543</pub-id>
</element-citation></ref><ref id="B111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prasad</surname><given-names>B</given-names></name>
<name><surname>Hemmett</surname><given-names>J</given-names></name>
<name><surname>Suri</surname><given-names>R</given-names></name>
</person-group><article-title>Five things to know about intradialytic hypertension</article-title><source>Can J Kidney Health Dis</source><year>2022</year><volume>9</volume><fpage>20543581221106657</fpage><pub-id pub-id-type="doi">10.1177/20543581221106657</pub-id><pub-id pub-id-type="pmid">35756329</pub-id>
</element-citation></ref><ref id="B112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parati</surname><given-names>G</given-names></name>
<name><surname>Ochoa</surname><given-names>JE</given-names></name>
<name><surname>Bilo</surname><given-names>G</given-names></name>
<name><surname>Agarwal</surname><given-names>R</given-names></name>
<name><surname>Covic</surname><given-names>A</given-names></name>
<name><surname>Dekker</surname><given-names>FW</given-names></name>
<etal/>
</person-group><article-title>Hypertension in Chronic Kidney Disease Part 2: Role of Ambulatory and Home Blood Pressure Monitoring for Assessing Alterations in Blood Pressure Variability and Blood Pressure Profiles</article-title><source>Hypertension</source><year>2016</year><volume>67</volume><issue>6</issue><fpage>1102</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.115.06896</pub-id><pub-id pub-id-type="pmid">27141057</pub-id>
</element-citation></ref><ref id="B113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>R</given-names></name>
</person-group><article-title>Pro: ambulatory blood pressure should be used in all patients on hemodialysis</article-title><source>Nephrol Dial Transplant</source><year>2015</year><volume>30</volume><issue>9</issue><fpage>1432</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfv243</pub-id><pub-id pub-id-type="pmid">26022728</pub-id>
</element-citation></ref><ref id="B114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parati</surname><given-names>G</given-names></name>
<name><surname>Stergiou</surname><given-names>GS</given-names></name>
<name><surname>Bilo</surname><given-names>G</given-names></name>
<name><surname>Kollias</surname><given-names>A</given-names></name>
<name><surname>Pengo</surname><given-names>M</given-names></name>
<name><surname>Ochoa</surname><given-names>JE</given-names></name>
<etal/>
</person-group><article-title>Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension</article-title><source>J Hypertens</source><year>2021</year><volume>39</volume><issue>9</issue><fpage>1742</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000002922</pub-id><pub-id pub-id-type="pmid">34269334</pub-id>
</element-citation></ref><ref id="B115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mayer</surname><given-names>CC</given-names></name>
<name><surname>Schmaderer</surname><given-names>C</given-names></name>
<name><surname>Loutradis</surname><given-names>C</given-names></name>
<name><surname>Matschkal</surname><given-names>J</given-names></name>
<name><surname>Theodorakopoulou</surname><given-names>M</given-names></name>
<name><surname>Lorenz</surname><given-names>G</given-names></name>
<etal/>
</person-group><article-title>Heart Failure and Atrial Fibrillation Modify the Associations of Nocturnal Blood Pressure Dipping Pattern With Mortality in Hemodialysis Patients</article-title><source>Hypertension</source><year>2020</year><volume>76</volume><issue>4</issue><fpage>1231</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.15420</pub-id><pub-id pub-id-type="pmid">32862707</pub-id>
</element-citation></ref><ref id="B116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>M</given-names></name>
<name><surname>Takahashi</surname><given-names>H</given-names></name>
<name><surname>Morita</surname><given-names>Y</given-names></name>
<name><surname>Maruyama</surname><given-names>S</given-names></name>
<name><surname>Mizuno</surname><given-names>M</given-names></name>
<name><surname>Yuzawa</surname><given-names>Y</given-names></name>
<etal/>
</person-group><article-title>Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients</article-title><source>Nephrol Dial Transplant</source><year>2003</year><volume>18</volume><issue>3</issue><fpage>563</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/ndt/18.3.563</pub-id><pub-id pub-id-type="pmid">12584280</pub-id>
</element-citation></ref><ref id="B117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mettang</surname><given-names>T</given-names></name>
<name><surname>Kremer</surname><given-names>AE</given-names></name>
</person-group><article-title>Uremic pruritus</article-title><source>Kidney Int</source><year>2015</year><volume>87</volume><issue>4</issue><fpage>685</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/ki.2013.454</pub-id><pub-id pub-id-type="pmid">24402092</pub-id>
</element-citation></ref><ref id="B118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bansal</surname><given-names>N</given-names></name>
<name><surname>Glidden</surname><given-names>DV</given-names></name>
<name><surname>Mehrotra</surname><given-names>R</given-names></name>
<name><surname>Townsend</surname><given-names>RR</given-names></name>
<name><surname>Cohen</surname><given-names>J</given-names></name>
<name><surname>Linke</surname><given-names>L</given-names></name>
<etal/>
</person-group><article-title>Treating home versus predialysis blood pressure among in-center hemodialysis patients: a pilot randomized trial</article-title><source>Am J Kidney Dis</source><year>2021</year><volume>77</volume><issue>1</issue><fpage>12</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2020.06.014</pub-id><pub-id pub-id-type="pmid">32800842</pub-id>
</element-citation></ref><ref id="B119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feitosa</surname><given-names>ADM</given-names></name>
<name><surname>Barroso</surname><given-names>WKS</given-names></name>
<name><surname>Mion</surname><given-names>D</given-names><suffix>Jr</suffix></name>
<name><surname>Nobre</surname><given-names>F</given-names></name>
<name><surname>Mota-Gomes</surname><given-names>MA</given-names></name>
<name><surname>Jardim</surname><given-names>PCBV</given-names></name>
<etal/>
</person-group><article-title>Brazilian Guidelines for In-office and Out-of-office Blood Pressure Measurement -2023</article-title><source>Scielo Preprints</source><year>2023</year><pub-id pub-id-type="doi">10.1590/SciELOPreprints.7057</pub-id></element-citation></ref><ref id="B120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>AY</given-names></name>
<name><surname>Brimble</surname><given-names>KS</given-names></name>
<name><surname>Brunier</surname><given-names>G</given-names></name>
<name><surname>Holt</surname><given-names>SG</given-names></name>
<name><surname>Jha</surname><given-names>V</given-names></name>
<name><surname>Johnson</surname><given-names>DW</given-names></name>
<etal/>
</person-group><article-title>ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I - Assessment and Management of Various Cardiovascular Risk Factors</article-title><source>Perit Dial Int</source><year>2015</year><volume>35</volume><issue>4</issue><fpage>379</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.3747/pdi.2014.00279</pub-id><pub-id pub-id-type="pmid">26228782</pub-id>
</element-citation></ref><ref id="B121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>R</given-names></name>
<name><surname>Sinha</surname><given-names>AD</given-names></name>
<name><surname>Light</surname><given-names>RP</given-names></name>
</person-group><article-title>Toward a definition of masked hypertension and white-coat hypertension among hemodialysis patients</article-title><source>Clin J Am Soc Nephrol</source><year>2011</year><volume>6</volume><issue>8</issue><fpage>2003</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2215/CJN.02700311</pub-id><pub-id pub-id-type="pmid">21737856</pub-id>
</element-citation></ref><ref id="B122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Minutolo</surname><given-names>R</given-names></name>
<name><surname>Gabbai</surname><given-names>FB</given-names></name>
<name><surname>Agarwal</surname><given-names>R</given-names></name>
<name><surname>Chiodini</surname><given-names>P</given-names></name>
<name><surname>Borrelli</surname><given-names>S</given-names></name>
<name><surname>Bellizzi</surname><given-names>V</given-names></name>
<etal/>
</person-group><article-title>Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study</article-title><source>Am J Kidney Dis</source><year>2014</year><volume>64</volume><issue>5</issue><fpage>744</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2014.06.014</pub-id><pub-id pub-id-type="pmid">25082100</pub-id>
</element-citation></ref><ref id="B123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pr&#x000e9;coma</surname><given-names>DB</given-names></name>
<name><surname>Oliveira</surname><given-names>GMM</given-names></name>
<name><surname>Sim&#x000e3;o</surname><given-names>AF</given-names></name>
<name><surname>Dutra</surname><given-names>OP</given-names></name>
<name><surname>Coelho</surname><given-names>OR</given-names></name>
<name><surname>Izar</surname><given-names>MCO</given-names></name>
<etal/>
</person-group><article-title>Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019</article-title><source>Arq Bras Cardiol</source><year>2019</year><volume>113</volume><issue>4</issue><fpage>787</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.5935/abc.20190204</pub-id><pub-id pub-id-type="pmid">31691761</pub-id>
</element-citation></ref><ref id="B124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McDonagh</surname><given-names>TA</given-names></name>
<name><surname>Metra</surname><given-names>M</given-names></name>
<name><surname>Adamo</surname><given-names>M</given-names></name>
<name><surname>Gardner</surname><given-names>RS</given-names></name>
<name><surname>Baumbach</surname><given-names>A</given-names></name>
<name><surname>Bohm</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure</article-title><source>Eur Heart J</source><year>2021</year><volume>42</volume><issue>36</issue><fpage>3599</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehab368</pub-id><pub-id pub-id-type="pmid">34447992</pub-id>
</element-citation></ref><ref id="B125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heidenreich</surname><given-names>PA</given-names></name>
<name><surname>Bozkurt</surname><given-names>B</given-names></name>
<name><surname>Aguilar</surname><given-names>D</given-names></name>
<name><surname>Allen</surname><given-names>LA</given-names></name>
<name><surname>Byun</surname><given-names>JJ</given-names></name>
<name><surname>Colvin</surname><given-names>MM</given-names></name>
<etal/>
</person-group><article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</article-title><source>J Am Coll Cardiol</source><year>2022</year><volume>79</volume><issue>17</issue><fpage>e263</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.12.012</pub-id><pub-id pub-id-type="pmid">35379503</pub-id>
</element-citation></ref><ref id="B126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Go</surname><given-names>AS</given-names></name>
<name><surname>Chertow</surname><given-names>GM</given-names></name>
<name><surname>Fan</surname><given-names>D</given-names></name>
<name><surname>McCulloch</surname><given-names>CE</given-names></name>
<name><surname>Hsu</surname><given-names>CY</given-names></name>
</person-group><article-title>Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><issue>13</issue><fpage>1296</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa041031</pub-id><pub-id pub-id-type="pmid">15385656</pub-id>
</element-citation></ref><ref id="B127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vallianou</surname><given-names>NG</given-names></name>
<name><surname>Mitesh</surname><given-names>S</given-names></name>
<name><surname>Gkogkou</surname><given-names>A</given-names></name>
<name><surname>Geladari</surname><given-names>E</given-names></name>
</person-group><article-title>Chronic kidney disease and cardiovascular disease: is there any relationship?</article-title><source>Curr Cardiol Rev</source><year>2019</year><volume>15</volume><issue>1</issue><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.2174/1573403X14666180711124825</pub-id><pub-id pub-id-type="pmid">29992892</pub-id>
</element-citation></ref><ref id="B128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names><suffix>Sr</suffix></name>
<name><surname>Grundy</surname><given-names>S</given-names></name>
<name><surname>Sullivan</surname><given-names>LM</given-names></name>
<name><surname>Wilson</surname><given-names>P</given-names></name>
<name><surname>CHD Risk</surname><given-names>Prediction Group</given-names></name>
</person-group><article-title>Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation</article-title><source>JAMA</source><year>2001</year><volume>286</volume><issue>2</issue><fpage>180</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1001/jama.286.2.180</pub-id><pub-id pub-id-type="pmid">11448281</pub-id>
</element-citation></ref><ref id="B129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muntner</surname><given-names>P</given-names></name>
<name><surname>Colantonio</surname><given-names>LD</given-names></name>
<name><surname>Cushman</surname><given-names>M</given-names></name>
<name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></name>
<name><surname>Howard</surname><given-names>G</given-names></name>
<name><surname>Howard</surname><given-names>VJ</given-names></name>
<etal/>
</person-group><article-title>Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations</article-title><source>JAMA</source><year>2014</year><volume>311</volume><issue>14</issue><fpage>1406</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.2630</pub-id><pub-id pub-id-type="pmid">24682252</pub-id>
</element-citation></ref><ref id="B130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mora</surname><given-names>SCGM</given-names></name>
<name><surname>Torres</surname><given-names>E</given-names></name>
<name><surname>Verdalles</surname><given-names>U</given-names></name>
<name><surname>P&#x000e9;rez de Jos&#x000e9;</surname><given-names>A</given-names></name>
<name><surname>Verde</surname><given-names>E</given-names></name>
<etal/>
</person-group><article-title>Predicci&#x000f3;n del riesgo cardiovascular en pacientes con enfermedad renal cr&#x000f3;nica</article-title><source>Nefrologia</source><year>2017</year><volume>37</volume><issue>3</issue><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.nefro.2016.10.002</pub-id><pub-id pub-id-type="pmid">28495396</pub-id>
</element-citation></ref><ref id="B131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Guan</surname><given-names>X</given-names></name>
<name><surname>Jiao</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>G</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
</person-group><article-title>Development and validation of an artificial intelligence prediction model and a survival risk stratification for lung metastasis in colorectal cancer from highly imbalanced data: A multicenter retrospective study</article-title><source>Eur J Surg Oncol</source><year>2023</year><volume>49</volume><issue>12</issue><fpage>107107</fpage><pub-id pub-id-type="doi">10.1016/j.ejso.2023.107107</pub-id><pub-id pub-id-type="pmid">37883884</pub-id>
</element-citation></ref><ref id="B132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsubara</surname><given-names>Y</given-names></name>
<name><surname>Kimachi</surname><given-names>M</given-names></name>
<name><surname>Fukuma</surname><given-names>S</given-names></name>
<name><surname>Onishi</surname><given-names>Y</given-names></name>
<name><surname>Fukuhara</surname><given-names>S</given-names></name>
</person-group><article-title>Development of a new risk model for predicting cardiovascular events among hemodialysis patients: population-based hemodialysis patients from the Japan Dialysis Outcome and Practice Patterns Study (J-DOPPS)</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><issue>3</issue><fpage>e0173468</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0173468</pub-id><pub-id pub-id-type="pmid">28273175</pub-id>
</element-citation></ref><ref id="B133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Floege</surname><given-names>J</given-names></name>
<name><surname>Gillespie</surname><given-names>IA</given-names></name>
<name><surname>Kronenberg</surname><given-names>F</given-names></name>
<name><surname>Anker</surname><given-names>SD</given-names></name>
<name><surname>Gioni</surname><given-names>I</given-names></name>
<name><surname>Richards</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Development and validation of a predictive mortality risk score from a European hemodialysis cohort</article-title><source>Kidney Int</source><year>2015</year><volume>87</volume><issue>5</issue><fpage>996</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1038/ki.2014.419</pub-id><pub-id pub-id-type="pmid">25651366</pub-id>
</element-citation></ref><ref id="B134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bozkurt</surname><given-names>B</given-names></name>
<name><surname>Coats</surname><given-names>AJ</given-names></name>
<name><surname>Tsutsui</surname><given-names>H</given-names></name>
<name><surname>Abdelhamid</surname><given-names>M</given-names></name>
<name><surname>Adamopoulos</surname><given-names>S</given-names></name>
<name><surname>Albert</surname><given-names>N</given-names></name>
<etal/>
</person-group><article-title>Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure</article-title><source>J Card Fail</source><year>2021</year><volume>27</volume><issue>4</issue><fpage>387</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.cardfail.2021.01.022</pub-id><pub-id pub-id-type="pmid">33663906</pub-id>
</element-citation></ref><ref id="B135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gori</surname><given-names>M</given-names></name>
<name><surname>Gupta</surname><given-names>DK</given-names></name>
<name><surname>Claggett</surname><given-names>B</given-names></name>
<name><surname>Selvin</surname><given-names>E</given-names></name>
<name><surname>Folsom</surname><given-names>AR</given-names></name>
<name><surname>Matsushita</surname><given-names>K</given-names></name>
<etal/>
</person-group><article-title>Natriuretic Peptide and high-sensitivity troponin for cardiovascular risk prediction in diabetes: the Atherosclerosis Risk in Communities (ARIC) study</article-title><source>Diabetes Care</source><year>2016</year><volume>39</volume><issue>5</issue><fpage>677</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.2337/dc15-1760</pub-id><pub-id pub-id-type="pmid">26740635</pub-id>
</element-citation></ref><ref id="B136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wolsk</surname><given-names>E</given-names></name>
<name><surname>Claggett</surname><given-names>B</given-names></name>
<name><surname>Pfeffer</surname><given-names>MA</given-names></name>
<name><surname>Diaz</surname><given-names>R</given-names></name>
<name><surname>Dickstein</surname><given-names>K</given-names></name>
<name><surname>Gerstein</surname><given-names>HC</given-names></name>
<etal/>
</person-group><article-title>Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and Type 2 Diabetes Mellitus</article-title><source>J Am Heart Assoc</source><year>2017</year><volume>6</volume><issue>6</issue><fpage>e004743</fpage><pub-id pub-id-type="doi">10.1161/JAHA.116.004743</pub-id><pub-id pub-id-type="pmid">28554908</pub-id>
</element-citation></ref><ref id="B137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malachias</surname><given-names>MVB</given-names></name>
<name><surname>Jhund</surname><given-names>PS</given-names></name>
<name><surname>Claggett</surname><given-names>BL</given-names></name>
<name><surname>Wijkman</surname><given-names>MO</given-names></name>
<name><surname>Bentley-Lewis</surname><given-names>R</given-names></name>
<name><surname>Chaturvedi</surname><given-names>N</given-names></name>
<etal/>
</person-group><article-title>NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus</article-title><source>J Am Heart Assoc</source><year>2020</year><volume>9</volume><issue>19</issue><fpage>e017462</fpage><pub-id pub-id-type="doi">10.1161/JAHA.120.017462</pub-id><pub-id pub-id-type="pmid">32964800</pub-id>
</element-citation></ref><ref id="B138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prausmuller</surname><given-names>S</given-names></name>
<name><surname>Resl</surname><given-names>M</given-names></name>
<name><surname>Arfsten</surname><given-names>H</given-names></name>
<name><surname>Spinka</surname><given-names>G</given-names></name>
<name><surname>Wurm</surname><given-names>R</given-names></name>
<name><surname>Neuhold</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus</article-title><source>Cardiovasc Diabetol</source><year>2021</year><volume>20</volume><issue>1</issue><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/s12933-021-01221-w</pub-id><pub-id pub-id-type="pmid">33530999</pub-id>
</element-citation></ref><ref id="B139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wijkman</surname><given-names>MO</given-names></name>
<name><surname>Claggett</surname><given-names>BL</given-names></name>
<name><surname>Pfeffer</surname><given-names>MA</given-names></name>
<name><surname>Pare</surname><given-names>G</given-names></name>
<name><surname>McQueen</surname><given-names>M</given-names></name>
<name><surname>Hess</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia - A brief report from the ORIGIN trial</article-title><source>J Diabetes Complications</source><year>2021</year><volume>35</volume><issue>7</issue><fpage>107928</fpage><pub-id pub-id-type="doi">10.1016/j.jdiacomp.2021.107928</pub-id><pub-id pub-id-type="pmid">33906818</pub-id>
</element-citation></ref><ref id="B140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malachias</surname><given-names>MVB</given-names></name>
<name><surname>Wijkman</surname><given-names>MO</given-names></name>
<name><surname>Bertoluci</surname><given-names>MC</given-names></name>
</person-group><article-title>NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes</article-title><source>Diabetol Metab Syndr</source><year>2022</year><volume>14</volume><issue>1</issue><fpage>64</fpage><pub-id pub-id-type="doi">10.1186/s13098-022-00837-6</pub-id><pub-id pub-id-type="pmid">35501909</pub-id>
</element-citation></ref><ref id="B141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harrison</surname><given-names>TG</given-names></name>
<name><surname>Shukalek</surname><given-names>CB</given-names></name>
<name><surname>Hemmelgarn</surname><given-names>BR</given-names></name>
<name><surname>Zarnke</surname><given-names>KB</given-names></name>
<name><surname>Ronksley</surname><given-names>PE</given-names></name>
<name><surname>Iragorri</surname><given-names>N</given-names></name>
<etal/>
</person-group><article-title>Association of NT-proBNP and BNP with future clinical outcomes in patients with ESKD: a systematic review and meta-analysis</article-title><source>Am J Kidney Dis</source><year>2020</year><volume>76</volume><issue>2</issue><fpage>233</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2019.12.017</pub-id><pub-id pub-id-type="pmid">32387090</pub-id>
</element-citation></ref><ref id="B142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wijkman</surname><given-names>MO</given-names></name>
<name><surname>Claggett</surname><given-names>BL</given-names></name>
<name><surname>Malachias</surname><given-names>MVB</given-names></name>
<name><surname>Vaduganathan</surname><given-names>M</given-names></name>
<name><surname>Ballantyne</surname><given-names>CM</given-names></name>
<name><surname>Kitzman</surname><given-names>DW</given-names></name>
<etal/>
</person-group><article-title>Importance of NT-proBNP and conventional risk factors for prediction of death in older adults with and without diabetes mellitus- A report from the Atherosclerosis Risk in Communities (ARIC) study</article-title><source>Diabetes Res Clin Pract</source><year>2022</year><volume>194</volume><fpage>110164</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2022.110164</pub-id><pub-id pub-id-type="pmid">36410558</pub-id>
</element-citation></ref><ref id="B143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bidadkosh</surname><given-names>A</given-names></name>
<name><surname>Lambooy</surname><given-names>SPH</given-names></name>
<name><surname>Heerspink</surname><given-names>HJ</given-names></name>
<name><surname>Pena</surname><given-names>MJ</given-names></name>
<name><surname>Henning</surname><given-names>RH</given-names></name>
<name><surname>Buikema</surname><given-names>H</given-names></name>
<etal/>
</person-group><article-title>Predictive properties of biomarkers GDF-15, NTproBNP, and hs-TnT for morbidity and mortality in patients with Type 2 Diabetes With Nephropathy</article-title><source>Diabetes Care</source><year>2017</year><volume>40</volume><issue>6</issue><fpage>784</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.2337/dc16-2175</pub-id><pub-id pub-id-type="pmid">28341782</pub-id>
</element-citation></ref><ref id="B144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McMurray</surname><given-names>JJ</given-names></name>
<name><surname>Uno</surname><given-names>H</given-names></name>
<name><surname>Jarolim</surname><given-names>P</given-names></name>
<name><surname>Desai</surname><given-names>AS</given-names></name>
<name><surname>de Zeeuw</surname><given-names>D</given-names></name>
<name><surname>Eckardt</surname><given-names>KU</given-names></name>
<etal/>
</person-group><article-title>Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)</article-title><source>Am Heart J</source><year>2011</year><volume>162</volume><issue>4</issue><fpage>748</fpage><lpage>755 e3</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2011.07.016</pub-id><pub-id pub-id-type="pmid">21982669</pub-id>
</element-citation></ref><ref id="B145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Locatelli</surname><given-names>F</given-names></name>
<name><surname>Eckardt</surname><given-names>KU</given-names></name>
<name><surname>Macdougall</surname><given-names>IC</given-names></name>
<name><surname>Tsakiris</surname><given-names>D</given-names></name>
<name><surname>Clyne</surname><given-names>N</given-names></name>
<name><surname>Burger</surname><given-names>HU</given-names></name>
<etal/>
</person-group><article-title>Value of N-terminal brain natriuretic peptide as a prognostic marker in patients with CKD: results from the CREATE study</article-title><source>Curr Med Res Opin</source><year>2010</year><volume>26</volume><issue>11</issue><fpage>2543</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1185/03007995.2010.516237</pub-id><pub-id pub-id-type="pmid">20849244</pub-id>
</element-citation></ref><ref id="B146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Cao</surname><given-names>X</given-names></name>
<name><surname>Yu</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<etal/>
</person-group><article-title>Association of N-Terminal Pro-brain natriuretic peptide with volume status and cardiac function in hemodialysis patients</article-title><source>Front Cardiovasc Med</source><year>2021</year><volume>8</volume><fpage>646402</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2021.646402</pub-id><pub-id pub-id-type="pmid">33693039</pub-id>
</element-citation></ref><ref id="B147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Satoh</surname><given-names>A</given-names></name>
<name><surname>Doi</surname><given-names>S</given-names></name>
<name><surname>Naito</surname><given-names>T</given-names></name>
<name><surname>Nakashima</surname><given-names>A</given-names></name>
<name><surname>Masaki</surname><given-names>T</given-names></name>
</person-group><article-title>N-terminal pro brain natriuretic peptide predicts both all-cause and cardiovascular disease mortality in Japanese hemodialysis patients</article-title><source>Clin Exp Nephrol</source><year>2021</year><volume>25</volume><issue>10</issue><fpage>1142</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/s10157-021-02073-0</pub-id><pub-id pub-id-type="pmid">34106372</pub-id>
</element-citation></ref><ref id="B148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>KH</given-names></name>
<name><surname>Moon</surname><given-names>I</given-names></name>
<name><surname>Oh</surname><given-names>YS</given-names></name>
<name><surname>Yu</surname><given-names>BC</given-names></name>
<name><surname>Park</surname><given-names>MY</given-names></name>
<name><surname>Kim</surname><given-names>JK</given-names></name>
<etal/>
</person-group><article-title>Prediction of heart function and volume status in end-stage kidney disease patients through N-Terminal Pro-Brain Natriuretic Peptide</article-title><source>Medicina (Kaunas)</source><year>2022</year><volume>58</volume><issue>8</issue><fpage>975</fpage><pub-id pub-id-type="doi">10.3390/medicina58080975</pub-id><pub-id pub-id-type="pmid">35893090</pub-id>
</element-citation></ref><ref id="B149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Booth</surname><given-names>J</given-names></name>
<name><surname>Pinney</surname><given-names>J</given-names></name>
<name><surname>Davenport</surname><given-names>A</given-names></name>
</person-group><article-title>N-terminal proBNP--marker of cardiac dysfunction, fluid overload, or malnutrition in hemodialysis patients?</article-title><source>Clin J Am Soc Nephrol</source><year>2010</year><volume>5</volume><issue>6</issue><fpage>1036</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.2215/CJN.09001209</pub-id><pub-id pub-id-type="pmid">20507952</pub-id>
</element-citation></ref><ref id="B150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamaoka</surname><given-names>M</given-names></name>
<name><surname>Yoshida</surname><given-names>M</given-names></name>
<name><surname>Nakashima</surname><given-names>A</given-names></name>
<name><surname>Doi</surname><given-names>S</given-names></name>
<name><surname>Naito</surname><given-names>T</given-names></name>
<name><surname>Masaki</surname><given-names>T</given-names></name>
</person-group><article-title>N-terminal pro-brain natriuretic peptide predicts hospitalization for ischemic stroke in Japanese hemodialysis patients</article-title><source>Clin Exp Nephrol</source><year>2022</year><volume>26</volume><issue>11</issue><fpage>1111</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s10157-022-02254-5</pub-id><pub-id pub-id-type="pmid">35838853</pub-id>
</element-citation></ref><ref id="B151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vickery</surname><given-names>S</given-names></name>
<name><surname>Price</surname><given-names>CP</given-names></name>
<name><surname>John</surname><given-names>RI</given-names></name>
<name><surname>Abbas</surname><given-names>NA</given-names></name>
<name><surname>Webb</surname><given-names>MC</given-names></name>
<name><surname>Kempson</surname><given-names>ME</given-names></name>
<etal/>
</person-group><article-title>B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy</article-title><source>Am J Kidney Dis</source><year>2005</year><volume>46</volume><issue>4</issue><fpage>610</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2005.06.017</pub-id><pub-id pub-id-type="pmid">16183415</pub-id>
</element-citation></ref><ref id="B152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Bortel</surname><given-names>LM</given-names></name>
<name><surname>Laurent</surname><given-names>S</given-names></name>
<name><surname>Boutouyrie</surname><given-names>P</given-names></name>
<name><surname>Chowienczyk</surname><given-names>P</given-names></name>
<name><surname>Cruickshank</surname><given-names>JK</given-names></name>
<name><surname>De Backer</surname><given-names>T</given-names></name>
<etal/>
</person-group><article-title>Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity</article-title><source>J Hypertens</source><year>2012</year><volume>30</volume><issue>3</issue><fpage>445</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/HJH.0b013e32834fa8b0</pub-id><pub-id pub-id-type="pmid">22278144</pub-id>
</element-citation></ref><ref id="B153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brand&#x000e3;o</surname><given-names>AA</given-names></name>
<name><surname>Amodeo</surname><given-names>C</given-names></name>
<name><surname>Alcantara</surname><given-names>C</given-names></name>
<name><surname>Barbosa</surname><given-names>E</given-names></name>
<name><surname>Nobre</surname><given-names>F</given-names></name>
<name><surname>Pinto</surname><given-names>F</given-names></name>
<etal/>
</person-group><article-title>I Luso-Brazilian Positioning on Central Arterial Pressure</article-title><source>Arq Bras Cardiol</source><year>2017</year><volume>108</volume><issue>2</issue><fpage>100</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.5935/abc.20170011</pub-id><pub-id pub-id-type="pmid">28327876</pub-id>
</element-citation></ref><ref id="B154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blacher</surname><given-names>J</given-names></name>
<name><surname>Guerin</surname><given-names>AP</given-names></name>
<name><surname>Pannier</surname><given-names>B</given-names></name>
<name><surname>Marchais</surname><given-names>SJ</given-names></name>
<name><surname>Safar</surname><given-names>ME</given-names></name>
<name><surname>London</surname><given-names>GM</given-names></name>
</person-group><article-title>Impact of aortic stiffness on survival in end-stage renal disease</article-title><source>Circulation</source><year>1999</year><volume>99</volume><issue>18</issue><fpage>2434</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.99.18.2434</pub-id><pub-id pub-id-type="pmid">10318666</pub-id>
</element-citation></ref><ref id="B155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ng</surname><given-names>XN</given-names></name>
<name><surname>Tsai</surname><given-names>JP</given-names></name>
<name><surname>Wang</surname><given-names>CH</given-names></name>
<name><surname>Hsu</surname><given-names>BG</given-names></name>
</person-group><article-title>Carotid-femoral pulse wave velocity could be a marker to predict cardiovascular and all-cause mortality of hemodialysis patients</article-title><source>J Clin Med</source><year>2023</year><volume>12</volume><issue>7</issue><fpage>2509</fpage><pub-id pub-id-type="doi">10.3390/jcm12072509</pub-id><pub-id pub-id-type="pmid">37048592</pub-id>
</element-citation></ref><ref id="B156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Onuigbo</surname><given-names>M</given-names></name>
<name><surname>Onuigbo</surname><given-names>N</given-names></name>
<name><surname>Bellasi</surname><given-names>A</given-names></name>
<name><surname>Russo</surname><given-names>D</given-names></name>
<name><surname>Di Iorio</surname><given-names>BR</given-names></name>
</person-group><article-title>Penultimate pulse wave velocity, better than baseline pulse wave velocity, predicted mortality in Italian ESRD cohort study - a case for daily hemodialysis for ESRD patients with accelerated pulse wave velocity changes</article-title><source>G Ital Nefrol</source><year>2013</year><volume>30</volume><issue>2</issue><comment>gin/30.2.22</comment><pub-id pub-id-type="pmid">23832464</pub-id>
</element-citation></ref><ref id="B157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarafidis</surname><given-names>PA</given-names></name>
<name><surname>Loutradis</surname><given-names>C</given-names></name>
<name><surname>Mayer</surname><given-names>CC</given-names></name>
<name><surname>Karpetas</surname><given-names>A</given-names></name>
<name><surname>Pagkopoulou</surname><given-names>E</given-names></name>
<name><surname>Bikos</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Weak within-individual association of blood pressure and pulse wave velocity in hemodialysis is related to adverse outcomes</article-title><source>J Hypertens</source><year>2019</year><volume>37</volume><issue>11</issue><fpage>2200</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000002153</pub-id><pub-id pub-id-type="pmid">31584899</pub-id>
</element-citation></ref><ref id="B158"><label>158.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Yimei</surname><given-names>XU</given-names></name>
<name><surname>Hao</surname><given-names>YAN</given-names></name>
<name><surname>Zanzhe</surname><given-names>YU</given-names></name>
<name><surname>Zhenyuan</surname><given-names>LI</given-names></name>
<name><surname>Dahua</surname><given-names>MA</given-names></name>
<name><surname>Yiwei</surname><given-names>SHEN</given-names></name>
<name><surname>Xinyu</surname><given-names>SU</given-names></name>
<name><surname>Jiangzi</surname><given-names>YUAN</given-names></name>
<name><surname>Zhaohui</surname><given-names>NI</given-names></name>
<name><surname>Wei</surname><given-names>FANG</given-names></name>
</person-group><source>Chinese Journal of Nephrology;</source><issue>12</issue><fpage>305</fpage><lpage>312</lpage><year>2021</year><comment>Dispon&#x000ed;vel em: <ext-link xlink:href="https://pesquisa.bvsalud.org/portal/resource/pt/wpr-885497" ext-link-type="uri">https://pesquisa.bvsalud.org/portal/resource/pt/wpr-885497</ext-link>
</comment></element-citation></ref><ref id="B159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Breitsameter</surname><given-names>G</given-names></name>
<name><surname>Freitas</surname><given-names>AR</given-names></name>
<name><surname>Poli-de-Figueiredo</surname><given-names>CE</given-names></name>
<name><surname>Figueiredo</surname><given-names>AE</given-names></name>
</person-group><article-title>Clinical evaluation to determine dry weight in hemodialysis is as good as bioelectrical impedance analysis</article-title><source>J Nephrol Urol Res</source><year>2015</year><volume>3</volume><issue>2</issue><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.12970/2310-984X.2015.03.02.31</pub-id></element-citation></ref><ref id="B160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mayne</surname><given-names>KJ</given-names></name>
<name><surname>Lees</surname><given-names>JS</given-names></name>
<name><surname>Herrington</surname><given-names>WG</given-names></name>
</person-group><article-title>Bioimpedance in CKD: an untapped resource?</article-title><source>Nephrol Dial Transplant</source><year>2023</year><volume>38</volume><issue>3</issue><fpage>583</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfac275</pub-id><pub-id pub-id-type="pmid">36260361</pub-id>
</element-citation></ref><ref id="B161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scotland</surname><given-names>G</given-names></name>
<name><surname>Cruickshank</surname><given-names>M</given-names></name>
<name><surname>Jacobsen</surname><given-names>E</given-names></name>
<name><surname>Cooper</surname><given-names>D</given-names></name>
<name><surname>Fraser</surname><given-names>C</given-names></name>
<name><surname>Shimonovich</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis: a systematic review and economic evaluation</article-title><source>Health Technol Assess</source><year>2018</year><volume>22</volume><issue>1</issue><fpage>1</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.3310/hta22010</pub-id><pub-id pub-id-type="pmid">29298736</pub-id>
</element-citation></ref><ref id="B162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tabinor</surname><given-names>M</given-names></name>
<name><surname>Elphick</surname><given-names>E</given-names></name>
<name><surname>Dudson</surname><given-names>M</given-names></name>
<name><surname>Kwok</surname><given-names>CS</given-names></name>
<name><surname>Lambie</surname><given-names>M</given-names></name>
<name><surname>Davies</surname><given-names>SJ</given-names></name>
</person-group><article-title>Bioimpedance-defined overhydration predicts survival in end stage kidney failure (ESKF): systematic review and subgroup meta-analysis</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>4441</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-21226-y</pub-id><pub-id pub-id-type="pmid">29535377</pub-id>
</element-citation></ref><ref id="B163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zoccali</surname><given-names>C</given-names></name>
<name><surname>Moissl</surname><given-names>U</given-names></name>
<name><surname>Chazot</surname><given-names>C</given-names></name>
<name><surname>Mallamaci</surname><given-names>F</given-names></name>
<name><surname>Tripepi</surname><given-names>G</given-names></name>
<name><surname>Arkossy</surname><given-names>O</given-names></name>
<etal/>
</person-group><article-title>Chronic fluid overload and mortality in ESRD</article-title><source>J Am Soc Nephrol</source><year>2017</year><volume>28</volume><issue>8</issue><fpage>2491-7</fpage><pub-id pub-id-type="doi">10.1681/ASN.2016121341</pub-id><pub-id pub-id-type="pmid">28473637</pub-id>
</element-citation></ref><ref id="B164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Covic</surname><given-names>A</given-names></name>
<name><surname>Ciumanghel</surname><given-names>AI</given-names></name>
<name><surname>Siriopol</surname><given-names>D</given-names></name>
<name><surname>Kanbay</surname><given-names>M</given-names></name>
<name><surname>Dumea</surname><given-names>R</given-names></name>
<name><surname>Gavrilovici</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Value of bioimpedance analysis estimated &#x0201c;dry weight&#x0201d; in maintenance dialysis patients: a systematic review and meta-analysis</article-title><source>Int Urol Nephrol</source><year>2017</year><volume>49</volume><issue>12</issue><fpage>2231</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/s11255-017-1698-4</pub-id><pub-id pub-id-type="pmid">28965299</pub-id>
</element-citation></ref><ref id="B165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beaubien-Souligny</surname><given-names>W</given-names></name>
<name><surname>Kontar</surname><given-names>L</given-names></name>
<name><surname>Blum</surname><given-names>D</given-names></name>
<name><surname>Bouchard</surname><given-names>J</given-names></name>
<name><surname>Denault</surname><given-names>AY</given-names></name>
<name><surname>Wald</surname><given-names>R</given-names></name>
</person-group><article-title>Meta-analysis of randomized controlled trials using tool-assisted target weight adjustments in chronic dialysis patients</article-title><source>Kidney Int Rep</source><year>2019</year><volume>4</volume><issue>10</issue><fpage>1426</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.ekir.2019.07.003</pub-id><pub-id pub-id-type="pmid">31701052</pub-id>
</element-citation></ref><ref id="B166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>K</given-names></name>
<name><surname>Pan</surname><given-names>S</given-names></name>
<name><surname>Yang</surname><given-names>N</given-names></name>
<name><surname>Wu</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>He</surname><given-names>Q</given-names></name>
</person-group><article-title>Effect of bioelectrical impedance technology on the prognosis of dialysis patients: a meta-analysis of randomized controlled trials</article-title><source>Ren Fail</source><year>2023</year><volume>45</volume><issue>1</issue><fpage>2203247</fpage><pub-id pub-id-type="doi">10.1080/0886022X.2023.2203247</pub-id><pub-id pub-id-type="pmid">37133857</pub-id>
</element-citation></ref><ref id="B167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Horowitz</surname><given-names>L</given-names></name>
<name><surname>Karadjian</surname><given-names>O</given-names></name>
<name><surname>Braam</surname><given-names>B</given-names></name>
<name><surname>Mavrakanas</surname><given-names>T</given-names></name>
<name><surname>Weber</surname><given-names>C</given-names></name>
</person-group><article-title>Bioimpedance-guided monitoring of volume status in patients with kidney disease: a systematic review and meta-analysis</article-title><source>Can J Kidney Health Dis</source><year>2023</year><volume>10</volume><fpage>20543581231185433</fpage><pub-id pub-id-type="doi">10.1177/20543581231185433</pub-id><pub-id pub-id-type="pmid">37457623</pub-id>
</element-citation></ref><ref id="B168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beaubien-Souligny</surname><given-names>W</given-names></name>
<name><surname>Rola</surname><given-names>P</given-names></name>
<name><surname>Haycock</surname><given-names>K</given-names></name>
<name><surname>Bouchard</surname><given-names>J</given-names></name>
<name><surname>Lamarche</surname><given-names>Y</given-names></name>
<name><surname>Spiegel</surname><given-names>R</given-names></name>
<etal/>
</person-group><article-title>Quantifying systemic congestion with Point-Of-Care ultrasound: development of the venous excess ultrasound grading system</article-title><source>Ultrasound J</source><year>2020</year><volume>12</volume><issue>1</issue><fpage>16</fpage><pub-id pub-id-type="doi">10.1186/s13089-020-00163-w</pub-id><pub-id pub-id-type="pmid">32270297</pub-id>
</element-citation></ref><ref id="B169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shu</surname><given-names>Y</given-names></name>
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Zeng</surname><given-names>X</given-names></name>
<name><surname>Hong</surname><given-names>HG</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Zhong</surname><given-names>H</given-names></name>
<etal/>
</person-group><article-title>The effect of overhydration on mortality and technique failure among peritoneal dialysis patients: a systematic review and meta-analysis</article-title><source>Blood Purif</source><year>2018</year><volume>46</volume><issue>4</issue><fpage>350</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1159/000492148</pub-id><pub-id pub-id-type="pmid">30189422</pub-id>
</element-citation></ref><ref id="B170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caron-Lienert</surname><given-names>RS</given-names></name>
<name><surname>Poli-de-Figueiredo</surname><given-names>CE</given-names></name>
<name><surname>Figueiredo</surname><given-names>A</given-names></name>
<name><surname>da Costa</surname><given-names>BEP</given-names></name>
<name><surname>Crepaldi</surname><given-names>C</given-names></name>
<name><surname>Pizzato</surname><given-names>AC</given-names></name>
<etal/>
</person-group><article-title>The influence of glucose exposure load and peritoneal membrane transport on body composition and nutritional status changes after 1 year on peritoneal dialysis</article-title><source>Perit Dial Int</source><year>2017</year><volume>37</volume><issue>4</issue><fpage>458</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.3747/pdi.2016.00265</pub-id><pub-id pub-id-type="pmid">28408713</pub-id>
</element-citation></ref><ref id="B171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Galindo</surname><given-names>P</given-names></name>
<name><surname>Gasca</surname><given-names>C</given-names></name>
<name><surname>Argaiz</surname><given-names>ER</given-names></name>
<name><surname>Koratala</surname><given-names>A</given-names></name>
</person-group><article-title>Point of care venous Doppler ultrasound: exploring the missing piece of bedside hemodynamic assessment</article-title><source>World J Crit Care Med</source><year>2021</year><volume>10</volume><issue>6</issue><fpage>310</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.5492/wjccm.v10.i6.310</pub-id><pub-id pub-id-type="pmid">34888157</pub-id>
</element-citation></ref><ref id="B172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zoccali</surname><given-names>C</given-names></name>
<name><surname>Torino</surname><given-names>C</given-names></name>
<name><surname>Mallamaci</surname><given-names>F</given-names></name>
<name><surname>Sarafidis</surname><given-names>P</given-names></name>
<name><surname>Papagianni</surname><given-names>A</given-names></name>
<name><surname>Ekart</surname><given-names>R</given-names></name>
<etal/>
</person-group><article-title>A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk</article-title><source>Kidney Int</source><year>2021</year><volume>100</volume><issue>6</issue><fpage>1325</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2021.07.024</pub-id><pub-id pub-id-type="pmid">34418415</pub-id>
</element-citation></ref><ref id="B173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robinson</surname><given-names>BM</given-names></name>
<name><surname>Tong</surname><given-names>L</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Wolfe</surname><given-names>RA</given-names></name>
<name><surname>Goodkin</surname><given-names>DA</given-names></name>
<name><surname>Greenwood</surname><given-names>RN</given-names></name>
<etal/>
</person-group><article-title>Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study</article-title><source>Kidney Int</source><year>2012</year><volume>82</volume><issue>5</issue><fpage>570</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/ki.2012.136</pub-id><pub-id pub-id-type="pmid">22718187</pub-id>
</element-citation></ref><ref id="B174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jhee</surname><given-names>JH</given-names></name>
<name><surname>Park</surname><given-names>J</given-names></name>
<name><surname>Kim</surname><given-names>H</given-names></name>
<name><surname>Kee</surname><given-names>YK</given-names></name>
<name><surname>Park</surname><given-names>JT</given-names></name>
<name><surname>Han</surname><given-names>SH</given-names></name>
<etal/>
</person-group><article-title>The optimal blood pressure target in different dialysis populations</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>14123</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-32281-w</pub-id><pub-id pub-id-type="pmid">30237432</pub-id>
</element-citation></ref><ref id="B175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarafidis</surname><given-names>PA</given-names></name>
<name><surname>Mallamaci</surname><given-names>F</given-names></name>
<name><surname>Loutradis</surname><given-names>C</given-names></name>
<name><surname>Ekart</surname><given-names>R</given-names></name>
<name><surname>Torino</surname><given-names>C</given-names></name>
<name><surname>Karpetas</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Prevalence and control of hypertension by 48-h ambulatory blood pressure monitoring in haemodialysis patients: a study by the European Cardiovascular and Renal Medicine (EURECA-m) working group of the ERA-EDTA</article-title><source>Nephrol Dial Transplant</source><year>2018</year><volume>33</volume><issue>10</issue><fpage>1872</fpage><pub-id pub-id-type="doi">10.1093/ndt/gfy263</pub-id><pub-id pub-id-type="pmid">30113666</pub-id>
</element-citation></ref><ref id="B176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sumida</surname><given-names>K</given-names></name>
<name><surname>Molnar</surname><given-names>MZ</given-names></name>
<name><surname>Potukuchi</surname><given-names>PK</given-names></name>
<name><surname>Thomas</surname><given-names>F</given-names></name>
<name><surname>Lu</surname><given-names>JL</given-names></name>
<name><surname>Ravel</surname><given-names>VA</given-names></name>
<etal/>
</person-group><article-title>Blood pressure before initiation of maintenance dialysis and subsequent mortality</article-title><source>Am J Kidney Dis</source><year>2017</year><volume>70</volume><issue>2</issue><fpage>207</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2016.12.020</pub-id><pub-id pub-id-type="pmid">28291617</pub-id>
</element-citation></ref><ref id="B177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Lima</surname><given-names>JJG</given-names></name>
<name><surname>Gowdak</surname><given-names>LHW</given-names></name>
<name><surname>Reusing</surname><given-names>JO</given-names><suffix>Jr</suffix></name>
<name><surname>David</surname><given-names>E</given-names><suffix>Neto</suffix></name>
<name><surname>Bortolotto</surname><given-names>LA</given-names></name>
</person-group><article-title>Interdialytic blood pressure and risk of cardiovascular events and death in hemodialysis patients</article-title><source>High Blood Press Cardiovasc Prev</source><year>2023</year><volume>30</volume><issue>3</issue><fpage>235</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/s40292-023-00575-4</pub-id><pub-id pub-id-type="pmid">37099259</pub-id>
</element-citation></ref><ref id="B178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miskulin</surname><given-names>DC</given-names></name>
<name><surname>Gassman</surname><given-names>J</given-names></name>
<name><surname>Schrader</surname><given-names>R</given-names></name>
<name><surname>Gul</surname><given-names>A</given-names></name>
<name><surname>Jhamb</surname><given-names>M</given-names></name>
<name><surname>Ploth</surname><given-names>DW</given-names></name>
<etal/>
</person-group><article-title>BP in Dialysis: Results of a Pilot Study</article-title><source>J Am Soc Nephrol</source><year>2018</year><volume>29</volume><issue>1</issue><fpage>307</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1681/ASN.2017020135</pub-id><pub-id pub-id-type="pmid">29212839</pub-id>
</element-citation></ref><ref id="B179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>K/DOQI Workgroup</collab>
</person-group><article-title>K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients</article-title><source>Am J Kidney Dis</source><year>2005</year><volume>45</volume><issue>4, Suppl 3</issue><fpage>S1</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">15806502</pub-id>
</element-citation></ref><ref id="B180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shafi</surname><given-names>T</given-names></name>
<name><surname>Waheed</surname><given-names>S</given-names></name>
<name><surname>Zager</surname><given-names>PG</given-names></name>
</person-group><article-title>Hypertension in hemodialysis patients: an opinion-based update</article-title><source>Semin Dial</source><year>2014</year><volume>27</volume><issue>2</issue><fpage>146</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1111/sdi.12195</pub-id><pub-id pub-id-type="pmid">24494716</pub-id>
</element-citation></ref><ref id="B181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goldfarb-Rumyantzev</surname><given-names>AS</given-names></name>
<name><surname>Baird</surname><given-names>BC</given-names></name>
<name><surname>Leypoldt</surname><given-names>JK</given-names></name>
<name><surname>Cheung</surname><given-names>AK</given-names></name>
</person-group><article-title>The association between BP and mortality in patients on chronic peritoneal dialysis</article-title><source>Nephrol Dial Transplant</source><year>2005</year><volume>20</volume><issue>8</issue><fpage>1693</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfh856</pub-id><pub-id pub-id-type="pmid">15899939</pub-id>
</element-citation></ref><ref id="B182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ryuzaki</surname><given-names>M</given-names></name>
</person-group><article-title>Blood pressure control in peritoneal dialysis patients</article-title><source>Contrib Nephrol</source><year>2018</year><volume>196</volume><fpage>148</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1159/000485715</pub-id><pub-id pub-id-type="pmid">30041220</pub-id>
</element-citation></ref><ref id="B183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vaios</surname><given-names>V</given-names></name>
<name><surname>Georgianos</surname><given-names>PI</given-names></name>
<name><surname>Liakopoulos</surname><given-names>V</given-names></name>
<name><surname>Agarwal</surname><given-names>R</given-names></name>
</person-group><article-title>Assessment and management of hypertension among patients on peritoneal dialysis</article-title><source>Clin J Am Soc Nephrol</source><year>2019</year><volume>14</volume><issue>2</issue><fpage>297</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.2215/CJN.07480618</pub-id><pub-id pub-id-type="pmid">30341090</pub-id>
</element-citation></ref><ref id="B184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Georgianos</surname><given-names>PI</given-names></name>
<name><surname>Agarwal</surname><given-names>R</given-names></name>
</person-group><article-title>Blood pressure in hemodialysis: targets?</article-title><source>Curr Opin Nephrol Hypertens</source><year>2017</year><volume>26</volume><issue>6</issue><fpage>523</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/MNH.0000000000000359</pub-id><pub-id pub-id-type="pmid">28832356</pub-id>
</element-citation></ref><ref id="B185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCallum</surname><given-names>W</given-names></name>
<name><surname>Sarnak</surname><given-names>MJ</given-names></name>
</person-group><article-title>Blood pressure target for the dialysis patient</article-title><source>Semin Dial</source><year>2019</year><volume>32</volume><issue>1</issue><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/sdi.12754</pub-id><pub-id pub-id-type="pmid">30422343</pub-id>
</element-citation></ref><ref id="B186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>National Kidney Foundation</collab>
</person-group><article-title>KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update</article-title><source>Am J Kidney Dis</source><year>2015</year><volume>66</volume><issue>5</issue><fpage>884</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2015.07.015</pub-id><pub-id pub-id-type="pmid">26498416</pub-id>
</element-citation></ref><ref id="B187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hirakata</surname><given-names>H</given-names></name>
<name><surname>Nitta</surname><given-names>K</given-names></name>
<name><surname>Inaba</surname><given-names>M</given-names></name>
<name><surname>Shoji</surname><given-names>T</given-names></name>
<name><surname>Fujii</surname><given-names>H</given-names></name>
<name><surname>Kobayashi</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis</article-title><source>Ther Apher Dial</source><year>2012</year><volume>16</volume><issue>5</issue><fpage>387</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1111/j.1744-9987.2012.01088.x</pub-id><pub-id pub-id-type="pmid">23046367</pub-id>
</element-citation></ref><ref id="B188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Unger</surname><given-names>T</given-names></name>
<name><surname>Borghi</surname><given-names>C</given-names></name>
<name><surname>Charchar</surname><given-names>F</given-names></name>
<name><surname>Khan</surname><given-names>NA</given-names></name>
<name><surname>Poulter</surname><given-names>NR</given-names></name>
<name><surname>Prabhakaran</surname><given-names>D</given-names></name>
<etal/>
</person-group><article-title>2020 International Society of Hypertension Global Hypertension Practice Guidelines</article-title><source>Hypertension</source><year>2020</year><volume>75</volume><issue>6</issue><fpage>1334</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.15026</pub-id><pub-id pub-id-type="pmid">32370572</pub-id>
</element-citation></ref><ref id="B189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Assimon</surname><given-names>MM</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Flythe</surname><given-names>JE</given-names></name>
</person-group><article-title>Failed target weight achievement associates with short-term hospital encounters among individuals receiving maintenance hemodialysis</article-title><source>J Am Soc Nephrol</source><year>2018</year><volume>29</volume><issue>8</issue><fpage>2178</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1681/ASN.2018010004</pub-id><pub-id pub-id-type="pmid">29793962</pub-id>
</element-citation></ref><ref id="B190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hecking</surname><given-names>M</given-names></name>
<name><surname>Moissl</surname><given-names>U</given-names></name>
<name><surname>Genser</surname><given-names>B</given-names></name>
<name><surname>Rayner</surname><given-names>H</given-names></name>
<name><surname>Dasgupta</surname><given-names>I</given-names></name>
<name><surname>Stuard</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Greater fluid overload and lower interdialytic weight gain are independently associated with mortality in a large international hemodialysis population</article-title><source>Nephrol Dial Transplant</source><year>2018</year><volume>33</volume><issue>10</issue><fpage>1832</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfy083</pub-id><pub-id pub-id-type="pmid">29688512</pub-id>
</element-citation></ref><ref id="B191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dasgupta</surname><given-names>I</given-names></name>
<name><surname>Thomas</surname><given-names>GN</given-names></name>
<name><surname>Clarke</surname><given-names>J</given-names></name>
<name><surname>Sitch</surname><given-names>A</given-names></name>
<name><surname>Martin</surname><given-names>J</given-names></name>
<name><surname>Bieber</surname><given-names>B</given-names></name>
<etal/>
</person-group><article-title>Associations between hemodialysis facility practices to manage fluid volume and intradialytic hypotension and patient outcomes</article-title><source>Clin J Am Soc Nephrol</source><year>2019</year><volume>14</volume><issue>3</issue><fpage>385</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.2215/CJN.08240718</pub-id><pub-id pub-id-type="pmid">30723164</pub-id>
</element-citation></ref><ref id="B192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torino</surname><given-names>C</given-names></name>
<name><surname>Gargani</surname><given-names>L</given-names></name>
<name><surname>Sicari</surname><given-names>R</given-names></name>
<name><surname>Letachowicz</surname><given-names>K</given-names></name>
<name><surname>Ekart</surname><given-names>R</given-names></name>
<name><surname>Fliser</surname><given-names>D</given-names></name>
<etal/>
</person-group><article-title>The agreement between auscultation and lung ultrasound in hemodialysis patients: the LUST study</article-title><source>Clin J Am Soc Nephrol</source><year>2016</year><volume>11</volume><issue>11</issue><fpage>2005</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.2215/CJN.03890416</pub-id><pub-id pub-id-type="pmid">27660305</pub-id>
</element-citation></ref><ref id="B193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rutkowski</surname><given-names>B</given-names></name>
<name><surname>Tam</surname><given-names>P</given-names></name>
<name><surname>van der Sande</surname><given-names>FM</given-names></name>
<name><surname>Vychytil</surname><given-names>A</given-names></name>
<name><surname>Schwenger</surname><given-names>V</given-names></name>
<name><surname>Himmele</surname><given-names>R</given-names></name>
<etal/>
</person-group><article-title>Low-Sodium versus standard-sodium peritoneal dialysis solution in hypertensive patients: a randomized controlled trial</article-title><source>Am J Kidney Dis</source><year>2016</year><volume>67</volume><issue>5</issue><fpage>753</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2015.07.031</pub-id><pub-id pub-id-type="pmid">26388284</pub-id>
</element-citation></ref><ref id="B194"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dunne</surname><given-names>N</given-names></name>
</person-group><article-title>A meta-analysis of sodium profiling techniques and the impact on intradialytic hypotension</article-title><source>Hemodial Int</source><year>2017</year><volume>21</volume><issue>3</issue><fpage>312</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1111/hdi.12488</pub-id><pub-id pub-id-type="pmid">27615278</pub-id>
</element-citation></ref><ref id="B195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nesrallah</surname><given-names>GE</given-names></name>
<name><surname>Suri</surname><given-names>RS</given-names></name>
<name><surname>Guyatt</surname><given-names>G</given-names></name>
<name><surname>Mustafa</surname><given-names>RA</given-names></name>
<name><surname>Walter</surname><given-names>SD</given-names></name>
<name><surname>Lindsay</surname><given-names>RM</given-names></name>
<etal/>
</person-group><article-title>Biofeedback dialysis for hypotension and hypervolemia: a systematic review and meta-analysis</article-title><source>Nephrol Dial Transplant</source><year>2013</year><volume>28</volume><issue>1</issue><fpage>182</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfs389</pub-id><pub-id pub-id-type="pmid">23197678</pub-id>
</element-citation></ref><ref id="B196"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Flythe</surname><given-names>JE</given-names></name>
<name><surname>Tugman</surname><given-names>MJ</given-names></name>
<name><surname>Narendra</surname><given-names>JH</given-names></name>
<name><surname>Assimon</surname><given-names>MM</given-names></name>
<name><surname>Li</surname><given-names>Q</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<etal/>
</person-group><article-title>Effect of ultrafiltration profiling on outcomes among maintenance hemodialysis patients: a pilot randomized crossover trial</article-title><source>J Nephrol</source><year>2021</year><volume>34</volume><issue>1</issue><fpage>113</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s40620-020-00862-6</pub-id><pub-id pub-id-type="pmid">32975783</pub-id>
</element-citation></ref><ref id="B197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mustafa</surname><given-names>RA</given-names></name>
<name><surname>Bdair</surname><given-names>F</given-names></name>
<name><surname>Akl</surname><given-names>EA</given-names></name>
<name><surname>Garg</surname><given-names>AX</given-names></name>
<name><surname>Thiessen-Philbrook</surname><given-names>H</given-names></name>
<name><surname>Salameh</surname><given-names>H</given-names></name>
<etal/>
</person-group><article-title>Effect of Lowering the dialysate temperature in chronic hemodialysis: a systematic review and meta-analysis</article-title><source>Clin J Am Soc Nephrol</source><year>2016</year><volume>11</volume><issue>3</issue><fpage>442</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.2215/CJN.04580415</pub-id><pub-id pub-id-type="pmid">26712807</pub-id>
</element-citation></ref><ref id="B198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Htay</surname><given-names>H</given-names></name>
<name><surname>Johnson</surname><given-names>DW</given-names></name>
<name><surname>Wiggins</surname><given-names>KJ</given-names></name>
<name><surname>Badve</surname><given-names>SV</given-names></name>
<name><surname>Craig</surname><given-names>JC</given-names></name>
<name><surname>Strippoli</surname><given-names>GF</given-names></name>
<etal/>
</person-group><article-title>Biocompatible dialysis fluids for peritoneal dialysis</article-title><source>Cochrane Database Syst Rev</source><year>2018</year><volume>10</volume><issue>10</issue><fpage>CD007554</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD007554.pub3</pub-id><pub-id pub-id-type="pmid">30362116</pub-id>
</element-citation></ref><ref id="B199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tawada</surname><given-names>M</given-names></name>
<name><surname>Hamada</surname><given-names>C</given-names></name>
<name><surname>Suzuki</surname><given-names>Y</given-names></name>
<name><surname>Sakata</surname><given-names>F</given-names></name>
<name><surname>Sun</surname><given-names>T</given-names></name>
<name><surname>Kinashi</surname><given-names>H</given-names></name>
<etal/>
</person-group><article-title>Effects of long-term treatment with low-GDP, pH-neutral solutions on peritoneal membranes in peritoneal dialysis patients</article-title><source>Clin Exp Nephrol</source><year>2019</year><volume>23</volume><issue>5</issue><fpage>689</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1007/s10157-018-1679-7</pub-id><pub-id pub-id-type="pmid">30547267</pub-id>
</element-citation></ref><ref id="B200"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elphick</surname><given-names>EH</given-names></name>
<name><surname>Teece</surname><given-names>L</given-names></name>
<name><surname>Chess</surname><given-names>JA</given-names></name>
<name><surname>Do</surname><given-names>JY</given-names></name>
<name><surname>Kim</surname><given-names>YL</given-names></name>
<name><surname>Lee</surname><given-names>HB</given-names></name>
<etal/>
</person-group><article-title>Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport</article-title><source>Clin J Am Soc Nephrol</source><year>2018</year><volume>13</volume><issue>10</issue><fpage>1526</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.2215/CJN.02380218</pub-id><pub-id pub-id-type="pmid">30171050</pub-id>
</element-citation></ref><ref id="B201"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>CT</given-names></name>
<name><surname>Chertow</surname><given-names>GM</given-names></name>
<name><surname>Daugirdas</surname><given-names>JT</given-names></name>
<name><surname>Greene</surname><given-names>TH</given-names></name>
<name><surname>Kotanko</surname><given-names>P</given-names></name>
<name><surname>Larive</surname><given-names>B</given-names></name>
<etal/>
</person-group><article-title>Effects of daily hemodialysis on heart rate variability: results from the Frequent Hemodialysis Network (FHN) Daily Trial</article-title><source>Nephrol Dial Transplant</source><year>2014</year><volume>29</volume><issue>1</issue><fpage>168</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1093/ndt/gft212</pub-id><pub-id pub-id-type="pmid">24078335</pub-id>
</element-citation></ref><ref id="B202"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>CT</given-names></name>
<name><surname>Kaysen</surname><given-names>GA</given-names></name>
<name><surname>Beck</surname><given-names>GJ</given-names></name>
<name><surname>Li</surname><given-names>M</given-names></name>
<name><surname>Lo</surname><given-names>JC</given-names></name>
<name><surname>Rocco</surname><given-names>MV</given-names></name>
<etal/>
</person-group><article-title>The effect of frequent hemodialysis on matrix metalloproteinases, their tissue inhibitors, and FGF23: implications for blood pressure and left ventricular mass modification in the Frequent Hemodialysis Network trials</article-title><source>Hemodial Int</source><year>2020</year><volume>24</volume><issue>2</issue><fpage>162</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1111/hdi.12807</pub-id><pub-id pub-id-type="pmid">31826326</pub-id>
</element-citation></ref><ref id="B203"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kotanko</surname><given-names>P</given-names></name>
<name><surname>Garg</surname><given-names>AX</given-names></name>
<name><surname>Depner</surname><given-names>T</given-names></name>
<name><surname>Pierratos</surname><given-names>A</given-names></name>
<name><surname>Chan</surname><given-names>CT</given-names></name>
<name><surname>Levin</surname><given-names>NW</given-names></name>
<etal/>
</person-group><article-title>Effects of frequent hemodialysis on blood pressure: results from the randomized frequent hemodialysis network trials</article-title><source>Hemodial Int</source><year>2015</year><volume>19</volume><issue>3</issue><fpage>386</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1111/hdi.12255</pub-id><pub-id pub-id-type="pmid">25560227</pub-id>
</element-citation></ref><ref id="B204"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cherukuri</surname><given-names>S</given-names></name>
<name><surname>Bajo</surname><given-names>M</given-names></name>
<name><surname>Colussi</surname><given-names>G</given-names></name>
<name><surname>Corciulo</surname><given-names>R</given-names></name>
<name><surname>Fessi</surname><given-names>H</given-names></name>
<name><surname>Ficheux</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Home hemodialysis treatment and outcomes: retrospective analysis of the Knowledge to Improve Home Dialysis Network in Europe (KIHDNEy) cohort</article-title><source>BMC Nephrol</source><year>2018</year><volume>19</volume><issue>1</issue><fpage>262</fpage><pub-id pub-id-type="doi">10.1186/s12882-018-1059-2</pub-id><pub-id pub-id-type="pmid">30314451</pub-id>
</element-citation></ref><ref id="B205"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mathew</surname><given-names>A</given-names></name>
<name><surname>McLeggon</surname><given-names>JA</given-names></name>
<name><surname>Mehta</surname><given-names>N</given-names></name>
<name><surname>Leung</surname><given-names>S</given-names></name>
<name><surname>Barta</surname><given-names>V</given-names></name>
<name><surname>McGinn</surname><given-names>T</given-names></name>
<etal/>
</person-group><article-title>Mortality and hospitalizations in intensive dialysis: a systematic review and meta-analysis</article-title><source>Can J Kidney Health Dis</source><year>2018</year><volume>5</volume><fpage>2054358117749531</fpage><pub-id pub-id-type="doi">10.1177/2054358117749531</pub-id><pub-id pub-id-type="pmid">29348924</pub-id>
</element-citation></ref><ref id="B206"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong</surname><given-names>B</given-names></name>
<name><surname>Collister</surname><given-names>D</given-names></name>
<name><surname>Muneer</surname><given-names>M</given-names></name>
<name><surname>Storie</surname><given-names>D</given-names></name>
<name><surname>Courtney</surname><given-names>M</given-names></name>
<name><surname>Lloyd</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>In-center nocturnal hemodialysis versus conventional hemodialysis: a systematic review of the evidence</article-title><source>Am J Kidney Dis</source><year>2017</year><volume>70</volume><issue>2</issue><fpage>218</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2017.01.047</pub-id><pub-id pub-id-type="pmid">28359656</pub-id>
</element-citation></ref><ref id="B207"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Culleton</surname><given-names>BF</given-names></name>
<name><surname>Walsh</surname><given-names>M</given-names></name>
<name><surname>Klarenbach</surname><given-names>SW</given-names></name>
<name><surname>Mortis</surname><given-names>G</given-names></name>
<name><surname>Scott-Douglas</surname><given-names>N</given-names></name>
<name><surname>Quinn</surname><given-names>RR</given-names></name>
<etal/>
</person-group><article-title>Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial</article-title><source>JAMA</source><year>2007</year><volume>298</volume><issue>11</issue><fpage>1291</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/jama.298.11.1291</pub-id><pub-id pub-id-type="pmid">17878421</pub-id>
</element-citation></ref><ref id="B208"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blankestijn</surname><given-names>PJ</given-names></name>
<name><surname>Vernooij</surname><given-names>RWM</given-names></name>
<name><surname>Hockham</surname><given-names>C</given-names></name>
<name><surname>Strippoli</surname><given-names>GFM</given-names></name>
<name><surname>Canaud</surname><given-names>B</given-names></name>
<name><surname>Hegbrant</surname><given-names>J</given-names></name>
<etal/>
</person-group><article-title>Effect of hemodiafiltration or hemodialysis on mortality in kidney failure</article-title><source>N Engl J Med</source><year>2023</year><volume>389</volume><issue>8</issue><fpage>700</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2304820</pub-id><pub-id pub-id-type="pmid">37326323</pub-id>
</element-citation></ref><ref id="B209"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rootjes</surname><given-names>PA</given-names></name>
<name><surname>de Roij van Zuijdewijn</surname><given-names>CLM</given-names></name>
<name><surname>Grooteman</surname><given-names>MPC</given-names></name>
<name><surname>Bots</surname><given-names>ML</given-names></name>
<name><surname>Canaud</surname><given-names>B</given-names></name>
<name><surname>Blankestijn</surname><given-names>PJ</given-names></name>
<etal/>
</person-group><article-title>Long-term peridialytic blood pressure patterns in patients treated by hemodialysis and hemodiafiltration</article-title><source>Kidney Int Rep</source><year>2020</year><volume>5</volume><issue>4</issue><fpage>503</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.ekir.2020.01.007</pub-id><pub-id pub-id-type="pmid">32274454</pub-id>
</element-citation></ref><ref id="B210"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nistor</surname><given-names>I</given-names></name>
<name><surname>Palmer</surname><given-names>SC</given-names></name>
<name><surname>Craig</surname><given-names>JC</given-names></name>
<name><surname>Saglimbene</surname><given-names>V</given-names></name>
<name><surname>Vecchio</surname><given-names>M</given-names></name>
<name><surname>Covic</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Convective versus diffusive dialysis therapies for chronic kidney failure: an updated systematic review of randomized controlled trials</article-title><source>Am J Kidney Dis</source><year>2014</year><volume>63</volume><issue>6</issue><fpage>954</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2013.12.004</pub-id><pub-id pub-id-type="pmid">24434188</pub-id>
</element-citation></ref><ref id="B211"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koda</surname><given-names>Y</given-names></name>
<name><surname>Aoike</surname><given-names>I</given-names></name>
</person-group><article-title>Prevention of Intradialytic hypotension with intermittent back-filtrate infusion haemodiafiltration: insights into the underlying mechanism</article-title><source>Blood Purif</source><year>2019</year><volume>48</volume><issue>Suppl 1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1159/000503878</pub-id><pub-id pub-id-type="pmid">31751990</pub-id>
</element-citation></ref><ref id="B212"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kayikcioglu</surname><given-names>M</given-names></name>
<name><surname>Tumuklu</surname><given-names>M</given-names></name>
<name><surname>Ozkahya</surname><given-names>M</given-names></name>
<name><surname>Ozdogan</surname><given-names>O</given-names></name>
<name><surname>Asci</surname><given-names>G</given-names></name>
<name><surname>Duman</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis</article-title><source>Nephrol Dial Transplant</source><year>2009</year><volume>24</volume><issue>3</issue><fpage>956</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfn599</pub-id><pub-id pub-id-type="pmid">19004849</pub-id>
</element-citation></ref><ref id="B213"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cole</surname><given-names>NI</given-names></name>
<name><surname>Swift</surname><given-names>PA</given-names></name>
<name><surname>He</surname><given-names>FJ</given-names></name>
<name><surname>MacGregor</surname><given-names>GA</given-names></name>
<name><surname>Suckling</surname><given-names>RJ</given-names></name>
</person-group><article-title>The effect of dietary salt on blood pressure in individuals receiving chronic dialysis: a systematic review and meta-analysis of randomised controlled trials</article-title><source>J Hum Hypertens</source><year>2019</year><volume>33</volume><issue>4</issue><fpage>319</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/s41371-018-0131-5</pub-id><pub-id pub-id-type="pmid">30413764</pub-id>
</element-citation></ref><ref id="B214"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mc Causland</surname><given-names>FR</given-names></name>
<name><surname>Waikar</surname><given-names>SS</given-names></name>
<name><surname>Brunelli</surname><given-names>SM</given-names></name>
</person-group><article-title>Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients</article-title><source>Kidney Int</source><year>2012</year><volume>82</volume><issue>2</issue><fpage>204</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/ki.2012.42</pub-id><pub-id pub-id-type="pmid">22418981</pub-id>
</element-citation></ref><ref id="B215"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davenport</surname><given-names>A</given-names></name>
</person-group><article-title>Interdialytic weight gain in diabetic haemodialysis patients and diabetic control as assessed by glycated haemoglobin</article-title><source>Nephron Clin Pract</source><year>2009</year><volume>113</volume><issue>1</issue><fpage>c33</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1159/000228073</pub-id><pub-id pub-id-type="pmid">19590233</pub-id>
</element-citation></ref><ref id="B216"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bacharaki</surname><given-names>D</given-names></name>
<name><surname>Petrakis</surname><given-names>I</given-names></name>
<name><surname>Kyriazis</surname><given-names>P</given-names></name>
<name><surname>Markaki</surname><given-names>A</given-names></name>
<name><surname>Pleros</surname><given-names>C</given-names></name>
<name><surname>Tsirpanlis</surname><given-names>G</given-names></name>
<etal/>
</person-group><article-title>Adherence to the Mediterranean Diet Is Associated with a More Favorable Left Ventricular Geometry in Patients with End-Stage Kidney Disease</article-title><source>J Clin Med</source><year>2022</year><volume>11</volume><issue>19</issue><fpage>5746</fpage><pub-id pub-id-type="doi">10.3390/jcm11195746</pub-id><pub-id pub-id-type="pmid">36233612</pub-id>
</element-citation></ref><ref id="B217"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Charkviani</surname><given-names>M</given-names></name>
<name><surname>Thongprayoon</surname><given-names>C</given-names></name>
<name><surname>Tangpanithandee</surname><given-names>S</given-names></name>
<name><surname>Krisanapan</surname><given-names>P</given-names></name>
<name><surname>Miao</surname><given-names>J</given-names></name>
<name><surname>Mao</surname><given-names>MA</given-names></name>
<etal/>
</person-group><article-title>Effects of mediterranean diet, DASH diet, and plant-based diet on outcomes among end stage kidney disease patients: a systematic review and meta-analysis</article-title><source>Clin Pract</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.3390/clinpract13010004</pub-id><pub-id pub-id-type="pmid">36648844</pub-id>
</element-citation></ref><ref id="B218"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marx</surname><given-names>W</given-names></name>
<name><surname>Kelly</surname><given-names>J</given-names></name>
<name><surname>Marshall</surname><given-names>S</given-names></name>
<name><surname>Nakos</surname><given-names>S</given-names></name>
<name><surname>Campbell</surname><given-names>K</given-names></name>
<name><surname>Itsiopoulos</surname><given-names>C</given-names></name>
</person-group><article-title>The effect of polyphenol-rich interventions on cardiovascular risk factors in haemodialysis: a systematic review and meta-analysis</article-title><source>Nutrients</source><year>2017</year><volume>9</volume><issue>12</issue><fpage>1345</fpage><pub-id pub-id-type="doi">10.3390/nu9121345</pub-id><pub-id pub-id-type="pmid">29232891</pub-id>
</element-citation></ref><ref id="B219"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Young</surname><given-names>HML</given-names></name>
<name><surname>March</surname><given-names>DS</given-names></name>
<name><surname>Graham-Brown</surname><given-names>MPM</given-names></name>
<name><surname>Jones</surname><given-names>AW</given-names></name>
<name><surname>Curtis</surname><given-names>F</given-names></name>
<name><surname>Grantham</surname><given-names>CS</given-names></name>
<etal/>
</person-group><article-title>Effects of intradialytic cycling exercise on exercise capacity, quality of life, physical function and cardiovascular measures in adult haemodialysis patients: a systematic review and meta-analysis</article-title><source>Nephrol Dial Transplant</source><year>2018</year><volume>33</volume><issue>8</issue><fpage>1436</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfy045</pub-id><pub-id pub-id-type="pmid">29608708</pub-id>
</element-citation></ref><ref id="B220"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrari</surname><given-names>F</given-names></name>
<name><surname>Andrade</surname><given-names>FP</given-names></name>
<name><surname>Teixeira</surname><given-names>MS</given-names></name>
<name><surname>Ziegelmann</surname><given-names>PK</given-names></name>
<name><surname>Carvalho</surname><given-names>G</given-names></name>
<name><surname>Bittencourt</surname><given-names>ESS</given-names></name>
<etal/>
</person-group><article-title>Efficacy of six exercise-based interventions for individuals undergoing hemodialysis: a network meta-analysis of randomized clinical trials</article-title><source>Nephrol Dial Transplant</source><year>2023</year><volume>38</volume><issue>10</issue><fpage>2389</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfad083</pub-id><pub-id pub-id-type="pmid">37118876</pub-id>
</element-citation></ref><ref id="B221"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Battaglia</surname><given-names>Y</given-names></name>
<name><surname>Amicone</surname><given-names>M</given-names></name>
<name><surname>Mantovani</surname><given-names>A</given-names></name>
<name><surname>Combe</surname><given-names>C</given-names></name>
<name><surname>Mitra</surname><given-names>S</given-names></name>
<name><surname>Basile</surname><given-names>C</given-names></name>
</person-group><article-title>Home-based exercise in patients on maintenance dialysis: a systematic review and meta-analysis of randomized clinical trials</article-title><source>Nephrol Dial Transplant</source><year>2023</year><volume>38</volume><issue>11</issue><fpage>2550</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfad102</pub-id><pub-id pub-id-type="pmid">37202219</pub-id>
</element-citation></ref><ref id="B222"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leimig</surname><given-names>MBC</given-names></name>
<name><surname>Lira</surname><given-names>RT</given-names></name>
<name><surname>Peres</surname><given-names>FB</given-names></name>
<name><surname>Ferreira</surname><given-names>AGC</given-names></name>
<name><surname>Falbo</surname><given-names>AR</given-names></name>
</person-group><article-title>Qualidade de vida, espiritualidade, religiosidade e esperan&#x000e7;a em pessoas com doen&#x000e7;a renal cr&#x000f4;nica em hemodi&#x000e1;lise.</article-title><source>Rev Soc Bras Clin Med</source><year>2018</year><volume>1</volume><issue>16</issue><fpage>30</fpage><lpage>6</lpage></element-citation></ref><ref id="B223"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burlacu</surname><given-names>A</given-names></name>
<name><surname>Artene</surname><given-names>B</given-names></name>
<name><surname>Nistor</surname><given-names>I</given-names></name>
<name><surname>Buju</surname><given-names>S</given-names></name>
<name><surname>Jugrin</surname><given-names>D</given-names></name>
<name><surname>Mavrichi</surname><given-names>I</given-names></name>
<etal/>
</person-group><article-title>Religiosity, spirituality and quality of life of dialysis patients: a systematic review</article-title><source>Int Urol Nephrol</source><year>2019</year><volume>51</volume><issue>5</issue><fpage>839</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/s11255-019-02129-x</pub-id><pub-id pub-id-type="pmid">30919258</pub-id>
</element-citation></ref><ref id="B224"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>SS</given-names></name>
<name><surname>Shah</surname><given-names>VS</given-names></name>
<name><surname>Peterson</surname><given-names>RA</given-names></name>
<name><surname>Kimmel</surname><given-names>PL</given-names></name>
</person-group><article-title>Psychosocial variables, quality of life, and religious beliefs in ESRD patients treated with hemodialysis</article-title><source>Am J Kidney Dis</source><year>2002</year><volume>40</volume><issue>5</issue><fpage>1013</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1053/ajkd.2002.36336</pub-id><pub-id pub-id-type="pmid">12407647</pub-id>
</element-citation></ref><ref id="B225"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berman</surname><given-names>E</given-names></name>
<name><surname>Merz</surname><given-names>JF</given-names></name>
<name><surname>Rudnick</surname><given-names>M</given-names></name>
<name><surname>Snyder</surname><given-names>RW</given-names></name>
<name><surname>Rogers</surname><given-names>KK</given-names></name>
<name><surname>Lee</surname><given-names>J</given-names></name>
<etal/>
</person-group><article-title>Religiosity in a hemodialysis population and its relationship to satisfaction with medical care, satisfaction with life, and adherence</article-title><source>Am J Kidney Dis</source><year>2004</year><volume>44</volume><issue>3</issue><fpage>488</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/S0272-6386(04)00818-2</pub-id><pub-id pub-id-type="pmid">15332222</pub-id>
</element-citation></ref><ref id="B226"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>PR</given-names></name>
<name><surname>Capote</surname><given-names>JRFG</given-names><suffix>Jr</suffix></name>
<name><surname>Cavalcante Fo</surname><given-names>JRM</given-names></name>
<name><surname>Ferreira</surname><given-names>TP</given-names></name>
<name><surname>Dos Santos Fo</surname><given-names>JNG</given-names></name>
<name><surname>da Silva Oliveira</surname><given-names>S</given-names></name>
</person-group><article-title>Religious coping methods predict depression and quality of life among end-stage renal disease patients undergoing hemodialysis: a cross-sectional study</article-title><source>BMC Nephrol</source><year>2017</year><volume>18</volume><issue>1</issue><fpage>197</fpage><pub-id pub-id-type="doi">10.1186/s12882-017-0619-1</pub-id><pub-id pub-id-type="pmid">28623903</pub-id>
</element-citation></ref><ref id="B227"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>R</given-names></name>
</person-group><article-title>Epidemiology of interdialytic ambulatory hypertension and the role of volume excess</article-title><source>Am J Nephrol</source><year>2011</year><volume>34</volume><issue>4</issue><fpage>381</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1159/000331067</pub-id><pub-id pub-id-type="pmid">21893975</pub-id>
</element-citation></ref><ref id="B228"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>R</given-names></name>
<name><surname>Sinha</surname><given-names>AD</given-names></name>
</person-group><article-title>Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis</article-title><source>Hypertension</source><year>2009</year><volume>53</volume><issue>5</issue><fpage>860</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.108.128116</pub-id><pub-id pub-id-type="pmid">19273737</pub-id>
</element-citation></ref><ref id="B229"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heerspink</surname><given-names>HJ</given-names></name>
<name><surname>Ninomiya</surname><given-names>T</given-names></name>
<name><surname>Zoungas</surname><given-names>S</given-names></name>
<name><surname>de Zeeuw</surname><given-names>D</given-names></name>
<name><surname>Grobbee</surname><given-names>DE</given-names></name>
<name><surname>Jardine</surname><given-names>MJ</given-names></name>
<etal/>
</person-group><article-title>Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials</article-title><source>Lancet</source><year>2009</year><volume>373</volume><issue>9668</issue><fpage>1009</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)60212-9</pub-id><pub-id pub-id-type="pmid">19249092</pub-id>
</element-citation></ref><ref id="B230"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trinh</surname><given-names>E</given-names></name>
<name><surname>Bargman</surname><given-names>JM</given-names></name>
</person-group><article-title>Are diuretics underutilized in dialysis patients?</article-title><source>Semin Dial</source><year>2016</year><volume>29</volume><issue>5</issue><fpage>338</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1111/sdi.12483</pub-id><pub-id pub-id-type="pmid">27060970</pub-id>
</element-citation></ref><ref id="B231"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>X</given-names></name>
<name><surname>Chen</surname><given-names>L</given-names></name>
<name><surname>Chen</surname><given-names>W</given-names></name>
<name><surname>Li</surname><given-names>P</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
<name><surname>Fu</surname><given-names>P</given-names></name>
</person-group><article-title>Effects of diuretics on intradialytic hypotension in maintenance dialysis patients: a systematic review and meta-analysis</article-title><source>Int Urol Nephrol</source><year>2021</year><volume>53</volume><issue>9</issue><fpage>1911</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1007/s11255-021-02805-x</pub-id><pub-id pub-id-type="pmid">33675484</pub-id>
</element-citation></ref><ref id="B232"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sibbel</surname><given-names>S</given-names></name>
<name><surname>Walker</surname><given-names>AG</given-names></name>
<name><surname>Colson</surname><given-names>C</given-names></name>
<name><surname>Tentori</surname><given-names>F</given-names></name>
<name><surname>Brunelli</surname><given-names>SM</given-names></name>
<name><surname>Flythe</surname><given-names>J</given-names></name>
</person-group><article-title>Association of continuation of loop diuretics at hemodialysis initiation with clinical outcomes</article-title><source>Clin J Am Soc Nephrol</source><year>2019</year><volume>14</volume><issue>1</issue><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.2215/CJN.05080418</pub-id><pub-id pub-id-type="pmid">30567905</pub-id>
</element-citation></ref><ref id="B233"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bragg-Gresham</surname><given-names>JL</given-names></name>
<name><surname>Fissell</surname><given-names>RB</given-names></name>
<name><surname>Mason</surname><given-names>NA</given-names></name>
<name><surname>Bailie</surname><given-names>GR</given-names></name>
<name><surname>Gillespie</surname><given-names>BW</given-names></name>
<name><surname>Wizemann</surname><given-names>V</given-names></name>
<etal/>
</person-group><article-title>Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS)</article-title><source>Am J Kidney Dis</source><year>2007</year><volume>49</volume><issue>3</issue><fpage>426</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2006.12.012</pub-id><pub-id pub-id-type="pmid">17336704</pub-id>
</element-citation></ref><ref id="B234"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Witoon</surname><given-names>R</given-names></name>
<name><surname>Yongsiri</surname><given-names>S</given-names></name>
<name><surname>Buranaburidej</surname><given-names>P</given-names></name>
<name><surname>Nanna</surname><given-names>P</given-names></name>
</person-group><article-title>Efficacy of triple diuretic treatment in continuous ambulatory peritoneal dialysis patients: a randomized controlled trial</article-title><source>Kidney Res Clin Pract</source><year>2019</year><volume>38</volume><issue>1</issue><fpage>108</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.23876/j.krcp.18.0115</pub-id><pub-id pub-id-type="pmid">30798586</pub-id>
</element-citation></ref><ref id="B235"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shaman</surname><given-names>AM</given-names></name>
<name><surname>Smyth</surname><given-names>B</given-names></name>
<name><surname>Arnott</surname><given-names>C</given-names></name>
<name><surname>Palmer</surname><given-names>SC</given-names></name>
<name><surname>Mihailidou</surname><given-names>AS</given-names></name>
<name><surname>Jardine</surname><given-names>MJ</given-names></name>
<etal/>
</person-group><article-title>Comparative efficacy and safety of bp-lowering pharmacotherapy in patients undergoing maintenance dialysis: a network meta-analysis of randomized, controlled trials</article-title><source>Clin J Am Soc Nephrol</source><year>2020</year><volume>15</volume><issue>8</issue><fpage>1129</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.2215/CJN.12201019</pub-id><pub-id pub-id-type="pmid">32675281</pub-id>
</element-citation></ref><ref id="B236"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cice</surname><given-names>G</given-names></name>
<name><surname>Di Benedetto</surname><given-names>A</given-names></name>
<name><surname>D&#x02019;Isa</surname><given-names>S</given-names></name>
<name><surname>D&#x02019;Andrea</surname><given-names>A</given-names></name>
<name><surname>Marcelli</surname><given-names>D</given-names></name>
<name><surname>Gatti</surname><given-names>E</given-names></name>
<etal/>
</person-group><article-title>Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>56</volume><issue>21</issue><fpage>1701</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2010.03.105</pub-id><pub-id pub-id-type="pmid">21070920</pub-id>
</element-citation></ref><ref id="B237"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Ma</surname><given-names>X</given-names></name>
<name><surname>Zheng</surname><given-names>J</given-names></name>
<name><surname>Jia</surname><given-names>J</given-names></name>
<name><surname>Yan</surname><given-names>T</given-names></name>
</person-group><article-title>Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials</article-title><source>BMC Nephrol</source><year>2017</year><volume>18</volume><issue>1</issue><fpage>206</fpage><pub-id pub-id-type="doi">10.1186/s12882-017-0605-7</pub-id><pub-id pub-id-type="pmid">28666408</pub-id>
</element-citation></ref><ref id="B238"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>JI</given-names></name>
<name><surname>Saxena</surname><given-names>AB</given-names></name>
<name><surname>Montez-Rath</surname><given-names>ME</given-names></name>
<name><surname>Chang</surname><given-names>TI</given-names></name>
<name><surname>Winkelmayer</surname><given-names>WC</given-names></name>
</person-group><article-title>Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis</article-title><source>Nephrol Dial Transplant</source><year>2017</year><volume>32</volume><issue>5</issue><fpage>862</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfw053</pub-id><pub-id pub-id-type="pmid">27190342</pub-id>
</element-citation></ref><ref id="B239"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moist</surname><given-names>LM</given-names></name>
<name><surname>Port</surname><given-names>FK</given-names></name>
<name><surname>Orzol</surname><given-names>SM</given-names></name>
<name><surname>Young</surname><given-names>EW</given-names></name>
<name><surname>Ostbye</surname><given-names>T</given-names></name>
<name><surname>Wolfe</surname><given-names>RA</given-names></name>
<etal/>
</person-group><article-title>Predictors of loss of residual renal function among new dialysis patients</article-title><source>J Am Soc Nephrol</source><year>2000</year><volume>11</volume><issue>3</issue><fpage>556</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1681/ASN.V113556</pub-id><pub-id pub-id-type="pmid">10703680</pub-id>
</element-citation></ref><ref id="B240"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ding</surname><given-names>L</given-names></name>
<name><surname>Yang</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>L</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
</person-group><article-title>Effects of ACEIs and ARBs on the residual renal function in peritoneal dialysis patients: a meta-analysis of randomized controlled trials</article-title><source>BioMed Res Int</source><year>2020</year><volume>2020</volume><fpage>6762029</fpage><pub-id pub-id-type="doi">10.1155/2020/6762029</pub-id><pub-id pub-id-type="pmid">33029520</pub-id>
</element-citation></ref><ref id="B241"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tro&#x00161;t Rupnik</surname><given-names>A</given-names></name>
<name><surname>Pajek</surname><given-names>J</given-names></name>
<name><surname>Guc&#x002c7;ek</surname><given-names>A</given-names></name>
<name><surname>Osredkar</surname><given-names>J</given-names></name>
<name><surname>Kovac&#x002c7;</surname><given-names>D</given-names></name>
<name><surname>Bren</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Influence of renin-angiotensin-aldosterone system-blocking drugs on peritoneal membrane in peritoneal dialysis patients</article-title><source>Ther Apher Dial</source><year>2013</year><volume>17</volume><issue>4</issue><fpage>425</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1111/1744-9987.12091</pub-id><pub-id pub-id-type="pmid">23931884</pub-id>
</element-citation></ref><ref id="B242"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jing</surname><given-names>S</given-names></name>
<name><surname>Kezhou</surname><given-names>Y</given-names></name>
<name><surname>Hong</surname><given-names>Z</given-names></name>
<name><surname>Qun</surname><given-names>W</given-names></name>
<name><surname>Rong</surname><given-names>W</given-names></name>
</person-group><article-title>Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients</article-title><source>Nephrology (Carlton)</source><year>2010</year><volume>15</volume><issue>1</issue><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1797.2009.01162.x</pub-id><pub-id pub-id-type="pmid">20377768</pub-id>
</element-citation></ref><ref id="B243"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Knoll</surname><given-names>GA</given-names></name>
<name><surname>Sahgal</surname><given-names>A</given-names></name>
<name><surname>Nair</surname><given-names>RC</given-names></name>
<name><surname>Graham</surname><given-names>J</given-names></name>
<name><surname>van Walraven</surname><given-names>C</given-names></name>
<name><surname>Burns</surname><given-names>KD</given-names></name>
</person-group><article-title>Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients</article-title><source>Am J Med</source><year>2002</year><volume>112</volume><issue>2</issue><fpage>110</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/S0002-9343(01)01068-3</pub-id><pub-id pub-id-type="pmid">11835948</pub-id>
</element-citation></ref><ref id="B244"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>HH</given-names></name>
<name><surname>Yang</surname><given-names>YF</given-names></name>
<name><surname>Chang</surname><given-names>JK</given-names></name>
<name><surname>Ting</surname><given-names>IW</given-names></name>
<name><surname>Kuo</surname><given-names>HL</given-names></name>
<name><surname>Wang</surname><given-names>IK</given-names></name>
<etal/>
</person-group><article-title>Renin-angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients</article-title><source>Ren Fail</source><year>2009</year><volume>31</volume><issue>10</issue><fpage>942</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.3109/08860220903216147</pub-id><pub-id pub-id-type="pmid">20030530</pub-id>
</element-citation></ref><ref id="B245"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ribeiro</surname><given-names>SC</given-names></name>
<name><surname>Figueiredo</surname><given-names>AE</given-names></name>
<name><surname>Barretti</surname><given-names>P</given-names></name>
<name><surname>Pecoits</surname><given-names>R</given-names><suffix>Filho</suffix></name>
<name><surname>de Moraes</surname><given-names>TP</given-names></name>
</person-group><article-title>BRAZPD Investigators. Impact of renin-angiotensin aldosterone system inhibition on serum potassium levels among peritoneal dialysis patients</article-title><source>Am J Nephrol</source><year>2017</year><volume>46</volume><issue>2</issue><fpage>150</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1159/000479011</pub-id><pub-id pub-id-type="pmid">28738355</pub-id>
</element-citation></ref><ref id="B246"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>R</given-names></name>
<name><surname>Sinha</surname><given-names>AD</given-names></name>
<name><surname>Pappas</surname><given-names>MK</given-names></name>
<name><surname>Abraham</surname><given-names>TN</given-names></name>
<name><surname>Tegegne</surname><given-names>GG</given-names></name>
</person-group><article-title>Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial</article-title><source>Nephrol Dial Transplant</source><year>2014</year><volume>29</volume><issue>3</issue><fpage>672</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1093/ndt/gft515</pub-id><pub-id pub-id-type="pmid">24398888</pub-id>
</element-citation></ref><ref id="B247"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tieu</surname><given-names>A</given-names></name>
<name><surname>Velenosi</surname><given-names>TJ</given-names></name>
<name><surname>Kucey</surname><given-names>AS</given-names></name>
<name><surname>Weir</surname><given-names>MA</given-names></name>
<name><surname>Urquhart</surname><given-names>BL</given-names></name>
</person-group><article-title>&#x003b2;-blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial</article-title><source>Clin J Am Soc Nephrol</source><year>2018</year><volume>13</volume><issue>4</issue><fpage>604</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.2215/CJN.07470717</pub-id><pub-id pub-id-type="pmid">29519953</pub-id>
</element-citation></ref><ref id="B248"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Assimon</surname><given-names>MM</given-names></name>
<name><surname>Brookhart</surname><given-names>MA</given-names></name>
<name><surname>Fine</surname><given-names>JP</given-names></name>
<name><surname>Heiss</surname><given-names>G</given-names></name>
<name><surname>Layton</surname><given-names>JB</given-names></name>
<name><surname>Flythe</surname><given-names>JE</given-names></name>
</person-group><article-title>A comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis</article-title><source>Am J Kidney Dis</source><year>2018</year><volume>72</volume><issue>3</issue><fpage>337</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2018.02.350</pub-id><pub-id pub-id-type="pmid">29653770</pub-id>
</element-citation></ref><ref id="B249"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>PH</given-names></name>
<name><surname>Lin</surname><given-names>YT</given-names></name>
<name><surname>Liu</surname><given-names>JS</given-names></name>
<name><surname>Tsai</surname><given-names>YC</given-names></name>
<name><surname>Kuo</surname><given-names>MC</given-names></name>
<name><surname>Chiu</surname><given-names>YW</given-names></name>
<etal/>
</person-group><article-title>Comparative effectiveness of bisoprolol and carvedilol among patients receiving maintenance hemodialysis</article-title><source>Clin Kidney J</source><year>2021</year><volume>14</volume><issue>3</issue><fpage>983</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1093/ckj/sfaa248</pub-id><pub-id pub-id-type="pmid">33779636</pub-id>
</element-citation></ref><ref id="B250"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yeh</surname><given-names>TH</given-names></name>
<name><surname>Tu</surname><given-names>KC</given-names></name>
<name><surname>Hung</surname><given-names>KC</given-names></name>
<name><surname>Chuang</surname><given-names>MH</given-names></name>
<name><surname>Chen</surname><given-names>JY</given-names></name>
</person-group><article-title>Impact of type of dialyzable beta-blockers on subsequent risk of mortality in patients receiving dialysis: a systematic review and meta-analysis</article-title><source>PLoS One</source><year>2022</year><volume>17</volume><issue>12</issue><fpage>e0279680</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0279680</pub-id><pub-id pub-id-type="pmid">36584227</pub-id>
</element-citation></ref><ref id="B251"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>CH</given-names></name>
<name><surname>Wang</surname><given-names>CC</given-names></name>
<name><surname>Chen</surname><given-names>TH</given-names></name>
<name><surname>Hong</surname><given-names>CY</given-names></name>
<name><surname>Sue</surname><given-names>YM</given-names></name>
</person-group><article-title>Prognostic benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release in hemodialysis patients with heart failure: a 10-year cohort</article-title><source>J Am Heart Assoc</source><year>2016</year><volume>5</volume><issue>1</issue><fpage>e002584</fpage><pub-id pub-id-type="doi">10.1161/JAHA.115.002584</pub-id><pub-id pub-id-type="pmid">26738790</pub-id>
</element-citation></ref><ref id="B252"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tepel</surname><given-names>M</given-names></name>
<name><surname>Hopfenmueller</surname><given-names>W</given-names></name>
<name><surname>Scholze</surname><given-names>A</given-names></name>
<name><surname>Maier</surname><given-names>A</given-names></name>
<name><surname>Zidek</surname><given-names>W</given-names></name>
</person-group><article-title>Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients</article-title><source>Nephrol Dial Transplant</source><year>2008</year><volume>23</volume><issue>11</issue><fpage>3605</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfn304</pub-id><pub-id pub-id-type="pmid">18511605</pub-id>
</element-citation></ref><ref id="B253"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>London</surname><given-names>GM</given-names></name>
<name><surname>Marchais</surname><given-names>SJ</given-names></name>
<name><surname>Guerin</surname><given-names>AP</given-names></name>
<name><surname>Metivier</surname><given-names>F</given-names></name>
<name><surname>Safar</surname><given-names>ME</given-names></name>
<name><surname>Fabiani</surname><given-names>F</given-names></name>
<etal/>
</person-group><article-title>Salt and water retention and calcium blockade in uremia</article-title><source>Circulation</source><year>1990</year><volume>82</volume><issue>1</issue><fpage>105</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.82.1.105</pub-id><pub-id pub-id-type="pmid">2364508</pub-id>
</element-citation></ref><ref id="B254"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mugendi</surname><given-names>GA</given-names></name>
<name><surname>Mutua</surname><given-names>FM</given-names></name>
<name><surname>Natale</surname><given-names>P</given-names></name>
<name><surname>Esterhuizen</surname><given-names>TM</given-names></name>
<name><surname>Strippoli</surname><given-names>GF</given-names></name>
</person-group><article-title>Calcium channel blockers for people with chronic kidney disease requiring dialysis</article-title><source>Cochrane Database Syst Rev</source><year>2020</year><volume>10</volume><issue>10</issue><fpage>CD011064</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD011064.pub2</pub-id><pub-id pub-id-type="pmid">33000470</pub-id>
</element-citation></ref><ref id="B255"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>KT</given-names></name>
<name><surname>Kang</surname><given-names>YN</given-names></name>
<name><surname>Lin</surname><given-names>YC</given-names></name>
<name><surname>Tsai</surname><given-names>IL</given-names></name>
<name><surname>Chang</surname><given-names>WC</given-names></name>
<name><surname>Fang</surname><given-names>TC</given-names></name>
<etal/>
</person-group><article-title>Efficacy and safety of mineralocorticoid receptor antagonists in kidney failure patients treated with dialysis: a systematic review and meta-analysis</article-title><source>Clin J Am Soc Nephrol</source><year>2021</year><volume>16</volume><issue>6</issue><fpage>916</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2215/CJN.15841020</pub-id><pub-id pub-id-type="pmid">34117083</pub-id>
</element-citation></ref><ref id="B256"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quach</surname><given-names>K</given-names></name>
<name><surname>Lvtvyn</surname><given-names>L</given-names></name>
<name><surname>Baigent</surname><given-names>C</given-names></name>
<name><surname>Bueti</surname><given-names>J</given-names></name>
<name><surname>Garg</surname><given-names>AX</given-names></name>
<name><surname>Hawley</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta-analysis</article-title><source>Am J Kidney Dis</source><year>2016</year><volume>68</volume><issue>4</issue><fpage>591</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2016.04.011</pub-id><pub-id pub-id-type="pmid">27265777</pub-id>
</element-citation></ref><ref id="B257"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Derk</surname><given-names>G</given-names></name>
<name><surname>Barton</surname><given-names>A</given-names></name>
<name><surname>An</surname><given-names>R</given-names></name>
<name><surname>Fang</surname><given-names>HY</given-names></name>
<name><surname>Ashrafi</surname><given-names>SA</given-names></name>
<name><surname>Wilund</surname><given-names>K</given-names></name>
</person-group><article-title>The safety and efficacy of clonidine in hemodialysis patients: a systematic review and meta-analysis</article-title><source>Pharmacology</source><year>2022</year><volume>107</volume><issue>11&#x02013;12</issue><fpage>545</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1159/000525424</pub-id><pub-id pub-id-type="pmid">36075189</pub-id>
</element-citation></ref><ref id="B258"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mavrakanas</surname><given-names>TA</given-names></name>
<name><surname>Soomro</surname><given-names>QH</given-names></name>
<name><surname>Charytan</surname><given-names>DM</given-names></name>
</person-group><article-title>Hydralazine-isosorbide dinitrate use in patients with end-stage kidney disease on dialysis</article-title><source>Kidney Int Rep</source><year>2022</year><volume>7</volume><issue>6</issue><fpage>1332</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.ekir.2022.03.032</pub-id><pub-id pub-id-type="pmid">35685328</pub-id>
</element-citation></ref><ref id="B259"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Charytan</surname><given-names>DM</given-names></name>
<name><surname>Hsu</surname><given-names>JY</given-names></name>
<name><surname>Mc Causland</surname><given-names>FR</given-names></name>
<name><surname>Waikar</surname><given-names>SS</given-names></name>
<name><surname>Ikizler</surname><given-names>TA</given-names></name>
<name><surname>Raj</surname><given-names>DS</given-names></name>
<etal/>
</person-group><article-title>Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): a randomized, placebo-controlled, pilot trial</article-title><source>Kidney360</source><year>2020</year><volume>1</volume><issue>12</issue><fpage>1380</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.34067/KID.0004342020</pub-id><pub-id pub-id-type="pmid">35372900</pub-id>
</element-citation></ref><ref id="B260"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>St Peter</surname><given-names>WL</given-names></name>
<name><surname>Sozio</surname><given-names>SM</given-names></name>
<name><surname>Shafi</surname><given-names>T</given-names></name>
<name><surname>Ephraim</surname><given-names>PL</given-names></name>
<name><surname>Luly</surname><given-names>J</given-names></name>
<name><surname>McDermott</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Patterns in blood pressure medication use in US incident dialysis patients over the first 6 months</article-title><source>BMC Nephrol</source><year>2013</year><volume>14</volume><issue>1</issue><fpage>249</fpage><pub-id pub-id-type="doi">10.1186/1471-2369-14-249</pub-id><pub-id pub-id-type="pmid">24219348</pub-id>
</element-citation></ref><ref id="B261"><label>261.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Moura</surname><given-names>AF</given-names></name>
<name><surname>Rodrigues</surname><given-names>CIS</given-names></name>
<name><surname>Almeida</surname><given-names>FA</given-names></name>
</person-group><part-title>Anti-hipertensivos orais: uma revis&#x000e3;o pr&#x000e1;tica. In: Moura AF &#x00026; Rodrigues CIS. Hipertens&#x000e3;o Arterial: manual pr&#x000e1;tico: uso di&#x000e1;rio ambulatorial e hospitalar</part-title><source>1a edi&#x000e7;&#x000e3;o, Piracicaba</source><publisher-name>SP</publisher-name><publisher-loc>Balieiro</publisher-loc><year>2022</year><fpage>128</fpage><lpage>62</lpage></element-citation></ref><ref id="B262"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alkhunaizi</surname><given-names>A</given-names></name>
<name><surname>Melamed</surname><given-names>N</given-names></name>
<name><surname>Hladunewich</surname><given-names>MA</given-names></name>
</person-group><article-title>Pregnancy in advanced chronic kidney disease and end-stage renal disease</article-title><source>Curr Opin Nephrol Hypertens</source><year>2015</year><volume>24</volume><issue>3</issue><fpage>252</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/MNH.0000000000000119</pub-id><pub-id pub-id-type="pmid">26066474</pub-id>
</element-citation></ref><ref id="B263"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hladunewich</surname><given-names>MA</given-names></name>
<name><surname>Melamed</surname><given-names>N</given-names></name>
<name><surname>Bramham</surname><given-names>K</given-names></name>
</person-group><article-title>Pregnancy across the spectrum of chronic kidney disease</article-title><source>Kidney Int</source><year>2016</year><volume>89</volume><issue>5</issue><fpage>995</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2015.12.050</pub-id><pub-id pub-id-type="pmid">27083278</pub-id>
</element-citation></ref><ref id="B264"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baouche</surname><given-names>H</given-names></name>
<name><surname>Jais</surname><given-names>JP</given-names></name>
<name><surname>Meriem</surname><given-names>S</given-names></name>
<name><surname>Kareche</surname><given-names>M</given-names></name>
<name><surname>Moranne</surname><given-names>O</given-names></name>
<name><surname>Vigneau</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Pregnancy in women on chronic dialysis in the last decade (2010&#x02013;2020): a systematic review</article-title><source>Clin Kidney J</source><year>2023</year><volume>16</volume><issue>1</issue><fpage>138</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1093/ckj/sfac204</pub-id><pub-id pub-id-type="pmid">36726433</pub-id>
</element-citation></ref><ref id="B265"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hui</surname><given-names>D</given-names></name>
<name><surname>Hladunewich</surname><given-names>MA</given-names></name>
</person-group><article-title>Chronic kidney disease and pregnancy</article-title><source>Obstet Gynecol</source><year>2019</year><volume>133</volume><issue>6</issue><fpage>1182</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1097/AOG.0000000000003256</pub-id><pub-id pub-id-type="pmid">31135733</pub-id>
</element-citation></ref><ref id="B266"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luders</surname><given-names>C</given-names></name>
<name><surname>Titan</surname><given-names>SM</given-names></name>
<name><surname>Kahhale</surname><given-names>S</given-names></name>
<name><surname>Francisco</surname><given-names>RP</given-names></name>
<name><surname>Zugaib</surname><given-names>M</given-names></name>
</person-group><article-title>Risk Factors for adverse fetal outcome in hemodialysis pregnant women</article-title><source>Kidney Int Rep</source><year>2018</year><volume>3</volume><issue>5</issue><fpage>1077</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.ekir.2018.04.013</pub-id><pub-id pub-id-type="pmid">30197974</pub-id>
</element-citation></ref><ref id="B267"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Magee</surname><given-names>LA</given-names></name>
<name><surname>von Dadelszen</surname><given-names>P</given-names></name>
<name><surname>Rey</surname><given-names>E</given-names></name>
<name><surname>Ross</surname><given-names>S</given-names></name>
<name><surname>Asztalos</surname><given-names>E</given-names></name>
<name><surname>Murphy</surname><given-names>KE</given-names></name>
<etal/>
</person-group><article-title>Less-tight versus tight control of hypertension in pregnancy</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>5</issue><fpage>407</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1404595</pub-id><pub-id pub-id-type="pmid">25629739</pub-id>
</element-citation></ref><ref id="B268"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shahir</surname><given-names>AK</given-names></name>
<name><surname>Briggs</surname><given-names>N</given-names></name>
<name><surname>Katsoulis</surname><given-names>J</given-names></name>
<name><surname>Levidiotis</surname><given-names>V</given-names></name>
</person-group><article-title>An observational outcomes study from 1966&#x02013;2008, examining pregnancy and neonatal outcomes from dialysed women using data from the ANZDATA Registry</article-title><source>Nephrology (Carlton)</source><year>2013</year><volume>18</volume><issue>4</issue><fpage>276</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1111/nep.12044</pub-id><pub-id pub-id-type="pmid">23441694</pub-id>
</element-citation></ref><ref id="B269"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piccoli</surname><given-names>GB</given-names></name>
<name><surname>Conijn</surname><given-names>A</given-names></name>
<name><surname>Consiglio</surname><given-names>V</given-names></name>
<name><surname>Vasario</surname><given-names>E</given-names></name>
<name><surname>Attini</surname><given-names>R</given-names></name>
<name><surname>Deagostini</surname><given-names>MC</given-names></name>
<etal/>
</person-group><article-title>Pregnancy in dialysis patients: is the evidence strong enough to lead us to change our counseling policy?</article-title><source>Clin J Am Soc Nephrol</source><year>2010</year><volume>5</volume><issue>1</issue><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.2215/CJN.05660809</pub-id><pub-id pub-id-type="pmid">19965547</pub-id>
</element-citation></ref><ref id="B270"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piccoli</surname><given-names>GB</given-names></name>
<name><surname>Minelli</surname><given-names>F</given-names></name>
<name><surname>Versino</surname><given-names>E</given-names></name>
<name><surname>Cabiddu</surname><given-names>G</given-names></name>
<name><surname>Attini</surname><given-names>R</given-names></name>
<name><surname>Vigotti</surname><given-names>FN</given-names></name>
<etal/>
</person-group><article-title>Pregnancy in dialysis patients in the new millennium: a systematic review and meta-regression analysis correlating dialysis schedules and pregnancy outcomes</article-title><source>Nephrol Dial Transplant</source><year>2016</year><volume>31</volume><issue>11</issue><fpage>1915</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfv395</pub-id><pub-id pub-id-type="pmid">26614270</pub-id>
</element-citation></ref><ref id="B271"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carey</surname><given-names>RM</given-names></name>
<name><surname>Calhoun</surname><given-names>DA</given-names></name>
<name><surname>Bakris</surname><given-names>GL</given-names></name>
<name><surname>Brook</surname><given-names>RD</given-names></name>
<name><surname>Daugherty</surname><given-names>SL</given-names></name>
<name><surname>Dennison-Himmelfarb</surname><given-names>CR</given-names></name>
<etal/>
</person-group><article-title>Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association</article-title><source>Hypertension</source><year>2018</year><volume>72</volume><issue>5</issue><fpage>e53</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1161/HYP.0000000000000084</pub-id><pub-id pub-id-type="pmid">30354828</pub-id>
</element-citation></ref><ref id="B272"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Acelajado</surname><given-names>MC</given-names></name>
<name><surname>Pisoni</surname><given-names>R</given-names></name>
<name><surname>Dudenbostel</surname><given-names>T</given-names></name>
<name><surname>Dell&#x02019;Italia</surname><given-names>LJ</given-names></name>
<name><surname>Cartmill</surname><given-names>F</given-names></name>
<name><surname>Zhang</surname><given-names>B</given-names></name>
<etal/>
</person-group><article-title>Refractory hypertension: definition, prevalence, and patient characteristics</article-title><source>J Clin Hypertens (Greenwich)</source><year>2012</year><volume>14</volume><issue>1</issue><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1111/j.1751-7176.2011.00556.x</pub-id><pub-id pub-id-type="pmid">22235818</pub-id>
</element-citation></ref><ref id="B273"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yugar-Toledo</surname><given-names>JC</given-names></name>
<name><surname>Moreno</surname><given-names>H</given-names><suffix>Jr</suffix></name>
<name><surname>Gus</surname><given-names>M</given-names></name>
<name><surname>Rosito</surname><given-names>GBA</given-names></name>
<name><surname>Scala</surname><given-names>LCN</given-names></name>
<name><surname>Muxfeldt</surname><given-names>ES</given-names></name>
<etal/>
</person-group><article-title>Brazilian Position Statement on Resistant Hypertension - 2020</article-title><source>Arq Bras Cardiol</source><year>2020</year><volume>114</volume><issue>3</issue><fpage>576</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.36660/abc.20200198</pub-id><pub-id pub-id-type="pmid">32267335</pub-id>
</element-citation></ref><ref id="B274"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Georgianos</surname><given-names>PI</given-names></name>
<name><surname>Agarwal</surname><given-names>R</given-names></name>
</person-group><article-title>Systolic and diastolic hypertension among patients on hemodialysis: musings on volume overload, arterial stiffness, and erythropoietin</article-title><source>Semin Dial</source><year>2019</year><volume>32</volume><issue>6</issue><fpage>507</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1111/sdi.12837</pub-id><pub-id pub-id-type="pmid">31463996</pub-id>
</element-citation></ref><ref id="B275"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>B</given-names></name>
<name><surname>Wang</surname><given-names>GH</given-names></name>
<name><surname>Ding</surname><given-names>XX</given-names></name>
<name><surname>Tang</surname><given-names>HX</given-names></name>
<name><surname>Zheng</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>BC</given-names></name>
<etal/>
</person-group><article-title>Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients</article-title><source>J Clin Hypertens (Greenwich)</source><year>2022</year><volume>24</volume><issue>3</issue><fpage>300</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/jch.14422</pub-id><pub-id pub-id-type="pmid">35099841</pub-id>
</element-citation></ref><ref id="B276"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Jia</surname><given-names>W</given-names></name>
<name><surname>Yu</surname><given-names>C</given-names></name>
</person-group><article-title>Safety and efficacy of spironolactone in dialysis-dependent patients: meta-analysis of randomized controlled trials</article-title><source>Front Med (Lausanne)</source><year>2022</year><volume>9</volume><fpage>828189</fpage><pub-id pub-id-type="doi">10.3389/fmed.2022.828189</pub-id><pub-id pub-id-type="pmid">35372414</pub-id>
</element-citation></ref><ref id="B277"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mundt</surname><given-names>HM</given-names></name>
<name><surname>Matenaer</surname><given-names>M</given-names></name>
<name><surname>Lammert</surname><given-names>A</given-names></name>
<name><surname>Gottmann</surname><given-names>U</given-names></name>
<name><surname>Kramer</surname><given-names>BK</given-names></name>
<name><surname>Birck</surname><given-names>R</given-names></name>
<etal/>
</person-group><article-title>Minoxidil for treatment of resistant hypertension in chronic kidney disease--a retrospective cohort analysis</article-title><source>J Clin Hypertens (Greenwich)</source><year>2016</year><volume>18</volume><issue>11</issue><fpage>1162</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/jch.12847</pub-id><pub-id pub-id-type="pmid">27246772</pub-id>
</element-citation></ref><ref id="B278"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scalise</surname><given-names>F</given-names></name>
<name><surname>Sole</surname><given-names>A</given-names></name>
<name><surname>Singh</surname><given-names>G</given-names></name>
<name><surname>Sorropago</surname><given-names>A</given-names></name>
<name><surname>Sorropago</surname><given-names>G</given-names></name>
<name><surname>Ballabeni</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis</article-title><source>J Hypertens</source><year>2020</year><volume>38</volume><issue>5</issue><fpage>936</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000002358</pub-id><pub-id pub-id-type="pmid">31990900</pub-id>
</element-citation></ref><ref id="B279"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Symonides</surname><given-names>B</given-names></name>
<name><surname>Lewandowski</surname><given-names>J</given-names></name>
<name><surname>Malyszko</surname><given-names>J</given-names></name>
</person-group><article-title>Resistant hypertension in dialysis</article-title><source>Nephrol Dial Transplant</source><year>2023</year><volume>38</volume><issue>9</issue><fpage>1952</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfad047</pub-id><pub-id pub-id-type="pmid">36898677</pub-id>
</element-citation></ref><ref id="B280"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zoccali</surname><given-names>C</given-names></name>
<name><surname>Tripepi</surname><given-names>R</given-names></name>
<name><surname>Torino</surname><given-names>C</given-names></name>
<name><surname>Tripepi</surname><given-names>G</given-names></name>
<name><surname>Mallamaci</surname><given-names>F</given-names></name>
</person-group><article-title>Moderator&#x02019;s view: ambulatory blood pressure monitoring and home blood pressure for the prognosis, diagnosis and treatment of hypertension in dialysis patients</article-title><source>Nephrol Dial Transplant</source><year>2015</year><volume>30</volume><issue>9</issue><fpage>1443</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfv241</pub-id><pub-id pub-id-type="pmid">26022727</pub-id>
</element-citation></ref><ref id="B281"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>London</surname><given-names>GM</given-names></name>
</person-group><article-title>Arterial stiffness in chronic kidney disease and end-stage renal disease</article-title><source>Blood Purif</source><year>2018</year><volume>45</volume><issue>1&#x02013;3</issue><fpage>154</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1159/000485146</pub-id><pub-id pub-id-type="pmid">29478047</pub-id>
</element-citation></ref><ref id="B282"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lobo</surname><given-names>MD</given-names></name>
<name><surname>Sobotka</surname><given-names>PA</given-names></name>
<name><surname>Stanton</surname><given-names>A</given-names></name>
<name><surname>Cockcroft</surname><given-names>JR</given-names></name>
<name><surname>Sulke</surname><given-names>N</given-names></name>
<name><surname>Dolan</surname><given-names>E</given-names></name>
<etal/>
</person-group><article-title>Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial</article-title><source>Lancet</source><year>2015</year><volume>385</volume><issue>9978</issue><fpage>1634</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)62053-5</pub-id><pub-id pub-id-type="pmid">25620016</pub-id>
</element-citation></ref><ref id="B283"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scholz</surname><given-names>SS</given-names></name>
<name><surname>Vukadinovic</surname><given-names>D</given-names></name>
<name><surname>Lauder</surname><given-names>L</given-names></name>
<name><surname>Ewen</surname><given-names>S</given-names></name>
<name><surname>Ukena</surname><given-names>C</given-names></name>
<name><surname>Townsend</surname><given-names>RR</given-names></name>
<etal/>
</person-group><article-title>Effects of arteriovenous fistula on blood pressure in patients with end-stage renal disease: a systematic meta-analysis</article-title><source>J Am Heart Assoc</source><year>2019</year><volume>8</volume><issue>4</issue><fpage>e011183</fpage><pub-id pub-id-type="doi">10.1161/JAHA.118.011183</pub-id><pub-id pub-id-type="pmid">30764686</pub-id>
</element-citation></ref><ref id="B284"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kurita</surname><given-names>N</given-names></name>
<name><surname>Mise</surname><given-names>N</given-names></name>
<name><surname>Tanaka</surname><given-names>S</given-names></name>
<name><surname>Tanaka</surname><given-names>M</given-names></name>
<name><surname>Sai</surname><given-names>K</given-names></name>
<name><surname>Nishi</surname><given-names>T</given-names></name>
<etal/>
</person-group><article-title>Arteriovenous access closure in hemodialysis patients with refractory heart failure: a single center experience</article-title><source>Ther Apher Dial</source><year>2011</year><volume>15</volume><issue>2</issue><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1111/j.1744-9987.2010.00907.x</pub-id><pub-id pub-id-type="pmid">21426513</pub-id>
</element-citation></ref><ref id="B285"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Duijnhoven</surname><given-names>EC</given-names></name>
<name><surname>Cheriex</surname><given-names>EC</given-names></name>
<name><surname>Tordoir</surname><given-names>JH</given-names></name>
<name><surname>Kooman</surname><given-names>JP</given-names></name>
<name><surname>van Hooff</surname><given-names>JP</given-names></name>
</person-group><article-title>Effect of closure of the arteriovenous fistula on left ventricular dimensions in renal transplant patients</article-title><source>Nephrol Dial Transplant</source><year>2001</year><volume>16</volume><issue>2</issue><fpage>368</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1093/ndt/16.2.368</pub-id><pub-id pub-id-type="pmid">11158414</pub-id>
</element-citation></ref><ref id="B286"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vaes</surname><given-names>RH</given-names></name>
<name><surname>Tordoir</surname><given-names>JH</given-names></name>
<name><surname>Scheltinga</surname><given-names>MR</given-names></name>
</person-group><article-title>Systemic effects of a high-flow arteriovenous fistula for hemodialysis.</article-title><source>J Vasc Access</source><year>2014</year><volume>15</volume><issue>3</issue><fpage>163</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.5301/jva.5000196</pub-id><pub-id pub-id-type="pmid">24170583</pub-id>
</element-citation></ref><ref id="B287"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aitken</surname><given-names>E</given-names></name>
<name><surname>Kerr</surname><given-names>D</given-names></name>
<name><surname>Geddes</surname><given-names>C</given-names></name>
<name><surname>Berry</surname><given-names>C</given-names></name>
<name><surname>Kingsmore</surname><given-names>D</given-names></name>
</person-group><article-title>Cardiovascular changes occurring with occlusion of a mature arteriovenous fistula</article-title><source>J Vasc Access</source><year>2015</year><volume>16</volume><issue>6</issue><fpage>459</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.5301/jva.5000336</pub-id><pub-id pub-id-type="pmid">25634156</pub-id>
</element-citation></ref><ref id="B288"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reddy</surname><given-names>YNV</given-names></name>
<name><surname>Obokata</surname><given-names>M</given-names></name>
<name><surname>Dean</surname><given-names>PG</given-names></name>
<name><surname>Melenovsky</surname><given-names>V</given-names></name>
<name><surname>Nath</surname><given-names>KA</given-names></name>
<name><surname>Borlaug</surname><given-names>BA</given-names></name>
</person-group><article-title>Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><issue>24</issue><fpage>1913</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx045</pub-id><pub-id pub-id-type="pmid">28329100</pub-id>
</element-citation></ref><ref id="B289"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chu</surname><given-names>G</given-names></name>
<name><surname>Price</surname><given-names>E</given-names></name>
<name><surname>Paech</surname><given-names>GM</given-names></name>
<name><surname>Choi</surname><given-names>P</given-names></name>
<name><surname>McDonald</surname><given-names>VM</given-names></name>
</person-group><article-title>Sleep apnea in maintenance hemodialysis: a mixed-methods study</article-title><source>Kidney Med</source><year>2020</year><volume>2</volume><issue>4</issue><fpage>388</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.xkme.2020.02.006</pub-id><pub-id pub-id-type="pmid">32775978</pub-id>
</element-citation></ref><ref id="B290"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>ST</given-names></name>
<name><surname>Lin</surname><given-names>CL</given-names></name>
<name><surname>Yu</surname><given-names>TM</given-names></name>
<name><surname>Kao</surname><given-names>CH</given-names></name>
<name><surname>Liang</surname><given-names>WM</given-names></name>
<name><surname>Chou</surname><given-names>TC</given-names></name>
</person-group><article-title>Risk, severity, and predictors of obstructive sleep apnea in hemodialysis and peritoneal dialysis patients</article-title><source>Int J Environ Res Public Health</source><year>2018</year><volume>15</volume><issue>11</issue><fpage>2377</fpage><pub-id pub-id-type="doi">10.3390/ijerph15112377</pub-id><pub-id pub-id-type="pmid">30373203</pub-id>
</element-citation></ref><ref id="B291"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>X</given-names></name>
<name><surname>Lv</surname><given-names>D</given-names></name>
<name><surname>Zheng</surname><given-names>H</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Han</surname><given-names>F</given-names></name>
<name><surname>Chen</surname><given-names>J</given-names></name>
</person-group><article-title>The associations of blood pressure parameters with all-cause and cardiovascular mortality in peritoneal dialysis patients: a cohort study in China</article-title><source>J Hypertens</source><year>2020</year><volume>38</volume><issue>11</issue><fpage>2252</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000002526</pub-id><pub-id pub-id-type="pmid">32618891</pub-id>
</element-citation></ref><ref id="B292"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>R</given-names></name>
</person-group><article-title>Blood pressure and mortality among hemodialysis patients</article-title><source>Hypertension</source><year>2010</year><volume>55</volume><issue>3</issue><fpage>762</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.109.144899</pub-id><pub-id pub-id-type="pmid">20083728</pub-id>
</element-citation></ref><ref id="B293"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarafidis</surname><given-names>PA</given-names></name>
<name><surname>Loutradis</surname><given-names>C</given-names></name>
<name><surname>Karpetas</surname><given-names>A</given-names></name>
<name><surname>Tzanis</surname><given-names>G</given-names></name>
<name><surname>Piperidou</surname><given-names>A</given-names></name>
<name><surname>Koutroumpas</surname><given-names>G</given-names></name>
<etal/>
</person-group><article-title>Ambulatory pulse wave velocity is a stronger predictor of cardiovascular events and all-cause mortality than office and ambulatory blood pressure in hemodialysis patients</article-title><source>Hypertension</source><year>2017</year><volume>70</volume><issue>1</issue><fpage>148</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.117.09023</pub-id><pub-id pub-id-type="pmid">28483919</pub-id>
</element-citation></ref><ref id="B294"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Georgianos</surname><given-names>PI</given-names></name>
<name><surname>Vaios</surname><given-names>V</given-names></name>
<name><surname>Zebekakis</surname><given-names>PE</given-names></name>
<name><surname>Liakopoulos</surname><given-names>V</given-names></name>
</person-group><article-title>The relation of clinic and ambulatory bp with the risk of cardiovascular events and all-cause mortality among patients on peritoneal dialysis</article-title><source>J Clin Med</source><year>2021</year><volume>10</volume><issue>11</issue><fpage>2232</fpage><pub-id pub-id-type="doi">10.3390/jcm10112232</pub-id><pub-id pub-id-type="pmid">34063995</pub-id>
</element-citation></ref><ref id="B295"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mayer</surname><given-names>CC</given-names></name>
<name><surname>Matschkal</surname><given-names>J</given-names></name>
<name><surname>Sarafidis</surname><given-names>PA</given-names></name>
<name><surname>Hagmair</surname><given-names>S</given-names></name>
<name><surname>Lorenz</surname><given-names>G</given-names></name>
<name><surname>Angermann</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Association of ambulatory blood pressure with all-cause and cardiovascular mortality in hemodialysis patients: effects of heart failure and atrial fibrillation</article-title><source>J Am Soc Nephrol</source><year>2018</year><volume>29</volume><issue>9</issue><fpage>2409</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1681/ASN.2018010086</pub-id><pub-id pub-id-type="pmid">30045925</pub-id>
</element-citation></ref><ref id="B296"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Charytan</surname><given-names>D</given-names></name>
</person-group><article-title>Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease</article-title><source>Curr Opin Nephrol Hypertens</source><year>2014</year><volume>23</volume><issue>6</issue><fpage>578</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1097/MNH.0000000000000067</pub-id><pub-id pub-id-type="pmid">25295959</pub-id>
</element-citation></ref><ref id="B297"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>X</given-names></name>
<name><surname>Zhu</surname><given-names>L</given-names></name>
<name><surname>Jin</surname><given-names>W</given-names></name>
<name><surname>Yang</surname><given-names>B</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Ni</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Echocardiographic left ventricular hypertrophy and geometry in Chinese chronic hemodialysis patients: the prevalence and determinants</article-title><source>BMC Cardiovasc Disord</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>55</fpage><pub-id pub-id-type="doi">10.1186/s12872-022-02506-y</pub-id><pub-id pub-id-type="pmid">35172749</pub-id>
</element-citation></ref><ref id="B298"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCullough</surname><given-names>PA</given-names></name>
<name><surname>Chan</surname><given-names>CT</given-names></name>
<name><surname>Weinhandl</surname><given-names>ED</given-names></name>
<name><surname>Burkart</surname><given-names>JM</given-names></name>
<name><surname>Bakris</surname><given-names>GL</given-names></name>
</person-group><article-title>Intensive hemodialysis, left ventricular hypertrophy, and cardiovascular disease</article-title><source>Am J Kidney Dis</source><year>2016</year><volume>68</volume><issue>5 Suppl 1</issue><fpage>S5</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2016.05.025</pub-id><pub-id pub-id-type="pmid">27772643</pub-id>
</element-citation></ref><ref id="B299"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>LY</given-names></name>
<name><surname>Ge</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>YL</given-names></name>
<name><surname>Ma</surname><given-names>KL</given-names></name>
<name><surname>Liu</surname><given-names>H</given-names></name>
<name><surname>Zhang</surname><given-names>XL</given-names></name>
<etal/>
</person-group><article-title>Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: a meta-analysis</article-title><source>Am J Med Sci</source><year>2013</year><volume>345</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/MAJ.0b013e318249d387</pub-id><pub-id pub-id-type="pmid">23018492</pub-id>
</element-citation></ref><ref id="B300"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hammer</surname><given-names>F</given-names></name>
<name><surname>Malzahn</surname><given-names>U</given-names></name>
<name><surname>Donhauser</surname><given-names>J</given-names></name>
<name><surname>Betz</surname><given-names>C</given-names></name>
<name><surname>Schneider</surname><given-names>MP</given-names></name>
<name><surname>Grupp</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients</article-title><source>Kidney Int</source><year>2019</year><volume>95</volume><issue>4</issue><fpage>983</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2018.11.025</pub-id><pub-id pub-id-type="pmid">30712923</pub-id>
</element-citation></ref><ref id="B301"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zimmerman</surname><given-names>D</given-names></name>
<name><surname>Sood</surname><given-names>MM</given-names></name>
<name><surname>Rigatto</surname><given-names>C</given-names></name>
<name><surname>Holden</surname><given-names>RM</given-names></name>
<name><surname>Hiremath</surname><given-names>S</given-names></name>
<name><surname>Clase</surname><given-names>CM</given-names></name>
</person-group><article-title>Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis</article-title><source>Nephrol Dial Transplant</source><year>2012</year><volume>27</volume><issue>10</issue><fpage>3816</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfs416</pub-id><pub-id pub-id-type="pmid">23114904</pub-id>
</element-citation></ref><ref id="B302"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Winkelmayer</surname><given-names>WC</given-names></name>
<name><surname>Patrick</surname><given-names>AR</given-names></name>
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Brookhart</surname><given-names>MA</given-names></name>
<name><surname>Setoguchi</surname><given-names>S</given-names></name>
</person-group><article-title>The increasing prevalence of atrial fibrillation among hemodialysis patients</article-title><source>J Am Soc Nephrol</source><year>2011</year><volume>22</volume><issue>2</issue><fpage>349</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1681/ASN.2010050459</pub-id><pub-id pub-id-type="pmid">21233416</pub-id>
</element-citation></ref><ref id="B303"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wizemann</surname><given-names>V</given-names></name>
<name><surname>Tong</surname><given-names>L</given-names></name>
<name><surname>Satayathum</surname><given-names>S</given-names></name>
<name><surname>Disney</surname><given-names>A</given-names></name>
<name><surname>Akiba</surname><given-names>T</given-names></name>
<name><surname>Fissell</surname><given-names>RB</given-names></name>
<etal/>
</person-group><article-title>Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy</article-title><source>Kidney Int</source><year>2010</year><volume>77</volume><issue>12</issue><fpage>1098</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/ki.2009.477</pub-id><pub-id pub-id-type="pmid">20054291</pub-id>
</element-citation></ref><ref id="B304"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wetmore</surname><given-names>JB</given-names></name>
<name><surname>Mahnken</surname><given-names>JD</given-names></name>
<name><surname>Rigler</surname><given-names>SK</given-names></name>
<name><surname>Ellerbeck</surname><given-names>EF</given-names></name>
<name><surname>Mukhopadhyay</surname><given-names>P</given-names></name>
<name><surname>Spertus</surname><given-names>JA</given-names></name>
<etal/>
</person-group><article-title>The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients</article-title><source>Kidney Int</source><year>2012</year><volume>81</volume><issue>5</issue><fpage>469</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1038/ki.2011.416</pub-id><pub-id pub-id-type="pmid">22189842</pub-id>
</element-citation></ref><ref id="B305"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J</given-names></name>
<name><surname>Mohler</surname><given-names>ER</given-names><suffix>3 rd</suffix></name>
<name><surname>Xie</surname><given-names>D</given-names></name>
<name><surname>Shlipak</surname><given-names>MG</given-names></name>
<name><surname>Townsend</surname><given-names>RR</given-names></name>
<name><surname>Appel</surname><given-names>LJ</given-names></name>
<etal/>
</person-group><article-title>Risk factors for peripheral arterial disease among patients with chronic kidney disease</article-title><source>Am J Cardiol</source><year>2012</year><volume>110</volume><issue>1</issue><fpage>136</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2012.02.061</pub-id><pub-id pub-id-type="pmid">22465315</pub-id>
</element-citation></ref><ref id="B306"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajagopalan</surname><given-names>S</given-names></name>
<name><surname>Dellegrottaglie</surname><given-names>S</given-names></name>
<name><surname>Furniss</surname><given-names>AL</given-names></name>
<name><surname>Gillespie</surname><given-names>BW</given-names></name>
<name><surname>Satayathum</surname><given-names>S</given-names></name>
<name><surname>Lameire</surname><given-names>N</given-names></name>
<etal/>
</person-group><article-title>Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS)</article-title><source>Circulation</source><year>2006</year><volume>114</volume><issue>18</issue><fpage>1914</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.607390</pub-id><pub-id pub-id-type="pmid">17060384</pub-id>
</element-citation></ref><ref id="B307"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fang</surname><given-names>LJ</given-names></name>
<name><surname>Dong</surname><given-names>L</given-names></name>
<name><surname>Li</surname><given-names>YF</given-names></name>
<name><surname>Wei</surname><given-names>WB</given-names></name>
</person-group><article-title>Retinal vein occlusion and chronic kidney disease: a meta-analysis</article-title><source>Eur J Ophthalmol</source><year>2021</year><volume>31</volume><issue>4</issue><fpage>1945</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1177/1120672120937669</pub-id><pub-id pub-id-type="pmid">32578456</pub-id>
</element-citation></ref><ref id="B308"><label>308.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>YS</given-names></name>
<name><surname>Weng</surname><given-names>SF</given-names></name>
<name><surname>Chang</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>JJ</given-names></name>
<name><surname>Tseng</surname><given-names>SH</given-names></name>
<name><surname>Wang</surname><given-names>JY</given-names></name>
<etal/>
</person-group><part-title>Risk of retinal vein occlusion following end-stage renal disease</part-title><source>Medicine</source><publisher-loc>Baltimore</publisher-loc><year>2016</year><volume>95(16)</volume><fpage>e3474</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000003474</pub-id><pub-id pub-id-type="pmid">27100450</pub-id>
</element-citation></ref><ref id="B309"><label>309.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>YS</given-names></name>
<name><surname>Weng</surname><given-names>SF</given-names></name>
<name><surname>Chang</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>JJ</given-names></name>
<name><surname>Tseng</surname><given-names>SH</given-names></name>
<name><surname>Ko</surname><given-names>SY</given-names></name>
<etal/>
</person-group><article-title>Risk of retinal artery occlusion in patients with end-stage renal disease: a retrospective large-scale cohort study</article-title><source>Medicine</source><publisher-loc>Baltimore</publisher-loc><year>2016</year><volume>95</volume><issue>14</issue><fpage>e3281</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000003281</pub-id><pub-id pub-id-type="pmid">27057891</pub-id>
</element-citation></ref></ref-list></back><sub-article article-type="translation" id="s1" xml:lang="pt"><front-stub><article-id pub-id-type="doi">10.1590/2175-8239-JBN-2024-0033pt</article-id><article-categories><subj-group subj-group-type="heading"><subject>Sociedade Brasileira de Nefrologia</subject></subj-group></article-categories><title-group><article-title>I Diretriz Brasileira de hipertens&#x000e3;o arterial na di&#x000e1;lise da Sociedade Brasileira de Nefrologia</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9490-7997</contrib-id><name><surname>Rodrigues</surname><given-names>Cibele Isaac Saad</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff29" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff30" ref-type="aff">
<sup>3</sup>
</xref><role>delineamento e coordena&#x000e7;&#x000e3;o-geral das diretrizes</role><role>coordena&#x000e7;&#x000e3;o de cap&#x000ed;tulo</role><role>revis&#x000e3;o cr&#x000ed;tica do manuscrito</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4176-9572</contrib-id><name><surname>Ferreira-Filho</surname><given-names>Sebasti&#x000e3;o Rodrigues</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff31" ref-type="aff">
<sup>4</sup>
</xref><role>delineamento e coordena&#x000e7;&#x000e3;o-geral das diretrizes</role><role>coordena&#x000e7;&#x000e3;o de cap&#x000ed;tulo</role><role>revis&#x000e3;o cr&#x000ed;tica do manuscrito</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7368-4704</contrib-id><name><surname>Moura</surname><given-names>Ana Fl&#x000e1;via de Souza</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff29" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff32" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7333-8884</contrib-id><name><surname>Poli-de-Figueiredo</surname><given-names>Carlos Eduardo</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff33" ref-type="aff">
<sup>6</sup>
</xref><role>coordena&#x000e7;&#x000e3;o de cap&#x000ed;tulo</role><role>revis&#x000e3;o cr&#x000ed;tica do manuscrito</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7587-0604</contrib-id><name><surname>Silva</surname><given-names>Dirceu Reis da</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff34" ref-type="aff">
<sup>7</sup>
</xref><role>coordena&#x000e7;&#x000e3;o de cap&#x000ed;tulo</role><role>revis&#x000e3;o cr&#x000ed;tica do manuscrito</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8803-1300</contrib-id><name><surname>Polacchini</surname><given-names>Fernanda Salom&#x000e3;o Gorayeb</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff29" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff35" ref-type="aff">
<sup>8</sup>
</xref><role>coordena&#x000e7;&#x000e3;o de cap&#x000ed;tulo</role><role>revis&#x000e3;o cr&#x000ed;tica do manuscrito</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9404-9707</contrib-id><name><surname>Almeida</surname><given-names>Fernando Ant&#x000f4;nio de</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff29" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff30" ref-type="aff">
<sup>3</sup>
</xref><role>coordena&#x000e7;&#x000e3;o de cap&#x000ed;tulo</role><role>revis&#x000e3;o cr&#x000ed;tica do manuscrito</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2566-0016</contrib-id><name><surname>Pinheiro</surname><given-names>Maria Eliete</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff36" ref-type="aff">
<sup>9</sup>
</xref><role>coordena&#x000e7;&#x000e3;o de cap&#x000ed;tulo</role><role>revis&#x000e3;o cr&#x000ed;tica do manuscrito</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9719-3176</contrib-id><name><surname>Bezerra</surname><given-names>Rodrigo</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff37" ref-type="aff">
<sup>10</sup>
</xref><role>coordena&#x000e7;&#x000e3;o de cap&#x000ed;tulo</role><role>revis&#x000e3;o cr&#x000ed;tica do manuscrito</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7778-2907</contrib-id><name><surname>Paula</surname><given-names>Rog&#x000e9;rio Baumgratz de</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff29" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff38" ref-type="aff">
<sup>11</sup>
</xref><role>coordena&#x000e7;&#x000e3;o de cap&#x000ed;tulo</role><role>revis&#x000e3;o cr&#x000ed;tica do manuscrito</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1525-2991</contrib-id><name><surname>Peixoto</surname><given-names>Aldo Jos&#x000e9;</given-names></name><xref rid="aff39" ref-type="aff">
<sup>12</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8555-8649</contrib-id><name><surname>Figueiredo</surname><given-names>Ana Elizabeth Prado Lima</given-names></name><xref rid="aff33" ref-type="aff">
<sup>6</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9983-4720</contrib-id><name><surname>Feitosa</surname><given-names>Audes Di&#x000f3;genes Magalh&#x000e3;es</given-names></name><xref rid="aff37" ref-type="aff">
<sup>10</sup>
</xref><xref rid="aff40" ref-type="aff">
<sup>13</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3056-3077</contrib-id><name><surname>Machado</surname><given-names>Carlos Alberto</given-names></name><xref rid="aff29" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff40" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff41" ref-type="aff">
<sup>14</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8523-760X</contrib-id><name><surname>Amodeo</surname><given-names>Celso</given-names></name><xref rid="aff40" ref-type="aff">
<sup>13</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1564-121X</contrib-id><name><surname>Mion</surname><given-names>D&#x000e9;cio</given-names><suffix>Junior</suffix></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff29" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff40" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff43" ref-type="aff">
<sup>16</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3853-7842</contrib-id><name><surname>Muxfeldt</surname><given-names>Elizabeth Silaid</given-names></name><xref rid="aff29" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff40" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff44" ref-type="aff">
<sup>17</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3370-9326</contrib-id><name><surname>Silva</surname><given-names>Giovanio Vieira da</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff43" ref-type="aff">
<sup>16</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1339-3731</contrib-id><name><surname>Moura-Neto</surname><given-names>Jos&#x000e9; Andrade</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff32" ref-type="aff">Pecoits <sup>5</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0508-9887</contrib-id><name><surname>Pazeli</surname><given-names>Jos&#x000e9; Muniz</given-names><suffix>J&#x000fa;nior</suffix></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff45" ref-type="aff">
<sup>18</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1390-8651</contrib-id><name><surname>Lotaif</surname><given-names>Leda Daud</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff42" ref-type="aff">
<sup>15</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2081-6846</contrib-id><name><surname>Drager</surname><given-names>Luciano F.</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff29" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff43" ref-type="aff">
<sup>16</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1435-7994</contrib-id><name><surname>Mart&#x000ed;n</surname><given-names>Luis Cuadrado</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff29" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff46" ref-type="aff">
<sup>19</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4865-6442</contrib-id><name><surname>Bortolotto</surname><given-names>Luiz Aparecido</given-names></name><xref rid="aff29" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff40" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff43" ref-type="aff">
<sup>16</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3651-9923</contrib-id><name><surname>Bastos</surname><given-names>Marcus Gomes</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff38" ref-type="aff">
<sup>11</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8171-3920</contrib-id><name><surname>Malachias</surname><given-names>Marcus Vin&#x000ed;cius Bol&#x000ed;var</given-names></name><xref rid="aff40" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff47" ref-type="aff">
<sup>20</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-0747-5051</contrib-id><name><surname>Moreira</surname><given-names>Marcos Vin&#x000ed;cius Paiva Cavalcanti</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9645-5303</contrib-id><name><surname>Canziani</surname><given-names>Maria Eugenia Fernandes</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff48" ref-type="aff">
<sup>21</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1582-7268</contrib-id><name><surname>Miranda</surname><given-names>Roberto Dischinger</given-names></name><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff21" ref-type="aff">
<sup>21</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9787-4393</contrib-id><name><surname>Franco</surname><given-names>Roberto Jorge da Silva</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff29" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff46" ref-type="aff">
<sup>19</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0255-6710</contrib-id><name><surname>Pecoits</surname><given-names>Roberto</given-names><suffix>Filho</suffix></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff49" ref-type="aff">
<sup>22</sup>
</xref><xref rid="aff50" ref-type="aff">
<sup>23</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5704-5248</contrib-id><name><surname>Mulinari</surname><given-names>Rogerio Andrade</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff51" ref-type="aff">
<sup>24</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2212-041X</contrib-id><name><surname>Elias</surname><given-names>Rosilene Motta</given-names></name><xref rid="aff28" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff43" ref-type="aff">
<sup>16</sup>
</xref><xref rid="aff52" ref-type="aff">
<sup>25</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1265-1930</contrib-id><name><surname>Barroso</surname><given-names>Weimar Kunz Sebba</given-names></name><xref rid="aff40" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff53" ref-type="aff">
<sup>26</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0003-5102</contrib-id><name><surname>Nadruz</surname><given-names>Wilson</given-names></name><xref rid="aff29" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff40" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff54" ref-type="aff">
<sup>27</sup>
</xref><role>reda&#x000e7;&#x000e3;o</role></contrib></contrib-group><aff id="aff28">
<label>1</label>Sociedade Brasileira de Nefrologia, S&#x000e3;o Paulo, SP, Brasil.</aff><aff id="aff29">
<label>2</label>Sociedade Brasileira de Hipertens&#x000e3;o, S&#x000e3;o Paulo, SP, Brasil.</aff><aff id="aff30">
<label>3</label>Pontif&#x000ed;cia Universidade Cat&#x000f3;lica de S&#x000e3;o Paulo, Sorocaba, SP, Brasil.</aff><aff id="aff31">
<label>4</label>Universidade Federal de Uberl&#x000e2;ndia, Uberl&#x000e2;ndia, MG, Brasil.</aff><aff id="aff32">
<label>5</label>Escola Bahiana de Medicina e Sa&#x000fa;de P&#x000fa;blica, Salvador, BA, Brasil.</aff><aff id="aff33">
<label>6</label>Pontif&#x000ed;cia Universidade Cat&#x000f3;lica do Rio Grande do Sul, Porto Alegre, RS, Brasil.</aff><aff id="aff34">
<label>7</label>Hospital de Cl&#x000ed;nicas de Porto Alegre, Porto Alegre, RS, Brasil.</aff><aff id="aff35">
<label>8</label>Hospital de Base de S&#x000e3;o Jos&#x000e9; do Rio Preto, S&#x000e3;o Jos&#x000e9; do Rio Preto, SP, Brasil.</aff><aff id="aff36">
<label>9</label>Universidade Federal de Alagoas, Alagoas, AL, Brasil.</aff><aff id="aff37">
<label>10</label>Universidade Federal de Pernambuco, Recife, PE, Brasil.</aff><aff id="aff38">
<label>11</label>Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brasil.</aff><aff id="aff39">
<label>12</label>Yale University, Yale School of Medicine, New Haven, United States.</aff><aff id="aff40">
<label>13</label>Sociedade Brasileira de Cardiologia, S&#x000e3;o Paulo, SP, Brasil.</aff><aff id="aff41">
<label>14</label>Secretaria Municipal de Sa&#x000fa;de de Campos do Jord&#x000e3;o, Campos do Jord&#x000e3;o, SP, Brasil.</aff><aff id="aff42">
<label>15</label>Hospital do Cora&#x000e7;&#x000e3;o da Associa&#x000e7;&#x000e3;o Beneficente S&#x000ed;ria de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, Brasil.</aff><aff id="aff43">
<label>16</label>Universidade de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, Brasil.</aff><aff id="aff44">
<label>17</label>Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.</aff><aff id="aff45">
<label>18</label>Faculdade de Medicina de Barbacena, Barbacena, MG, Brasil.</aff><aff id="aff46">
<label>19</label>Universidade Estadual Paulista, Botucatu, SP, Brasil.</aff><aff id="aff47">
<label>20</label>Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas de Minas Gerais, Belo Horizonte, MG, Brasil.</aff><aff id="aff48">
<label>21</label>Universidade Federal de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, Brasil.</aff><aff id="aff49">
<label>22</label>Pontif&#x000ed;cia Universidade Cat&#x000f3;lica do Paran&#x000e1;, Curitiba, PR, Brasil.</aff><aff id="aff50">
<label>23</label>Arbor Research Collaborative for Health, Ann Arbor, Estados Unidos.</aff><aff id="aff51">
<label>24</label>Universidade Federal do Paran&#x000e1;, Curitiba, PR, Brasil.</aff><aff id="aff52">
<label>25</label>Universidade Nove de Julho, S&#x000e3;o Paulo, SP, Brasil.</aff><aff id="aff53">
<label>26</label>Universidade Federal de Goi&#x000e1;s, Goiania, GO, Brasil.</aff><aff id="aff54">
<label>27</label>Universidade Estadual de Campinas, Campinas, SP, Brasil.</aff><author-notes><corresp id="c002">
<bold>Correspond&#x000ea;ncia para:</bold> Cibele Isaac Saad Rodrigues. E-mail: <email>cibele.sr@gmail.com</email>
</corresp><fn fn-type="other" id="FN4"><label>*</label><p>
<bold>Realiza&#x000e7;&#x000e3;o:</bold> Sociedade Brasileira de Nefrologia, Departamento de Hipertens&#x000e3;o Arterial e Departamento de Di&#x000e1;lise.</p></fn><fn fn-type="other" id="FN5"><label>*</label><p>
<bold>Coordenadores-gerais:</bold> Cibele Isaac Saad Rodrigues e Sebasti&#x000e3;o Rodrigues Ferreira-Filho.</p></fn><fn fn-type="other" id="FN6"><label>*</label><p>
<bold>Coordenadores de cap&#x000ed;tulo:</bold> Cibele Isaac Saad Rodrigues, Sebasti&#x000e3;o Rodrigues Ferreira-Filho, Ana Fl&#x000e1;via Moura, Carlos Eduardo Poli de Figueiredo, Dirceu Reis da Silva, Fernanda Salom&#x000e3;o Gorayeb Polacchini, Fernando Ant&#x000f4;nio de Almeida, Maria Eliete Pinheiro, Rodrigo Bezerra, Rog&#x000e9;rio Baumgratz de Paula.</p></fn><fn fn-type="COI-statement"><p>
<bold>Conflito de Interesses</bold>
<table-wrap position="float" id="d67e18039"><table frame="box" rules="all" cellpadding="5" cellspacing="5"><tbody><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>Declara&#x000e7;&#x000e3;o de potencial conflito de interesse dos autores/colaboradores das Diretrizes Brasileiras de Hipertens&#x000e3;o Arterial</bold>
</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>Relacionamento do autor/colaborador da Diretriz com a ind&#x000fa;stria farmac&#x000ea;utica nos &#x000fa;ltimos 3 anos</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Integrante da Diretriz</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Relacionamento com a ind&#x000fa;stria farmac&#x000ea;utica</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aldo Jos&#x000e9; Peixoto</td><td align="left" valign="top" rowspan="1" colspan="1">Recebe aux&#x000ed;lio pessoal ou institucional da ind&#x000fa;stria: Todos os aux&#x000ed;lios foram institucionais (todos de pesquisa na qual fui Investigador Principal) e todos direcionados a Yale University (New Haven, CT, EUA) pelas seguintes companhias farmac&#x000ea;uticas ou de equipamentos: Bayer, Boehringer-Ingelheim, Lundbeck, Reata, Vascular Dynamics.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ana Elizabeth Prado Lima Figueiredo</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ana Fl&#x000e1;via de Souza Moura</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Audes Di&#x000f3;genes Magalh&#x000e3;es Feitosa</td><td align="left" valign="top" rowspan="1" colspan="1">&#x000c9; membro do conselho consultivo ou diretivo da ind&#x000fa;stria farmac&#x000ea;utica ou de equipamentos.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Carlos Eduardo Poli-de-Figueiredo</td><td align="left" valign="top" rowspan="1" colspan="1">Participou de comit&#x000ea;s normativos de estudos cient&#x000ed;ficos patrocinados pela ind&#x000fa;stria (HD Fit: n&#x000e3;o relacionado a esta Diretriz).<break/>Recebeu aux&#x000ed;lio pessoal ou institucional da ind&#x000fa;stria (Mayo Clinic PucRS).<break/>Elaborou textos cient&#x000ed;ficos em peri&#x000f3;dicos patrocinados pela ind&#x000fa;stria (HD Fit).</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Carlos Alberto Machado</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Celso Amodeo</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cibele Isaac Saad Rodrigues</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">D&#x000e9;cio Mion Junior</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dirceu Reis da Silva</td><td align="left" valign="top" rowspan="1" colspan="1">&#x000c9; membro do conselho consultivo ou diretivo da ind&#x000fa;stria farmac&#x000ea;utica ou de equipamentos.<break/>Recebeu aux&#x000ed;lio pessoal ou institucional da ind&#x000fa;stria.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Elizabeth Silaid Muxfeldt</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fernanda Salom&#x000e3;o Gorayeb Polacchini</td><td align="left" valign="top" rowspan="1" colspan="1">Recebeu aux&#x000ed;lio pessoal ou institucional da ind&#x000fa;stria.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fernando Ant&#x000f4;nio de Almeida</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Giovanio Vieira da Silva</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Jos&#x000e9; Andrade Moura-Neto</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Jos&#x000e9; Muniz Pazeli J&#x000fa;nior</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Leda Daud Lotaif</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Luciano F. Drager</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Luis Cuadrado Mart&#x000ed;n</td><td align="left" valign="top" rowspan="1" colspan="1">Recebeu aux&#x000ed;lio pessoal ou institucional da ind&#x000fa;stria.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Luiz Aparecido Bortolotto</td><td align="left" valign="top" rowspan="1" colspan="1">Elaborou textos cient&#x000ed;ficos em peri&#x000f3;dicos patrocinados pela ind&#x000fa;stria.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marcus Gomes Bastos</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marcus Vin&#x000ed;cius Bol&#x000ed;var Malachias</td><td align="left" valign="top" rowspan="1" colspan="1">Foi palestrante em eventos ou atividades patrocinadas pela ind&#x000fa;stria relacionados ao posicionamento em quest&#x000e3;o. <break/>Elaborou textos cient&#x000ed;ficos em peri&#x000f3;dicos patrocinados pela ind&#x000fa;stria.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marcus Vinicius P. Cavalcanti Moreira</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Maria Eliete Pinheiro</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Maria Eugenia Fernandes Canziani</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Roberto Jorge da Silva Franco</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Roberto Dischinger Miranda</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Roberto Pecoits Filho</td><td align="left" valign="top" rowspan="1" colspan="1">&#x000c9; membro do conselho consultivo ou diretivo da ind&#x000fa;stria farmac&#x000ea;utica ou de equipamentos. <break/>Participou de comit&#x000ea;s normativos de estudos cient&#x000ed;ficos patrocinados pela ind&#x000fa;stria.<break/>Recebeu aux&#x000ed;lio pessoal ou institucional da ind&#x000fa;stria. <break/>Elaborou textos cient&#x000ed;ficos em peri&#x000f3;dicos patrocinados pela ind&#x000fa;stria.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rodrigo Bezerra</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rog&#x000e9;rio Baumgratz de Paula</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rogerio Andrade Mulinari</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rosilene Motta Elias</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sebasti&#x000e3;o Rodrigues Ferreira-Filho</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weimar Kunz Sebba Barroso</td><td align="left" valign="top" rowspan="1" colspan="1">Participou de estudos cl&#x000ed;nicos e/ou experimentais subvencionados pela ind&#x000fa;stria farmac&#x000ea;utica ou de equipamentos relacionados &#x000e0; diretriz em quest&#x000e3;o.<break/>Foi palestrante em eventos ou atividades patrocinados pela ind&#x000fa;stria relacionados ao posicionamento em quest&#x000e3;o. <break/>&#x000c9; membro do conselho consultivo ou diretivo da ind&#x000fa;stria farmac&#x000ea;utica ou de equipamentos.<break/>Participou de comit&#x000ea;s normativos de estudos cient&#x000ed;ficos patrocinados pela ind&#x000fa;stria. <break/>Recebeu aux&#x000ed;lio pessoal ou institucional da ind&#x000fa;stria. <break/>Elaborou textos cient&#x000ed;ficos em peri&#x000f3;dicos patrocinados pela ind&#x000fa;stria.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wilson Nadruz</td><td align="left" valign="top" rowspan="1" colspan="1">Nada a declarar.</td></tr></tbody></table></table-wrap>
</p></fn></author-notes><abstract><title>Resumo</title><p>A hipertens&#x000e3;o arterial em pacientes em di&#x000e1;lise (HAD) tem alta preval&#x000ea;ncia, de pelo menos 80% ou mais, e seu manejo na pr&#x000e1;tica do nefrologista ocorre de forma heterog&#x000ea;nea e, frequentemente, emp&#x000ed;rica. Saber definir, conhecer a fisiopatologia, diagnosticar, acompanhar e tratar com mudan&#x000e7;as no estilo de vida, e adequar os medicamentos anti-hipertensivos para alcan&#x000e7;ar a meta de press&#x000e3;o arterial (PA) recomendada, com vistas &#x000e0; redu&#x000e7;&#x000e3;o da morbidade e mortalidade, requerem conhecimentos e abordagens espec&#x000ed;ficos nos contextos da hemodi&#x000e1;lise (HD) e da di&#x000e1;lise peritoneal (DP). Este documento &#x000e9; a primeira diretriz da Sociedade Brasileira de Nefrologia, elaborada pelos departamentos de Hipertens&#x000e3;o e de Di&#x000e1;lise, que visa orientar os m&#x000e9;dicos que prestam assist&#x000ea;ncia em centros de di&#x000e1;lise a como manejar pacientes com HAD, de forma integral e individualizada, com base no julgamento cr&#x000ed;tico das melhores evid&#x000ea;ncias cient&#x000ed;ficas dispon&#x000ed;veis e, quando essas s&#x000e3;o escassas ou indispon&#x000ed;veis, indicar a opini&#x000e3;o de especialistas. Os diferentes temas abordados envolvem: a defini&#x000e7;&#x000e3;o (PA pr&#x000e9;-HD &#x02265; 140/90 mmHg e PA p&#x000f3;s-HD &#x02265; 130/80 mmHg), epidemiologia e fisiopatologia; diagn&#x000f3;stico da HAD preferencialmente com medidas da PA fora do ambiente de di&#x000e1;lise (PA &#x02265; 130/80 mmHg); avalia&#x000e7;&#x000e3;o complementar; metas press&#x000f3;ricas; tratamento n&#x000e3;o medicamentoso; uso dos anti-hipertensivos mais adequados; situa&#x000e7;&#x000f5;es especiais; e complica&#x000e7;&#x000f5;es da HAD, predominantemente as cardiovasculares.</p></abstract><kwd-group><title>Descritores:</title><kwd>Hipertens&#x000e3;o</kwd><kwd>Di&#x000e1;lise Renal</kwd><kwd>Di&#x000e1;lise Peritoneal</kwd><kwd>Fatores de Risco</kwd><kwd>Tratamento Farmacol&#x000f3;gico</kwd><kwd>Guias de Pr&#x000e1;tica Cl&#x000ed;nica Como Assunto</kwd><kwd>Fal&#x000ea;ncia Renal Cr&#x000f4;nica</kwd><kwd>Hipertens&#x000e3;o Renal</kwd><kwd>Determina&#x000e7;&#x000e3;o da Press&#x000e3;o Arterial</kwd><kwd>Insufici&#x000ea;ncia Renal Cr&#x000f4;nica</kwd></kwd-group></front-stub><body><sec><title>Regras Para Recomenda&#x000e7;&#x000f5;es e N&#x000ed;veis de Evid&#x000ea;ncia<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>
</title><p>As recomenda&#x000e7;&#x000f5;es foram estratificadas em Classes ou Graus I, IIa, IIb ou III e n&#x000ed;veis de evid&#x000ea;ncia, assim descritas:</p><sec><title>Classes (Graus) de Recomenda&#x000e7;&#x000e3;o</title><p>Classe I &#x02013; Condi&#x000e7;&#x000f5;es para as quais h&#x000e1; evid&#x000ea;ncias conclusivas, ou, na sua falta, h&#x000e1; recomenda&#x000e7;&#x000e3;o de que o procedimento seja seguro e &#x000fa;til/eficaz;</p><p>Classe II &#x02013; Condi&#x000e7;&#x000f5;es para as quais h&#x000e1; evid&#x000ea;ncias conflitantes e/ou diverg&#x000ea;ncia de opini&#x000e3;o sobre seguran&#x000e7;a e utilidade/ efic&#x000e1;cia do procedimento;</p><p>Classe IIA &#x02013; Peso ou evid&#x000ea;ncia/opini&#x000e3;o a favor do procedimento. A maioria aprova;</p><p>Classe IIB &#x02013; Seguran&#x000e7;a e utilidade/efic&#x000e1;cia menos bem estabelecida, n&#x000e3;o havendo predom&#x000ed;nio de opini&#x000f5;es a favor;</p><p>Classe III &#x02013; Condi&#x000e7;&#x000f5;es para as quais h&#x000e1; evid&#x000ea;ncias e/ou consenso de que o procedimento n&#x000e3;o &#x000e9; &#x000fa;til/eficaz e, em alguns casos, pode ser prejudicial.</p></sec><sec><title>N&#x000ed;veis de Evid&#x000ea;ncia</title><p>N&#x000ed;vel A &#x02013; Dados obtidos a partir de m&#x000fa;ltiplos estudos randomizados de bom porte, concordantes e/ou de meta-an&#x000e1;lise robusta de estudos cl&#x000ed;nicos randomizados;</p><p>N&#x000ed;vel B &#x02013; Dados obtidos a partir de meta-an&#x000e1;lise menos robusta, a partir de um &#x000fa;nico estudo randomizado ou de estudos n&#x000e3;o randomizados (observacionais);</p><p>N&#x000ed;vel C &#x02013; Dados obtidos de opini&#x000f5;es consensuais de especialistas.</p></sec></sec><sec sec-type="intro"><title>Introdu&#x000e7;ao</title><p>O objetivo principal desta publica&#x000e7;&#x000e3;o &#x000e9; trazer ao m&#x000e9;dico nefrologista, que atua no cuidado de pacientes renais cr&#x000f4;nicos em di&#x000e1;lise, as melhores evid&#x000ea;ncias cient&#x000ed;ficas dispon&#x000ed;veis sobre os diferentes aspectos da HA, desde sua fisiopatologia at&#x000e9; o tratamento. Trata-se da constru&#x000e7;&#x000e3;o de um documento in&#x000e9;dito em l&#x000ed;ngua portuguesa que seja &#x000fa;til na pr&#x000e1;tica cl&#x000ed;nica di&#x000e1;ria do nefrologista.</p><p>Os departamentos da SBN envolvidos almejam que as recomenda&#x000e7;&#x000f5;es e sugest&#x000f5;es aqui expressas tenham repercuss&#x000e3;o nacional, contribuindo para a melhor abordagem e o tratamento das pessoas que necessitam de terapias dial&#x000ed;ticas, com consequentes benef&#x000ed;cios na redu&#x000e7;&#x000e3;o da morbidade e mortalidade cardiovascular e renal.</p><p>&#x000c9; fato que, mesmo o prestigioso KDIGO (<italic>Kidney Diseases Improving Global Outcomes</italic>), em seus <italic>guidelines</italic> de HA na DRC, n&#x000e3;o postulou recomenda&#x000e7;&#x000f5;es para o est&#x000e1;gio 5D, provavelmente pela falta de estudos cl&#x000ed;nicos randomizados e controlados e de revis&#x000f5;es sistem&#x000e1;ticas e meta-an&#x000e1;lises nessa popula&#x000e7;&#x000e3;o que pudessem ancorar recomenda&#x000e7;&#x000f5;es com altos n&#x000ed;veis de confian&#x000e7;a e qualidade.</p><p>Atualmente, no Brasil, segundo o Censo da Sociedade Brasileira de Nefrologia, de 2022, existem 872 centros de di&#x000e1;lise, com preval&#x000ea;ncia estimada de 153.831 pacientes em est&#x000e1;gio 5D, sendo 91% em HD. A HA &#x000e9; apontada como causa direta respons&#x000e1;vel pela DRC 5D em cerca de 34% dos pacientes e est&#x000e1; presente como comorbidade em mais de 80% dos pacientes em programas de di&#x000e1;lise. Ou seja, existe um enorme problema a ser enfrentado e possivelmente uma in&#x000e9;rcia terap&#x000ea;utica que pode ser respons&#x000e1;vel por desfechos piores de morbidade e mortalidade<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>.</p></sec><sec><title>Defini&#x000e7;&#x000e3;o, Epidemiologia e Fisiopatologia da ha no Paciente em Di&#x000e1;lise (HAD)</title><sec><title>Defini&#x000e7;&#x000e3;o/Epidemiologia</title><p>HAD &#x000e9; definida a partir das observa&#x000e7;&#x000f5;es previamente estabelecidas para a popula&#x000e7;&#x000e3;o geral, e os limites sobre o que &#x000e9; normotens&#x000e3;o ou hipertens&#x000e3;o variam nas diferentes diretrizes<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>. Assim, a medida da PA em pacientes em di&#x000e1;lise representa um desafio &#x000e0; padroniza&#x000e7;&#x000e3;o. O ideal &#x000e9; que o diagn&#x000f3;stico de HAD seja baseado em avalia&#x000e7;&#x000f5;es interdial&#x000ed;ticas domiciliares com MRPA ou MAPA, com a padroniza&#x000e7;&#x000e3;o recomendada<sup>
<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>
</sup>.</p><p>Em termos epidemiol&#x000f3;gicos, a HA ocorre em mais de 80% dos pacientes em di&#x000e1;lise, sendo, frequentemente, mal controlada<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>A HID tem preval&#x000ea;ncia estimada de 5% a 15% e correlaciona-se com hospitaliza&#x000e7;&#x000f5;es e mortalidade<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup>. (Classe I/N&#x000ed;vel B);</p></list-item><list-item><p>Muitos trabalhos mostram a presen&#x000e7;a de epidemiologia reversa, com curvas em J ou U<sup>
<xref rid="B8" ref-type="bibr">8</xref>
</sup> (Classe I/N&#x000ed;vel B).</p></list-item></list><p>Para o diagn&#x000f3;stico de HAD, recomenda-se:</p><list list-type="bullet"><list-item><p>MRPA: m&#x000e9;dia &#x02265; 130/80 mmHg, considerando o dia de instala&#x000e7;&#x000e3;o e mais 6 dias consecutivos (vide protocolo no cap&#x000ed;tulo 3);</p></list-item><list-item><p>MAPA em HD: m&#x000e9;dia &#x02265; 130/80 mmHg em 44h (vide protocolo no cap&#x000ed;tulo 3);</p></list-item><list-item><p>MAPA em DP: m&#x000e9;dia &#x02265; 130/80 mmHg em 24h (vide protocolo no cap&#x000ed;tulo 3);</p></list-item><list-item><p>MRPA/MAPA indispon&#x000ed;veis: medidas realizadas em dia n&#x000e3;o dial&#x000ed;tico no meio da semana na HD, ou no consult&#x000f3;rio na DP;</p></list-item><list-item><p>HID &#x000e9; definida por aumento &#x02265; 10 mmHg na PAS durante ou imediatamente ap&#x000f3;s a HD em 4 de 6 sess&#x000f5;es. Motiva avalia&#x000e7;&#x000e3;o adicional<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup>.</p></list-item></list><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>As medidas da PA pr&#x000e9;, intra e p&#x000f3;s-HD s&#x000e3;o imprecisas para diagn&#x000f3;stico, mas &#x000fa;teis para diagnosticar HID e para o controle hemodin&#x000e2;mico<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup> (Classe I/N&#x000ed;vel B).</p></list-item><list-item><p>O limite diagn&#x000f3;stico pr&#x000e9;-HD &#x000e9; &#x0003e; 140/90 mmHg e p&#x000f3;s-HD &#x0003e; 130/80 mmHg<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup> (Classe I/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Fisiopatologia da HAD</title><p>A fisiopatologia da HAD &#x000e9; complexa e multifatorial, englobando fatores gerais e espec&#x000ed;ficos da DRC<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup> (<xref rid="F08" ref-type="fig">Figura 1</xref>). Entretanto, a maioria dos pacientes com DRC 5D tem como causas principais a HA e o DM, ou seja, trata-se de uma popula&#x000e7;&#x000e3;o com HA que pode anteceder em d&#x000e9;cadas o in&#x000ed;cio da terapia dial&#x000ed;tica. Al&#x000e9;m disso, pacientes com DRC de outras etiologias tamb&#x000e9;m apresentam HA, frequentemente secund&#x000e1;ria &#x000e0; doen&#x000e7;a renal de base.</p><fig position="float" id="F08"><label>Figura 1</label><caption><title>Fisiopatologia da hipertens&#x000e3;o arterial em pacientes sob tratamento dial&#x000ed;tico.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf08" position="float"/><attrib>Abreviaturas &#x02013; DRC Grau 5D: doen&#x000e7;a renal cr&#x000f4;nica est&#x000e1;gio 5 em di&#x000e1;lise; AOS: apneia obstrutiva do sono; Na+: s&#x000f3;dio; TRS: terapia renal substitutiva; SRAA: sistema renina angiotensina aldosterona; SNS: sistema nervoso simp&#x000e1;tico; EPO: eritropoietina recombinante humana.</attrib></fig></sec><sec><title>Rela&#x000e7;&#x000e3;o entre sobrecarga de volume e hipertens&#x000e3;o arterial em DRC</title><p>O papel da hipervolemia na HAD pode ser evidenciado pela redu&#x000e7;&#x000e3;o da PA associada &#x000e0; intensifica&#x000e7;&#x000e3;o da UF. Em um estudo, a realiza&#x000e7;&#x000e3;o de HD di&#x000e1;ria e de longa dura&#x000e7;&#x000e3;o resultou no controle press&#x000f3;rico em cerca de 90% dos pacientes<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup>, sendo observada dissocia&#x000e7;&#x000e3;o entre a obten&#x000e7;&#x000e3;o do PS estimado e o controle press&#x000f3;rico, verificado ap&#x000f3;s semanas ou meses do alcance da euvolemia. Esse fen&#x000f4;meno, conhecido como &#x0201c;<italic>lag phenomenum</italic>&#x0201d;, parece se relacionar &#x000e0; remo&#x000e7;&#x000e3;o adicional de sal, &#x000e0; medida que se intensifica a UF<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup>. Resultados semelhantes foram observados na Turquia<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup>. Estrat&#x000e9;gias comuns nesses estudos inclu&#x000ed;ram a restri&#x000e7;&#x000e3;o de sal na dieta e a realiza&#x000e7;&#x000e3;o de sess&#x000f5;es de di&#x000e1;lises prolongadas. Estudo randomizado, no qual a intensifica&#x000e7;&#x000e3;o da UF foi obtida sem amplia&#x000e7;&#x000e3;o do tempo das sess&#x000f5;es de HD, confirmou significativa melhora do controle da PA nos pacientes que atingiram o PS estimado, quando comparados aos do grupo controle<sup>
<xref rid="B14" ref-type="bibr">14</xref>
</sup>.</p><p>Em pacientes em DP, poucos s&#x000e3;o os estudos que avaliaram a rela&#x000e7;&#x000e3;o da hipervolemia com a HA<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup>. Um deles avaliou pacientes em DP, submetidos &#x000e0; intensifica&#x000e7;&#x000e3;o da UF, com redu&#x000e7;&#x000e3;o do peso corporal em 5%<sup>
<xref rid="B16" ref-type="bibr">16</xref>
</sup>. Ap&#x000f3;s 5 semanas, foram observadas redu&#x000e7;&#x000f5;es do peso corporal, da &#x000e1;gua extracelular, do di&#x000e2;metro inspirat&#x000f3;rio da veia cava inferior e melhor controle press&#x000f3;rico. A hipervolemia parece exercer papel preponderante na HA em pacientes em DP.</p><p>Nas &#x000fa;ltimas d&#x000e9;cadas, um novo elemento tem sido associado ao excesso de s&#x000f3;dio presente na DRC. Em 2003, Titze e cols.<sup>
<xref rid="B17" ref-type="bibr">17</xref>
</sup> mostraram reten&#x000e7;&#x000e3;o de s&#x000f3;dio complexado &#x000e0; glicosaminoglicanos na pele e m&#x000fa;sculos de modelos animais, portanto sem reten&#x000e7;&#x000e3;o de &#x000e1;gua. O ac&#x000fa;mulo n&#x000e3;o osm&#x000f3;tico de s&#x000f3;dio forma um sistema &#x0201c;tamp&#x000e3;o&#x0201d; de armazenamento de s&#x000f3;dio<sup>
<xref rid="B18" ref-type="bibr">18</xref>
</sup>, com recrutamento de macr&#x000f3;fagos, indu&#x000e7;&#x000e3;o da express&#x000e3;o do gene da <italic>&#x0201c;tonicity-responsive enhancer-binding protein</italic>&#x0201d; (TonE) e do fator de crescimento derivado do endot&#x000e9;lio (VEGF), que induzem &#x000e0; hipertrofia de vasos linf&#x000e1;ticos, &#x000e0; libera&#x000e7;&#x000e3;o de ON e vasodilata&#x000e7;&#x000e3;o. Contudo, em situa&#x000e7;&#x000f5;es de excesso de s&#x000f3;dio ou de incapacidade de sua elimina&#x000e7;&#x000e3;o, o funcionamento desse sistema &#x0201c;tamp&#x000e3;o&#x0201d; est&#x000e1; comprometido, gerando aumento do s&#x000f3;dio na pele e nos m&#x000fa;sculos, com ativa&#x000e7;&#x000e3;o do sistema imune, inflama&#x000e7;&#x000e3;o e fibrose<sup>
<xref rid="B19" ref-type="bibr">19</xref>
</sup>. Aumento do conte&#x000fa;do de s&#x000f3;dio subcut&#x000e2;neo, demonstr&#x000e1;vel por meio de resson&#x000e2;ncia nuclear magn&#x000e9;tica, contribui para a HA e para aumento de eventos CV em renais cr&#x000f4;nicos<sup>
<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>O papel da hipervolemia na HA da DRC est&#x000e1;gio 5D pode ser evidenciado pela redu&#x000e7;&#x000e3;o da PA associada &#x000e0; intensifica&#x000e7;&#x000e3;o da UF (Classe I/N&#x000ed;vel B). Em pacientes em DP, tamb&#x000e9;m parece exercer papel preponderante na HA (Classe I/N&#x000ed;vel C).</p></list-item></list><sec><title>Par&#x000e2;metros que interferem na pa: s&#x000f3;dio/composi&#x000e7;&#x000e3;o da solu&#x000e7;&#x000e3;o de di&#x000e1;lise</title><p>Pacientes em di&#x000e1;lise s&#x000e3;o habitualmente hipervol&#x000ea;micos e hipertensos, em especial por sensibilidade exacerbada ao sal, ativa&#x000e7;&#x000e3;o inapropriada do SRAA &#x000e0; ingest&#x000e3;o de s&#x000f3;dio e natriurese diminu&#x000ed;da<sup>
<xref rid="B22" ref-type="bibr">22</xref>
</sup>. O pool corporal de s&#x000f3;dio inclui dep&#x000f3;sitos cut&#x000e2;neos e musculares, particularmente em diab&#x000e9;ticos<sup>
<xref rid="B23" ref-type="bibr">23</xref>
</sup>, com remo&#x000e7;&#x000e3;o parcial pela HD<sup>
<xref rid="B21" ref-type="bibr">21</xref>
</sup> e impacta no controle press&#x000f3;rico e na HVE<sup>
<xref rid="B24" ref-type="bibr">24</xref>
</sup>. Quando persiste ao final da HD, a HA pode traduzir hipervolemia residual<sup>
<xref rid="B25" ref-type="bibr">25</xref>
</sup>, assim como no intervalo interdial&#x000ed;tico<sup>
<xref rid="B26" ref-type="bibr">26</xref>
</sup>.</p><p>Concentra&#x000e7;&#x000f5;es diferentes de s&#x000f3;dio na solu&#x000e7;&#x000e3;o de di&#x000e1;lise podem relacionar-se com o controle vol&#x000ea;mico e da PA<sup>
<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>
</sup> e, se superiores &#x000e0;s concentra&#x000e7;&#x000f5;es s&#x000e9;ricas, resulta em aumento do GPID, sem se correlacionar com varia&#x000e7;&#x000f5;es da PA<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup>. Os pacientes submetidos a menor concentra&#x000e7;&#x000e3;o de s&#x000f3;dio na solu&#x000e7;&#x000e3;o de di&#x000e1;lise tiveram maior ocorr&#x000ea;ncia de hipotens&#x000e3;o intradial&#x000ed;tica<sup>
<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B31" ref-type="bibr">31</xref>
</sup>, menor GPID<sup>
<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>
</sup>, menor PA<sup>
<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>
</sup> e uso minimizado de anti-hipertensivos<sup>
<xref rid="B29" ref-type="bibr">29</xref>
</sup>, mas sem efeitos positivos na redu&#x000e7;&#x000e3;o da HVE<sup>
<xref rid="B28" ref-type="bibr">28</xref>
</sup>, nas taxas de interna&#x000e7;&#x000e3;o<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup> e na mortalidade<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup>. Estudo em andamento pretende avaliar o efeito de diferentes concentra&#x000e7;&#x000f5;es de s&#x000f3;dio do dialisato em eventos CV e mortalidade em pacientes em HD (RESOLVE, NCT02823821).</p><p>Al&#x000e9;m disso, a natremia pr&#x000e9;-HD costuma aproximar-se do n&#x000ed;vel fisiol&#x000f3;gico de ajuste individual (<italic>set point</italic>), e pode-se adotar s&#x000f3;dio da solu&#x000e7;&#x000e3;o de di&#x000e1;lise semelhante a esse n&#x000ed;vel (di&#x000e1;lise isonatr&#x000ea;mica), com base na retirada do s&#x000f3;dio em convec&#x000e7;&#x000e3;o, e evitando balan&#x000e7;o positivo<sup>
<xref rid="B32" ref-type="bibr">32</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se cautela quanto &#x000e0;s manobras de aumento ou diminui&#x000e7;&#x000e3;o do s&#x000f3;dio da solu&#x000e7;&#x000e3;o de di&#x000e1;lise, pois o s&#x000f3;dio alto aumenta o GPID e, ao contr&#x000e1;rio, s&#x000f3;dio baixo diminui o GPID e a PA, mas aumenta o risco de hipotens&#x000e3;o intradial&#x000ed;tica (Classe I/N&#x000ed;vel B).</p></list-item><list-item><p>N&#x000e3;o h&#x000e1; indica&#x000e7;&#x000e3;o de ajustar a concentra&#x000e7;&#x000e3;o de s&#x000f3;dio na solu&#x000e7;&#x000e3;o de di&#x000e1;lise com objetivo de reduzir interna&#x000e7;&#x000e3;o ou mortalidade (Classe I/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Taxa de ultrafiltra&#x000e7;&#x000e3;o (UF)</title><p>Taxas de UF elevadas associam-se &#x000e0; hipotens&#x000e3;o arterial, mas, caso estejam demasiadamente baixas, podem perpetuar a hipervolemia, principal determinante da HA<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup>. A rela&#x000e7;&#x000e3;o entre UF e redu&#x000e7;&#x000e3;o da PA &#x000e9; consistente, mas em hipertensos pode sofrer influ&#x000ea;ncia de outros fatores envolvidos na fisiopatologia da HA<sup>
<xref rid="B33" ref-type="bibr">33</xref>
</sup>.</p><p>Necess&#x000e1;ria para se evitar hipotens&#x000e3;o, a manuten&#x000e7;&#x000e3;o do volume plasm&#x000e1;tico durante a HD depende do <italic>refilling</italic> (absor&#x000e7;&#x000e3;o de fluidos intersticiais e linf&#x000e1;ticos na microcircula&#x000e7;&#x000e3;o), que independe <italic>per se</italic> da ado&#x000e7;&#x000e3;o de taxas de UF maiores ou n&#x000e3;o<sup>
<xref rid="B34" ref-type="bibr">34</xref>
</sup>.</p><p>Mecanismos compensat&#x000f3;rios contrarregulat&#x000f3;rios &#x000e0; UF s&#x000e3;o a taquicardia reflexa e vasoconstri&#x000e7;&#x000e3;o. Portanto, pacientes com disfun&#x000e7;&#x000e3;o auton&#x000f4;mica e/ou ventricular podem desenvolver hipotens&#x000e3;o intradial&#x000ed;tica mesmo com taxas baixas de UF<sup>
<xref rid="B35" ref-type="bibr">35</xref>
</sup>. Taxas elevadas de UF associam-se &#x000e0; hipotens&#x000e3;o intradial&#x000ed;tica, redu&#x000e7;&#x000e3;o da FRR e aumento de mortalidade<sup>
<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>,<xref rid="B39" ref-type="bibr">39</xref>
</sup>. A ado&#x000e7;&#x000e3;o de taxa de UF &#x0003e; 13 mL/kg/h<sup>
<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>,<xref rid="B39" ref-type="bibr">39</xref>
</sup> pareceu globalmente delet&#x000e9;ria e taxas de UF &#x0003e; 10 mL/kg/h<sup>
<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B39" ref-type="bibr">39</xref>
</sup> s&#x000e3;o prejudiciais, principalmente na presen&#x000e7;a de disfun&#x000e7;&#x000e3;o ventricular<sup>
<xref rid="B35" ref-type="bibr">35</xref>
</sup>. Em esquema de HD de 1 a 2 vezes por semana, parecem ser necess&#x000e1;rias taxas ainda menores de UF (inferiores a 6 mL/Kg/h)<sup>
<xref rid="B36" ref-type="bibr">36</xref>
</sup>. Se a FRR permanece preservada, a associa&#x000e7;&#x000e3;o de alta taxa de UF com mortalidade &#x000e9; atenuada<sup>
<xref rid="B36" ref-type="bibr">36</xref>
</sup>.</p><p>A hipotens&#x000e3;o est&#x000e1; associada &#x000e0; redu&#x000e7;&#x000e3;o acelerada da FRR, atenuando o efeito positivo desta sobre a mortalidade, tanto em HD como em DP<sup>
<xref rid="B40" ref-type="bibr">40</xref>
</sup>. Recomenda-se aumentar o tempo da sess&#x000e3;o de HD ou sua frequ&#x000ea;ncia para evitar taxas de UF &#x0003e; 13 mL/kg/h e, ainda assim, manejar hipervolemia<sup>
<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B41" ref-type="bibr">41</xref>
</sup>. Essencialmente, esses limites de taxa de UF podem ser adotados, mas deve-se considerar ainda um conjunto de fatores, incluindo hemodin&#x000e2;mica intradial&#x000ed;tica, comorbidades, sintomas e uso de medicamentos<sup>
<xref rid="B41" ref-type="bibr">41</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se evitar taxas elevadas de UF, ou seja, &#x0003e; 13 mL/kg/h, pois se associa a aumento da mortalidade, hipotens&#x000e3;o intradial&#x000ed;tica e redu&#x000e7;&#x000e3;o acelerada da FRR.</p></list-item><list-item><p>Recomenda-se que, em pacientes com disfun&#x000e7;&#x000e3;o ventricular, o limiar sugerido &#x000e9; ainda menor (at&#x000e9; 10 mL/kg/h) (Classe I/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Ativa&#x000e7;&#x000e3;o do sistema renina angiotensina aldosterona (SRAA)</title><p>Os rins s&#x000e3;o capazes de sintetizar todos os componentes do SRAA, inclusive em pacientes em di&#x000e1;lise<sup>
<xref rid="B42" ref-type="bibr">42</xref>
</sup>, sendo que neles a APR est&#x000e1; inapropriadamente elevada em rela&#x000e7;&#x000e3;o &#x000e0; hipervolemia. Esses dados s&#x000e3;o refor&#x000e7;ados pelo aumento da APR ap&#x000f3;s as sess&#x000f5;es de di&#x000e1;lise, indicando que n&#x000e9;frons remanescentes s&#x000e3;o capazes de perceber as varia&#x000e7;&#x000f5;es de s&#x000f3;dio e aumentar a atividade do SRAA. A angiotensina II exerce efeitos delet&#x000e9;rios ao estimular a produ&#x000e7;&#x000e3;o de aldosterona e a reten&#x000e7;&#x000e3;o de s&#x000f3;dio ao causar les&#x000e3;o endotelial e estimular o SNS<sup>
<xref rid="B42" ref-type="bibr">42</xref>,<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B44" ref-type="bibr">44</xref>
</sup>. A administra&#x000e7;&#x000e3;o de lisinopril a pacientes em HD resultou em melhor controle da PA, avaliada por meio da MAPA de 44 horas, quando comparados ao grupo controle<sup>
<xref rid="B45" ref-type="bibr">45</xref>
</sup>.</p><p>Al&#x000e9;m da angiotensina II, tem sido evidenciada a a&#x000e7;&#x000e3;o vasculot&#x000f3;xica da aldosterona, principalmente na presen&#x000e7;a de sal. Tal achado sugere que a aldosterona possa desempenhar um papel permissivo na toxicidade do s&#x000f3;dio no endot&#x000e9;lio, tornando-se assim um fator de risco para complica&#x000e7;&#x000f5;es CV<sup>
<xref rid="B46" ref-type="bibr">46</xref>
</sup>.</p><p>Em concord&#x000e2;ncia, o bloqueio dos receptores mineralocorticoides com espironolactona resultou em melhor controle press&#x000f3;rico e em redu&#x000e7;&#x000e3;o de mortalidade CV em pacientes em HD<sup>
<xref rid="B47" ref-type="bibr">47</xref>
</sup>. Assim, a aldosterona contribui para o agravamento da HA ao exercer efeitos gen&#x000f4;micos e n&#x000e3;o gen&#x000f4;micos, com indu&#x000e7;&#x000e3;o de inflama&#x000e7;&#x000e3;o e toxicidade vascular, na presen&#x000e7;a de excesso de sal.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se o bloqueio do SRAA devido &#x000e0; sua ativa&#x000e7;&#x000e3;o inapropriada, a despeito da hipervolemia, o que contribui de modo significativo para a g&#x000ea;nese da HA e para o aumento do risco CV em pacientes com DRC (Classe I/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Ativa&#x000e7;&#x000e3;o do Sistema Nrvoso Simp&#x000e1;tico (SNS)</title><p>Ativa&#x000e7;&#x000e3;o do SNS na DRC constitui um dos principais mecanismos relacionados &#x000e0; fisiopatologia da HA. Entre os fatores respons&#x000e1;veis pela hiperatividade do SNS na DRC, est&#x000e3;o a redu&#x000e7;&#x000e3;o da biodisponibilidade de ON, DE, toxicidade ur&#x000ea;mica e inflama&#x000e7;&#x000e3;o, al&#x000e9;m de elevada preval&#x000ea;ncia de AOS<sup>
<xref rid="B48" ref-type="bibr">48</xref>,<xref rid="B49" ref-type="bibr">49</xref>,<xref rid="B50" ref-type="bibr">50</xref>
</sup>.</p><p>Aumento das concentra&#x000e7;&#x000f5;es de norepinefrina plasm&#x000e1;tica e da atividade simp&#x000e1;tica, avaliada por meio da atividade simp&#x000e1;tica muscular (MSNA), evidenciam a import&#x000e2;ncia do SNS na fisiopatologia da HA em DRC. Aferentes simp&#x000e1;ticos renais que inervam as art&#x000e9;rias renais e eferentes do SNC estimulados por receptores B1, causam vasoconstri&#x000e7;&#x000e3;o arteriolar renal e ativa&#x000e7;&#x000e3;o do SRAA, com consequente aumento da resist&#x000ea;ncia vascular renal e reten&#x000e7;&#x000e3;o de s&#x000f3;dio<sup>
<xref rid="B51" ref-type="bibr">51</xref>
</sup>. Pacientes com DRC apresentam defici&#x000ea;ncia de renalase, enzima produzida pelos rins e respons&#x000e1;vel pela metaboliza&#x000e7;&#x000e3;o de catecolaminas<sup>
<xref rid="B52" ref-type="bibr">52</xref>
</sup>.</p><p>A hiperatividade do SNS tamb&#x000e9;m contribui para a mortalidade CV, estando associada a doen&#x000e7;a ateroscler&#x000f3;tica, HVE e presen&#x000e7;a de arritmias card&#x000ed;acas, respons&#x000e1;veis por cerca de 25% dos &#x000f3;bitos de pacientes em di&#x000e1;lise<sup>
<xref rid="B53" ref-type="bibr">53</xref>
</sup>. A hiperatividade simp&#x000e1;tica &#x000e9; confirmada pelo melhor controle press&#x000f3;rico ap&#x000f3;s nefrectomia de rins nativos em pacientes com DRC est&#x000e1;gio 5D<sup>
<xref rid="B54" ref-type="bibr">54</xref>
</sup> e pela denerva&#x000e7;&#x000e3;o renal em pacientes em diferentes est&#x000e1;gios da DRC<sup>
<xref rid="B55" ref-type="bibr">55</xref>
</sup> e em HD<sup>
<xref rid="B56" ref-type="bibr">56</xref>
</sup>. Finalmente, a administra&#x000e7;&#x000e3;o de BB em pacientes em di&#x000e1;lise reduz a progress&#x000e3;o da DRC e da mortalidade<sup>
<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B58" ref-type="bibr">58</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se o bloqueio do SNS para o tratamento da HA, pois a hiperatividade simp&#x000e1;tica &#x000e9; importante mecanismo fisiopatol&#x000f3;gico na HA e na mortalidade em DRC (Classe I/N&#x000ed;vel A).</p></list-item></list></sec><sec><title>Disfun&#x000e7;&#x000e3;o endotelial (DE)</title><p>&#x000c9; razo&#x000e1;vel afirmar que a DE associada &#x000e0; HA em pacientes em HD ou DP precede em d&#x000e9;cadas o diagn&#x000f3;stico da DRC, considerando-se que a maioria dos pacientes com DRC tem DM e/ou HA, ou &#x000e9; idoso e apresenta diversos fatores de risco CV. Estudo em ratos submetidos &#x000e0; nefrectomia 5/6 documentaram a redu&#x000e7;&#x000e3;o da atividade da ON-sintase endotelial, com consequente menor disponibilidade de ON e eleva&#x000e7;&#x000e3;o da PA<sup>
<xref rid="B59" ref-type="bibr">59</xref>
</sup>. A redu&#x000e7;&#x000e3;o da oferta de ON tem sido atribu&#x000ed;da &#x000e0;s altera&#x000e7;&#x000f5;es no metabolismo das pteridinas, que s&#x000e3;o compostos arom&#x000e1;ticos que agem como cofatores em diversos processos inflamat&#x000f3;rios e imunol&#x000f3;gicos<sup>
<xref rid="B60" ref-type="bibr">60</xref>
</sup>. Em pacientes com DRC est&#x000e1;gio 5D, a redu&#x000e7;&#x000e3;o da rela&#x000e7;&#x000e3;o entre BH4/BH2, compostos pertencentes ao grupo das pteridinas, se associou &#x000e0; redu&#x000e7;&#x000e3;o da disponibilidade de NO endotelial, ao processo de inflama&#x000e7;&#x000e3;o/desnutri&#x000e7;&#x000e3;o e &#x000e0; DCV<sup>
<xref rid="B61" ref-type="bibr">61</xref>
</sup>. Tamb&#x000e9;m o estresse oxidativo presente na DR<sup>
<xref rid="B62" ref-type="bibr">62</xref>
</sup> e, particularmente, o aumento dos n&#x000ed;veis plasm&#x000e1;ticos de dimetil-arginina-assim&#x000e9;trica (DMAA) interferem na produ&#x000e7;&#x000e3;o de NO e est&#x000e3;o associados &#x000e0; HVE e mortalidade CV em pacientes em HD<sup>
<xref rid="B63" ref-type="bibr">63</xref>,<xref rid="B64" ref-type="bibr">64</xref>,<xref rid="B65" ref-type="bibr">65</xref>
</sup>. A DMAA &#x000e9; inibidor end&#x000f3;geno da s&#x000ed;ntese de NO, que se acumula devido &#x000e0;s redu&#x000e7;&#x000f5;es da TFG e da metaboliza&#x000e7;&#x000e3;o intracelular<sup>
<xref rid="B65" ref-type="bibr">65</xref>
</sup>.</p><p>Pacientes com DRC no est&#x000e1;gio 5D apresentam eleva&#x000e7;&#x000e3;o dos n&#x000ed;veis de ET1, o que contribui para o agravamento da HA<sup>
<xref rid="B66" ref-type="bibr">66</xref>
</sup> e desempenha papel significativo na ocorr&#x000ea;ncia de HID<sup>
<xref rid="B67" ref-type="bibr">67</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>A disfun&#x000e7;&#x000e3;o endotelial previamente existente na maioria dos pacientes com DRC torna-se ainda mais grave &#x000e0; medida que ocorre redu&#x000e7;&#x000e3;o da TFG, contribuindo desse modo para a fisiopatologia da HA e para a ocorr&#x000ea;ncia de eventos CV e morte (Classe II/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Aumento da Rigidez Arterial (RA)</title><p>A RA causa aumento nas press&#x000f5;es arteriais perif&#x000e9;ricas e centrais, tais como PAS, PP e da massa do VE, assim como redu&#x000e7;&#x000f5;es na PAD e perfus&#x000e3;o coronariana. A RA tamb&#x000e9;m pode ser considerada um fator independente de mortalidade CV e progress&#x000e3;o da DRC.</p><p>Os mecanismos envolvidos na RA dos pacientes com DRC ainda n&#x000e3;o est&#x000e3;o completamente definidos, mas incluem calcifica&#x000e7;&#x000e3;o arterial, sobrecarga cr&#x000f4;nica de volume, estresse mec&#x000e2;nico pela HA, microinflama&#x000e7;&#x000e3;o cr&#x000f4;nica, hiperatividade simp&#x000e1;tica e do SRAA, ac&#x000fa;mulo dos produtos da degrada&#x000e7;&#x000e3;o da glicose, peroxida&#x000e7;&#x000e3;o lip&#x000ed;dica e anormalidades do sistema de ON. Mesmo uma leve redu&#x000e7;&#x000e3;o na TFG &#x000e9; fator de risco para o desenvolvimento da RA. A UF na HD n&#x000e3;o &#x000e9; capaz de reverter/diminuir significativamente a RA<sup>
<xref rid="B68" ref-type="bibr">68</xref>,<xref rid="B69" ref-type="bibr">69</xref>,<xref rid="B70" ref-type="bibr">70</xref>,<xref rid="B71" ref-type="bibr">71</xref>
</sup>.</p><p>A RA &#x000e9; multifatorial e alguns deles s&#x000e3;o exclusivos para DRC: a) n&#x000ed;veis elevados de f&#x000f3;sforo, que ativa genes relacionados ao fen&#x000f3;tipo osteobl&#x000e1;stico nas c&#x000e9;lulas musculares lisas, levando &#x000e0; calcifica&#x000e7;&#x000e3;o arterial<sup>
<xref rid="B72" ref-type="bibr">72</xref>
</sup>; b) a desnutri&#x000e7;&#x000e3;o proteico-energ&#x000e9;tica, que &#x000e9; comum na DRC e causa aumento na RA<sup>
<xref rid="B73" ref-type="bibr">73</xref>
</sup>; c) eleva&#x000e7;&#x000e3;o do DMAA; d) aumento do FGF 23; e) redu&#x000e7;&#x000e3;o de magn&#x000e9;sio<sup>
<xref rid="B74" ref-type="bibr">74</xref>,<xref rid="B75" ref-type="bibr">75</xref>,<xref rid="B76" ref-type="bibr">76</xref>
</sup>. Baixas concentra&#x000e7;&#x000f5;es s&#x000e9;ricas de fetu&#x000ed;na-A est&#x000e3;o associadas &#x000e0; calcifica&#x000e7;&#x000e3;o vascular na DRC<sup>
<xref rid="B77" ref-type="bibr">77</xref>
</sup>.</p></sec><sec><title>Apneia obstrutiva do sono na HAD</title><p>AOS &#x000e9; definida como obstru&#x000e7;&#x000e3;o parcial ou completa das vias &#x000e1;reas superiores durante o sono, promovendo despertares e hipoxemia intermitente. O diagn&#x000f3;stico e a gravidade da AOS &#x000e9; baseada no &#x000ed;ndice apneia-hipopneia (IAH) obtida pela polissonografia ou poligrafia: at&#x000e9; 4,9 = aus&#x000ea;ncia de AOS; 5,0 a 14,9 = AOS leve; 15 a 29,9 = AOS moderada; e &#x02265; 30 eventos por hora = AOS grave<sup>
<xref rid="B78" ref-type="bibr">78</xref>
</sup>.</p><p>A AOS &#x000e9; muito prevalente na popula&#x000e7;&#x000e3;o dial&#x000ed;tica, atingindo 50% a 70% dos pacientes. Quando associada a HA, apresenta mecanismos fisiopatol&#x000f3;gicos que se amplificam, destacando-se entre eles a hipervolemia<sup>
<xref rid="B79" ref-type="bibr">79</xref>,<xref rid="B80" ref-type="bibr">80</xref>
</sup>.</p><p>O quadro cl&#x000ed;nico &#x000e9; pouco espec&#x000ed;fico e a preval&#x000ea;ncia de ronco e sonol&#x000ea;ncia diurna s&#x000e3;o menos relatadas na DRC 5D<sup>
<xref rid="B81" ref-type="bibr">81</xref>
</sup>. Indica&#x000e7;&#x000e3;o de um exame objetivo do sono deve ser considerada de maneira mais liberal nesses pacientes<italic>.</italic> AOS grave pode estar relacionada &#x000e0; HA resistente e refrat&#x000e1;ria<sup>
<xref rid="B82" ref-type="bibr">82</xref>
</sup>.</p><p>Identificada AOS moderada ou grave, independentemente do comportamento da PA, o tratamento deve ser individualizado. A indica&#x000e7;&#x000e3;o de press&#x000e3;o positiva nas vias &#x000e1;reas durante o sono (CPAP) pode n&#x000e3;o ser a primeira escolha em pacientes em di&#x000e1;lise. Para diminuir a hipervolemia nesse subgrupo, t&#x000e9;cnicas de otimiza&#x000e7;&#x000e3;o da UF, como HD longa noturna ou DP com m&#x000e1;quinas cicladoras, mostraram-se efetivas em ensaios cl&#x000ed;nicos pequenos<sup>
<xref rid="B78" ref-type="bibr">78</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>O quadro cl&#x000ed;nico da AOS em pacientes com DRC 5D &#x000e9; pouco espec&#x000ed;fico. A indica&#x000e7;&#x000e3;o de exame objetivo do sono (polissonografia ou poligrafia) deve ser considerada de maneira mais liberal e individualizada, assim como o uso de CPAP (Classe IIB/N&#x000ed;vel C).</p></list-item></list></sec><sec><title>Medicamentos que interferem no controle press&#x000f3;rico</title><p>Aumento da PA &#x000e9; uma complica&#x000e7;&#x000e3;o bem reconhecida da terapia com EPO em pacientes em HD<sup>
<xref rid="B83" ref-type="bibr">83</xref>
</sup>. Aproximadamente 30% dos pacientes desenvolvem HA ou necessitam de ajuste dos medicamentos anti-hipertensivos, ap&#x000f3;s algumas semanas ou meses. A fisiopatologia da HA por uso de EPO parece ser independente do seu efeito sobre a massa e viscosidade das hem&#x000e1;cias<sup>
<xref rid="B84" ref-type="bibr">84</xref>
</sup>. Os mecanismos mais prov&#x000e1;veis envolvem aumento na produ&#x000e7;&#x000e3;o ou resposta aumentada &#x000e0; ET-1, aumento acentuado na resposta da PA &#x000e0; infus&#x000e3;o de angiotensina II e hipersensibilidade &#x000e0; noradrenalina<sup>
<xref rid="B83" ref-type="bibr">83</xref>
</sup>. H&#x000e1; relatos da associa&#x000e7;&#x000e3;o entre anormalidades no ritmo circadiano da PA e uso de EPO na MAPA<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>. A preven&#x000e7;&#x000e3;o da hipertens&#x000e3;o induzida por EPO &#x000e9; um desafio cl&#x000ed;nico com v&#x000e1;rias estrat&#x000e9;gias de manejo poss&#x000ed;veis listadas abaixo como recomenda&#x000e7;&#x000f5;es<sup>
<xref rid="B83" ref-type="bibr">83</xref>,<xref rid="B84" ref-type="bibr">84</xref>
</sup>.</p><p>Por fim, deve-se evitar o uso de medica&#x000e7;&#x000f5;es que notoriamente elevam a PA, sobre as quais as Diretrizes Brasileiras de Hipertens&#x000e3;o j&#x000e1; fazem ampla men&#x000e7;&#x000e3;o<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup>.</p><p>Principais mensagens:</p><p>Na HA induzida por EPO refrat&#x000e1;ria ao manejo dos anti-hipertensivos recomenda-se:</p><list list-type="bullet"><list-item><p>Aten&#x000e7;&#x000e3;o ao peso seco (Classe IIA/N&#x000ed;vel B);</p></list-item><list-item><p>Prefer&#x000ea;ncia pela via subcut&#x000e2;nea da EPO (Classe IIA/N&#x000ed;vel B);</p></list-item><list-item><p>Reduzir o alvo da hemoglobina (Classe IIA/N&#x000ed;vel C);</p></list-item><list-item><p>Iniciar com baixa dose de EPO, aumentar lentamente e, em casos extremos, suspender o uso (Classe IIA/N&#x000ed;vel B);</p></list-item><list-item><p>Evitar o uso de medica&#x000e7;&#x000f5;es que notoriamente elevam a PA (Classe IIA/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>In&#x000e9;rcia da equipe assistencial</title><p>In&#x000e9;rcia cl&#x000ed;nica ou terap&#x000ea;utica (IT) consiste na falha dos profissionais de sa&#x000fa;de em iniciar, intensificar ou encerrar tratamentos quando indicado, e inclui medidas medicamentosas ou n&#x000e3;o<sup>
<xref rid="B85" ref-type="bibr">85</xref>
</sup>. A IT &#x000e9; observada em cerca de 2/3 das visitas de hipertensos<sup>
<xref rid="B86" ref-type="bibr">86</xref>
</sup>, e na literatura em di&#x000e1;lise encontram-se evid&#x000ea;ncias associadas &#x000e0; fal&#x000ea;ncia em introduzir ou intensificar a terapia anti-hipertensiva ou ajuste da volemia. Em an&#x000e1;lise retrospectiva de pacientes com DRC e HA n&#x000e3;o controlada, parece ter ocorrido IT em aproximadamente 44% das ocasi&#x000f5;es, a julgar pela n&#x000e3;o identifica&#x000e7;&#x000e3;o de justificativa para a falha de decis&#x000e3;o m&#x000e9;dica<sup>
<xref rid="B87" ref-type="bibr">87</xref>
</sup>.</p><p>Quanto ao perfil psicol&#x000f3;gico do m&#x000e9;dico mais propenso &#x000e0; IT, parece predominar a prefer&#x000ea;ncia pela aparente seguran&#x000e7;a no curto prazo com a ina&#x000e7;&#x000e3;o<sup>
<xref rid="B88" ref-type="bibr">88</xref>
</sup>. O enfrentamento desse comportamento envolve o encorajamento continuado de condutas proativas destinadas a atingir as metas terap&#x000ea;uticas, dentro de pol&#x000ed;tica de melhoria da qualidade assistencial<sup>
<xref rid="B89" ref-type="bibr">89</xref>
</sup>.</p><p>IT &#x000e9; descrita em v&#x000e1;rios cen&#x000e1;rios de preven&#x000e7;&#x000e3;o CV<sup>
<xref rid="B89" ref-type="bibr">89</xref>
</sup>, como no manejo de pacientes em di&#x000e1;lise com DM<sup>
<xref rid="B90" ref-type="bibr">90</xref>
</sup> ou que sejam idosos em uso de polifarm&#x000e1;cia<sup>
<xref rid="B91" ref-type="bibr">91</xref>
</sup>. Fatores implic&#x000e1;veis incluem: incerteza cl&#x000ed;nica sobre a medida da PA, baixa ades&#x000e3;o medicamentosa e hipotens&#x000e3;o diast&#x000f3;lica e/ou ortost&#x000e1;tica<sup>
<xref rid="B87" ref-type="bibr">87</xref>
</sup>.</p><p>Examinando o emprego de medica&#x000e7;&#x000f5;es potencialmente inapropriadas (alfa-agonistas de a&#x000e7;&#x000e3;o central ou alfa-bloqueadores), o risco de IT em idosos em di&#x000e1;lise foi maior em negros, com polifarm&#x000e1;cia e sem limita&#x000e7;&#x000f5;es funcionais, mas n&#x000e3;o ocorreu maior n&#x000fa;mero de hospitaliza&#x000e7;&#x000f5;es ou mortalidade naqueles que mantiveram esses medicamentos<sup>
<xref rid="B87" ref-type="bibr">87</xref>
</sup>.</p><p>Entre pacientes hipertensos, houve &#x000ea;xito com o emprego de educa&#x000e7;&#x000e3;o m&#x000e9;dica estruturada e de um sistema de <italic>feedback</italic> regular, com maior controle da HA, mas sem melhora em desfechos CV<sup>
<xref rid="B92" ref-type="bibr">92</xref>
</sup>.</p><p>Recomenda&#x000e7;&#x000f5;es existentes na literatura indicam que a educa&#x000e7;&#x000e3;o e participa&#x000e7;&#x000e3;o dos pacientes no manejo dos seus riscos CV reduzem a IT<sup>
<xref rid="B88" ref-type="bibr">88</xref>,<xref rid="B93" ref-type="bibr">93</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se, para reduzir a in&#x000e9;rcia terap&#x000ea;utica, que os protocolos para a obten&#x000e7;&#x000e3;o de metas cl&#x000ed;nicas do controle da HA devam envolver pacientes, cuidadores, m&#x000e9;dicos e equipe multiprofissional (Classe I/ N&#x000ed;vel B).</p></list-item></list></sec><sec><title>M&#x000e1; ades&#x000e3;o do tratamento anti-hipertensivo</title><p>Ades&#x000e3;o pode ser definida como o grau em que uma pessoa corresponde &#x000e0;s recomenda&#x000e7;&#x000f5;es do prestador de assist&#x000ea;ncia &#x000e0; sa&#x000fa;de<sup>
<xref rid="B94" ref-type="bibr">94</xref>
</sup>. Baixa ades&#x000e3;o ao tratamento est&#x000e1; associada a desfechos cl&#x000ed;nicos desfavor&#x000e1;veis e &#x000e9; comum em pacientes com DRC 5D<sup>
<xref rid="B95" ref-type="bibr">95</xref>
</sup>.</p><p>Em rela&#x000e7;&#x000e3;o ao controle da PA em HD ou DP, a m&#x000e1;-ades&#x000e3;o pode trazer uma s&#x000e9;rie de dificuldades para o manejo da HA, visto que a n&#x000e3;o implementa&#x000e7;&#x000e3;o de medidas comportamentais, como a redu&#x000e7;&#x000e3;o do consumo de sal e a limita&#x000e7;&#x000e3;o do ganho de peso no per&#x000ed;odo interdial&#x000ed;tico, aliado &#x000e0; falha no uso dos medicamentos anti-hipertensivos prescritos, seja por esquemas posol&#x000f3;gicos complexos, efeitos colaterais associados e, particularmente em paciente em HD, o receio de epis&#x000f3;dios de hipotens&#x000e3;o intradial&#x000ed;ticas, possam inviabilizar o alcance das metas terap&#x000ea;uticas.</p><p>Quanto &#x000e0;s estrat&#x000e9;gias para melhorar a ades&#x000e3;o, os estudos nessa popula&#x000e7;&#x000e3;o s&#x000e3;o escassos. De forma geral, recomendam-se as seguintes estrat&#x000e9;gias:</p><list list-type="order"><list-item><p>Redu&#x000e7;&#x000e3;o do consumo de sal/limita&#x000e7;&#x000e3;o do ganho de peso interdial&#x000ed;tico: interven&#x000e7;&#x000f5;es estruturadas baseadas em educa&#x000e7;&#x000e3;o continuada do paciente, realizadas por equipe multiprofissional, podem melhorar essas vari&#x000e1;veis<sup>
<xref rid="B96" ref-type="bibr">96</xref>
</sup>.</p></list-item><list-item><p>Medida da PA no per&#x000ed;odo interdial&#x000ed;tico, por meio da MRPA, promovem maior ades&#x000e3;o aos anti-hipertensivos, impactando diretamente no controle da PA<sup>
<xref rid="B97" ref-type="bibr">97</xref>
</sup>.</p></list-item><list-item><p>Tratamento medicamentoso: escolha de medicamentos com menor perfil de eventos adversos e melhor comodidade posol&#x000f3;gica<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup>.</p></list-item><list-item><p>Nos pacientes em HD, o hor&#x000e1;rio de tomada dos medicamentos deve ser ajustado de acordo com a sess&#x000e3;o, n&#x000e3;o suspendendo os anti-hipertensivos, particularmente nos pacientes com tend&#x000ea;ncia a hipertens&#x000e3;o intradial&#x000ed;tica<sup>
<xref rid="B98" ref-type="bibr">98</xref>
</sup>.</p></list-item></list><p>Principais mensagens:</p><p>S&#x000e3;o estrat&#x000e9;gias para melhorar a ades&#x000e3;o ao tratamento anti-hipertensivo em pacientes em HD:</p><list list-type="bullet"><list-item><p>Educa&#x000e7;&#x000e3;o continuada visando &#x000e0; limita&#x000e7;&#x000e3;o do consumo de sal e do ganho de peso interdial&#x000ed;tico (Classe IIA/N&#x000ed;vel B).</p></list-item><list-item><p>Medida domiciliar ou ambulatorial da PA no per&#x000ed;odo interdial&#x000ed;tico (Classe IIA/N&#x000ed;vel B).</p></list-item><list-item><p>Uso de anti-hipertensivos, preferencialmente em dose &#x000fa;nica di&#x000e1;ria (Classe I/ N&#x000ed;vel A).</p></list-item></list></sec></sec></sec><sec><title>Diagn&#x000f3;stico de Hipertens&#x000e3;o em Pacientes Submetidos &#x000e0; Di&#x000e1;lise Peritoneal (DP) e Hemodi&#x000e1;lise (HD)</title><p>As medidas da PA relacionadas &#x000e0; sess&#x000e3;o de HD s&#x000e3;o insuficientes para o diagn&#x000f3;stico de HA e apresentam pobre valor progn&#x000f3;stico. Estudos observacionais relatam associa&#x000e7;&#x000e3;o em forma de &#x0201c;U&#x0201d; entre a PA peridial&#x000ed;tica e mortalidade. Em contraste, a PA fora da unidade de di&#x000e1;lise apresenta associa&#x000e7;&#x000e3;o linear e direta com mortalidade<sup>
<xref rid="B99" ref-type="bibr">99</xref>,<xref rid="B100" ref-type="bibr">100</xref>
</sup>. O comportamento da PA no paciente em di&#x000e1;lise est&#x000e1; diretamente relacionado ao seu estado vol&#x000ea;mico, de modo que a medida antes da HD superestima a PA e ap&#x000f3;s a HD subestima a PA<sup>
<xref rid="B101" ref-type="bibr">101</xref>
</sup>. Oposto a essa esperada queda da PA durante a HD, 7&#x02013;30% desses pacientes apresentam eleva&#x000e7;&#x000e3;o da PA nesse per&#x000ed;odo<sup>
<xref rid="B102" ref-type="bibr">102</xref>
</sup>. Tudo isso contribui para uma variabilidade e inconsist&#x000ea;ncia das medidas da PA no per&#x000ed;odo peridial&#x000ed;tico. Em contrapartida, crescem as evid&#x000ea;ncias da superioridade das medidas fora da unidade de HD.</p><sec><title>Medida da Press&#x000e3;o Arterial Relacionada &#x000e0; Sess&#x000e3;o de Hd</title><p>A aferi&#x000e7;&#x000e3;o da PA relacionada &#x000e0; sess&#x000e3;o de HD pode ser avaliada a partir de tr&#x000ea;s medidas: PA pr&#x000e9;-dial&#x000ed;tica, PA intradial&#x000ed;tica e PA p&#x000f3;s-dial&#x000ed;tica. A determina&#x000e7;&#x000e3;o da quantidade de medidas a serem realizadas no per&#x000ed;odo intradial&#x000ed;tico depender&#x000e1; do julgamento cl&#x000ed;nico do nefrologista. Para essa decis&#x000e3;o, ser&#x000e3;o considerados os valores de PA pr&#x000e9;-di&#x000e1;lise, o hist&#x000f3;rico de epis&#x000f3;dios de hipotens&#x000e3;o ou hipertens&#x000e3;o intradial&#x000ed;tica, a necessidade de taxas de ultrafiltra&#x000e7;&#x000e3;o elevadas, pacientes em processo de ajuste do peso seco e o estado cl&#x000ed;nico geral do paciente.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>A PA durante a sess&#x000e3;o de HD apresenta baixo valor progn&#x000f3;stico (Classe I/N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se que durante a sess&#x000e3;o de HD sejam realizadas, no m&#x000ed;nimo, a medida de PA a cada hora (Classe IIA/ N&#x000ed;vel C).</p></list-item><list-item><p>De acordo com o <italic>Kidney Disease Outcomes Quality Initiative</italic> (KDOQI), nos pacientes em HD, recomenda-se que a HA deve ser diagnosticada como PA pr&#x000e9;-dial&#x000ed;tica &#x0003e; 140/90 mmHg ou PA p&#x000f3;s-dial&#x000ed;tica &#x0003e; 130/80 mmHg<sup>10</sup> (Classe IIA/N&#x000ed;vel B).</p></list-item></list><p>Contudo, s&#x000e3;o realizadas em circunst&#x000e2;ncias que fogem ao preconizado para a medida adequada da PA, entre elas: ansiedade pelo in&#x000ed;cio do tratamento, expectativa pela dor da pun&#x000e7;&#x000e3;o da f&#x000ed;stula arteriovenosa<sup>
<xref rid="B103" ref-type="bibr">103</xref>
</sup>, interrup&#x000e7;&#x000e3;o da medica&#x000e7;&#x000e3;o anti-hipertensiva no dia da HD (em alguns pacientes), depura&#x000e7;&#x000e3;o das medica&#x000e7;&#x000f5;es anti-hipertensivas, uso de medica&#x000e7;&#x000f5;es estimulantes da eritropoiese, efeito do avental-branco e do mascaramento, alimenta&#x000e7;&#x000e3;o pr&#x000e9; ou intradial&#x000ed;tica, valida&#x000e7;&#x000e3;o dos aparelhos oscilom&#x000e9;tricos utilizados nas m&#x000e1;quinas de HD, e n&#x000fa;mero elevado de pacientes a serem avaliados pelo mesmo profissional de sa&#x000fa;de em curto intervalo de tempo.</p><p>Diversos estudos foram realizados com o intuito de avaliar a acur&#x000e1;cia diagn&#x000f3;stica das medidas da PA peridial&#x000ed;tica, bem como sua representatividade da PA no per&#x000ed;odo interdial&#x000ed;tico<sup>
<xref rid="B101" ref-type="bibr">101</xref>,<xref rid="B104" ref-type="bibr">104</xref>,<xref rid="B105" ref-type="bibr">105</xref>
</sup>. O padr&#x000e3;o encontrado na maioria dos pacientes &#x000e9; uma tend&#x000ea;ncia &#x000e0; redu&#x000e7;&#x000e3;o da PA p&#x000f3;s-di&#x000e1;lise em rela&#x000e7;&#x000e3;o &#x000e0; PA pr&#x000e9;-di&#x000e1;lise. Isso pode ser explicado pela resposta hemodin&#x000e2;mica &#x000e0; UF durante a di&#x000e1;lise e, em geral, a magnitude dessa redu&#x000e7;&#x000e3;o est&#x000e1; associada ao volume ultrafiltrado. Do mesmo modo, estudos sugerem que o GPID tem influ&#x000ea;ncia direta na eleva&#x000e7;&#x000e3;o da PA pr&#x000e9;-di&#x000e1;lise<sup>
<xref rid="B105" ref-type="bibr">105</xref>
</sup>. A execu&#x000e7;&#x000e3;o da t&#x000e9;cnica correta da medida da PA na unidade de HD &#x000e9; um desafio e, por essa raz&#x000e3;o, a t&#x000e9;cnica inadequada j&#x000e1; foi responsabilizada pelo mau desempenho da PA pr&#x000e9; e p&#x000f3;s-HD para diagnosticar e/ou avaliar progn&#x000f3;stico da HA nesses pacientes. No entanto, um estudo mostrou que, mesmo com correta execu&#x000e7;&#x000e3;o, esse tipo de medida n&#x000e3;o apresenta significado progn&#x000f3;stico<sup>
<xref rid="B104" ref-type="bibr">104</xref>
</sup>. Algumas condi&#x000e7;&#x000f5;es s&#x000e3;o inerentes ao ambiente de di&#x000e1;lise, e realizar as medidas da PA pr&#x000e9; e p&#x000f3;s-di&#x000e1;lise em local discriminado, que preserve os crit&#x000e9;rios necess&#x000e1;rios para a medida correta da PA, pode n&#x000e3;o ser ajust&#x000e1;vel &#x000e0; log&#x000ed;stica de uma sess&#x000e3;o de HD. Assim, as aferi&#x000e7;&#x000f5;es da PA durante a sess&#x000e3;o de HD n&#x000e3;o devem ser utilizadas para diagn&#x000f3;stico de HA ou defini&#x000e7;&#x000e3;o de ajustes no esquema anti-hipertensivo do paciente<sup>
<xref rid="B101" ref-type="bibr">101</xref>
</sup>.</p><p>As medidas da PA peridial&#x000ed;ticas s&#x000e3;o estimativas imprecisas da PA, limitando sua capacidade de fornecer associa&#x000e7;&#x000f5;es progn&#x000f3;sticas claras e diretas, mesmo quando tal associa&#x000e7;&#x000e3;o realmente existe.</p></sec><sec><title>Hipertens&#x000e3;o Intradial&#x000ed;tica (HID)</title><p>Apesar da retirada de l&#x000ed;quidos com a UF, existe um subconjunto de pacientes que apresenta eleva&#x000e7;&#x000e3;o da PA durante e/ou ap&#x000f3;s a sess&#x000e3;o de HD, em compara&#x000e7;&#x000e3;o aos n&#x000ed;veis press&#x000f3;ricos pr&#x000e9;-HD. Esses pacientes s&#x000e3;o classificados como portadores de HID<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup>. A eleva&#x000e7;&#x000e3;o da PAS &#x02265; 10 mmHg durante ou ap&#x000f3;s a sess&#x000e3;o de HD em rela&#x000e7;&#x000e3;o aos n&#x000ed;veis pr&#x000e9;-di&#x000e1;lise em 4 de 6 sess&#x000f5;es &#x000e9; comumente usada para caracterizar o paciente com HID<sup>
<xref rid="B106" ref-type="bibr">106</xref>
</sup>. No entanto, Singh e cols. relataram que quaisquer aumentos observados na PAS est&#x000e3;o relacionados a maior risco de eventos CV fatais<sup>
<xref rid="B107" ref-type="bibr">107</xref>
</sup>.</p><p>&#x000c9; importante notar que a HID n&#x000e3;o &#x000e9; detectada em todas as sess&#x000f5;es de HD para um mesmo paciente. Por outro lado, existe maior correla&#x000e7;&#x000e3;o entre os valores press&#x000f3;ricos detectados nos primeiros 90 minutos de HD e os valores aferidos imediatamente ap&#x000f3;s a sess&#x000e3;o de HD. No Brasil, uma an&#x000e1;lise unic&#x000ea;ntrica mostrou que 11% dos pacientes tinham aumento da PAS &#x02265; 10 mmHg em mais de 50% das sess&#x000f5;es de HD<sup>
<xref rid="B108" ref-type="bibr">108</xref>
</sup>. Os mecanismos fisiopatol&#x000f3;gicos que justificam essa condi&#x000e7;&#x000e3;o incluem a hipervolemia, o balan&#x000e7;o positivo de s&#x000f3;dio, a hiperatividade do SRAA e do SNS, a DE e a depura&#x000e7;&#x000e3;o maior ou menor das medica&#x000e7;&#x000f5;es anti-hipertensivas<sup>
<xref rid="B109" ref-type="bibr">109</xref>
</sup>.</p><p>Os principais mecanismos envolvidos na HA intradial&#x000ed;tica est&#x000e3;o destacados no <xref rid="T12" ref-type="table">Quadro 1</xref>.</p><table-wrap position="float" id="T12"><label>Quadro 1</label><caption><title>Mecanismos fisiopatol&#x000f3;gicos da hipertens&#x000e3;o intradial&#x000ed;tica (HID)</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Hipervolemia</td><td align="left" valign="top" rowspan="1" colspan="1">O excesso de fluido &#x000e9; uma das mais importantes causas de eleva&#x000e7;&#x000e3;o dos n&#x000ed;veis press&#x000f3;ricos em pacientes com HID. Os achados indicam que o aumento paradoxal dos valores press&#x000f3;ricos que ocorre em alguns pacientes durante a UF pode ser causado por aumento do DC na presen&#x000e7;a de hipervolemia e dilata&#x000e7;&#x000e3;o de c&#x000e2;maras card&#x000ed;acas, sugerindo a intensifica&#x000e7;&#x000e3;o da UF como forma de tratamento da HID.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ativa&#x000e7;&#x000e3;o do sistema renina-angiotensina-aldosterona</td><td align="left" valign="top" rowspan="1" colspan="1">O est&#x000ed;mulo do SRAA &#x000e9; causado pela hipovolemia induzida pela UF.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hiperatividade do sistema nervoso simp&#x000e1;tico</td><td align="left" valign="top" rowspan="1" colspan="1">Indiv&#x000ed;duos portadores de DRC usualmente apresentam hiperatividade simp&#x000e1;tica e que pode ser reduzida com o aumento da frequ&#x000ea;ncia das sess&#x000f5;es de HD110.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Controle do s&#x000f3;dio</td><td align="left" valign="top" rowspan="1" colspan="1">O balan&#x000e7;o positivo do s&#x000f3;dio &#x000e9; um dos principais mecanismos de sobrecarga de l&#x000ed;quido extracelular e hipertens&#x000e3;o em pacientes em di&#x000e1;lise. A remo&#x000e7;&#x000e3;o satisfat&#x000f3;ria do s&#x000f3;dio pode ser atingida por meio de adequa&#x000e7;&#x000e3;o da taxa de UF e da concentra&#x000e7;&#x000e3;o do s&#x000f3;dio na solu&#x000e7;&#x000e3;o de di&#x000e1;lise.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Disfun&#x000e7;&#x000e3;o endotelial</td><td align="left" valign="top" rowspan="1" colspan="1">Em resposta &#x000e0; UF, aos est&#x000ed;mulos mec&#x000e2;nicos e hormonais, as c&#x000e9;lulas endoteliais sintetizam e liberam fatores humorais que contribuem para a homeostase da PA. Pacientes com HID apresentavam acr&#x000e9;scimo significativo nos n&#x000ed;veis plasm&#x000e1;ticos de endotelina-1 e decr&#x000e9;scimo nos n&#x000ed;veis de ON, comparado aos controles109.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Depura&#x000e7;&#x000e3;o dial&#x000ed;tica das medica&#x000e7;&#x000f5;es anti-hipertensivas</td><td align="left" valign="top" rowspan="1" colspan="1">As medica&#x000e7;&#x000f5;es anti-hipertensivas apresentam diferentes suscetibilidades &#x000e0; filtra&#x000e7;&#x000e3;o pela membrana do dialisador.</td></tr></tbody></table><table-wrap-foot><fn id="T12FN1"><p>Abreviaturas &#x02013; HID: hipertens&#x000e3;o intradial&#x000ed;tica; DC: d&#x000e9;bito card&#x000ed;aco; UF: ultrafiltra&#x000e7;&#x000e3;o; PS: peso seco; SRAA: sistema renina angiotensina aldosterona; DRC: doen&#x000e7;a renal cr&#x000f4;nica; ON: &#x000f3;xido n&#x000ed;trico.</p></fn></table-wrap-foot></table-wrap><p>V&#x000e1;rias estrat&#x000e9;gias t&#x000ea;m sido propostas para tratamento da HID, tais como<sup>
<xref rid="B111" ref-type="bibr">111</xref>
</sup>:</p><list list-type="bullet"><list-item><p>Otimiza&#x000e7;&#x000e3;o do tratamento anti-hipertensivo: certificar-se do uso de medicamentos apropriados, buscar o peso seco ideal, verificar a ades&#x000e3;o ao tratamento farmacol&#x000f3;gico e n&#x000e3;o farmacol&#x000f3;gico, al&#x000e9;m de estender o tempo e/ou a frequ&#x000ea;ncia das sess&#x000f5;es de HD;</p></list-item><list-item><p>Considerar o uso de BB com atividade alfa bloqueadora;</p></list-item><list-item><p>Usar anti-hipertensivos de curta dura&#x000e7;&#x000e3;o antes do in&#x000ed;cio da sess&#x000e3;o de HD;</p></list-item><list-item><p>Escolha de anti-hipertensivos menos dialis&#x000e1;veis;</p></list-item><list-item><p>Considerar reduzir a concentra&#x000e7;&#x000e3;o do s&#x000f3;dio da solu&#x000e7;&#x000e3;o de di&#x000e1;lise;</p></list-item><list-item><p>Evitar concentra&#x000e7;&#x000e3;o de c&#x000e1;lcio muito elevada na solu&#x000e7;&#x000e3;o de di&#x000e1;lise;</p></list-item><list-item><p>Considerar a eleva&#x000e7;&#x000e3;o da temperatura do dialisato. Banhos muito frios s&#x000e3;o favor&#x000e1;veis ao surgimento de HID;</p></list-item><list-item><p>Considerar administrar os agentes estimulantes da eritropoiese pela via subcut&#x000e2;nea.</p></list-item></list></sec><sec><title>Medidas da Press&#x000e3;o Arterial Fora da Unidade de Hemodi&#x000e1;lise</title><p>Essas medidas se mostraram melhor par&#x000e2;metro para avaliar altera&#x000e7;&#x000f5;es na PA relacionadas &#x000e0; redu&#x000e7;&#x000e3;o do PS, al&#x000e9;m de estar mais associadas a les&#x000f5;es de &#x000f3;rg&#x000e3;os-alvo e eventos CV. Nesses pacientes as preval&#x000ea;ncias de HA noturna (<italic>risers</italic>) e do padr&#x000e3;o <italic>non-dipper</italic> costumam ser superiores &#x000e0;s da popula&#x000e7;&#x000e3;o hipertensa geral<sup>
<xref rid="B112" ref-type="bibr">112</xref>,<xref rid="B113" ref-type="bibr">113</xref>
</sup>.</p><sec><title>Automedida da press&#x000e3;o arterial (AMPA) no paciente em di&#x000e1;lise</title><p>N&#x000e3;o existem evid&#x000ea;ncias conclusivas que validem protocolos espec&#x000ed;ficos (n&#x000fa;mero de medidas e hor&#x000e1;rios de realiza&#x000e7;&#x000e3;o) e nem valores de normalidade para esse m&#x000e9;todo<sup>
<xref rid="B114" ref-type="bibr">114</xref>
</sup>. Entretanto, a AMPA deve seguir as mesmas recomenda&#x000e7;&#x000f5;es e cuidados da medida da PA realizada em consult&#x000f3;rio.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>AMPA n&#x000e3;o &#x000e9; recomendada como rotina para o diagn&#x000f3;stico e manejo da HA em pacientes em HD ou DP, devendo apenas ser utilizada como m&#x000e9;todo de triagem (Classe I, N&#x000ed;vel C).</p></list-item></list></sec><sec><title>Monitoriza&#x000e7;&#x000e3;o Ambulatorial da Press&#x000e3;o Arterial (MAPA) e Monitoriza&#x000e7;&#x000e3;o Residencial da Press&#x000e3;o Arterial (MRPA)</title><p>Nos pacientes em HD, a MAPA e MRPA demonstraram melhor correla&#x000e7;&#x000e3;o com les&#x000e3;o de &#x000f3;rg&#x000e3;o-alvo, eventos CV e morte por todas as causas<sup>
<xref rid="B100" ref-type="bibr">100</xref>,<xref rid="B101" ref-type="bibr">101</xref>,<xref rid="B104" ref-type="bibr">104</xref>
</sup>. Ambas apresentam boa correla&#x000e7;&#x000e3;o entre si, como relatado no estudo DRIP, no qual as altera&#x000e7;&#x000f5;es da PA avaliadas pela MRPA, depois de 4 e 8 semanas de ajuste do PS, foram associadas &#x000e0;s altera&#x000e7;&#x000f5;es da PA avaliada pela MAPA de 44h<sup>
<xref rid="B105" ref-type="bibr">105</xref>
</sup>. Outro benef&#x000ed;cio mostrado em estudo com pacientes em HD foi a constata&#x000e7;&#x000e3;o de que uma estrat&#x000e9;gia de ajuste das medica&#x000e7;&#x000f5;es anti-hipertensivas baseada na MRPA mostrou ser mais eficaz no controle da PA do que uma estrat&#x000e9;gia baseada na PAS pr&#x000e9;-HD<sup>
<xref rid="B97" ref-type="bibr">97</xref>
</sup>.</p><p>A MAPA de 44h fornece informa&#x000e7;&#x000f5;es progn&#x000f3;sticas em pacientes em HD, al&#x000e9;m de ser o &#x000fa;nico m&#x000e9;todo capaz de avaliar o comportamento da PA no sono. Assim como na popula&#x000e7;&#x000e3;o geral, a rela&#x000e7;&#x000e3;o vig&#x000ed;lia/sono &#x000e9; um preditor significativo de desfechos cl&#x000ed;nicos em pacientes em di&#x000e1;lise. Portanto, a aus&#x000ea;ncia de descenso da PA durante o sono (&#x0003c; 10% da m&#x000e9;dia da PA no sono em rela&#x000e7;&#x000e3;o &#x000e0; vig&#x000ed;lia) ou o descenso reverso (eleva&#x000e7;&#x000e3;o da PA no sono em rela&#x000e7;&#x000e3;o &#x000e0; vig&#x000ed;lia), associa-se ao risco de mortalidade geral e CV<sup>
<xref rid="B115" ref-type="bibr">115</xref>,<xref rid="B116" ref-type="bibr">116</xref>
</sup>. Entretanto, a MAPA n&#x000e3;o &#x000e9; um exame de execu&#x000e7;&#x000e3;o pr&#x000e1;tica e apresenta baixa aceita&#x000e7;&#x000e3;o nessa popula&#x000e7;&#x000e3;o, em parte por causa da prevalente frequ&#x000ea;ncia de dist&#x000fa;rbios do sono e de prurido associados &#x000e0; DRC<sup>
<xref rid="B78" ref-type="bibr">78</xref>,<xref rid="B117" ref-type="bibr">117</xref>
</sup>. Por outro lado, a MRPA, al&#x000e9;m de apresentar boa correla&#x000e7;&#x000e3;o com progn&#x000f3;stico, apresenta baixo custo e melhor tolerabilidade<sup>
<xref rid="B118" ref-type="bibr">118</xref>
</sup>. As vantagens dos m&#x000e9;todos est&#x000e3;o listadas no <xref rid="T13" ref-type="table">Quadro 2</xref> e os protocolos recomendados para sua execu&#x000e7;&#x000e3;o est&#x000e3;o apresentados nos <xref rid="T14" ref-type="table">Quadros 3</xref> e <xref rid="T15" ref-type="table">4</xref> (Classe IIA/N&#x000ed;vel C).</p><table-wrap position="float" id="T13"><label>Quadro 2</label><caption><title>Vantagens da monitoriza&#x000e7;&#x000e3;o ambulatorial da press&#x000e3;o arterial (MAPA) e da monitoriza&#x000e7;&#x000e3;o residencial da press&#x000e3;o arterial (MRPA)</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="center" colspan="2" valign="top" rowspan="1">Vantagens comuns da MAPA e MRPA</th></tr></thead><tbody><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Caracteriza&#x000e7;&#x000e3;o da hipertens&#x000e3;o do avental branco</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Caracteriza&#x000e7;&#x000e3;o da hipertens&#x000e3;o mascarada</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Identifica&#x000e7;&#x000e3;o da hipertens&#x000e3;o arterial resistente verdadeira</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Maior ades&#x000e3;o ao diagn&#x000f3;stico e ao tratamento da hipertens&#x000e3;o arterial</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Melhor efic&#x000e1;cia no controle da press&#x000e3;o arterial</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Boa reprodutibilidade</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">&#x02022; Melhor correla&#x000e7;&#x000e3;o com les&#x000f5;es de &#x000f3;rg&#x000e3;os-alvo e eventos CV do que a PA medida na HD</td></tr><tr style="border-top:solid black 0.1em;border-bottom:solid black 0.1em; border-color: #000000"><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Vantagens MAPA</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Vantagens MRPA</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Considerada o padr&#x000e3;o-ouro na avalia&#x000e7;&#x000e3;o da PA</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Avalia&#x000e7;&#x000e3;o do maior n&#x000fa;mero de medidas da PA e em maior n&#x000fa;mero de dias</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Avalia&#x000e7;&#x000e3;o da PA durante o sono e atividades di&#x000e1;rias</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Envolve o paciente no seu autocuidado (medi&#x000e7;&#x000e3;o da PA)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Avalia&#x000e7;&#x000e3;o da eleva&#x000e7;&#x000e3;o r&#x000e1;pida da PA matinal</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Apresenta baixo custo</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Avalia o controle da PA nas 24h</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Apresenta boa aceita&#x000e7;&#x000e3;o pelos pacientes</td></tr></tbody></table><table-wrap-foot><fn id="T13FN1"><p>Abreviaturas &#x02013; MAPA: monitoriza&#x000e7;&#x000e3;o ambulatorial de press&#x000e3;o arterial; MPRA: monitoriza&#x000e7;&#x000e3;o residencial da press&#x000e3;o arterial; CV: cardiovasculares; PA: press&#x000e3;o arterial; HD: hemodi&#x000e1;lise.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T14"><label>Quadro 3</label><caption><title>Protocolo para realiza&#x000e7;&#x000e3;o da monitoriza&#x000e7;&#x000e3;o ambulatorial da press&#x000e3;o arterial (MAPA) nos pacientes em di&#x000e1;lise, segundo as <italic>Diretrizes brasileiras de medidas da press&#x000e3;o arterial dentro e fora do consult&#x000f3;rio</italic> &#x02013; 2023<sup>
<xref rid="B119" ref-type="bibr">119</xref>
</sup>
</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="center" colspan="2" valign="top" rowspan="1">Monitoriza&#x000e7;&#x000e3;o Ambulatorial da Press&#x000e3;o Arterial (MAPA)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Nos pacientes que fazem HD tr&#x000ea;s vezes por semana, a MAPA de 24h n&#x000e3;o contempla a avalia&#x000e7;&#x000e3;o da PA ao longo do ciclo interdial&#x000ed;tico. Recomenda-se a realiza&#x000e7;&#x000e3;o de MAPA de 44<sup>5</sup>. Vale ressaltar que o manguito <bold>n&#x000e3;o</bold> deve ser instalado no bra&#x000e7;o da FAV.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Per&#x000ed;odo de verifica&#x000e7;&#x000e3;o:</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; 44h (se o <italic>software</italic> utilizado n&#x000e3;o contempla o protocolo de 44h, sugerimos a realiza&#x000e7;&#x000e3;o de dois exames de 22h consecutivos);</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>N&#x000fa;mero de medidas:</bold> no m&#x000ed;nimo 48 medidas v&#x000e1;lidas na MAPA de 44h (32 medidas v&#x000e1;lidas na vig&#x000ed;lia e 16 durante o per&#x000ed;odo de sono) e 24 medidas v&#x000e1;lidas na MAPA de 24h (16 medidas v&#x000e1;lidas na vig&#x000ed;lia e 8 durante o per&#x000ed;odo de sono).</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; <bold>Dia de instala&#x000e7;&#x000e3;o:</bold> na HD deve ser instalada ap&#x000f3;s a sess&#x000e3;o de di&#x000e1;lise do meio da semana e retirada imediatamente ap&#x000f3;s a sess&#x000e3;o seguinte.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Laudo da MRPA:</bold> no laudo dever&#x000e1; conter a data e o hor&#x000e1;rio de in&#x000ed;cio e t&#x000e9;rmino do exame (adicionar em qual per&#x000ed;odo interdial&#x000ed;tico foi realizado), n&#x000fa;mero e porcentagem das medidas realizadas e das efetivamente v&#x000e1;lidas, as m&#x000e9;dias de PAS e PAD (nas 24h, vig&#x000ed;lia e sono), o comportamento da PA entre vig&#x000ed;lia e sono, epis&#x000f3;dios de hipotens&#x000e3;o e/ou picos de PA, se houve correla&#x000e7;&#x000e3;o entre atividades, sintomas e medicamentos, e na conclus&#x000e3;o especificar se o comportamento da PA foi considerado normal ou alterado (&#x000e9; considerado alterado quando as m&#x000e9;dias forem &#x02265; 130 mmHg e/ou &#x02265; 80 mmHg, <xref rid="T21" ref-type="table">Tabela 1</xref>).</td></tr></tbody></table><table-wrap-foot><fn id="T14FN1"><p>Abreviaturas &#x02013; MAPA: monitoriza&#x000e7;&#x000e3;o ambulatorial da press&#x000e3;o arterial; HD: hemodi&#x000e1;lise; PA: press&#x000e3;o arterial; h: horas; FAV: f&#x000ed;stula arteriovenosa; MRPA: monitoriza&#x000e7;&#x000e3;o residencial da press&#x000e3;o arterial; PAS: press&#x000e3;o arterial sist&#x000f3;lica; PAD: press&#x000e3;o arterial diast&#x000f3;lica.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T21"><label>Tabela 1</label><caption><title>Valores de press&#x000e3;o arterial considerados anormais nas medidas pela MAPA (monitoriza&#x000e7;&#x000e3;o ambulatorial da press&#x000e3;o arterial) nas 24 horas, vig&#x000ed;lia e durante o sono e na MRPA (monitoriza&#x000e7;&#x000e3;o residencial da press&#x000e3;o arterial) para defini&#x000e7;&#x000e3;o de diagn&#x000f3;sticos</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" colspan="2" valign="top" rowspan="1">PAS (mmHg)</th><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" colspan="2" valign="top" rowspan="1">PAD (mmHg)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">MAPA 44h</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265; 130</td><td align="center" valign="top" rowspan="1" colspan="1">e/ou</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265; 80</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MAPA Vig&#x000ed;lia</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265; 135</td><td align="center" valign="top" rowspan="1" colspan="1">e/ou</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265; 85</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MAPA Sono</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265; 120</td><td align="center" valign="top" rowspan="1" colspan="1">e/ou</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265; 70</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MRPA</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265; 130</td><td align="center" valign="top" rowspan="1" colspan="1">e/ou</td><td align="center" colspan="2" valign="top" rowspan="1">&#x02265; 80</td></tr></tbody></table><table-wrap-foot><fn id="T21FN1"><p>Abreviaturas &#x02013; MAPA: monitoriza&#x000e7;&#x000e3;o arterial da press&#x000e3;o arterial; MRPA: monitoriza&#x000e7;&#x000e3;o residencial da press&#x000e3;o arterial; PAS: press&#x000e3;o arterial sist&#x000f3;lica; PAD: press&#x000e3;o arterial diast&#x000f3;lica.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T15"><label>Quadro 4</label><caption><title>Protocolo para realiza&#x000e7;&#x000e3;o da monitoriza&#x000e7;&#x000e3;o residencial da press&#x000e3;o arterial (MRPA) nos pacientes em di&#x000e1;lise, segundo as <italic>Diretrizes brasileiras de medidas da press&#x000e3;o arterial dentro e fora do consult&#x000f3;rio</italic> &#x02013; 2023<sup>
<xref rid="B119" ref-type="bibr">119</xref>
</sup>
</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="center" colspan="2" valign="top" rowspan="1">Monitoriza&#x000e7;&#x000e3;o Residencial da Press&#x000e3;o Arterial (MRPA)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Per&#x000ed;odo de verifica&#x000e7;&#x000e3;o:<break/>&#x02022; Dia da instala&#x000e7;&#x000e3;o + 6 dias consecutivos.<break/>&#x02022; Na DP ou HD di&#x000e1;ria: dia da instala&#x000e7;&#x000e3;o + 6 (seis) dias consecutivos ao longo de uma semana.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>N&#x000fa;mero de medidas:</bold> idealmente, 36 medidas (no m&#x000ed;nimo 18 medidas v&#x000e1;lidas e com medidas em todos os dias, com representa&#x000e7;&#x000e3;o dos per&#x000ed;odos da manh&#x000e3; e da noite).</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Dia 0 ou dia de instala&#x000e7;&#x000e3;o:</bold> para HD e DP s&#x000e3;o realizadas medidas no consult&#x000f3;rio ou cl&#x000ed;nica de HD, nunca no bra&#x000e7;o da FAV, idealmente tr&#x000ea;s medidas (utilizando-se a m&#x000e9;dia das duas &#x000fa;ltimas para o c&#x000e1;lculo de rea&#x000e7;&#x000e3;o de alarme/mascaramento) e medidas &#x000e0; noite em domic&#x000ed;lio, para diminuir um poss&#x000ed;vel efeito do avental branco. As medidas realizadas no consult&#x000f3;rio ou no domic&#x000ed;lio no dia de instala&#x000e7;&#x000e3;o devem ser exclu&#x000ed;das do c&#x000e1;lculo da m&#x000e9;dia da MRPA.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Dias da MRPA:</bold> no domic&#x000ed;lio s&#x000e3;o realizadas medidas de PA por mais 6 dias. O paciente dever&#x000e1; fazer 3 medidas pela manh&#x000e3; e 3 medidas ao entardecer ou &#x000e0; noite. Sempre nos pacientes que realizam HD convencional (duas a tr&#x000ea;s vezes semanais), as medidas realizadas nos dias de di&#x000e1;lise devem ser exclu&#x000ed;das do c&#x000e1;lculo da m&#x000e9;dia da MRPA. Nos casos de HD di&#x000e1;ria e DP, todas as medidas ser&#x000e3;o consideradas para o c&#x000e1;lculo da m&#x000e9;dia.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Laudo da MRPA:</bold> deve conter o motivo da solicita&#x000e7;&#x000e3;o do exame; o n&#x000fa;mero de dias de medidas efetivas, hor&#x000e1;rio e n&#x000fa;mero das medidas de cada dia; a qualidade do procedimento; as m&#x000e9;dias de PA (total, di&#x000e1;rias e as dos per&#x000ed;odos da manh&#x000e3; e do fim de tarde/noite), se houve rea&#x000e7;&#x000e3;o de alarme ou mascaramento e se o resultado foi considerado normal ou n&#x000e3;o (considerado exame anormal quando as m&#x000e9;dias forem &#x02265; 130 mmHg e/ou &#x02265; 80 mmHg, <xref rid="T21" ref-type="table">Tabela 1</xref>).</td></tr></tbody></table><table-wrap-foot><fn id="T15FN1"><p>Abreviaturas &#x02013; MRPA: monitoriza&#x000e7;&#x000e3;o residencial da press&#x000e3;o arterial; HD: hemodi&#x000e1;lise; DP: di&#x000e1;lise peritoneal; PA: press&#x000e3;o arterial; FAV: f&#x000ed;stula arteriovenosa.</p></fn></table-wrap-foot></table-wrap><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Mensagem: MAPA e MRPA apresentam melhor correla&#x000e7;&#x000e3;o com les&#x000f5;es em &#x000f3;rg&#x000e3;os-alvo, eventos CV e morte por todas as causas quando comparadas com as medidas peridial&#x000ed;ticas (Classe I/N&#x000ed;vel B).</p></list-item><list-item><p>MAPA e MRPA apresentam boa correla&#x000e7;&#x000e3;o entre si em HD e DP (Classe I/N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se a MAPA de 44h como m&#x000e9;todo padr&#x000e3;o ouro para o diagn&#x000f3;stico de HA nos pacientes em HD e DP<sup>
<xref rid="B113" ref-type="bibr">113</xref>
</sup> (Classe I, N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se a MRPA (dia de instala&#x000e7;&#x000e3;o e mais 6 dias) como alternativa, quando a MAPA estiver indispon&#x000ed;vel (Classe I, N&#x000ed;vel C).</p></list-item><list-item><p>Recomenda-se para DP e HD di&#x000e1;ria seguir as recomenda&#x000e7;&#x000f5;es para a popula&#x000e7;&#x000e3;o hipertensa em geral, para MRPA e MAPA de 24h (Classe I/N&#x000ed;vel C).</p></list-item></list><p>Em rela&#x000e7;&#x000e3;o &#x000e0; di&#x000e1;lise peritoneal (DP), por ser uma modalidade dial&#x000ed;tica domiciliar, sugere-se que a MRPA deva ser amplamente aplicada. Em sua &#x000fa;ltima atualiza&#x000e7;&#x000e3;o, a Sociedade Internacional de Di&#x000e1;lise Peritoneal recomenda que, al&#x000e9;m da medida da PA na visita cl&#x000ed;nica, tamb&#x000e9;m seja realizada medida da PA domiciliar semanalmente<sup>
<xref rid="B120" ref-type="bibr">120</xref>
</sup>. Por&#x000e9;m, por causa da escassez de evid&#x000ea;ncias, estudos prospectivos s&#x000e3;o necess&#x000e1;rios para elucidar o real significado progn&#x000f3;stico das medidas de PA fora do consult&#x000f3;rio na DP.</p></sec><sec><title>Fen&#x000f3;tipos</title><p>Levando-se em considera&#x000e7;&#x000e3;o a PA de consult&#x000f3;rio e a fora do consult&#x000f3;rio, a PA apresenta 9 tipos poss&#x000ed;veis de comportamento: Normotens&#x000e3;o Verdadeira (NV), Hipertens&#x000e3;o Controlada (HC), Hipertens&#x000e3;o Sustentada (HS), Hipertens&#x000e3;o Sustentada N&#x000e3;o Controlada (HSNC), Hipertens&#x000e3;o do Avental Branco (HAB), Hipertens&#x000e3;o do Avental Branco N&#x000e3;o Controlada (HABNC), Hipertens&#x000e3;o Mascarada (HM), Hipertens&#x000e3;o Mascarada N&#x000e3;o Controlada (HMNC) e Hipertens&#x000e3;o Noturna (HN).</p><p>A HAB refere-se &#x000e0; condi&#x000e7;&#x000e3;o em que a PA &#x000e9; anormal no consult&#x000f3;rio, mas &#x000e9; normal quando medida pela MAPA ou MRPA. A HM refere-se a pacientes nos quais a PA &#x000e9; normal no consult&#x000f3;rio, mas &#x000e9; anormal quando medida pela MRPA ou MAPA. Nos pacientes que utilizam medica&#x000e7;&#x000f5;es anti-hipertensivas, deve-se adicionar o termo &#x0201c;n&#x000e3;o controlada&#x0201d;. A NV &#x000e9; quando as medidas da PA no consult&#x000f3;rio e fora dele s&#x000e3;o normais e o paciente n&#x000e3;o utiliza medica&#x000e7;&#x000e3;o anti-hipertensiva; caso utilize, &#x000e9; definida como HC. A HS &#x000e9; usada quando ambas s&#x000e3;o anormais na aus&#x000ea;ncia de anti-hipertensivos. Se o paciente utiliza medica&#x000e7;&#x000e3;o anti-hipertensiva, &#x000e9; definida como HSNC. A HN &#x000e9; definida quando a medida da m&#x000e9;dia da PA pela MAPA est&#x000e1; alterada no sono e nas 24h ou 44h, por&#x000e9;m normal na vig&#x000ed;lia. A preval&#x000ea;ncia dos fen&#x000f3;tipos varia consideravelmente de acordo com o m&#x000e9;todo de medi&#x000e7;&#x000e3;o da PA e defini&#x000e7;&#x000e3;o de HA. Em um dos poucos estudos que avaliaram a preval&#x000ea;ncia dos fen&#x000f3;tipos entre os pacientes em HD, foram utilizados os valores de anormalidade da MAPA de 44h &#x02265; 135/85 mmHg e de &#x02265; 140/80 mmHg para a mediana da PA pr&#x000e9;-HD e p&#x000f3;s-HD de seis sess&#x000f5;es de meio da semana consecutivas. As preval&#x000ea;ncias encontradas podem ser visualizadas na <xref rid="F09" ref-type="fig">Figura 2</xref>
<sup>
<xref rid="B121" ref-type="bibr">121</xref>
</sup>.</p><fig position="float" id="F09"><label>Figura 2</label><caption><title>Preval&#x000ea;ncia dos fen&#x000f3;tipos de hipertens&#x000e3;o arterial em pacientes com doen&#x000e7;a renal cr&#x000f4;nica em hemodi&#x000e1;lise.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf09" position="float"/><attrib>Abreviaturas &#x02013; PA: press&#x000e3;o arterial; MRPA: medida residencial da press&#x000e3;o arterial; MAPA: medida ambulatorial da press&#x000e3;o arterial.</attrib></fig><p>H&#x000e1; car&#x000ea;ncia de estudos que avaliem o progn&#x000f3;stico dos fen&#x000f3;tipos em pacientes dial&#x000ed;ticos. Entretanto, entre pacientes com DRC n&#x000e3;o dial&#x000ed;tica, o risco de morbidade e mortalidade CV n&#x000e3;o aumentou naqueles com HABNC, mas aumentou naqueles com HMNC e HSNC<sup>
<xref rid="B122" ref-type="bibr">122</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>S&#x000e3;o necess&#x000e1;rios mais estudos para avaliar os fen&#x000f3;tipos de HA na popula&#x000e7;&#x000e3;o em todas as modalidades dial&#x000ed;ticas.</p></list-item></list></sec></sec></sec><sec><title>Avalia&#x000e7;&#x000f5;es Complementares de Hipertens&#x000e3;o e Risco Cardiovascular na Di&#x000e1;lise Peritoneal (DP) e Hemodi&#x000e1;lise (HD)</title><sec><title>C&#x000e1;lculo do Risco Cardiovascular na Doen&#x000e7;a Renal Cr&#x000f4;nica Dial&#x000ed;tica</title><p>Se por um lado a DRC &#x000e9; um forte preditor independente de doen&#x000e7;a CV<sup>
<xref rid="B123" ref-type="bibr">123</xref>
<xref rid="B124" ref-type="bibr">124</xref>,<xref rid="B125" ref-type="bibr">125</xref>
</sup>, temos que a pr&#x000f3;pria doen&#x000e7;a CV &#x000e9; a principal causa de morte em doentes renais cr&#x000f4;nicos, traduzindo a import&#x000e2;ncia da identifica&#x000e7;&#x000e3;o dos pacientes com alto risco de eventos e morte CV<sup>
<xref rid="B126" ref-type="bibr">126</xref>,<xref rid="B127" ref-type="bibr">127</xref>
</sup>. Na popula&#x000e7;&#x000e3;o geral, existem m&#x000e9;todos capazes de prever a probabilidade de ocorr&#x000ea;ncia em 10 anos de um evento CV, destacando-se o escore de Framingham e o algoritmo de risco Atherosclerotic Cardiovascular Disease (ASCVD), que consideram apenas fatores tradicionais de risco CV<sup>
<xref rid="B128" ref-type="bibr">128</xref>,<xref rid="B129" ref-type="bibr">129</xref>
</sup>. Nos pacientes com DRC, esses escores apresentam menor acur&#x000e1;cia, provavelmente pela exist&#x000ea;ncia de fatores de risco n&#x000e3;o tradicionais relacionados &#x000e0; perda de fun&#x000e7;&#x000e3;o renal e ao tratamento dial&#x000ed;tico<sup>
<xref rid="B130" ref-type="bibr">130</xref>,<xref rid="B131" ref-type="bibr">131</xref>,<xref rid="B132" ref-type="bibr">132</xref>,<xref rid="B133" ref-type="bibr">133</xref>
</sup>. Coerentemente com essa vis&#x000e3;o, os fatores tradicionais de risco s&#x000e3;o predominantes nos est&#x000e1;gios iniciais da DRC, ao passo que aqueles n&#x000e3;o tradicionais ganham relev&#x000e2;ncia com a progress&#x000e3;o da DRC<sup>
<xref rid="B130" ref-type="bibr">130</xref>
</sup>.</p><p>Modelos de c&#x000e1;lculos de risco valorizando fatores espec&#x000ed;ficos para pacientes em di&#x000e1;lise t&#x000ea;m sido propostos<sup>
<xref rid="B131" ref-type="bibr">131</xref>,<xref rid="B132" ref-type="bibr">132</xref>,<xref rid="B133" ref-type="bibr">133</xref>
</sup>. A partir da an&#x000e1;lise de pacientes em HD, avaliando o risco de eventos CV e de morte em 5 anos, foi desenvolvido escore preditivo com inclus&#x000e3;o de sete caracter&#x000ed;sticas (idade, sexo, DM, doen&#x000e7;a CV pr&#x000e9;via, tipo de acesso vascular ao iniciar em di&#x000e1;lise, rela&#x000e7;&#x000e3;o mon&#x000f3;cito/linf&#x000f3;cito e &#x000e1;cido &#x000fa;rico), resultando em melhor desempenho que o escore de Framingham<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup>. Avaliando pacientes japoneses em HD (J-DOPPS) ao longo de um ano, desenvolveu-se um modelo incluindo seis vari&#x000e1;veis (idade, DM, doen&#x000e7;a CV pr&#x000e9;via, tempo da sess&#x000e3;o de di&#x000e1;lise, f&#x000f3;sforo e albumina), tamb&#x000e9;m com melhor discrimina&#x000e7;&#x000e3;o de risco que o escore de Framingham<sup>
<xref rid="B132" ref-type="bibr">132</xref>
</sup>. Um estudo europeu com pacientes em HD, seguidos por at&#x000e9; 2 anos e incluindo dados cl&#x000ed;nicos e laboratoriais (idade, IMC, tabagismo, doen&#x000e7;a CV pr&#x000e9;via, etiologia da DRC, PA pr&#x000e9;-di&#x000e1;lise, UF, hemoglobina, PCR, albumina, creatinina e c&#x000e1;lcio), demonstrou-se boa predi&#x000e7;&#x000e3;o de risco de mortalidade geral<sup>
<xref rid="B133" ref-type="bibr">133</xref>
</sup>. No conjunto, esses estudos mostram que o acr&#x000e9;scimo de fatores de risco n&#x000e3;o tradicionais aos modelos preditivos melhorou sua acur&#x000e1;cia em pacientes dial&#x000ed;ticos, ainda que a taxa observada de morte persista superior &#x000e0; predita, fazendo crer que fatores de risco adicionais possam ser inclu&#x000ed;dos na constru&#x000e7;&#x000e3;o de modelo mais definitivo<sup>
<xref rid="B131" ref-type="bibr">131</xref>,<xref rid="B132" ref-type="bibr">132</xref>,<xref rid="B133" ref-type="bibr">133</xref>
</sup>. De todo modo, n&#x000e3;o h&#x000e1; ferramenta dispon&#x000ed;vel para predizer o risco CV em pacientes dial&#x000ed;ticos com ampla aceita&#x000e7;&#x000e3;o, e que contemple simplicidade e boa acur&#x000e1;cia.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Pacientes com DRC devem ser considerados de alto risco CV (Classe I/N&#x000ed;vel A).</p></list-item><list-item><p>A avalia&#x000e7;&#x000e3;o do risco CV de pacientes com DRC pode ser realizada por modelos de c&#x000e1;lculo de risco da popula&#x000e7;&#x000e3;o geral (Classe IIA/N&#x000ed;vel B).</p></list-item><list-item><p>A discrimina&#x000e7;&#x000e3;o do risco CV em pacientes com DRC tem sua acur&#x000e1;cia aumentada pelo emprego de modelos espec&#x000ed;ficos que incluem fatores de risco tradicionais e n&#x000e3;o tradicionais relacionados &#x000e0; DRC e &#x000e0; di&#x000e1;lise (Classe IIA/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Pept&#x000ed;deos Natriur&#x000e9;ticos em Pacientes com Doen&#x000e7;a Renal Cr&#x000f4;nica</title><p>As dosagens s&#x000e9;ricas de pept&#x000ed;deos natriur&#x000e9;ticos s&#x000e3;o usualmente utilizadas na pr&#x000e1;tica cl&#x000ed;nica para o diagn&#x000f3;stico e seguimento de pacientes com IC<sup>
<xref rid="B134" ref-type="bibr">134</xref>
</sup>. O diagn&#x000f3;stico de IC &#x000e9; corroborado por pelo menos um dos seguintes fatores: eleva&#x000e7;&#x000f5;es das concentra&#x000e7;&#x000f5;es s&#x000e9;ricas de BNP ou de NT-proBNP ou evid&#x000ea;ncias objetivas de congest&#x000e3;o pulmonar ou sist&#x000ea;mica de origem cardiog&#x000ea;nica<sup>
<xref rid="B134" ref-type="bibr">134</xref>
</sup>.</p><p>Esses pept&#x000ed;deos, principalmente o NT-proBNP, parecem predizer o risco de desfechos CV e morte em indiv&#x000ed;duos com alto risco CV<sup>
<xref rid="B135" ref-type="bibr">135</xref>,<xref rid="B136" ref-type="bibr">136</xref>,<xref rid="B137" ref-type="bibr">137</xref>,<xref rid="B138" ref-type="bibr">138</xref>,<xref rid="B139" ref-type="bibr">139</xref>,<xref rid="B140" ref-type="bibr">140</xref>,<xref rid="B141" ref-type="bibr">141</xref>
</sup>, incluindo o potencial de uso do NT-proBNP como vari&#x000e1;vel isolada que se assemelha ou mesmo supera as predi&#x000e7;&#x000f5;es de modelos de risco multivariados<sup>
<xref rid="B136" ref-type="bibr">136</xref>,<xref rid="B137" ref-type="bibr">137</xref>,<xref rid="B138" ref-type="bibr">138</xref>,<xref rid="B139" ref-type="bibr">139</xref>,<xref rid="B140" ref-type="bibr">140</xref>,<xref rid="B142" ref-type="bibr">142</xref>
</sup>.</p><p>Na <xref rid="T16" ref-type="table">Quadro 5</xref> est&#x000e3;o exemplificados alguns estudos mostrando a associa&#x000e7;&#x000e3;o do NT-proBNP com risco CV aumentado na popula&#x000e7;&#x000e3;o com DRC<sup>
<xref rid="B139" ref-type="bibr">139</xref>,<xref rid="B141" ref-type="bibr">141</xref>,<xref rid="B143" ref-type="bibr">143</xref>,<xref rid="B144" ref-type="bibr">144</xref>,<xref rid="B145" ref-type="bibr">145</xref>,<xref rid="B146" ref-type="bibr">146</xref>,<xref rid="B147" ref-type="bibr">147</xref>
</sup>.</p><table-wrap position="float" id="T16"><label>Quadro 5</label><caption><title>Estudos em pacientes com doen&#x000e7;a renal, avaliando os pept&#x000ed;deos natriur&#x000e9;ticos como biomarcadores de riscos de doen&#x000e7;as, eventos e morte cardiovascular</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Estudo</th><th align="left" valign="top" rowspan="1" colspan="1">Desenho do estudo</th><th align="left" valign="top" rowspan="1" colspan="1">Doen&#x000e7;a renal/ outras comorbidades</th><th align="left" valign="top" rowspan="1" colspan="1">Resultados</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">TREAT<sup>
<xref rid="B144" ref-type="bibr">144</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Avalia&#x000e7;&#x000e3;o da inser&#x000e7;&#x000e3;o de NT-proBNP e troponina T a um modelo de predi&#x000e7;&#x000e3;o multivari&#x000e1;vel</td><td align="left" valign="top" rowspan="1" colspan="1">DRC, com DM2 e anemia</td><td align="left" valign="top" rowspan="1" colspan="1">Aumentou em <sup>
<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B8" ref-type="bibr">8</xref>
</sup>% a habilidade preditiva de desfechos CV</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALTITUDE<sup>
<xref rid="B137" ref-type="bibr">137</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">An&#x000e1;lise <italic>post hoc</italic> da predi&#x000e7;&#x000e3;o de NT-proBNP (vari&#x000e1;vel &#x000fa;nica) comparada a modelo com 20 vari&#x000e1;veis</td><td align="left" valign="top" rowspan="1" colspan="1">DRC e/ou doen&#x000e7;a CV</td><td align="left" valign="top" rowspan="1" colspan="1">Preditor de risco de eventos e morte CV, similar ao modelo multivari&#x000e1;vel</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CREATE<sup>
<xref rid="B145" ref-type="bibr">145</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">NT-proBNP (vari&#x000e1;vel &#x000fa;nica)</td><td align="left" valign="top" rowspan="1" colspan="1">DRC (TFG 15&#x02013;35 mL/min) e anemia</td><td align="left" valign="top" rowspan="1" colspan="1">N&#x000ed;vel plasm&#x000e1;tico elevado como preditor de risco de eventos CV e de progress&#x000e3;o da DRC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Harrison TG et al., 2020<sup>
<xref rid="B141" ref-type="bibr">141</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Meta-an&#x000e1;lise com 49 estudos, avaliou BNP e NT-proBNP como marcador de risco de eventos CV e morte</td><td align="left" valign="top" rowspan="1" colspan="1">DRC 5D</td><td align="left" valign="top" rowspan="1" colspan="1">N&#x000ed;veis elevados de NT-proBNP e de BNP foram preditores de mortalidade CV e morte por todas as causas</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Satoh A et al., 2021<sup>
<xref rid="B147" ref-type="bibr">147</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">NT-proBNP com dosagem antes da primeira HD da semana</td><td align="left" valign="top" rowspan="1" colspan="1">Pacientes em HD</td><td align="left" valign="top" rowspan="1" colspan="1">N&#x000ed;veis s&#x000e9;ricos elevados foram preditores de risco de morte CV e geral</td></tr></tbody></table><table-wrap-foot><fn id="T16FN1"><p>Abreviatura &#x02013; DM2: diabetes <italic>mellitus</italic> tipo 2, CV: cardiovascular, DRC: doen&#x000e7;a renal cr&#x000f4;nica, TFG: Taxa de filtra&#x000e7;&#x000e3;o glomerular pelo <italic>clearance</italic> de creatinina, HD: hemodi&#x000e1;lise.</p></fn></table-wrap-foot></table-wrap><p>Em pacientes dial&#x000ed;ticos, o NT-proBNP parece predizer independentemente de morte CV e por todas as causas<sup>
<xref rid="B141" ref-type="bibr">141</xref>,<xref rid="B147" ref-type="bibr">147</xref>
</sup>, al&#x000e9;m de ser um fator preditivo para sobrecarga de volume em pacientes em HD (com ou sem decl&#x000ed;nio da fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o do VE)<sup>
<xref rid="B147" ref-type="bibr">147</xref>,<xref rid="B148" ref-type="bibr">148</xref>,<xref rid="B149" ref-type="bibr">149</xref>
</sup> e para o aumento do risco de hospitaliza&#x000e7;&#x000f5;es por AVC<sup>
<xref rid="B150" ref-type="bibr">150</xref>
</sup>.</p><p>Como a disfun&#x000e7;&#x000e3;o renal faz-se acompanhar de concentra&#x000e7;&#x000f5;es aumentadas de BNP e NT-proBNP<sup>
<xref rid="B141" ref-type="bibr">141</xref>,<xref rid="B151" ref-type="bibr">151</xref>
</sup>, a estrat&#x000e9;gia de medi&#x000e7;&#x000f5;es sequenciais &#x000e9; superior &#x000e0; de medida &#x000fa;nica em pacientes com DRC<sup>
<xref rid="B141" ref-type="bibr">141</xref>
</sup>. Assim, na indefini&#x000e7;&#x000e3;o de valores de corte de BNP e NT-proBNP para pacientes em di&#x000e1;lise, valores sequenciais podem traduzir melhor e de forma din&#x000e2;mica a trajet&#x000f3;ria da fun&#x000e7;&#x000e3;o card&#x000ed;aca e o <italic>status</italic> de hidrata&#x000e7;&#x000e3;o.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se realizar dosagens seriadas de pept&#x000ed;deos natriur&#x000e9;ticos em pacientes dial&#x000ed;ticos (preferencialmente o NT proBNP), se dispon&#x000ed;vel, pois podem auxiliar na avalia&#x000e7;&#x000e3;o de sobrecarga volum&#x000e9;trica, identifica&#x000e7;&#x000e3;o e controle de IC associada &#x000e0; DRC dial&#x000ed;tica e, principalmente, na predi&#x000e7;&#x000e3;o do risco de desfechos CV e morte (Classe I/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Rigidez Arterial (RA) Avaliada Pela Medida da Velocidade da Onda de Pulso (VOP)</title><p>O grau de RA &#x000e9; um marcador de sa&#x000fa;de e de envelhecimento vascular. Uma das formas de estim&#x000e1;-lo &#x000e9; pela medida da VOP arterial, definida pela medida do tempo gasto (m/s) para que a onda de pulso (gerada pela s&#x000ed;stole) transite entre dois pontos no sistema arterial, geralmente a art&#x000e9;ria car&#x000f3;tida e a art&#x000e9;ria femoral. A VOP carot&#x000ed;deo-femoral (a&#x000f3;rtica) reflete as propriedades viscoel&#x000e1;sticas da aorta, sendo considerada o m&#x000e9;todo padr&#x000e3;o-ouro para avalia&#x000e7;&#x000e3;o da RA<sup>
<xref rid="B125" ref-type="bibr">152</xref>
</sup>.</p><p>A eleva&#x000e7;&#x000e3;o da VOP a&#x000f3;rtica indica maior RA, sendo associada a um risco aumentado de doen&#x000e7;a CV e mortalidade<sup>
<xref rid="B152" ref-type="bibr">152</xref>
</sup>. Os valores normais para a VOP a&#x000f3;rtica variam de acordo com idade e sexo (<xref rid="T22" ref-type="table">Tabela 2</xref>)<sup>
<xref rid="B153" ref-type="bibr">153</xref>
</sup>.</p><table-wrap position="float" id="T22"><label>Tabela 2</label><caption><title>Valores normais de VOP para homens e mulheres de acordo com a faixa et&#x000e1;ria</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" rowspan="2" valign="top" colspan="1">Faixa et&#x000e1;ria</th><th align="center" colspan="2" valign="top" rowspan="1">Velocidade de onda de pulso (VOP) (m/s)<hr/>
</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">Homens</th><th align="center" valign="top" rowspan="1" colspan="1">Mulheres</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">20&#x02013;29 anos</td><td align="center" valign="top" rowspan="1" colspan="1">6,4</td><td align="center" valign="top" rowspan="1" colspan="1">6,0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">30&#x02013;39 anos</td><td align="center" valign="top" rowspan="1" colspan="1">6,9</td><td align="center" valign="top" rowspan="1" colspan="1">6,4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">40&#x02013;49 anos</td><td align="center" valign="top" rowspan="1" colspan="1">7,4</td><td align="center" valign="top" rowspan="1" colspan="1">7,0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">50&#x02013;59 anos</td><td align="center" valign="top" rowspan="1" colspan="1">8,0</td><td align="center" valign="top" rowspan="1" colspan="1">7,7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e; 60 anos</td><td align="center" valign="top" rowspan="1" colspan="1">9,2</td><td align="center" valign="top" rowspan="1" colspan="1">8,6</td></tr></tbody></table></table-wrap><p>Em pacientes em HD, o maior valor de VOP a&#x000f3;rtica prediz maior mortalidade<sup>
<xref rid="B154" ref-type="bibr">154</xref>
</sup>, e VOP &#x0003e; 10 m/s &#x000e9; um preditor independente de mortalidade CV e por todas as causas<sup>
<xref rid="B155" ref-type="bibr">155</xref>
</sup>. Da mesma forma, a evolu&#x000e7;&#x000e3;o acelerada da VOP (medida no tempo 0 e a cada 6 meses) pode prever a mortalidade CV em pacientes em HD<sup>
<xref rid="B156" ref-type="bibr">156</xref>
</sup>.</p><p>Os pacientes em HD parecem ter n&#x000ed;veis de VOP menos sens&#x000ed;veis ao controle da PA, traduzindo a superposi&#x000e7;&#x000e3;o dos fatores tradicionais de risco CV aos fatores n&#x000e3;o tradicionais (relacionados &#x000e0; uremia e ao tratamento dial&#x000ed;tico), que s&#x000e3;o determinantes da maior RA que caracteriza essa popula&#x000e7;&#x000e3;o. No conjunto, isso pode justificar o reconhecimento de que a menor varia&#x000e7;&#x000e3;o da VOP observada quanto ao manejo da HA nesses indiv&#x000ed;duos associou-se a maior risco de eventos CV<sup>
<xref rid="B157" ref-type="bibr">157</xref>
</sup>.</p><p>O aumento da rigidez arterial &#x000e9; relativamente comum em pacientes com DP. Maior VOP em pacientes com DP est&#x000e1; associado ao aumento da idade, presen&#x000e7;a de DM e hiperidrata&#x000e7;&#x000e3;o, e se mostrou preditor de resultado em pacientes com DP<sup>
<xref rid="B158" ref-type="bibr">158</xref>
</sup>.</p><p>Em conclus&#x000e3;o, a medida da VOP, ferramenta considerada padr&#x000e3;o-ouro de RA, auxilia no c&#x000e1;lculo do risco CV, ainda que mais pesquisas sejam necess&#x000e1;rias para definir padr&#x000f5;es definitivos de normalidade de VOP e seu papel em desfechos na popula&#x000e7;&#x000e3;o dial&#x000ed;tica.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se a avalia&#x000e7;&#x000e3;o da rigidez arterial (RA) por meio da velocidade de onda de pulso arterial (VOP) carot&#x000ed;deo femoral, se dispon&#x000ed;vel e de forma seriada, pois potencialmente prediz eventos CV e mortalidade em HD e DP (Classe I/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Bioimped&#x000e2;ncia (BIA) Como M&#x000e9;todo Diagn&#x000f3;stico da Composi&#x000e7;&#x000e3;o Corporal e do <italic>Status</italic> Vol&#x000ea;mico</title><p>A bioimped&#x000e2;ncia (BIA) avalia a composi&#x000e7;&#x000e3;o corporal atrav&#x000e9;s da passagem de corrente el&#x000e9;trica de diferentes frequ&#x000ea;ncias pelo corpo, sendo um m&#x000e9;todo diagn&#x000f3;stico empregado no contexto de pacientes dial&#x000ed;ticos para estimativa do n&#x000ed;vel de hidrata&#x000e7;&#x000e3;o e do apoio no gerenciamento da PA<sup>
<xref rid="B159" ref-type="bibr">159</xref>,<xref rid="B160" ref-type="bibr">160</xref>,<xref rid="B161" ref-type="bibr">161</xref>
</sup>.</p><p>Em revis&#x000e3;o sistem&#x000e1;tica com meta-an&#x000e1;lise reunindo pacientes cr&#x000f4;nicos em HD e DP, Tabinor et al. sugerem que a mortalidade &#x000e9; predita pelo &#x000ed;ndice de hiper-hidrata&#x000e7;&#x000e3;o &#x0003e; 15% e pelo &#x000e2;ngulo de fase reduzido em 1 grau, independentemente de comorbidades<sup>
<xref rid="B162" ref-type="bibr">162</xref>
</sup>. No maior dos estudos inclu&#x000ed;dos, Zoccali et al. demonstraram maior mortalidade em pacientes hiper-hidratados, independentemente da PA pr&#x000e9;-di&#x000e1;lise<sup>
<xref rid="B163" ref-type="bibr">163</xref>
</sup>. Outras revis&#x000f5;es sistem&#x000e1;ticas e meta-an&#x000e1;lises se dedicaram a mostrar o impacto do uso da BIA em pacientes em di&#x000e1;lise, e est&#x000e3;o resumidas no <xref rid="T17" ref-type="table">Quadro 6</xref>
<sup>
<xref rid="B161" ref-type="bibr">161</xref>,<xref rid="B164" ref-type="bibr">164</xref>,<xref rid="B165" ref-type="bibr">165</xref>,<xref rid="B166" ref-type="bibr">166</xref>,<xref rid="B167" ref-type="bibr">167</xref>
</sup>.</p><table-wrap position="float" id="T17"><label>Quadro 6</label><caption><title>Resumo dos principais estudos demonstrando o impacto no uso de bioimped&#x000e2;ncia em pacientes em di&#x000e1;lise</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Estudos</th><th align="left" valign="top" rowspan="1" colspan="1">Tipo de estudo</th><th align="left" valign="top" rowspan="1" colspan="1">Melhor controle da hiper-hidrata&#x000e7;&#x000e3;o</th><th align="left" valign="top" rowspan="1" colspan="1">Melhor controle da PA</th><th align="left" valign="top" rowspan="1" colspan="1">Outros desfechos</th><th align="left" valign="top" rowspan="1" colspan="1">Observa&#x000e7;&#x000f5;es</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Scotland et al., 2018<sup>
<xref rid="B161" ref-type="bibr">161</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Revis&#x000e3;o sistem&#x000e1;tica</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>sim</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">n&#x000e3;o</td><td align="left" valign="top" rowspan="1" colspan="1">I: n&#x000e3;o<break/>M: n&#x000e3;o</td><td align="left" valign="top" rowspan="1" colspan="1">BIA sem efeito na rigidez arterial e n&#x000e3;o foi custo efetivo</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Covic et al., 2017164</td><td align="left" valign="top" rowspan="1" colspan="1">Revis&#x000e3;o sistem&#x000e1;tica e meta-an&#x000e1;lise</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>sim</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>sim</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">M: n&#x000e3;o</td><td align="left" valign="top" rowspan="1" colspan="1">Sem altera&#x000e7;&#x000e3;o da composi&#x000e7;&#x000e3;o corporal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Beaubien- Souligny et al., 2020<sup>
<xref rid="B168" ref-type="bibr">168</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Revis&#x000e3;o sistem&#x000e1;tica e meta-an&#x000e1;lise de estudos randomizados</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>sim</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>sim</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">HVE: n&#x000e3;o<break/>ECV: n&#x000e3;o<break/>
<bold>I: sim</bold>
<break/>M: n&#x000e3;o</td><td align="left" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yang K et al., 2023<sup>
<xref rid="B166" ref-type="bibr">166</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Meta-an&#x000e1;lise de estudos randomizados</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>sim</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>sim</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HVE: sim (HD)</bold>
<break/>
<bold>M: sim</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Redu&#x000e7;&#x000e3;o do</bold>
<break/>
<bold>NT Pro-BNP e VOP</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Horowitz et al., 2023167</td><td align="left" valign="top" rowspan="1" colspan="1">Revis&#x000e3;o sistem&#x000e1;tica e meta-an&#x000e1;lise de estudos randomizados</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>sim</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>sim</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">HVE: n&#x000e3;o<break/>ECV: n&#x000e3;o<break/>I: n&#x000e3;o<break/>
<bold>M: sim</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn id="T17FN1"><p>Abreviaturas &#x02013; PA: press&#x000e3;o arterial; BIA: bioimped&#x000e2;ncia el&#x000e9;trica; HVE: hipertrofia ventricular esquerda; ECV: eventos cardiovasculares; I: interna&#x000e7;&#x000e3;o; M: mortalidade; VOP: velocidade de onda de pulso.</p></fn></table-wrap-foot></table-wrap><p>Importante destacar a diversidade de par&#x000e2;metros advindos do uso da BIA para avaliar o estado vol&#x000ea;mico do paciente dial&#x000ed;tico, n&#x000e3;o havendo um consenso para a escolha preferencial de um deles<sup>
<xref rid="B169" ref-type="bibr">169</xref>,<xref rid="B170" ref-type="bibr">170</xref>
</sup>. Por outro lado, a literatura &#x000e9; mais robusta em indicar o uso da BIA como aux&#x000ed;lio no controle da hipervolemia do que como orientador primordial na condu&#x000e7;&#x000e3;o da terapia anti-hipertensiva. O uso da BIA pode ter impacto no controle da PA, por&#x000e9;m &#x000e9; crucial perceber que deve ser vista como uma entre v&#x000e1;rias alternativas dispon&#x000ed;veis para a gest&#x000e3;o da volemia e PA.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se utilizar a BIA como m&#x000e9;todo complementar para avalia&#x000e7;&#x000e3;o e manejo da hiper-hidrata&#x000e7;&#x000e3;o e da PA em pacientes em HD e em DP (Classe I/N&#x000ed;vel A).</p></list-item></list></sec><sec><title>Ultrassonografia <italic>Point-of-Care</italic> (POCUS) na Avalia&#x000e7;&#x000e3;o da Volemia do Paciente Com DRC: Avalia&#x000e7;&#x000e3;o do Cora&#x000e7;&#x000e3;o, Pulm&#x000e3;o e Veia Cava Inferior (VCI)</title><p>A volemia &#x000e9; um par&#x000e2;metro fundamental em todo o espectro da DRC, sendo que sua avalia&#x000e7;&#x000e3;o cl&#x000ed;nica tem limita&#x000e7;&#x000f5;es, estimulando o desenvolvimento de instrumentos de estimativa vol&#x000ea;mica mais objetivos, como a ultrassonografia <italic>point-of-care</italic> (POCUS)<sup>
<xref rid="B171" ref-type="bibr">171</xref>
</sup>. A POCUS permite uma abordagem multiorg&#x000e2;nica, com avalia&#x000e7;&#x000e3;o de facetas diversas do <italic>status</italic> de volume do paciente.</p><p>A abordagem <italic>pump-pipes-leaks</italic> &#x000e9; uma proposta de avalia&#x000e7;&#x000e3;o pr&#x000e1;tica e objetiva da volemia. A insona&#x000e7;&#x000e3;o do cora&#x000e7;&#x000e3;o atrav&#x000e9;s da janela card&#x000ed;aca paraesternal eixo longo permite avaliar a fun&#x000e7;&#x000e3;o sist&#x000f3;lica do VE a partir da varia&#x000e7;&#x000e3;o dos seus volumes sist&#x000f3;lico e diast&#x000f3;lico, espessamento da parede lateral e do septo interventricular na s&#x000ed;stole e amplitude do deslocamento septal do folheto anterior da v&#x000e1;lvula mitral (<italic>pump</italic>)<sup>
<xref rid="B171" ref-type="bibr">171</xref>
</sup>. &#x0201c;<italic>Pipes</italic>&#x0201d; alude &#x000e0; avalia&#x000e7;&#x000e3;o do di&#x000e2;metro da VCI (<xref rid="F10" ref-type="fig">Figura 3A-B</xref>).</p><fig position="float" id="F10"><label>Figura 3</label><caption><title>Ultrassonografia <italic>point-of-care</italic> para identifica&#x000e7;&#x000e3;o do <italic>status</italic> vol&#x000ea;mico. Legenda: A e B, ultrassonografia da veia cava inferior (VCI): A, VCI &#x0003c; 1,7 cm, cujo di&#x000e2;metro diminui mais de 50% com a inspira&#x000e7;&#x000e3;o, compat&#x000ed;vel com quadro de euvolemia; B: VCI plet&#x000f3;rica, com di&#x000e2;metro de 2,7 cm e que diminui menos que 50% com a inspira&#x000e7;&#x000e3;o, sugestivo de hipervolemia; C: ultrassonografia pulmonar: linhas-B identificam s&#x000ed;ndrome intersticial pulmonar, como no edema agudo de pulm&#x000e3;o; D: derrame pleural identificado pela imagem anecoica acima do diafragma; E: ascite, imagem anecoica no espa&#x000e7;o hepatorrenal; e F: derrame peric&#x000e1;rdico, identificado pela imagem anecoica no espa&#x000e7;o peric&#x000e1;rdico.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf10" position="float"/></fig><p>Um modelo mais objetivo de avalia&#x000e7;&#x000e3;o vol&#x000ea;mica foi desenvolvido com exame Doppler das veias hep&#x000e1;tica, porta e interlobar renal, denominado <italic>Venous Excess Ultrasound</italic> (VExUS). A <xref rid="F11" ref-type="fig">Figura 4</xref> sumariza os padr&#x000f5;es de Doppler das veias hep&#x000e1;tica, porta e interlobar renal no contexto de congest&#x000e3;o venosa leve, moderada e grave. Destaca-se a baixa qualidade de evid&#x000ea;ncias dispon&#x000ed;veis para emprego de VExUS na avalia&#x000e7;&#x000e3;o vol&#x000ea;mica do paciente com DRC<sup>
<xref rid="B168" ref-type="bibr">168</xref>
</sup>.</p><fig position="float" id="F11"><label>Figura 4</label><caption><title>Padr&#x000f5;es de Doppler das veias hep&#x000e1;tica, porta e interlobar renal no contexto de congest&#x000e3;o venosa leve, moderada e grave.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf11" position="float"/><attrib>Abreviaturas &#x02013; VCI: veia cava inferior; a: contra&#x000e7;&#x000e3;o atrial; S: s&#x000ed;stole; D: di&#x000e1;stole. Nota &#x02013; baseado em Dinh V. POCUS 101 Vexus ultrasound score &#x02013; fluid overload and venous congestion assessment.</attrib></fig><p>
<italic>Leaks</italic> denota a pesquisa de congest&#x000e3;o pulmonar atrav&#x000e9;s da identifica&#x000e7;&#x000e3;o das linhas-B (<xref rid="F10" ref-type="fig">Figura 3C</xref>) com alta sensibilidade, mas menor especificidade para congest&#x000e3;o, al&#x000e9;m de derrame pleural (<xref rid="F10" ref-type="fig">Figura 3D</xref>), ascite (<xref rid="F10" ref-type="fig">Figura 3E</xref>) e derrame peric&#x000e1;rdico (<xref rid="F10" ref-type="fig">Figura 3F</xref>), permitindo detectar congest&#x000e3;o extravascular antes do in&#x000ed;cio dos sintomas cl&#x000ed;nicos, e assim adequar o tratamento de pacientes dial&#x000ed;ticos<sup>
<xref rid="B172" ref-type="bibr">172</xref>
</sup>.</p><p>No paciente em di&#x000e1;lise, a identifica&#x000e7;&#x000e3;o do PS &#x000e9; desafiadora. Se superestimado, o PS contribui para a sobrecarga persistente de volume e suas consequ&#x000ea;ncias; quando subestimado, o PS pode causar hipotens&#x000e3;o intradial&#x000ed;tica e complica&#x000e7;&#x000f5;es associadas. No contexto do paciente em tratamento dial&#x000ed;tico, a POCUS pode fornecer informa&#x000e7;&#x000f5;es valiosas.</p><p>A estrat&#x000e9;gia <italic>pump-pipes-leaks</italic> permite responder, &#x000e0; beira-leito, a quest&#x000f5;es relacionadas &#x000e0; intera&#x000e7;&#x000e3;o entre ganho absoluto de volume, redistribui&#x000e7;&#x000e3;o multicompartimental do volume extracelular e o impacto adverso multiorg&#x000e2;nico. Necessitamos de mais estudos para avaliar seu impacto na sobrevida do paciente em HD<sup>
<xref rid="B172" ref-type="bibr">172</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se utilizar o instrumento de estimativa vol&#x000ea;mica <italic>pump-pipes-leaks</italic> &#x000e0; beira do leito, incluindo o escore VExUS, que podem ser uma alternativa para avaliar a gravidade de congest&#x000e3;o venosa em pacientes com DRC (Classe II A/N&#x000ed;vel B).</p></list-item></list></sec></sec><sec><title>Metas Press&#x000f3;ricas na Di&#x000e1;lise Peritoneal (DP) e Hemodi&#x000e1;lise (HD)</title><p>As metas de PA em pacientes em di&#x000e1;lise, independentemente da modalidade, permanecem controversas, e a extrapola&#x000e7;&#x000e3;o dos alvos press&#x000f3;ricos da popula&#x000e7;&#x000e3;o geral para esse subgrupo n&#x000e3;o parece a melhor op&#x000e7;&#x000e3;o. Encontra-se documentado na literatura, em estudos observacionais, que h&#x000e1; uma curva U ou J no controle press&#x000f3;rico de pacientes em HD e em DP, mas podem existir vieses de interpreta&#x000e7;&#x000e3;o, por terem inclu&#x000ed;do indiv&#x000ed;duos que apresentavam hipotens&#x000e3;o, doen&#x000e7;a CV grave ou fragilidade, contribuindo para o mau progn&#x000f3;stico<sup>
<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B120" ref-type="bibr">120</xref>
</sup>,<sup>
<xref rid="B173" ref-type="bibr">173</xref>,<xref rid="B174" ref-type="bibr">174</xref>
</sup>.</p><p>O CRIC Study (<italic>The Chronic Renal Insufficiency Cohort Study</italic>), um estudo de coorte prospectivo multic&#x000ea;ntrico, apresentou resultados interessantes sobre a rela&#x000e7;&#x000e3;o entre mortalidade por todas as causas e PAS. Entre os participantes que iniciaram a HD (n = 326), foi observada associa&#x000e7;&#x000e3;o em forma de U entre PAS medida &#x0201c;na unidade de di&#x000e1;lise&#x0201d;, presumidamente antes do in&#x000ed;cio da sess&#x000e3;o, e mortalidade (HR 1,26 a cada aumento de 10 mmHg), enquanto a PAS &#x0201c;fora da unidade de di&#x000e1;lise&#x0201d; teve associa&#x000e7;&#x000e3;o linear com a mortalidade. Esses resultados sugerem que a PA alvo ideal para o tratamento deve ser determinada pela monitoriza&#x000e7;&#x000e3;o ambulatorial da PA (MAPA), que nem sempre est&#x000e1; dispon&#x000ed;vel, &#x000e9; bem tolerada ou considerada custo-efetiva<sup>
<xref rid="B100" ref-type="bibr">100</xref>,<xref rid="B175" ref-type="bibr">175</xref>
</sup>.</p><p>Um estudo americano envolvendo mais de 17 mil pacientes em HD concluiu que pacientes com PAS pr&#x000e9;-di&#x000e1;lise &#x0003c; 140 mmHg apresentaram mortalidade significativamente mais elevada, especialmente nos primeiros 3 meses ap&#x000f3;s o in&#x000ed;cio da HD<sup>
<xref rid="B176" ref-type="bibr">176</xref>
</sup>. Achados semelhantes relacionados a desfechos menos desfavor&#x000e1;veis com controle press&#x000f3;rico no per&#x000ed;odo interdial&#x000ed;tico foram encontrados em um centro brasileiro, que incluiu 2672 pacientes em HD seguidos por 31 meses<sup>
<xref rid="B177" ref-type="bibr">177</xref>
</sup>.</p><p>O estudo mais bem desenhado, com potencial definidor de metas press&#x000f3;ricas, por&#x000e9;m sob a forma de piloto, o <italic>Blood-Pressure-in-Dialysis</italic> (BID), randomizou 126 participantes para duas metas de PAS medida na cl&#x000ed;nica antes do in&#x000ed;cio da sess&#x000e3;o de di&#x000e1;lise: intensiva (110&#x02013;140 mmHg) ou padr&#x000e3;o (155&#x02013;165 mmHg), com o objetivo principal de avaliar a viabilidade e seguran&#x000e7;a comparativa no per&#x000ed;odo de um ano de seguimento. O estudo mostrou a viabilidade da interven&#x000e7;&#x000e3;o; mas, apesar do protocolo exigir que os investigadores ajustassem o peso p&#x000f3;s-di&#x000e1;lise como etapa inicial para atingir a PAS alvo, a meta de PAS intensiva s&#x000f3; foi alcan&#x000e7;ada pelo uso de medicamentos anti-hipertensivos adicionais. Os autores indicaram que possivelmente houve manejo inadequado do volume extracelular para obten&#x000e7;&#x000e3;o do peso seco<sup>
<xref rid="B178" ref-type="bibr">178</xref>
</sup>.</p><p>A diretriz do <italic>Kidney Disease Outcomes Quality Initiative</italic> (2005), n&#x000e3;o atualizada, recomenda arbitrariamente uma PA pr&#x000e9;-di&#x000e1;lise &#x0003c; 140/80 mmHg e p&#x000f3;s-di&#x000e1;lise &#x0003c; 130/80 mmHg em pacientes em HD, baseada principalmente na opini&#x000e3;o de especialistas (Classe IIA/N&#x000ed;vel C)<sup>
<xref rid="B179" ref-type="bibr">179</xref>
</sup>.</p><p>Como a PA &#x000e9; um biomarcador da &#x0201c;s&#x000ed;ndrome cardiovascular&#x0201d;, o manejo da HA deve abordar a preven&#x000e7;&#x000e3;o e o tratamento de todas as suas complica&#x000e7;&#x000f5;es CV. Na aus&#x000ea;ncia de dados provenientes de estudos cl&#x000ed;nicos controlados e randomizados em pacientes em di&#x000e1;lise, os objetivos do tratamento devem ser extrapolados a partir dos estudos observacionais dispon&#x000ed;veis e aqueles desenvolvidos na popula&#x000e7;&#x000e3;o em geral. Com base nessa premissa, &#x000e9; razo&#x000e1;vel apontar para uma PA pr&#x000e9;-di&#x000e1;lise &#x02264; 140/90 mmHg ou uma PA domiciliar &#x02264; 130/80 mmHg (Classe IIA/N&#x000ed;vel C). Um grupo de especialistas participantes de uma iniciativa do KDIGO que discutiu controv&#x000e9;rsias no manejo vol&#x000ea;mico e da HA em di&#x000e1;lise optou por n&#x000e3;o recomendar metas de PA para pacientes em TRS e definiu que estrat&#x000e9;gias gerais no manejo da HA se aplicam a pacientes em di&#x000e1;lise, tais como &#x0201c;Individualizar alvos e agentes de PA de acordo com a idade, doen&#x000e7;a CV coexistente e outras comorbidades, al&#x000e9;m da toler&#x000e2;ncia ao tratamento&#x0201d; e &#x0201c;Indagar sobre tontura postural e verificar hipotens&#x000e3;o ortost&#x000e1;tica&#x0201d;<sup>
<xref rid="B180" ref-type="bibr">180</xref>
</sup>.</p><p>Nos pacientes em DP, um estudo observacional mostrou que PAS &#x02264; 110 mmHg foi associada a aumento da mortalidade, e um efeito protetor foi observado com uma PAS &#x0003e; 120 mmHg<sup>
<xref rid="B181" ref-type="bibr">181</xref>
</sup>. Assim, com base em dados da popula&#x000e7;&#x000e3;o geral e da popula&#x000e7;&#x000e3;o com DRC, recomenda-se que a PA alvo seja &#x0003c; 140/90 mmHg em pacientes com DP, em concord&#x000e2;ncia com a <italic>International Society of Peritoneal Dialysis</italic> (ISPD) e outros autores (classe IIA/N&#x000ed;vel B)<sup>
<xref rid="B120" ref-type="bibr">120</xref>,<xref rid="B182" ref-type="bibr">182</xref>,<xref rid="B183" ref-type="bibr">183</xref>
</sup>.</p><p>Na aus&#x000ea;ncia de evid&#x000ea;ncias de ensaios cl&#x000ed;nicos randomizados e controlados, de longo prazo, desenhados com a finalidade espec&#x000ed;fica de definir os alvos ideais de PA em HD e DP, recomenda-se o desenvolvimento de pesquisas cl&#x000ed;nicas comparando diferentes limiares de medida da PA em domic&#x000ed;lio em rela&#x000e7;&#x000e3;o a desfechos cl&#x000ed;nicos e mortalidade<sup>
<xref rid="B184" ref-type="bibr">184</xref>,<xref rid="B185" ref-type="bibr">185</xref>,<xref rid="B186" ref-type="bibr">186</xref>,<xref rid="B187" ref-type="bibr">187</xref>,<xref rid="B188" ref-type="bibr">188</xref>
</sup>.</p><p>No <xref rid="T18" ref-type="table">Quadro 7</xref>, podemos observar as recomenda&#x000e7;&#x000f5;es dos principais <italic>Guidelines</italic> que citam metas a serem atingidas em pacientes em HD.</p><table-wrap position="float" id="T18"><label>Quadro 7</label><caption><title>Metas press&#x000f3;ricas na hipertens&#x000e3;o arterial de pacientes em di&#x000e1;lise, segundo os principais <italic>Guidelines</italic>
</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">
<italic>Guidelines</italic>
</th><th align="left" valign="top" rowspan="1" colspan="1">Meta de press&#x000e3;o arterial (mmHg)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">KDOQI 2005<sup>
<xref rid="B179" ref-type="bibr">179</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Pr&#x000e9;-di&#x000e1;lise: &#x0003c; 140/90<break/>P&#x000f3;s-di&#x000e1;lise: &#x0003c; 130/80</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KDOQI 2015 (<italic>update</italic>)<sup>
<xref rid="B186" ref-type="bibr">186</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">N&#x000e3;o cita e alega falta de dados</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EURECA-m (ERA &#x02013; EDTA) 2017175</td><td align="left" valign="top" rowspan="1" colspan="1">N&#x000e3;o cita e alega falta de dados</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic>Japanese Society for Dialysis Therapy</italic> 2012<sup>
<xref rid="B187" ref-type="bibr">187</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Pr&#x000e9;-di&#x000e1;lise: &#x0003c; 140/90</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diretrizes Brasileiras de HA 2020<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Pr&#x000e9;-di&#x000e1;lise: &#x02264; 140/90<break/>P&#x000f3;s-di&#x000e1;lise: &#x02264; 130/80</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2020 <italic>International Society of Hypertension Global Hypertension Practice Guidelines</italic>
<sup>
<xref rid="B188" ref-type="bibr">188</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">N&#x000e3;o cita</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic>International Society of Peritoneal Dialysis</italic> (ISPD) 2015<sup>
<xref rid="B120" ref-type="bibr">120</xref>
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">Di&#x000e1;lise peritoneal: &#x0003c; 140/90 mmHg</td></tr></tbody></table></table-wrap><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se que as metas press&#x000f3;ricas devem ser pr&#x000e9;-HD: &#x02264; 140/90 mmHg e p&#x000f3;s-HD &#x02264; 130/80 mmHg (Classe IIA/N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se que a meta de PA em DP seja &#x0003c; 140/90 mmHg (Classe IIA/N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se a prescri&#x000e7;&#x000e3;o de metas individualizadas para pacientes em HD e DP, de acordo com idade, grau de fragilidade, toler&#x000e2;ncia, presen&#x000e7;a de doen&#x000e7;a CV grave e comorbidades (Classe IIA/N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se a realiza&#x000e7;&#x000e3;o de ensaios cl&#x000ed;nicos randomizados, controlados e comparativos de metas press&#x000f3;ricas para uma indica&#x000e7;&#x000e3;o baseada em evid&#x000ea;ncias de alta qualidade.</p></list-item></list></sec><sec><title>Tratamento n&#x000e3;o Medicamentoso da ha na DP e HD</title><sec><title>A Import&#x000e2;ncia de Conhecer, Atingir e Manter o Peso Seco</title><p>O PS representa aquele no qual n&#x000e3;o se verificam sinais ou sintomas de hipervolemia ou hipo-hidrata&#x000e7;&#x000e3;o. Para cada sess&#x000e3;o de HD, &#x000e9; necess&#x000e1;rio definir um peso-alvo (eventualmente superior ao PS), levando-se em considera&#x000e7;&#x000e3;o o <italic>status</italic> vol&#x000ea;mico, o GPID e a taxa de UF tolerada, de forma a se evitar o peso-alvo demasiadamente baixo (porque pode levar &#x000e0; hipotens&#x000e3;o e acelerar a perda da FRR)<sup>
<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B105" ref-type="bibr">105</xref>
</sup>, ou inapropriadamente elevado incorrendo em HA e hipervolemia<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup>. A hipervolemia cr&#x000f4;nica pode causar HA e aumento do risco de interna&#x000e7;&#x000e3;o<sup>
<xref rid="B189" ref-type="bibr">189</xref>
</sup> e de morte<sup>
<xref rid="B163" ref-type="bibr">163</xref>,<xref rid="B190" ref-type="bibr">190</xref>
</sup> (<xref rid="F12" ref-type="fig">Figura 5</xref>). Prioriza-se ent&#x000e3;o a meta de atingir o PS ao longo das sess&#x000f5;es de HD, evitando assim a hipervolemia cr&#x000f4;nica, mesmo com maior risco de hipotens&#x000e3;o intradial&#x000ed;tica<sup>
<xref rid="B105" ref-type="bibr">105</xref>
</sup>.</p><fig position="float" id="F12"><label>Figura 5</label><caption><title>Consequ&#x000ea;ncias da manuten&#x000e7;&#x000e3;o da hipervolemia.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf12" position="float"/><attrib>Abreviatura &#x02013; UF: ultrafiltra&#x000e7;&#x000e3;o.</attrib></fig><p>A aplica&#x000e7;&#x000e3;o regular de um protocolo de avalia&#x000e7;&#x000e3;o do PS, preferencialmente com m&#x000fa;ltiplos instrumentos<sup>
<xref rid="B105" ref-type="bibr">105</xref>
</sup>, foi associada &#x000e0; menor mortalidade, e o uso da medida da PA ortost&#x000e1;tica foi associado a menor risco de hospitaliza&#x000e7;&#x000e3;o e eventos CV<sup>
<xref rid="B191" ref-type="bibr">191</xref>
</sup>. Ainda assim, a confiabilidade dos sinais cl&#x000ed;nicos na estimativa acurada da volemia tem sido questionada<sup>
<xref rid="B192" ref-type="bibr">192</xref>
</sup>.</p><p>Em DP, para atingir o PS e o controle da PA, prioriza-se a otimiza&#x000e7;&#x000e3;o do d&#x000e9;bito urin&#x000e1;rio com uso de diur&#x000e9;ticos (em pacientes com FRR)<sup>
<xref rid="B193" ref-type="bibr">193</xref>
</sup> e da UF peritoneal, com o ajuste apropriado da carga de glicose considerando a prescri&#x000e7;&#x000e3;o de DP e a velocidade de transporte peritoneal<sup>
<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B9" ref-type="bibr">9</xref>
</sup>. Recomenda-se para esses pacientes a ado&#x000e7;&#x000e3;o da preserva&#x000e7;&#x000e3;o da FRR, do manejo diet&#x000e9;tico e de esfor&#x000e7;os para limitar a les&#x000e3;o peritoneal.</p><p>As barreiras para se atingir o PS s&#x000e3;o apresentadas na <xref rid="F13" ref-type="fig">Figura 6</xref>.</p><fig position="float" id="F13"><label>Figura 6</label><caption><title>Barreiras usuais de n&#x000e3;o atingimento do peso seco em pacientes em hemodi&#x000e1;lise.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf13" position="float"/><attrib>Abreviaturas &#x02013; UF: ultrafiltra&#x000e7;&#x000e3;o; HA: hipertens&#x000e3;o arterial.</attrib></fig><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Para controle da HA, recomenda-se a estrat&#x000e9;gia de ajustar gradualmente a UF at&#x000e9; sintomas m&#x000ed;nimos de hipovolemia, a fim de definir e atingir o PS (Classe I/N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se que a avalia&#x000e7;&#x000e3;o do PS seja feita regularmente e com m&#x000fa;ltiplos instrumentos, tais como avalia&#x000e7;&#x000e3;o cl&#x000ed;nica, ultrassonografia e bioimped&#x000e2;ncia (Classe I/N&#x000ed;vel B).</p></list-item><list-item><p>Em DP, recomenda-se estrat&#x000e9;gias para a preserva&#x000e7;&#x000e3;o da FRR e da integridade da membrana peritoneal (Classe I/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Mudan&#x000e7;as nos Par&#x000e2;metros Dial&#x000ed;ticos na DP e HD</title><p>H&#x000e1; fatores relacionados aos par&#x000e2;metros dial&#x000ed;ticos que podem interferir na PA, tanto em HD quanto em DP (<xref rid="F14" ref-type="fig">Figura 7</xref>).</p><fig position="float" id="F14"><label>Figura 7</label><caption><title>Fatores relacionados &#x000e0; modalidade de di&#x000e1;lise e ao paciente que podem interferir no controle da press&#x000e3;o arterial.</title></caption><graphic xlink:href="2175-8239-jbn-47-1-e20240033-gf14" position="float"/><attrib>Abreviaturas &#x02013; HD: hemodi&#x000e1;lise; HDF: hemodiafiltra&#x000e7;&#x000e3;o on-line; UF: ultrafiltra&#x000e7;&#x000e3;o.</attrib></fig><p>Os estudos que analisaram a concentra&#x000e7;&#x000e3;o de s&#x000f3;dio na solu&#x000e7;&#x000e3;o de di&#x000e1;lise de HD n&#x000e3;o s&#x000e3;o conclusivos quanto ao seu impacto na PA e j&#x000e1; foram detalhados no Cap&#x000ed;tulo 2, item 2.2.2 (Par&#x000e2;metros que interferem na PA)<sup>
<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B29" ref-type="bibr">29</xref>
</sup>. N&#x000e3;o h&#x000e1; evid&#x000ea;ncias que comprovem a redu&#x000e7;&#x000e3;o da mortalidade na individualiza&#x000e7;&#x000e3;o do s&#x000f3;dio<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup>.</p><p>O benef&#x000ed;cio do perfil de s&#x000f3;dio empregado na expectativa de evitar hipotens&#x000e3;o intradial&#x000ed;tica e diminuir o aporte desse elemento &#x000e9; controverso<sup>
<xref rid="B103" ref-type="bibr">103</xref>,<xref rid="B191" ref-type="bibr">191</xref>,<xref rid="B194" ref-type="bibr">194</xref>
</sup>.</p><p>Em um estudo, o uso desse perfil associou-se a balan&#x000e7;o positivo de s&#x000f3;dio, determinando maiores taxas de GPID, eleva&#x000e7;&#x000e3;o da PA, eventos CV e morte<sup>
<xref rid="B191" ref-type="bibr">191</xref>
</sup>. Outro estudo mostrou que o perfil linear n&#x000e3;o reduziu hipotens&#x000e3;o, embora o perfil &#x0201c;em etapas&#x0201d; (<italic>stepwise</italic>) tenha se mostrado eficaz<sup>
<xref rid="B194" ref-type="bibr">194</xref>
</sup>.</p><p>Os m&#x000e9;todos de ajuste de UF incluem o emprego de perfil, UF isolada seguida de HD (di&#x000e1;lise sequencial) ou dispositivos de <italic>biofeedback</italic>
<sup>
<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B195" ref-type="bibr">195</xref>
</sup>. Um estudo avaliando perfil linear de UF n&#x000e3;o mostrou menor risco de hipotens&#x000e3;o, nem diferen&#x000e7;as nos n&#x000ed;veis de troponina e fun&#x000e7;&#x000e3;o do VE<sup>
<xref rid="B196" ref-type="bibr">196</xref>
</sup>. Os dispositivos de <italic>biofeedback</italic> de UF podem diminuir hipotens&#x000e3;o intradial&#x000ed;tica<sup>
<xref rid="B195" ref-type="bibr">195</xref>
</sup>.</p><p>A redu&#x000e7;&#x000e3;o da temperatura da solu&#x000e7;&#x000e3;o de di&#x000e1;lise (em diferentes defini&#x000e7;&#x000f5;es: diminui&#x000e7;&#x000e3;o em rela&#x000e7;&#x000e3;o &#x000e0; temperatura corporal, fixa em 35,5&#x000ba;C ou 36&#x000ba;C, ou ajustada em sistema de <italic>biofeedback</italic>) associa-se &#x000e0; diminui&#x000e7;&#x000e3;o da hipotens&#x000e3;o intradial&#x000ed;tica<sup>
<xref rid="B197" ref-type="bibr">197</xref>
</sup> e da mortalidade CV<sup>
<xref rid="B191" ref-type="bibr">191</xref>
</sup>, al&#x000e9;m de ser bem tolerada<sup>
<xref rid="B197" ref-type="bibr">197</xref>
</sup>. Estudo em andamento (MY TEMP, NCT02628366) avaliar&#x000e1; o resfriamento da solu&#x000e7;&#x000e3;o de di&#x000e1;lise em rela&#x000e7;&#x000e3;o a desfechos de interna&#x000e7;&#x000e3;o e &#x000f3;bito por eventos CV.</p><p>Em DP, as manobras sugeridas para controle da HA incluem<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup>: otimiza&#x000e7;&#x000e3;o do d&#x000e9;bito urin&#x000e1;rio com uso de diur&#x000e9;ticos (em pacientes com FRR)<sup>
<xref rid="B193" ref-type="bibr">193</xref>
</sup>; reduzir o tempo de perman&#x000ea;ncia intraperitoneal (de solu&#x000e7;&#x000f5;es &#x000e0; base de glicose) em pacientes alto transportadores; solu&#x000e7;&#x000f5;es &#x000e0; base de glicose de maior tonicidade (menos prefer&#x000ed;vel, pelo impacto peritoneal e sist&#x000ea;mico); solu&#x000e7;&#x000e3;o de icodextrina (aumento da UF sem maior carga de glicose)<sup>
<xref rid="B198" ref-type="bibr">198</xref>
</sup>, dialisato de baixo s&#x000f3;dio, pois reduz HA, sem altera&#x000e7;&#x000e3;o de adequa&#x000e7;&#x000e3;o)<sup>
<xref rid="B193" ref-type="bibr">193</xref>
</sup> e solu&#x000e7;&#x000f5;es de maior biocompatibilidade, pH neutro ou menor conte&#x000fa;do de produtos finais de degrada&#x000e7;&#x000e3;o da glicose para preserva&#x000e7;&#x000e3;o do perit&#x000f4;nio e da FRR<sup>
<xref rid="B198" ref-type="bibr">198</xref>&#x02013;<xref rid="B200" ref-type="bibr">200</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se cautela no ajuste da concentra&#x000e7;&#x000e3;o de s&#x000f3;dio na solu&#x000e7;&#x000e3;o de di&#x000e1;lise com finalidade de controle press&#x000f3;rico e vol&#x000ea;mico (Classe I/N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se cautela no uso do perfil de s&#x000f3;dio para evitar hipotens&#x000e3;o intradial&#x000ed;tica devido ao risco de balan&#x000e7;o positivo e seus malef&#x000ed;cios (Classe I/N&#x000ed;vel B).</p></list-item><list-item><p>N&#x000e3;o se recomenda que o uso de perfil linear de UF seja utilizado para prevenir epis&#x000f3;dios de hipotens&#x000e3;o intradial&#x000ed;tica (Classe I/N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se o resfriamento da solu&#x000e7;&#x000e3;o de di&#x000e1;lise para prevenir hipotens&#x000e3;o intradial&#x000ed;tica (Classe I/N&#x000ed;vel A).</p></list-item><list-item><p>Para controle da HA em DP, recomenda-se a preserva&#x000e7;&#x000e3;o da FRR e da membrana peritoneal (Classe I/ N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Mudan&#x000e7;as na Modalidade de Hemodi&#x000e1;lise (HDF, HD Di&#x000e1;ria)</title><p>As alternativas &#x000e0; HD convencional incluem regimes intensivos (com aumento da frequ&#x000ea;ncia e/ou da dura&#x000e7;&#x000e3;o, como na HD curta di&#x000e1;ria e na HD longa diurna ou noturna), e o emprego de convec&#x000e7;&#x000e3;o (HDF), podendo ser realizados em centros de HD ou em domic&#x000ed;lio. HD di&#x000e1;ria &#x000e9; compreendida na literatura como qualquer esquema de 5 a 7 vezes por semana<sup>
<xref rid="B201" ref-type="bibr">201</xref>,<xref rid="B202" ref-type="bibr">202</xref>,<xref rid="B203" ref-type="bibr">203</xref>,<xref rid="B204" ref-type="bibr">204</xref>,<xref rid="B205" ref-type="bibr">205</xref>
</sup>.</p><p>O emprego de HD di&#x000e1;ria permite reduzir: a PA<sup>
<xref rid="B201" ref-type="bibr">201</xref>,<xref rid="B202" ref-type="bibr">202</xref>,<xref rid="B203" ref-type="bibr">203</xref>
</sup>, a quantidade de medicamentos anti-hipertensivos<sup>
<xref rid="B203" ref-type="bibr">203</xref>
</sup>, a HVE<sup>
<xref rid="B202" ref-type="bibr">202</xref>
</sup>, os fatores inibidores teciduais da metaloproteinase<sup>
<xref rid="B202" ref-type="bibr">202</xref>
</sup> e o f&#x000f3;sforo, que, por sua vez, se associa &#x000e0; redu&#x000e7;&#x000e3;o do FGF23<sup>
<xref rid="B202" ref-type="bibr">202</xref>
</sup>. Estudo multic&#x000ea;ntrico de HD curta di&#x000e1;ria em ambiente domiciliar confirmou redu&#x000e7;&#x000e3;o do n&#x000fa;mero de anti-hipertensivos<sup>
<xref rid="B204" ref-type="bibr">204</xref>
</sup>. A HD intensiva tamb&#x000e9;m pode resultar na redu&#x000e7;&#x000e3;o de hospitaliza&#x000e7;&#x000f5;es (em rela&#x000e7;&#x000e3;o &#x000e0; HD convencional) e da mortalidade (em compara&#x000e7;&#x000e3;o com HD convencional ou DP)<sup>
<xref rid="B205" ref-type="bibr">205</xref>
</sup>.</p><p>Alguns estudos mostraram que HD noturna reduziu a PAS<sup>
<xref rid="B202" ref-type="bibr">202</xref>,<xref rid="B206" ref-type="bibr">206</xref>,<xref rid="B207" ref-type="bibr">207</xref>
</sup>, o n&#x000fa;mero de anti-hipertensivos<sup>
<xref rid="B207" ref-type="bibr">207</xref>
</sup> e a HVE<sup>
<xref rid="B202" ref-type="bibr">202</xref>,<xref rid="B207" ref-type="bibr">207</xref>
</sup>, al&#x000e9;m de proporcionar melhora da anemia<sup>
<xref rid="B206" ref-type="bibr">206</xref>
</sup> e da hiperfosfatemia<sup>
<xref rid="B202" ref-type="bibr">202</xref>,<xref rid="B206" ref-type="bibr">206</xref>,<xref rid="B207" ref-type="bibr">207</xref>
</sup>.</p><p>A hemodiafiltra&#x000e7;&#x000e3;o on-line de alto volume convectivo (HDF) proporciona menor risco de morte por todas as causas, em contraste com a HD de alto fluxo<sup>
<xref rid="B208" ref-type="bibr">208</xref>
</sup>. Estudo avaliando par&#x000e2;metros peridial&#x000ed;ticos da PA n&#x000e3;o mostrou benef&#x000ed;cio da HDF em rela&#x000e7;&#x000e3;o a HD convencional<sup>
<xref rid="B209" ref-type="bibr">209</xref>
</sup>. Em outro estudo, a HDF reduziu a mortalidade CV e epis&#x000f3;dios de hipotens&#x000e3;o<sup>
<xref rid="B210" ref-type="bibr">210</xref>
</sup>. Para reduzir a hipotens&#x000e3;o intradial&#x000ed;tica, o emprego intermitente de infus&#x000f5;es de dialisato puro trouxe benef&#x000ed;cios para idosos e aqueles com alto GPID<sup>
<xref rid="B211" ref-type="bibr">211</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se, sempre que dispon&#x000ed;vel, utilizar regimes intensivos de HD (di&#x000e1;rio e/ou longo) com benef&#x000ed;cios na redu&#x000e7;&#x000e3;o da PA (Classe I/N&#x000ed;vel A), da medica&#x000e7;&#x000e3;o anti-hipertensiva (Classe I/N&#x000ed;vel A) e da massa ventricular esquerda (Classe I, N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Recomenda&#x000e7;&#x000f5;es Diet&#x000e9;ticas e de Ingest&#x000e3;o H&#x000ed;drica Para Pessoas com HA em DP e HD, Especialmente Para Prevenir o Ganho de Peso Interdial&#x000ed;tico (GPID)</title><p>Recomenda-se que a ingest&#x000e3;o de s&#x000f3;dio na dieta para a popula&#x000e7;&#x000e3;o hipertensa (n&#x000e3;o dial&#x000ed;tica) seja de at&#x000e9; 2 g/dia, correspondente a 5,0 g/dia de sal<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup>. Em indiv&#x000ed;duos em di&#x000e1;lise, tipicamente sens&#x000ed;veis ao sal, h&#x000e1; maior impacto da restri&#x000e7;&#x000e3;o de sal sobre a PA, sugerindo-se uma ingest&#x000e3;o diet&#x000e9;tica de at&#x000e9; 1,5 g de s&#x000f3;dio ou 3,6 g de sal<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup>. Em compara&#x000e7;&#x000e3;o com o tratamento anti-hipertensivo, a restri&#x000e7;&#x000e3;o diet&#x000e9;tica de s&#x000f3;dio associada a uma UF mais intensiva, resultou em diminui&#x000e7;&#x000e3;o do GPID, da HVE, da carga anti-hipertensiva e de epis&#x000f3;dios de hipotens&#x000e3;o intradial&#x000ed;tica<sup>
<xref rid="B212" ref-type="bibr">212</xref>
</sup>.</p><p>Uma meta-an&#x000e1;lise identificou que a redu&#x000e7;&#x000e3;o de pelo menos 1 g de sal associa-se &#x000e0; redu&#x000e7;&#x000e3;o da PA<sup>
<xref rid="B213" ref-type="bibr">213</xref>
</sup>. Por outro lado, a ingest&#x000e3;o elevada de s&#x000f3;dio relacionou-se a risco aumentado de hipervolemia e de morte, mas sem associa&#x000e7;&#x000e3;o com a PA<sup>
<xref rid="B214" ref-type="bibr">214</xref>
</sup>.</p><p>Adicionalmente, a hiperglicemia pode aumentar a sede e a ingest&#x000e3;o de sal, levando a um aumento do GPID e da PA<sup>
<xref rid="B215" ref-type="bibr">215</xref>
</sup>. Em pacientes em di&#x000e1;lise, a dieta mediterr&#x000e2;nea parece melhorar o remodelamento mioc&#x000e1;rdico<sup>
<xref rid="B216" ref-type="bibr">216</xref>
</sup>, mas n&#x000e3;o foi capaz de reduzir a mortalidade, assim como dietas DASH (<italic>Dietary Approaches to Stop Hypertension</italic>) e vegetariana<sup>
<xref rid="B217" ref-type="bibr">217</xref>
</sup>. Por sua vez, dietas ricas em polifen&#x000f3;is melhoraram a PA diast&#x000f3;lica na popula&#x000e7;&#x000e3;o dial&#x000ed;tica<sup>
<xref rid="B218" ref-type="bibr">218</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se a restri&#x000e7;&#x000e3;o de s&#x000f3;dio na dieta de 1,5 a 2,0 g/dia para paciente dial&#x000ed;tico, para redu&#x000e7;&#x000e3;o da PA e GPID (Classe I/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Exerc&#x000ed;cios F&#x000ed;sicos Para Hipertensos em DP e HD</title><p>Estudos que verificaram o efeito do exerc&#x000ed;cio f&#x000ed;sico sobre a PA em pacientes dial&#x000ed;ticos produziram resultados divergentes. Uma meta-an&#x000e1;lise n&#x000e3;o identificou efeito do treinamento f&#x000ed;sico sobre a PA<sup>
<xref rid="B219" ref-type="bibr">219</xref>
</sup>, mas em outra meta-an&#x000e1;lise de 78 estudos randomizados com 3326 participantes, foi poss&#x000ed;vel evidenciar maior redu&#x000e7;&#x000e3;o da PAD com exerc&#x000ed;cios aer&#x000f3;bicos combinados com exerc&#x000ed;cios resistivos, que envolvem carga tolerada pelo paciente nos MMII e MS sem FAV.<sup>
<xref rid="B220" ref-type="bibr">220</xref>
</sup> Por outro lado, s&#x000e3;o documentadas melhoras em vari&#x000e1;veis associadas a desfechos CV, les&#x000f5;es em &#x000f3;rg&#x000e3;os-alvo, qualidade de vida e fun&#x000e7;&#x000e3;o cognitiva<sup>
<xref rid="B219" ref-type="bibr">219</xref>,<xref rid="B220" ref-type="bibr">220</xref>
</sup>. Para os tipos de exerc&#x000ed;cio f&#x000ed;sico, h&#x000e1; evid&#x000ea;ncias de benef&#x000ed;cios tanto com exerc&#x000ed;cios aer&#x000f3;bicos quanto resistivos. Quanto ao local, exerc&#x000ed;cios intradial&#x000ed;ticos ou domiciliares podem ser empregados<sup>
<xref rid="B221" ref-type="bibr">221</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se o est&#x000ed;mulo &#x000e0; atividade aer&#x000f3;bica com dura&#x000e7;&#x000e3;o m&#x000ed;nima de 30 minutos, pelo menos 5 vezes na semana, para pacientes tanto em DP quanto em HD (Classe IIA/ N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se que exerc&#x000ed;cios resistivos supervisionados tamb&#x000e9;m devem ser prescritos (Classe IIA/N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se que seja realizada atividade f&#x000ed;sica, intradial&#x000ed;tica ou no intervalo interdial&#x000ed;tico, fora do ambiente de di&#x000e1;lise (Classe IIA/N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se que, sempre que poss&#x000ed;vel, os exerc&#x000ed;cios f&#x000ed;sicos sejam supervisionados por educadores f&#x000ed;sicos e/ou fisioterapeutas nas unidades de di&#x000e1;lise (Classe IIA/N&#x000ed;vel C).</p></list-item></list></sec><sec><title>Outras Mudan&#x000e7;as no Estilo de Vida (Espiritualidade, Controle de Estresse etc.)</title><p>Espiritualidade e religiosidade s&#x000e3;o instrumentos potencialmente importantes para o paciente dial&#x000ed;tico, relacionando-se positivamente com a intera&#x000e7;&#x000e3;o m&#x000e9;dico-paciente, qualidade e esperan&#x000e7;a de vida, enfrentamento da doen&#x000e7;a, e do tratamento e suas consequ&#x000ea;ncias, sendo por isso objetos de considera&#x000e7;&#x000e3;o pelos profissionais<sup>
<xref rid="B222" ref-type="bibr">222</xref>
</sup>.</p><p>A espiritualidade pode ser entendida como a busca de significados e prop&#x000f3;sitos de vida, e como a transcend&#x000ea;ncia de si, que &#x000e9; uma viv&#x000ea;ncia que pode desenvolver-se por meio da religiosidade e/ou cren&#x000e7;a em Deus, fam&#x000ed;lia, naturalismo, racionalismo, humanismo e artes, por exemplo<sup>
<xref rid="B222" ref-type="bibr">222</xref>
</sup>. A religiosidade, por sua vez, implica a rela&#x000e7;&#x000e3;o do ser humano com um ser transcendente<sup>
<xref rid="B222" ref-type="bibr">222</xref>
</sup>.</p><p>Esses conceitos correspondem a uma constru&#x000e7;&#x000e3;o psicol&#x000f3;gica na rela&#x000e7;&#x000e3;o com doen&#x000e7;as cr&#x000f4;nicas, convertendo uma situa&#x000e7;&#x000e3;o pessoalmente dram&#x000e1;tica em algo &#x000fa;til<sup>
<xref rid="B223" ref-type="bibr">223</xref>
</sup>. As fortes cren&#x000e7;as religiosas em pessoas em di&#x000e1;lise foram correlacionadas com percep&#x000e7;&#x000f5;es atenuadas do fardo da doen&#x000e7;a e maior sensa&#x000e7;&#x000e3;o de apoio social<sup>
<xref rid="B223" ref-type="bibr">223</xref>,<xref rid="B224" ref-type="bibr">224</xref>
</sup>.</p><p>A ades&#x000e3;o &#x000e0; di&#x000e1;lise &#x000e9; afetada pela f&#x000e9; religiosa, idade e educa&#x000e7;&#x000e3;o: (a) mu&#x000e7;ulmanos s&#x000e3;o aderentes ao desejo de viver, e menos frequentemente interrompem a di&#x000e1;lise<sup>
<xref rid="B215" ref-type="bibr">215</xref>,<xref rid="B223" ref-type="bibr">223</xref>
</sup>; (b) crist&#x000e3;os com religiosidade extr&#x000ed;nseca (comportamento religioso) e intr&#x000ed;nseca (fortes cren&#x000e7;as e compromissos) manifestam maior ades&#x000e3;o<sup>
<xref rid="B223" ref-type="bibr">223</xref>
</sup>; (c) idade mais avan&#x000e7;ada e maior tempo de di&#x000e1;lise correlacionaram-se com maior ades&#x000e3;o<sup>
<xref rid="B223" ref-type="bibr">223</xref>,<xref rid="B225" ref-type="bibr">225</xref>
</sup>; (d) aconselhamento e educa&#x000e7;&#x000e3;o do paciente fornecem melhores resultados, maior ades&#x000e3;o e potencial redu&#x000e7;&#x000e3;o nos custos relacionados &#x000e0; sa&#x000fa;de<sup>
<xref rid="B223" ref-type="bibr">223</xref>
</sup>.</p><p>Em alguns centros de di&#x000e1;lise, assistentes sociais e psic&#x000f3;logos t&#x000ea;m apoiado e estimulado atividades religiosas n&#x000e3;o formais (literatura religiosa, ora&#x000e7;&#x000e3;o, grupos de discuss&#x000e3;o) como m&#x000e9;todos positivos de enfrentamento<sup>
<xref rid="B223" ref-type="bibr">223</xref>,<xref rid="B226" ref-type="bibr">226</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se o respeito e o est&#x000ed;mulo &#x000e0; religiosidade e &#x000e0; espiritualidade como medida de melhor ades&#x000e3;o e enfrentamento da DRC dial&#x000ed;tica, envolvendo a equipe multiprofissional (Classe I/N&#x000ed;vel B).</p></list-item></list></sec></sec><sec><title>Tratamento Medicamentoso da ha na DP e HD</title><p>Existe aparente paradoxo em rela&#x000e7;&#x000e3;o ao uso de medicamentos anti-hipertensivos e o controle press&#x000f3;rico nos pacientes em di&#x000e1;lise, pois, quanto maior o n&#x000fa;mero de medicamentos, maior a chance de a PA n&#x000e3;o estar controlada, sugerindo que o uso combinado dos diferentes anti-hipertensivos dificulta atingir a meta do peso seco<sup>
<xref rid="B227" ref-type="bibr">227</xref>
</sup>. Os anti-hipertensivos devem ser utilizados, se necess&#x000e1;rio, ap&#x000f3;s controle vol&#x000ea;mico, sendo prefer&#x000ed;vel os medicamentos avaliados em ECR, embora estes sejam pouco dispon&#x000ed;veis e com n&#x000fa;mero limitado de participantes, dificultando a generaliza&#x000e7;&#x000e3;o de diretrizes para a utiliza&#x000e7;&#x000e3;o de anti-hipertensivos na DRC dial&#x000ed;tica. O frequente comprometimento CV e a presen&#x000e7;a de comorbidades nos pacientes em di&#x000e1;lise torna a combina&#x000e7;&#x000e3;o de fatores t&#x000e3;o diversa e peculiar que algumas diretrizes recomendam uma abordagem individualizada em rela&#x000e7;&#x000e3;o &#x000e0;s classes de medicamentos a serem utilizados<sup>
<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B48" ref-type="bibr">48</xref>
</sup>.</p><p>O uso de anti-hipertensivos em pacientes em di&#x000e1;lise traz benef&#x000ed;cios, reduzindo a morbidade e a mortalidade geral e CV<sup>
<xref rid="B228" ref-type="bibr">228</xref>,<xref rid="B229" ref-type="bibr">229</xref>
</sup>. Todas as classes de anti-hipertensivos podem ser utilizadas no controle da PA em pacientes em di&#x000e1;lise, desde que sejam considerados riscos e benef&#x000ed;cios<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup>.</p><sec><title>Diur&#x000e9;ticos</title><p>O uso desses medicamentos n&#x000e3;o tem respaldo em pacientes em HD ou em DP, sem diurese residual (&#x0003c; 100 mL/dia). Nos pacientes em DP, o uso de diur&#x000e9;ticos pode melhorar o <italic>status</italic> vol&#x000ea;mico e minimizar a necessidade de solu&#x000e7;&#x000f5;es contendo maior concentra&#x000e7;&#x000e3;o de glicose, embora os <italic>Guidelines</italic> da <italic>International Society of Peritoneal Dialysis</italic> n&#x000e3;o recomendem seu uso<sup>
<xref rid="B120" ref-type="bibr">120</xref>
</sup>. Em pacientes em HD, os diur&#x000e9;ticos podem auxiliar na redu&#x000e7;&#x000e3;o do GPID, resultando em diminui&#x000e7;&#x000e3;o das taxas de UF e menos epis&#x000f3;dios de hipotens&#x000e3;o intradial&#x000ed;tica.<sup>
<xref rid="B230" ref-type="bibr">230</xref>,<xref rid="B231" ref-type="bibr">231</xref>
</sup>
</p><p>Em um estudo coorte prospectivo com 5219 pacientes que continuaram utilizando diur&#x000e9;tico de al&#x000e7;a ap&#x000f3;s o in&#x000ed;cio de HD comparado a 6078 controles que n&#x000e3;o o fizeram, verificou-se menores taxas de hospitaliza&#x000e7;&#x000e3;o, hipotens&#x000e3;o intradial&#x000ed;tica e GPID, sem diferen&#x000e7;a significante na PA ou na taxa de mortalidade no primeiro ano de di&#x000e1;lise. Nos EUA, o diur&#x000e9;tico mais utilizado em pacientes em HD &#x000e9; a furosemida, em doses de 20 a &#x02265; 320 mg/dia<sup>
<xref rid="B232" ref-type="bibr">232</xref>
</sup>.</p><p>Um estudo prospectivo observacional acompanhou 16420 pacientes em HD em tr&#x000ea;s continentes e observou que o uso de diur&#x000e9;ticos (&#x0003e; 90% diur&#x000e9;ticos de al&#x000e7;a) nos primeiros 3 meses de HD foi maior no Jap&#x000e3;o (47,8%) e na Europa (45,1%) em compara&#x000e7;&#x000e3;o aos Estados Unidos (2,4%), caindo progressivamente ao longo desse per&#x000ed;odo<sup>
<xref rid="B233" ref-type="bibr">233</xref>
</sup>. Nesse estudo, usar diur&#x000e9;ticos associou-se a menor GPID e menor chance de hipercalemia. Pacientes com FRR em terapia diur&#x000e9;tica tiveram quase o dobro de chances de manter a diurese residual ap&#x000f3;s um ano de acompanhamento comparado aos pacientes que n&#x000e3;o utilizavam diur&#x000e9;ticos. Os pacientes que receberam diur&#x000e9;ticos tiveram menor risco de mortalidade geral (&#x02013;7%; p = 0,12) e CV (&#x02013;14%; p = 0,03)<sup>
<xref rid="B233" ref-type="bibr">233</xref>
</sup>.</p><p>N&#x000e3;o foram encontrados estudos que avaliaram o uso de diur&#x000e9;ticos tiaz&#x000ed;dicos ou tiaz&#x000ed;dicos-s&#x000ed;mile como monoterapia em pacientes em DP ou HD. Um estudo com tripla terapia diur&#x000e9;tica em doses altas (furosemida 1000 mg/dia, hidroclorotiazida 100 mg/dia e espironolactona 50 mg/dia) em 51 pacientes em DP mostrou aumento da diurese e melhor controle de volume em compara&#x000e7;&#x000e3;o com a furosemida isoladamente<sup>
<xref rid="B234" ref-type="bibr">234</xref>
</sup>.</p><p>Meta-an&#x000e1;lise que incluiu 28226 pacientes em HD evidenciou benef&#x000ed;cio potencial em reduzir hipotens&#x000e3;o intradial&#x000ed;tica, mortalidade CV e por todas as causas<sup>
<xref rid="B231" ref-type="bibr">231</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se o uso de diur&#x000e9;ticos de al&#x000e7;a em pacientes em HD e DP, enquanto houver diurese residual (Classe I/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Inibidores do Sistema Renina Angiotensina-Aldosterona (SRAA)</title><p>Os inibidores do SRAA, IECA e BRA s&#x000e3;o os mais utilizados em DRC em seus diferentes est&#x000e1;gios. Meta-an&#x000e1;lise de ensaios cl&#x000ed;nicos randomizados que avaliou o efeito anti-hipertensivo das diferentes classes de medicamentos em compara&#x000e7;&#x000e3;o &#x000e0; placebo ou entre si observou que os IECA/BRA reduzem a PA de forma modesta quando comparados a placebo (&#x02013;4,3 mmHg na PAS), como esperado para o estado de hipervolemia pr&#x000f3;prio da DRC em fase dial&#x000ed;tica<sup>
<xref rid="B235" ref-type="bibr">235</xref>
</sup>. Quando comparados &#x000e0; placebo, os antagonistas dos receptores mineralocorticoides (ARM) s&#x000e3;o os mais potentes em reduzir a PA (&#x02013;10,8 mmHg), seguidos pelos BB (&#x02013;8,7 mmHg) e BCC (&#x02013;4,6 mmHg)<sup>
<xref rid="B235" ref-type="bibr">235</xref>
</sup>.</p><p>Em pacientes em di&#x000e1;lise, o uso de IECA ou BRA est&#x000e1; associado a redu&#x000e7;&#x000e3;o do &#x000ed;ndice de massa ventricular esquerda, de eventos m&#x000f3;rbidos, particularmente IC, e de mortalidade CV<sup>
<xref rid="B236" ref-type="bibr">236</xref>,<xref rid="B237" ref-type="bibr">237</xref>,<xref rid="B238" ref-type="bibr">238</xref>
</sup>. Al&#x000e9;m disso, h&#x000e1; evid&#x000ea;ncias de que a prote&#x000e7;&#x000e3;o renal dessas classes de medicamentos continua ocorrendo nessa fase da doen&#x000e7;a, pois seu uso est&#x000e1; associado &#x000e0; manuten&#x000e7;&#x000e3;o da fun&#x000e7;&#x000e3;o renal ou diurese residual, o que permite melhor controle vol&#x000ea;mico e reduz o risco de hipotens&#x000e3;o intradial&#x000ed;tica<sup>
<xref rid="B239" ref-type="bibr">239</xref>,<xref rid="B240" ref-type="bibr">240</xref>
</sup>. Em pacientes em DP, o uso de IECA/BRA preferencialmente, associa-se &#x000e0; preserva&#x000e7;&#x000e3;o da membrana peritoneal com redu&#x000e7;&#x000e3;o da fibrose e manuten&#x000e7;&#x000e3;o da depura&#x000e7;&#x000e3;o peritoneal e da UF<sup>
<xref rid="B241" ref-type="bibr">241</xref>,<xref rid="B242" ref-type="bibr">242</xref>
</sup>. O risco de hiperpotassemia &#x000e9; plaus&#x000ed;vel, mas controverso, pois n&#x000e3;o &#x000e9; observado em todos os estudos<sup>
<xref rid="B243" ref-type="bibr">243</xref>,<xref rid="B244" ref-type="bibr">244</xref>.<xref rid="B245" ref-type="bibr">245</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se o uso de IECA ou BRA em pacientes em HD e DP como medicamentos anti-hipertensivos por seus efeitos pleiotr&#x000f3;picos: redu&#x000e7;&#x000e3;o de HVE, IC, redu&#x000e7;&#x000e3;o de fibrose peritoneal em DP e mortalidade CV (Classe I/N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se o acompanhamento dos n&#x000ed;veis s&#x000e9;ricos de pot&#x000e1;ssio, embora o risco de hiperpotassemia seja controverso e nem sempre observado (Classe IIA/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Betabloqueadores (BB)</title><p>Na DRC dial&#x000ed;tica os BB s&#x000e3;o recomendados como medica&#x000e7;&#x000e3;o preferencial. Dois ECR evidenciaram a efic&#x000e1;cia e a prote&#x000e7;&#x000e3;o CV proporcionada pelos BB na subpopula&#x000e7;&#x000e3;o de pessoas em di&#x000e1;lise, sendo o primeiro, um ECR contra placebo, que demonstrou que o carvedilol utilizado em 114 pacientes em HD e IC (miocardiopatia dilatada e fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o reduzida), resultou em melhora cl&#x000ed;nica, redu&#x000e7;&#x000e3;o (&#x02013;49%) da mortalidade geral e CV (&#x02013;68%) e das interna&#x000e7;&#x000f5;es por IC (&#x02013;81%)<sup>
<xref rid="B58" ref-type="bibr">58</xref>
</sup>. O segundo estudo prop&#x000f4;s comparar o efeito de redu&#x000e7;&#x000e3;o da HVE com atenolol ou lisinopril (administrados ap&#x000f3;s as sess&#x000f5;es de HD) em pacientes em HD com PA &#x02265; 140/90 mmHg e HVE, mas foi interrompido precocemente porque os resultados intermedi&#x000e1;rios foram t&#x000e3;o ben&#x000e9;ficos a favor do atenolol que n&#x000e3;o seria &#x000e9;tico continuar o estudo<sup>
<xref rid="B246" ref-type="bibr">246</xref>
</sup>. Embora com n&#x000fa;mero limitado de participantes, 100 em cada grupo, o estudo tornou-se uma refer&#x000ea;ncia. As taxas de eventos CV graves e de interna&#x000e7;&#x000f5;es foram pelo menos metade no grupo randomizado para o atenolol quando comparado ao lisinopril<sup>
<xref rid="B246" ref-type="bibr">246</xref>
</sup>. A MAPA de 44h foi consistentemente menor no grupo que recebeu atenolol, ainda que os participantes do grupo com lisinopril tivessem recebido mais medicamentos anti-hipertensivos e reduzido o peso seco em 3 quilos a mais durante o acompanhamento, indicando a superioridade do atenolol sobre lisinopril<sup>
<xref rid="B246" ref-type="bibr">246</xref>
</sup>. Outros estudos com BB (carvedilol, bisoprolol e atenolol) mostraram resultados semelhantes em rela&#x000e7;&#x000e3;o &#x000e0; redu&#x000e7;&#x000e3;o da PA, em m&#x000e9;dia &#x02013;8,7 mmHg na PAS<sup>
<xref rid="B235" ref-type="bibr">235</xref>
</sup>.</p><p>H&#x000e1; controv&#x000e9;rsia na literatura em rela&#x000e7;&#x000e3;o aos BB dialis&#x000e1;veis (atenolol, bisoprolol, metoprolol, nadolol) e os n&#x000e3;o dialis&#x000e1;veis (carvedilol, nebivolol, propranolol, pindolol)<sup>
<xref rid="B247" ref-type="bibr">247</xref>
</sup>. Alguns estudos apresentam dados objetivos e sugerem que os BB dialis&#x000e1;veis s&#x000e3;o superiores aos n&#x000e3;o dialis&#x000e1;veis, pois, quando comparados, apresentam redu&#x000e7;&#x000e3;o dos eventos CV maiores (AVC, IAM e ICC) e da mortalidade CV e geral<sup>
<xref rid="B248" ref-type="bibr">248</xref>,<xref rid="B249" ref-type="bibr">249</xref>
</sup>. Existe tamb&#x000e9;m uma meta-an&#x000e1;lise de estudos observacionais que n&#x000e3;o encontrou diferen&#x000e7;as entre os efeitos protetores CV dos BB dialis&#x000e1;veis e n&#x000e3;o dialis&#x000e1;veis em pessoas em HD<sup>
<xref rid="B250" ref-type="bibr">250</xref>
</sup>. Todos os estudos que avaliaram poss&#x000ed;veis diferen&#x000e7;as na prote&#x000e7;&#x000e3;o CV entre BB dialis&#x000e1;veis e n&#x000e3;o dialis&#x000e1;veis s&#x000e3;o observacionais, coortes retrospectivas ou prospectivas e baseados em dados de prescri&#x000e7;&#x000e3;o de medicamentos.</p><p>Independentemente do BB, h&#x000e1; uma pergunta importante que se imp&#x000f5;e: sua associa&#x000e7;&#x000e3;o com outros anti-hipertensivos, poderia ter efeito ben&#x000e9;fico somat&#x000f3;rio? H&#x000e1; pelo menos um estudo observacional que avaliou esse aspecto em pacientes em HD e que desenvolveram IC ap&#x000f3;s in&#x000ed;cio da di&#x000e1;lise e passaram a utilizar BB, IECA/BRA ou ambos<sup>
<xref rid="B251" ref-type="bibr">251</xref>
</sup>. No acompanhamento da mortalidade por 5 anos, os pacientes que utilizaram apenas BB foram considerados refer&#x000ea;ncia para os que utilizaram apenas IECA/BRA, para os que utilizaram BB e IECA/BRA e para os que utilizaram quaisquer outros medicamentos. Em rela&#x000e7;&#x000e3;o &#x000e0; refer&#x000ea;ncia (uso apenas de BB), a mortalidade para os que utilizaram apenas IECA/BRA foi semelhante (+8%; n&#x000e3;o signific&#x000e2;ncia estat&#x000ed;stica), para os que utilizaram a associa&#x000e7;&#x000e3;o de BB e IECA/BRA a mortalidade foi menor (&#x02013;33%; p &#x0003c; 0,001) e para os que n&#x000e3;o utilizaram BB nem IECA/BRA a mortalidade foi maior (+74%; p &#x0003c; 0,001)<sup>
<xref rid="B251" ref-type="bibr">251</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se a utiliza&#x000e7;&#x000e3;o de betabloqueadores como medicamentos preferenciais nos pacientes em HD e DP, exceto se contraindicados (Classe I/N&#x000ed;vel B).</p></list-item><list-item><p>Recomenda-se o uso preferencial de atenolol, exceto se contraindicado (Classe I/N&#x000ed;vel B).</p></list-item><list-item><p>N&#x000e3;o h&#x000e1; evid&#x000ea;ncias suficientes sobre o uso preferencial daqueles dialis&#x000e1;veis <italic>vs</italic>. n&#x000e3;o dialis&#x000e1;veis (Classe IIB/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Bloqueadores dos Canais de C&#x000e1;lcio (BCC)</title><p>Existem poucos estudos avaliando os BCC no tratamento da HA e na preven&#x000e7;&#x000e3;o de complica&#x000e7;&#x000f5;es CV em pacientes em di&#x000e1;lise. Uma meta-an&#x000e1;lise de estudos randomizados<sup>
<xref rid="B235" ref-type="bibr">235</xref>
</sup> encontrou apenas 3 estudos com BCC comparados a placebo (nitrendipino, diltiazem e anlodipino), nos quais, em m&#x000e9;dia, o efeito hipotensor foi semelhante aos IECA (-4,6 mmHg na PA sist&#x000f3;lica). O ECR mais robusto incluiu 251 pacientes e comparou anlodipino <italic>vs.</italic> placebo, e evidenciou redu&#x000e7;&#x000e3;o m&#x000e9;dia de -10 mmHg na PAS, redu&#x000e7;&#x000e3;o n&#x000e3;o significante da mortalidade geral, desfecho prim&#x000e1;rio, (RR = 0,62) e redu&#x000e7;&#x000e3;o significante (RR = 0,53; p = 0,03) nos desfechos secund&#x000e1;rios (IAM, AVC, revasculariza&#x000e7;&#x000e3;o mioc&#x000e1;rdica e doen&#x000e7;a arterial perif&#x000e9;rica com necessidade de revasculariza&#x000e7;&#x000e3;o ou amputa&#x000e7;&#x000e3;o)<sup>
<xref rid="B252" ref-type="bibr">252</xref>
</sup>. Observou-se que o efeito hipotensor da nitrendipina foi mais pronunciado nos pacientes com maior GPID<sup>
<xref rid="B253" ref-type="bibr">253</xref>
</sup>.</p><p>Uma revis&#x000e3;o sistem&#x000e1;tica com meta-an&#x000e1;lise identificou 13 estudos randomizados ou quasi-randomizados envolvendo o uso de BBC em pacientes em di&#x000e1;lise<sup>
<xref rid="B254" ref-type="bibr">254</xref>
</sup>. Embora o n&#x000fa;mero de pacientes inclu&#x000ed;dos nessa an&#x000e1;lise fosse grande (1459), a diversidade dos estudos e o baixo grau de confian&#x000e7;a limitaram as conclus&#x000f5;es<sup>
<xref rid="B254" ref-type="bibr">254</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se o uso de BCC em pacientes em HD e DP, pois mant&#x000e9;m seus efeitos anti-hipertensivos e protetores CV mesmo na presen&#x000e7;a de hipervolemia (Classe I/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Antagonistas dos Receptores Mineralocorticoides (ARM)</title><p>Uma meta-an&#x000e1;lise incluiu 1133 pacientes em HD em 11 estudos com ARM (10 com espironolactona e 1 com eplerenone) e observou maior efeito hipotensor quando comparado a placebo (&#x02013;10,8 mmHg na PAS) e maiores taxas de descontinua&#x000e7;&#x000e3;o do medicamento, embora sem risco adicional de hiperpotassemia<sup>
<xref rid="B235" ref-type="bibr">235</xref>
</sup>.</p><p>Outra meta-an&#x000e1;lise, que incluiu 1309 pacientes em HD, em 14 ECR que envolveram o uso de ARMC (13 com espironolactona) <italic>vs.</italic> placebo ou sem tratamento, evidenciou importante redu&#x000e7;&#x000e3;o de eventos CV n&#x000e3;o fatais (&#x02013;49%), redu&#x000e7;&#x000e3;o de mortalidade geral (&#x02013;56%) e CV (&#x02013;59%), sem causar hiperpotassemia estatisticamente significante<sup>
<xref rid="B255" ref-type="bibr">255</xref>
</sup>.</p><p>Uma meta-an&#x000e1;lise que incluiu 829 pacientes em di&#x000e1;lise oriundos de 9 ECR com ARM observou redu&#x000e7;&#x000e3;o significante da mortalidade geral (&#x02013;60%) e CV (&#x02013;66%), mas foi observado aumento em 3 vezes do risco de hiperpotassemia e at&#x000e9; 5 vezes de ginecomastia<sup>
<xref rid="B256" ref-type="bibr">256</xref>
</sup>. Nas meta-an&#x000e1;lises dispon&#x000ed;veis, ainda que a hiperpotassemia possa ser um risco, parece n&#x000e3;o mitigar o efeito ben&#x000e9;fico sobre a mortalidade CV e geral<sup>
<xref rid="B255" ref-type="bibr">255</xref>,<xref rid="B256" ref-type="bibr">256</xref>
</sup>.</p><p>Dois grandes ECR em andamento poder&#x000e3;o fornecer dados mais confi&#x000e1;veis sobre a efic&#x000e1;cia e seguran&#x000e7;a do uso de espironolactona na DRC dial&#x000ed;tica. O <italic>Aldosterone Antagonist Chronic Hemodialysis Interventional Survival Trial</italic> (ALCHEMIST), que j&#x000e1; recrutou 825 pacientes em HD e deve ser conclu&#x000ed;do em 2024, avalia os efeitos da espironolactona em rela&#x000e7;&#x000e3;o aos desfechos cl&#x000ed;nicos de interesse. O estudo <italic>Aldosterone Blockade for Health Improvement Evaluation in ESKD Trial</italic> (ACHIEVE) planeja inscrever 2750 pacientes em di&#x000e1;lise e comparar os efeitos da espironolactona em rela&#x000e7;&#x000e3;o &#x000e0; morte CV ou hospitaliza&#x000e7;&#x000e3;o.</p><p>Ressalte-se que os estudos existentes s&#x000e3;o predominantemente com espironolactona, com maior risco de ginecomastia e risco de hiperpotassemia baixo e controverso (Classe I/N&#x000ed;vel B). N&#x000e3;o h&#x000e1; ECR, at&#x000e9; o presente momento, que tenha utilizado ARM n&#x000e3;o esteroidais seletivos em HD ou DP.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se o uso dos ARM em pacientes em HD, pois t&#x000ea;m bom efeito anti-hipertensivo e reduzem a morbidade e mortalidade CV e geral (Classe I/N&#x000ed;vel A). Para pacientes em DP, o n&#x000fa;mero de estudos e as evid&#x000ea;ncias s&#x000e3;o fr&#x000e1;geis (Classe IIB/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Outras Classes de Anti-Hipertensivos</title><sec><title>Simpatol&#x000ed;ticos de a&#x000e7;&#x000e3;o central</title><p>N&#x000e3;o h&#x000e1; estudos com metildopa e foi encontrada uma revis&#x000e3;o sistem&#x000e1;tica com meta-an&#x000e1;lise que concluiu que n&#x000e3;o h&#x000e1; evid&#x000ea;ncias que suportem o uso de clonidina cronicamente em HD, al&#x000e9;m de seu uso estar associado a um perfil de efeitos colaterais significativos<sup>
<xref rid="B257" ref-type="bibr">257</xref>
</sup>.</p></sec><sec><title>Vasodilatadores de a&#x000e7;&#x000e3;o direta</title><p>N&#x000e3;o h&#x000e1; estudos com vasodilatadores de a&#x000e7;&#x000e3;o direta, como a hidralazina e o minoxidil na popula&#x000e7;&#x000e3;o em di&#x000e1;lise. Hidralazina tem sido utilizada em associa&#x000e7;&#x000e3;o &#x000e0; isossorbida em pacientes em HD com IC com fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o reduzida, mas n&#x000e3;o como anti-hipertensivo<sup>
<xref rid="B258" ref-type="bibr">258</xref>,<xref rid="B259" ref-type="bibr">259</xref>
</sup>.</p><p>Entretanto, simpatol&#x000ed;ticos e vasodilatadores diretos s&#x000e3;o utilizados de forma emp&#x000ed;rica na DRC dial&#x000ed;tica, particularmente na HA resistente e refrat&#x000e1;ria. Um estudo realizado em 210 cl&#x000ed;nicas de di&#x000e1;lise nos Estados Unidos identificou que, nos 6 primeiros meses de di&#x000e1;lise, os simpatol&#x000ed;ticos s&#x000e3;o utilizados por 19% dos pacientes e os vasodilatadores, por 4% a 10%<sup>
<xref rid="B260" ref-type="bibr">260</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se que simpatol&#x000ed;ticos de a&#x000e7;&#x000e3;o central e vasodilatadores diretos sejam utilizados como 5&#x000aa; ou 6&#x000aa; medica&#x000e7;&#x000e3;o anti-hipertensiva em pacientes em di&#x000e1;lise, ou se houver contraindica&#x000e7;&#x000f5;es para os demais anti-hipertensivos (Classe IIA/N&#x000ed;vel C).</p></list-item></list></sec></sec><sec><title>Depura&#x000e7;&#x000e3;o Renal e Pela Hemodi&#x000e1;lise dos Anti-Hipertensivos</title><p>A necessidade de ajuste de dose ou reposi&#x000e7;&#x000e3;o p&#x000f3;s-di&#x000e1;lise do anti-hipertensivo prescrito &#x000e9; uma preocupa&#x000e7;&#x000e3;o recorrente do nefrologista no acompanhamento dos pacientes em HD. O <xref rid="T19" ref-type="table">Quadro 8</xref> mostra um resumo dos anti-hipertensivos, dispon&#x000ed;veis no Brasil, que t&#x000ea;m elimina&#x000e7;&#x000e3;o renal ou que s&#x000e3;o mais extensamente dialis&#x000e1;veis e, por isso, podem requerer ajustes. Os anti-hipertensivos n&#x000e3;o mencionados n&#x000e3;o precisam de ajuste ou reposi&#x000e7;&#x000e3;o p&#x000f3;s-HD<sup>
<xref rid="B261" ref-type="bibr">261</xref>
</sup>.</p><table-wrap position="float" id="T19"><label>Quadro 8</label><caption><title>Principais anti-hipertensivos dispon&#x000ed;veis no Brasil. Ajuste de dose na doen&#x000e7;a renal cr&#x000f4;nica e taxa de remo&#x000e7;&#x000e3;o pela di&#x000e1;lise<xref rid="T19FN2" ref-type="table-fn">*</xref>
</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Classe e medicamento</th><th align="left" valign="top" rowspan="1" colspan="1">Ajuste de dose na DRC</th><th align="left" valign="top" rowspan="1" colspan="1">Remo&#x000e7;&#x000e3;o na di&#x000e1;lise</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Inibidores ECA</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Captopril</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>TFG &#x0003c; 10 mL/min:</bold> administrar 50% da dose a cada 24h.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> administrar uma dose extra ap&#x000f3;s a HD. <break/>
<bold>DP:</bold> remo&#x000e7;&#x000e3;o insignificante.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Enalapril</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>TFG &#x02264; 30 mL/min:</bold> 2,5 mg a cada 24h. Aumentar progressivamente de acordo com a PA.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> taxa de remo&#x000e7;&#x000e3;o 20%-50%. Dose extra de 2,5 mg ap&#x000f3;s HD. <break/>
<bold>DP:</bold> ajustar a dose para 25% da dose usual.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Benazepril</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>TFG &#x02264; 30 mL/min:</bold> 5 mg a cada 24h. Aumentar progressivamente de acordo com a PA.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> ajustar dose para 25% a 50% da dose habitual. Sem dose extra p&#x000f3;s-HD.<break/>
<bold>DP:</bold> ajustar dose para 25% a 50% da dose habitual.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Lisinopril</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>TFG 10&#x02013;30 mL/min:</bold> 2,5 mg&#x02013;5 mg a cada 24h. Aumentar progressivamente de acordo com a PA.<break/>
<bold>TFG &#x0003c; 10 mL/min:</bold> considerar substituir por outro medicamento (risco elevado de EA).</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> taxa de remo&#x000e7;&#x000e3;o de 50%. Recomendar o uso de 10 mg ap&#x000f3;s HD (3x/semana), aumentando a dose progressivamente de acordo com a PA.<break/>
<bold>DP:</bold> 2,5 mg a cada 24h. Aumentar progressivamente de acordo com a PA.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Ramipril</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>TFG &#x02264; 40 mL/min:</bold> 25% da dose habitual.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> remo&#x000e7;&#x000e3;o insignificante. <break/>
<bold>DP</bold>: remo&#x000e7;&#x000e3;o insignificante.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Perindopril</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>TFG &#x0003c; 30 mL/min:</bold> uso n&#x000e3;o recomendado.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> usar dose ap&#x000f3;s HD. <break/>
<bold>DP:</bold> sem ajuste recomendado.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Beta-bloqueadores</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Atenolol Bisoprolol Metoprolol Nadolol</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>TFG &#x0003e; 30 mL/min:</bold> n&#x000e3;o necessita ajuste da dose.<break/>
<bold>TFG 10&#x02013;30 mL/min:</bold> metade da dose/dia.<break/>
<bold>TFG &#x0003c; 10 mL/min:</bold> &#x000bc; da dose/dia.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> taxa de remo&#x000e7;&#x000e3;o 25% a 50%. Uso da dose ap&#x000f3;s HD.<break/>
<bold>DP:</bold> remo&#x000e7;&#x000e3;o insignificante. Usar &#x000bc; da dose/dia.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Propranolol Pindolol</bold>
<break/>
<bold>Carvedilol Nebivolol</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">N&#x000e3;o necessita ajuste da dose.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> remo&#x000e7;&#x000e3;o insignificante. <break/>
<bold>DP:</bold> remo&#x000e7;&#x000e3;o insignificante.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Simpatol&#x000ed;ticos</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Metildopa</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>TFG &#x0003c; 10 mL/min:</bold> administrar a cada 12h a 24h.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> taxa de remo&#x000e7;&#x000e3;o at&#x000e9; 60%. Uso da dose ap&#x000f3;s HD.<break/>
<bold>DP:</bold> administrar a cada 12h a 24h.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Clonidina</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>TFG &#x0003c; 30 mL/min:</bold> iniciar baixa dose e aumentar lentamente conforme PA e EA.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> remo&#x000e7;&#x000e3;o insignificante. <break/>
<bold>DP:</bold> remo&#x000e7;&#x000e3;o insignificante.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>BRA</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Bloqueadores dos Receptores da Angiotensina</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">N&#x000e3;o necessita ajuste da dose.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> remo&#x000e7;&#x000e3;o insignificante. <break/>
<bold>DP:</bold> remo&#x000e7;&#x000e3;o insignificante.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>BCC</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Bloqueadores dos canais de c&#x000e1;lcio</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">N&#x000e3;o necessita ajuste da dose.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> remo&#x000e7;&#x000e3;o insignificante. <break/>
<bold>DP:</bold> remo&#x000e7;&#x000e3;o insignificante.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Diur&#x000e9;ticos</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Diur&#x000e9;ticos de al&#x000e7;a</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">N&#x000e3;o necessita ajuste da dose.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> remo&#x000e7;&#x000e3;o insignificante. <break/>
<bold>DP:</bold> remo&#x000e7;&#x000e3;o insignificante.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Alfa-bloqueadores</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Alfa-bloqueadores</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">N&#x000e3;o necessita ajuste da dose.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD</bold> remo&#x000e7;&#x000e3;o insignificante. <break/>
<bold>DP:</bold> remo&#x000e7;&#x000e3;o insignificante.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Vasodilatadores</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Vasodilatadores diretos</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">N&#x000e3;o necessita ajuste da dose.</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HD:</bold> remo&#x000e7;&#x000e3;o insignificante.<break/>
<bold>DP:</bold> remo&#x000e7;&#x000e3;o insignificante.</td></tr></tbody></table><table-wrap-foot><fn id="T19FN1"><p>Abreviaturas &#x02013; ECA: enzima conversora da angiotensina; TFG: taxa de filtra&#x000e7;&#x000e3;o glomerular; DRC: doen&#x000e7;a renal cr&#x000f4;nica; HD: hemodi&#x000e1;lise; DP: di&#x000e1;lise peritoneal; EA: efeitos adversos; BRA: bloqueadores dos receptores da angiotensina; BCC: bloqueadores dos canais de c&#x000e1;lcio. Notas &#x02013;</p></fn><fn id="T19FN2"><p>*Quadro adaptado da refer&#x000ea;ncia<sup>
<xref rid="B261" ref-type="bibr">261</xref>
</sup>. Informa&#x000e7;&#x000f5;es para ajuste de dose e remo&#x000e7;&#x000e3;o na di&#x000e1;lise baseadas nas recomenda&#x000e7;&#x000f5;es do <italic>UpToDate</italic> 2021 para cada medicamento citado.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Hor&#x000e1;rio da Administra&#x000e7;&#x000e3;o ou Suspens&#x000e3;o de Doses dos Medicamentos Pr&#x000e9;-Di&#x000e1;lise</title><p>A hipotens&#x000e3;o intradial&#x000ed;tica &#x000e9; sempre um risco para os pacientes em HD, particularmente se houver GPID excessivo ou uso de medicamentos que bloqueiam os mecanismos de defesa no caso de hipovolemia transit&#x000f3;ria durante a HD (simpatol&#x000ed;ticos, BB e IECA/BRA). Por isso, &#x000e9; tentador reduzir a dose ou n&#x000e3;o administrar algum(ns) medicamento(s) no dia da HD ou horas antes dela. H&#x000e1; um &#x000fa;nico estudo randomizado por <italic>cluster</italic>, em cinco centros que mantinham a medica&#x000e7;&#x000e3;o anti-hipertensiva (65 participantes) e cinco centros que suspendiam a medica&#x000e7;&#x000e3;o no dia da HD (n = 66)<sup>
<xref rid="B98" ref-type="bibr">98</xref>
</sup>. Nos dois grupos, a medica&#x000e7;&#x000e3;o utilizada em dose &#x000fa;nica di&#x000e1;ria foi mantida como dose noturna. O estudo mostrou que n&#x000e3;o houve menor risco de hipotens&#x000e3;o intradial&#x000ed;tica e nem maior frequ&#x000ea;ncia de atingir o peso seco estimado no grupo em que a medica&#x000e7;&#x000e3;o foi suspensa no dia da HD, mas houve maior risco de hipertens&#x000e3;o (PAS &#x0003e; 160 mmHg) pr&#x000e9;-di&#x000e1;lise<sup>
<xref rid="B98" ref-type="bibr">98</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>N&#x000e3;o h&#x000e1; evid&#x000ea;ncias de benef&#x000ed;cios em retirar ou diminuir a dose da medica&#x000e7;&#x000e3;o anti-hipertensiva no dia da HD (Classe III/N&#x000ed;vel B).</p></list-item></list></sec><sec><title>Terapia Combinada</title><p>As classes de anti-hipertensivos que apresentam perfil mais adequado, levando-se em conta o efeito sobre a PA, a redu&#x000e7;&#x000e3;o de complica&#x000e7;&#x000f5;es CV e seguran&#x000e7;a, seriam: os BB, seguidos pelos BCC e IECA/BRA e, por fim, os ARM. No entanto, essa n&#x000e3;o &#x000e9; a realidade da pr&#x000e1;tica cl&#x000ed;nica. A maioria dos pacientes chega ao tratamento dial&#x000ed;tico usando BB, IECA/BRA e BCC<sup>
<xref rid="B260" ref-type="bibr">260</xref>
</sup>. Dessa forma, a estrat&#x000e9;gia inicial mais razo&#x000e1;vel deveria ser controlar a hipervolemia, alcan&#x000e7;ando o PS estimado, evitando a associa&#x000e7;&#x000e3;o de anti-hipertensivos e (re)introduzindo-os de acordo com as caracter&#x000ed;sticas de cada paciente, na ordem sugerida acima. Os demais anti-hipertensivos poderiam ser associados, se necess&#x000e1;rio, apenas ap&#x000f3;s atingido o estado de euvolemia.</p></sec></sec><sec><title>Situa&#x000e7;&#x000f5;es Especiais de Hipertens&#x000e3;o em Di&#x000e1;lise</title><sec><title>Hipertens&#x000e3;o em Gestante em DP e HD</title><p>Estima-se que a preval&#x000ea;ncia de gesta&#x000e7;&#x000f5;es em mulheres em di&#x000e1;lise seja de 1% a 7%, sendo mais frequente em pacientes em HD do que em DP<sup>
<xref rid="B262" ref-type="bibr">262</xref>,<xref rid="B263" ref-type="bibr">263</xref>
</sup>. A hipertens&#x000e3;o cr&#x000f4;nica no in&#x000ed;cio da gravidez &#x000e9; um fator importante para complica&#x000e7;&#x000f5;es maternas, mas n&#x000e3;o est&#x000e1; associada a complica&#x000e7;&#x000f5;es neonatais (1/5 = 20,0% <italic>vs</italic>. 2/9 = 22,2% sem hipertens&#x000e3;o cr&#x000f4;nica)<sup>
<xref rid="B262" ref-type="bibr">262</xref>,<xref rid="B263" ref-type="bibr">263</xref>
</sup>. Recentemente, tem sido observado um aumento no n&#x000fa;mero de gesta&#x000e7;&#x000f5;es em mulheres com DRC, possivelmente devido a melhorias no manejo da HA e redu&#x000e7;&#x000e3;o de complica&#x000e7;&#x000f5;es como polidr&#x000e2;mnios<sup>
<xref rid="B264" ref-type="bibr">264</xref>
</sup>.</p><p>As complica&#x000e7;&#x000f5;es maternas mais comuns em mulheres com DRC, dial&#x000ed;tica ou n&#x000e3;o, durante a gravidez s&#x000e3;o as doen&#x000e7;as hipertensivas. Identificar a diferen&#x000e7;a entre pr&#x000e9;-ecl&#x000e2;mpsia e descompensa&#x000e7;&#x000e3;o da DRC pode ser um desafio. A HA nessas pacientes pode estar relacionada &#x000e0; sobrecarga h&#x000ed;drica e o seu manejo com UF pode levar &#x000e0; hipoperfus&#x000e3;o de &#x000f3;rg&#x000e3;os-alvo, incluindo a placenta<sup>
<xref rid="B262" ref-type="bibr">262</xref>
</sup>. N&#x000e3;o h&#x000e1; estudos cl&#x000ed;nicos randomizados que estabele&#x000e7;am a PA ideal para gestantes com DRC em di&#x000e1;lise<sup>
<xref rid="B265" ref-type="bibr">265</xref>
</sup>. Os estudos dispon&#x000ed;veis costumam seguir as recomenda&#x000e7;&#x000f5;es de manejo da HA das principais diretrizes obst&#x000e9;tricas<sup>
<xref rid="B263" ref-type="bibr">263</xref>,<xref rid="B264" ref-type="bibr">264</xref>,<xref rid="B265" ref-type="bibr">265</xref>,<xref rid="B266" ref-type="bibr">266</xref>
</sup>. Al&#x000e9;m disso, &#x000e9; necess&#x000e1;rio um controle rigoroso da PA, com uma meta de press&#x000e3;o &#x0003c; 140/90 mmHg ou uma PAD &#x0003c; 85 mmHg, de acordo com o estudo CHIPS<sup>
<xref rid="B267" ref-type="bibr">267</xref>
</sup>.</p><p>A gesta&#x000e7;&#x000e3;o em pacientes em di&#x000e1;lise apresenta melhores desfechos quando h&#x000e1; uma intensifica&#x000e7;&#x000e3;o do tempo e da dose de di&#x000e1;lise, com base nos n&#x000ed;veis s&#x000e9;ricos de ureia (abaixo de 50&#x02013;70 mg/dL)<sup>
<xref rid="B265" ref-type="bibr">265</xref>
</sup>. Uma revis&#x000e3;o sistem&#x000e1;tica destacou haver maior risco de complica&#x000e7;&#x000f5;es na gravidez em mulheres com DRC, incluindo pr&#x000e9;-ecl&#x000e2;mpsia (raz&#x000e3;o de chances [OR] 10,4, IC 95% 6,3&#x02013;17,1), parto prematuro (OR 5,7, IC 95% 3,3&#x02013;10,0), restri&#x000e7;&#x000e3;o de crescimento intrauterino ou baixo peso ao nascer (OR 4,9, IC 95% 3,0&#x02013;7,8), cesarianas (OR 2,7, IC 95% 2,0&#x02013;3,5) e falhas na gravidez [incluindo natimorto e morte fetal e neonatal (OR 1,8, IC 95% 1,0&#x02013;3,1), em compara&#x000e7;&#x000e3;o com mulheres saud&#x000e1;veis do grupo de controle<sup>
<xref rid="B264" ref-type="bibr">264</xref>
</sup>.</p><p>A taxa de nascidos vivos em di&#x000e1;lise tem apresentado melhorias significativas ao longo das d&#x000e9;cadas, evoluindo de 25%, em 1960, para mais de 75% atualmente. No entanto, 53,4% dos beb&#x000ea;s ainda nascem prematuros e 65% com baixo peso ao nascer, ou seja, menos de 2,5 quilos<sup>
<xref rid="B268" ref-type="bibr">268</xref>
</sup>. Uma revis&#x000e3;o que analisou 10 artigos revelou que a maioria das mulheres gr&#x000e1;vidas em HD segue regimes terap&#x000ea;uticos que variam de 15 a 40 horas semanais (em esquemas di&#x000e1;rios ou de quatro vezes na semana), meta de ureia abaixo de 60 mg/dL e de creatinina de 6 mg/dL. A mesma revis&#x000e3;o mostrou que a maioria das pacientes utiliza um fluxo de dialisato de 500 mL/min, enquanto o fluxo de sangue e o tipo de dialisador variaram consideravelmente<sup>
<xref rid="B269" ref-type="bibr">269</xref>
</sup>. Outra revis&#x000e3;o sistem&#x000e1;tica identificou uma taxa geral de nascidos vivos de 82%, com uma rela&#x000e7;&#x000e3;o positiva entre o n&#x000fa;mero de horas em di&#x000e1;lise e melhores resultados, incluindo risco reduzido de parto prematuro antes das 37 semanas de gesta&#x000e7;&#x000e3;o e rec&#x000e9;m-nascidos pequenos para a idade gestacional abaixo do percentil dez<sup>
<xref rid="B270" ref-type="bibr">270</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>O manejo da HA nas gestantes em DP ou HD deve ser feita de acordo com as diretrizes estabelecidas para o controle da PA na popula&#x000e7;&#x000e3;o geral.</p></list-item><list-item><p>O aumento do tempo e da dose de di&#x000e1;lise est&#x000e1; relacionado a melhores desfechos maternos e fetais (Classe I/N&#x000ed;vel 2A).</p></list-item></list></sec><sec><title>Hipertens&#x000e3;o Resistente e Refrat&#x000e1;ria em Pacientes em Di&#x000e1;lise Peritoneal e Hemodi&#x000e1;lise</title><p>Segundo os principais <italic>Guidelines</italic>, a hipertens&#x000e3;o resistente (HAR) &#x000e9; caracterizada pela falta de controle da PA (em geral PA &#x0003c; 140/90 mmHg), por mais de 3 meses, mesmo com o uso de tr&#x000ea;s anti-hipertensivos, preferencialmente um diur&#x000e9;tico tiaz&#x000ed;dico, um inibidor do SRAA e um bloqueador de canal de c&#x000e1;lcio ou o uso de quatro medicamentos com controle press&#x000f3;rico<sup>
<xref rid="B271" ref-type="bibr">271</xref>
</sup>. J&#x000e1; a HARf ocorre quando a PA permanece fora do alvo terap&#x000ea;utico, por mais de 6 meses, mesmo com o uso de cinco ou mais f&#x000e1;rmacos, incluindo um antagonista do receptor mineralocorticoide (espironolactona) e um diur&#x000e9;tico tiaz&#x000ed;dico de longa a&#x000e7;&#x000e3;o (clortalidona)<sup>
<xref rid="B272" ref-type="bibr">272</xref>,<xref rid="B273" ref-type="bibr">273</xref>
</sup>.</p><p>Para o diagn&#x000f3;stico dessas condi&#x000e7;&#x000f5;es, &#x000e9; importante avaliar a ades&#x000e3;o ao tratamento e confirmar o descontrole da PA por meio da MAPA ou da MRPA, conforme protocolos discutidos no Cap&#x000ed;tulo 3.</p><p>Apesar do mecanismo fisiopatol&#x000f3;gico da HAR estar diretamente relacionado &#x000e0; sobrecarga de volume, que se agrava na presen&#x000e7;a de DRC 5D, na pr&#x000e1;tica cl&#x000ed;nica observa-se que muitos pacientes, ao iniciar o tratamento dial&#x000ed;tico, ainda apresentam valores elevados de PA, apesar de adequada UF. Estudos relatam preval&#x000ea;ncia de HAR variando de 18%<sup>
<xref rid="B274" ref-type="bibr">274</xref>
</sup> a 24%<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup>.</p><p>Para melhor controle da HAR e HARf &#x000e9; importante garantir: adequado controle do volume, atingindo o PS ideal, al&#x000e9;m de prescri&#x000e7;&#x000e3;o individualizada de s&#x000f3;dio no l&#x000ed;quido dial&#x000ed;tico, dura&#x000e7;&#x000e3;o adequada da di&#x000e1;lise e restri&#x000e7;&#x000e3;o da ingest&#x000e3;o de sal no per&#x000ed;odo interdial&#x000ed;tico<sup>
<xref rid="B274" ref-type="bibr">274</xref>
</sup>.</p><p>O tratamento farmacol&#x000f3;gico para pacientes em tratamento dial&#x000ed;tico com HAR ou HARf tem algumas particularidades. O uso de diur&#x000e9;ticos n&#x000e3;o &#x000e9; recomendado para pacientes sem FRR e o tratamento medicamentoso segue as recomenda&#x000e7;&#x000f5;es j&#x000e1; descritas no Cap&#x000ed;tulo 7. Um estudo de interven&#x000e7;&#x000e3;o n&#x000e3;o randomizado chamou a aten&#x000e7;&#x000e3;o para a resposta press&#x000f3;rica ao sacubitril/valsartan nesses pacientes, embora com amostra reduzida e dura&#x000e7;&#x000e3;o curta<sup>
<xref rid="B275" ref-type="bibr">275</xref>
</sup>.</p><p>O uso de espironolactona tem se mostrado pouco eficaz para controle press&#x000f3;rico, mas tem efeito positivo na redu&#x000e7;&#x000e3;o da mortalidade total e da incid&#x000ea;ncia de eventos CV<sup>
<xref rid="B276" ref-type="bibr">276</xref>
</sup>.</p><p>Em casos mais desafiadores de controle da PA em pacientes HAR ou HARf, esgotadas as op&#x000e7;&#x000f5;es de outras classes anti-hipertensivas, podem ser considerados os vasodilatadores diretos, como a hidralazina ou o minoxidil, como op&#x000e7;&#x000f5;es terap&#x000ea;uticas<sup>
<xref rid="B277" ref-type="bibr">277</xref>
</sup>. Al&#x000e9;m disso, o uso da denerva&#x000e7;&#x000e3;o renal em HAR em di&#x000e1;lise tem sido proposto, embora ainda haja debates em torno dessa abordagem. Estudos recentes, como ECR, mostraram resposta favor&#x000e1;vel em curto e longo prazos da PA em pacientes submetidos a essa interven&#x000e7;&#x000e3;o<sup>
<xref rid="B278" ref-type="bibr">278</xref>,<xref rid="B279" ref-type="bibr">279</xref>
</sup>. O tratamento medicamentoso segue as recomenda&#x000e7;&#x000f5;es estabelecidas no Cap&#x000ed;tulo 7.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se que, para diagn&#x000f3;stico de HAR verdadeira e HARf, &#x000e9; necess&#x000e1;rio checar a ades&#x000e3;o ao tratamento e confirmar, preferencialmente pela MAPA ou pela MRPA (Classe I/N&#x000ed;vel A).</p></list-item><list-item><p>Denerva&#x000e7;&#x000e3;o renal pode ser uma op&#x000e7;&#x000e3;o terap&#x000ea;utica (Classe 2B/N&#x000ed;vel C).</p></list-item></list></sec><sec><title>Hipertens&#x000e3;o Sist&#x000f3;lica (HAS) no Idoso em Di&#x000e1;lise</title><p>A hipertens&#x000e3;o arterial sist&#x000f3;lica isolada (HAS) &#x000e9; bastante prevalente nos pacientes idosos devido &#x000e0; perda da elasticidade dos grandes vasos tor&#x000e1;cicos. Por outro lado, sabe-se que a HAS, com ou sem eleva&#x000e7;&#x000e3;o dos n&#x000ed;veis diast&#x000f3;licos, avaliada no per&#x000ed;odo interdial&#x000ed;tico atrav&#x000e9;s da MAPA ou MRPA, &#x000e9; diagnosticada em mais de 70% dos pacientes DRC 5D<sup>
<xref rid="B280" ref-type="bibr">280</xref>
</sup>. Assim, os idosos, ao iniciarem o tratamento dial&#x000ed;tico, como todas as outras subpopula&#x000e7;&#x000f5;es, podem apresentar acelera&#x000e7;&#x000e3;o do dano vascular, caracter&#x000ed;stico dos pacientes em DRC 5<sup>
<xref rid="B281" ref-type="bibr">281</xref>
</sup>.</p><p>O paciente idoso em di&#x000e1;lise pode apresentar HAS, mesmo ap&#x000f3;s ter atingido seu PS. Nessas situa&#x000e7;&#x000f5;es, &#x000e9; necess&#x000e1;rio considerar a possibilidade de que os aumentos dos n&#x000ed;veis sist&#x000f3;licos sejam consequ&#x000ea;ncia da rigidez vascular central.<sup>
<xref rid="B274" ref-type="bibr">274</xref>
</sup> A chamada pseudo-hipertens&#x000e3;o deve ser inclu&#x000ed;da no diagn&#x000f3;stico diferencial desses pacientes.<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup> N&#x000e3;o &#x000e9; incomum prescrever a retirada gradual de fluidos por meio da UF, na tentativa de normalizar a PA nessas condi&#x000e7;&#x000f5;es. No entanto, &#x000e9; importante ter em mente que o idoso com pseudo-hipertens&#x000e3;o pode desenvolver hipovolemia intravascular com graves consequ&#x000ea;ncias CV. Al&#x000e9;m disso, &#x000e9; importante considerar que os idosos hipertensos em di&#x000e1;lise tamb&#x000e9;m podem apresentar hipertens&#x000e3;o secund&#x000e1;ria (ver item 8.5) e outros fen&#x000f3;tipos de HA, como HAB e HM (ver item 3.4.3), e que as investiga&#x000e7;&#x000f5;es cl&#x000ed;nicas devem ser feitas de forma menos invasiva poss&#x000ed;vel.</p><p>A falta de ECR sobre os efeitos prejudiciais da HAS em pacientes dial&#x000ed;ticos faz com que todas as recomenda&#x000e7;&#x000f5;es sejam baseadas em opini&#x000f5;es dos especialistas. A situa&#x000e7;&#x000e3;o se torna mais complexa quando se trata de sugest&#x000f5;es para idosos submetidos &#x000e0; terapia dial&#x000ed;tica.</p></sec><sec><title>Hipertens&#x000e3;o Arterial em Hemodi&#x000e1;lise Associada ao Hiperfluxo da F&#x000ed;stula Arteriovenosa (FAV)</title><p>Os efeitos hemodin&#x000e2;micos da instala&#x000e7;&#x000e3;o de uma f&#x000ed;stula arteriovenosa (FAV)<sup>
<xref rid="B282" ref-type="bibr">282</xref>
</sup> t&#x000ea;m sido estudados em pacientes que precisam de HD. Antes de realizar a FAV, &#x000e9; muito importante cumprir uma avalia&#x000e7;&#x000e3;o abrangente da fun&#x000e7;&#x000e3;o card&#x000ed;aca, com &#x000ea;nfase no VD, complementada por informa&#x000e7;&#x000f5;es sobre o VE. Em conjunto, uma avalia&#x000e7;&#x000e3;o cardiovascular detalhada, eletrocardiograma e ecocardiograma transtor&#x000e1;cico permitem avaliar as fun&#x000e7;&#x000f5;es e estruturas card&#x000ed;acas antes da FAV. Al&#x000e9;m disso, &#x000e9; essencial realizar uma avalia&#x000e7;&#x000e3;o minuciosa para estabelecer o di&#x000e2;metro ideal da anastomose arteriovenosa, garantindo que a consequente redu&#x000e7;&#x000e3;o do fluxo consiga diminuir a PA, com benef&#x000ed;cios superiores ao risco de sobrecarga de volume e aumento de press&#x000e3;o no VD.</p><p>Altera&#x000e7;&#x000f5;es hemodin&#x000e2;micas significativas ocorrem devido &#x000e0; redistribui&#x000e7;&#x000e3;o de fluidos do sistema arterial de alta press&#x000e3;o e baixa capacit&#x000e2;ncia para um sistema de baixa press&#x000e3;o e alta capacit&#x000e2;ncia, resultando na redu&#x000e7;&#x000e3;o da resist&#x000ea;ncia perif&#x000e9;rica, aumento da pr&#x000e9;-carga do VD e da p&#x000f3;s-carga VE<sup>
<xref rid="B283" ref-type="bibr">283</xref>
</sup>. Estudos cl&#x000ed;nicos mostram que a PAS e a PAD diminuem em curto e longo prazo, ap&#x000f3;s a cria&#x000e7;&#x000e3;o de uma FAV, mas aumentam ap&#x000f3;s a sua ligadura. <sup>
<xref rid="B284" ref-type="bibr">284</xref>,<xref rid="B285" ref-type="bibr">285</xref>,<xref rid="B286" ref-type="bibr">286</xref>
</sup>. Scholz et al.<sup>
<xref rid="B283" ref-type="bibr">283</xref>
</sup> em meta-an&#x000e1;lise, confirmaram esses achados.</p><p>&#x000c9; muito importante avaliar os efeitos hemodin&#x000e2;micos e card&#x000ed;acos da FAV e suas poss&#x000ed;veis complica&#x000e7;&#x000f5;es, como insufici&#x000ea;ncia card&#x000ed;aca direita causada pelo aumento do retorno venoso, sobrecarga VD e remodela&#x000e7;&#x000e3;o VE. Al&#x000e9;m disso, efeitos colaterais como estenose venosa, aumento da press&#x000e3;o pulmonar e disfun&#x000e7;&#x000e3;o card&#x000ed;aca direita podem ocorrer devido ao aumento do fluxo venoso<sup>
<xref rid="B284" ref-type="bibr">284</xref>,<xref rid="B285" ref-type="bibr">285</xref>
<xref rid="B286" ref-type="bibr">286</xref>
</sup>. Essas altera&#x000e7;&#x000f5;es podem levar &#x000e0; necessidade de fechamento da FAV em pacientes sintom&#x000e1;ticos<sup>
<xref rid="B287" ref-type="bibr">287</xref>
</sup>. &#x000c9; fundamental considerar os efeitos em longo prazo dessa carga de volume artificialmente aumentada no cora&#x000e7;&#x000e3;o direito. Reddy et al.<sup>
<xref rid="B288" ref-type="bibr">288</xref>
</sup> mostraram que a cria&#x000e7;&#x000e3;o de uma FAV resultou em dilata&#x000e7;&#x000e3;o significativa do cora&#x000e7;&#x000e3;o direito e deteriora&#x000e7;&#x000e3;o da fun&#x000e7;&#x000e3;o card&#x000ed;aca direita, e consequentemente em insufici&#x000ea;ncia card&#x000ed;aca em mais de 40% dos pacientes. Por outro lado, a cria&#x000e7;&#x000e3;o de uma FAV pode levar a uma redu&#x000e7;&#x000e3;o modesta no tamanho e na massa do ventr&#x000ed;culo esquerdo, al&#x000e9;m de retardar a progress&#x000e3;o da DRC em alguns casos.<sup>
<xref rid="B288" ref-type="bibr">288</xref>
</sup>
</p></sec><sec><title>Hipertens&#x000e3;o Secund&#x000e1;ria em Di&#x000e1;lise</title><p>Pacientes em di&#x000e1;lise que se mant&#x000ea;m dentro dos crit&#x000e9;rios consagrados de HAR/HARf (ver item 8.2) s&#x000e3;o candidatos a avalia&#x000e7;&#x000e3;o para poss&#x000ed;veis causas subjacentes, al&#x000e9;m da pr&#x000f3;pria condi&#x000e7;&#x000e3;o de DRC, que por si s&#x000f3; poderia justificar a dificuldade de manejo press&#x000f3;rico<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup>. Raramente ser&#x000e3;o encontrados pacientes com causas secund&#x000e1;rias endocrinol&#x000f3;gicas ou n&#x000e3;o, e particularmente devem ser lembrados o uso de medicamentos que podem resultar no descontrole da PA, tais como anti-inflamat&#x000f3;rios n&#x000e3;o esteroidais, eritropoetina recombinante humana e corticoides<sup>
<xref rid="B84" ref-type="bibr">84</xref>
</sup>. Outra causa n&#x000e3;o endocrinol&#x000f3;gica muito comum entre renais cr&#x000f4;nicos, incluindo mais de 50% daqueles em HD e DP, &#x000e9; a AOS, que deve ser reconhecida e tratada<sup>
<xref rid="B78" ref-type="bibr">78</xref>,<xref rid="B289" ref-type="bibr">289</xref>,<xref rid="B290" ref-type="bibr">290</xref>
</sup>. Todas as poss&#x000ed;veis etiologias devem ser pensadas e pesquisadas em pacientes selecionados cl&#x000ed;nica e laboratorialmente, ap&#x000f3;s ter-se obtido o peso seco adequado.</p></sec></sec><sec><title>Complica&#x000e7;&#x000f5;es da HA nos Pacientes em Di&#x000e1;lise</title><p>As complica&#x000e7;&#x000f5;es da HA nos pacientes em di&#x000e1;lise s&#x000e3;o eminentemente CV e se encontram no espectro das les&#x000f5;es de &#x000f3;rg&#x000e3;os-alvo da HA em pacientes com fun&#x000e7;&#x000e3;o renal normal (<xref rid="T20" ref-type="table">Quadro 9</xref>). No entanto, devido a m&#x000fa;ltiplos outros mecanismos de les&#x000e3;o CV na DRC, como inflama&#x000e7;&#x000e3;o sist&#x000ea;mica, disfun&#x000e7;&#x000e3;o endotelial, calcifica&#x000e7;&#x000e3;o arterial, hiperparatireoidismo, anemia, sobrecarga salina e presen&#x000e7;a de FAV, &#x000e9; dif&#x000ed;cil demonstrar a rela&#x000e7;&#x000e3;o independente entre a HA e as complica&#x000e7;&#x000f5;es CV na DRC dial&#x000ed;tica. H&#x000e1; pouqu&#x000ed;ssimos estudos relatando melhora dessas complica&#x000e7;&#x000f5;es com o tratamento da HA, o que &#x000e9; fator limitante de conclus&#x000f5;es.</p><table-wrap position="float" id="T20"><label>Quadro 9</label><caption><title>Complica&#x000e7;&#x000f5;es cardiovasculares da hipertens&#x000e3;o arterial na doen&#x000e7;a renal cr&#x000f4;nica dial&#x000ed;tica</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Insufici&#x000ea;ncia card&#x000ed;aca</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Doen&#x000e7;a coronariana</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Morte card&#x000ed;aca s&#x000fa;bita</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fibrila&#x000e7;&#x000e3;o atrial</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Acidente vascular cerebral</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Doen&#x000e7;a arterial obstrutiva perif&#x000e9;rica (incluindo territ&#x000f3;rio carot&#x000ed;deo)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aneurismas da aorta (tor&#x000e1;cica, abdominal)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oclus&#x000e3;o da art&#x000e9;ria central da retina ou da veia central da retina</td></tr></tbody></table></table-wrap><p>A mais importante associa&#x000e7;&#x000e3;o &#x000e9; a com desfechos CV clinicamente manifestos, como a IC, a DAC, morte s&#x000fa;bita card&#x000ed;aca e AVC. A rela&#x000e7;&#x000e3;o entre a HA e eventos CV na DRC dial&#x000ed;tica &#x000e9; complexa. Estudos indicam associa&#x000e7;&#x000e3;o de forma U entre a PA obtida na unidade de di&#x000e1;lise e eventos CV coronarianos e cerebrais<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup> e com medidas ambulatoriais de PA em DP<sup>
<xref rid="B291" ref-type="bibr">291</xref>
</sup>. Os eventos ocorrem com as taxas mais altas em pacientes com PAS pr&#x000e9;-di&#x000e1;lise abaixo de 110&#x02013;120 mmHg. A incid&#x000ea;ncia de eventos mais baixa se encontra em valores de PAS entre 140&#x02013;160 mmHg, e ocorre um aumento discreto, mas significativo, acima desses n&#x000ed;veis. H&#x000e1; duas poss&#x000ed;veis explica&#x000e7;&#x000f5;es com evid&#x000ea;ncias para esse paradoxo. Uma se refere ao m&#x000e9;todo de aferi&#x000e7;&#x000e3;o da PA, especialmente a medida fora da unidade de di&#x000e1;lise, j&#x000e1; que alguns estudos sugerem que o uso da MAPA em vez da PA peridial&#x000ed;tica transforma a rela&#x000e7;&#x000e3;o U numa rela&#x000e7;&#x000e3;o linear mais semelhante ao que se observa em pacientes hipertensos sem doen&#x000e7;a renal<sup>
<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B5" ref-type="bibr">5</xref>
</sup>,<sup>
<xref rid="B99" ref-type="bibr">99</xref>,<xref rid="B292" ref-type="bibr">292</xref>,<xref rid="B293" ref-type="bibr">293</xref>
</sup>. Analogamente, na DP, a aus&#x000ea;ncia de rela&#x000e7;&#x000e3;o linear entre PA e desfechos CV passa a ser positiva quando baseada em valores de PAS obtidos por MAPA<sup>
<xref rid="B294" ref-type="bibr">294</xref>
</sup>. A outra explana&#x000e7;&#x000e3;o &#x000e9; ligada &#x000e0; coexist&#x000ea;ncia de disfun&#x000e7;&#x000e3;o card&#x000ed;aca em pacientes com PA mais baixa. Um estudo mostrou que, em pacientes avaliados por MAPA, uma an&#x000e1;lise que excluiu os pacientes com IC ou FA transformou uma rela&#x000e7;&#x000e3;o em U em uma rela&#x000e7;&#x000e3;o linear positiva entre PA e desfechos<sup>
<xref rid="B295" ref-type="bibr">295</xref>
</sup>.</p><p>A HVE &#x000e9; uma complica&#x000e7;&#x000e3;o comum da HA que com frequ&#x000ea;ncia antecede o aparecimento da IC e predisp&#x000f5;e a arritmias causais da morte card&#x000ed;aca s&#x000fa;bita. Apesar da presen&#x000e7;a de v&#x000e1;rios outros fatores na g&#x000ea;nese da HVE em di&#x000e1;lise, a HA &#x000e9; um fator causal independente em v&#x000e1;rios estudos<sup>
<xref rid="B296" ref-type="bibr">296</xref>
</sup>. Um estudo recente mostrou que a HVE em pacientes em HD aumentou progressivamente com o aumento da PAS pr&#x000e9;-di&#x000e1;lise (1,9&#x000d7; entre 131&#x02013;139 mmHg, 7,7&#x000d7; entre 140&#x02013;149 mmHg, e 12,9&#x000d7; se &#x0003e; 150 mmHg)<sup>
<xref rid="B297" ref-type="bibr">297</xref>
</sup>. Infelizmente, n&#x000e3;o &#x000e9; claro que a redu&#x000e7;&#x000e3;o da PA resulta em melhora da HVE em pacientes em di&#x000e1;lise. No estudo BID (<italic>BP in Dialysis</italic>), n&#x000e3;o houve diferen&#x000e7;as na massa do VE entre pacientes randomizados ao controle intensivo da PA (PAS 115&#x02013;140 mmHg) <italic>vs</italic>. grupo controle (PAS 155&#x02013;165 mmHg), ap&#x000f3;s um ano de seguimento<sup>
<xref rid="B178" ref-type="bibr">178</xref>
</sup>. Por outro lado, restri&#x000e7;&#x000e3;o salina e di&#x000e1;lise prolongada, duas interven&#x000e7;&#x000f5;es que resultam em melhor controle press&#x000f3;rico, proporcionam regress&#x000e3;o da HVE em pacientes em di&#x000e1;lise<sup>
<xref rid="B298" ref-type="bibr">298</xref>
</sup>. Os BRA e IECA resultam em regress&#x000e3;o da HVE em pacientes em HD e PD<sup>
<xref rid="B299" ref-type="bibr">299</xref>
</sup>, o que n&#x000e3;o &#x000e9; o caso com bloqueadores dos receptores da aldosterona<sup>
<xref rid="B300" ref-type="bibr">300</xref>
</sup>. N&#x000e3;o est&#x000e1; definido se esse efeito &#x000e9; mediado pela redu&#x000e7;&#x000e3;o da PA ou por outros mecanismos.</p><p>A FA tem preval&#x000ea;ncia m&#x000e9;dia de 11,6% e incid&#x000ea;ncia anual m&#x000e9;dia de 2,7% na DRC dial&#x000ed;tica<sup>
<xref rid="B301" ref-type="bibr">301</xref>
</sup>. Enquanto a rela&#x000e7;&#x000e3;o entre HA e FA &#x000e9; forte em pacientes sem DRC, essa associa&#x000e7;&#x000e3;o em di&#x000e1;lise n&#x000e3;o &#x000e9; consistente entre as publica&#x000e7;&#x000f5;es. Entre os maiores estudos avaliando o problema, houve aumento do risco de FA cr&#x000f4;nica de aproximadamente 22% em pacientes com HA num estudo do USRDS<sup>
<xref rid="B302" ref-type="bibr">302</xref>
</sup>, enquanto dois estudos de outros bancos de dados (<italic>Medicare/Medicaid</italic> e DOPPS)<sup>
<xref rid="B303" ref-type="bibr">303</xref>,<xref rid="B304" ref-type="bibr">304</xref>
</sup> demonstraram diminui&#x000e7;&#x000e3;o de risco de FA na presen&#x000e7;a de HA, tanto de forma bin&#x000e1;ria (diminui&#x000e7;&#x000e3;o de 21%)<sup>
<xref rid="B304" ref-type="bibr">304</xref>
</sup> quanto linear (diminui&#x000e7;&#x000e3;o de 6% para cada 10 mmHg de aumento da PAS pr&#x000e9;-HD)<sup>
<xref rid="B303" ref-type="bibr">303</xref>
</sup>. N&#x000e3;o h&#x000e1; estudos analisando o impacto do tratamento da HA sobre a incid&#x000ea;ncia da FA em pacientes em di&#x000e1;lise.</p><p>A DAOP &#x000e9; comum em pacientes com DRC. A rela&#x000e7;&#x000e3;o entre HA e DAOP em pacientes em di&#x000e1;lise &#x000e9; inconsistente. No estudo CRIC, a HA n&#x000e3;o foi um marcador de risco para DAOP<sup>
<xref rid="B305" ref-type="bibr">305</xref>
</sup>. Por outro lado, o estudo DOPPS mostrou uma rela&#x000e7;&#x000e3;o significativa entre HA e preval&#x000ea;ncia de DAOP em pacientes em HD<sup>
<xref rid="B306" ref-type="bibr">306</xref>
</sup>. N&#x000e3;o h&#x000e1; evid&#x000ea;ncias de que o tratamento da HA tenha qualquer impacto no aparecimento ou regress&#x000e3;o da DAOP na DRC. Por extrapola&#x000e7;&#x000e3;o, faz sentido que pacientes com aneurismas da aorta tenham manuseio com controle de impulso (redu&#x000e7;&#x000e3;o tanto da PA quanto da FC).</p><p>A oclus&#x000e3;o de vasos retinianos (art&#x000e9;ria central, veia central) &#x000e9; complica&#x000e7;&#x000e3;o associada a v&#x000e1;rios fatores de risco, incluindo a HA. A oclus&#x000e3;o da art&#x000e9;ria central da retina &#x000e9; 4,5 vezes mais frequente na DRC dial&#x000ed;tica do que em pacientes com fun&#x000e7;&#x000e3;o renal normal. Da mesma forma, a oclus&#x000e3;o da veia central da retina, entidade mais comum que a oclus&#x000e3;o da art&#x000e9;ria central, ocorre com frequ&#x000ea;ncia 2,6 vezes maior em pacientes em di&#x000e1;lise<sup>
<xref rid="B307" ref-type="bibr">307</xref>
</sup>. Em estudos retrospectivos com an&#x000e1;lises multivariadas, a HA encontra-se independentemente associada a ambas as complica&#x000e7;&#x000f5;es<sup>
<xref rid="B308" ref-type="bibr">308</xref>,<xref rid="B309" ref-type="bibr">309</xref>
</sup>.</p><p>Principais mensagens:</p><list list-type="bullet"><list-item><p>Recomenda-se, para diminuir o risco complica&#x000e7;&#x000f5;es cardiovasculares em pacientes dial&#x000ed;ticos hipertensos, evitar a PAS pr&#x000e9;-di&#x000e1;lise &#x0003c; 120 ou &#x0003e; 160 mmHg (Classe IIA/ N&#x000ed;vel B).</p></list-item></list></sec><sec sec-type="conclusions"><title>Conclus&#x000f5;es</title><p>O diagn&#x000f3;stico e o manejo da HA na DRC dial&#x000ed;tica s&#x000e3;o mais complexos ainda do que para a popula&#x000e7;&#x000e3;o geral. Diferentes determinantes fisiopatol&#x000f3;gicos est&#x000e3;o envolvidos na HA da DRC 5D, com a sobrecarga de s&#x000f3;dio e volume desempenhando um papel preponderante. Tecnologias para essa an&#x000e1;lise precisam mostrar-se seguras e fact&#x000ed;veis.</p><p>H&#x000e1; maior variabilidade no ritmo circadiano da PA e a MAPA de 44 horas parece conferir o melhor diagn&#x000f3;stico e informa&#x000e7;&#x000f5;es progn&#x000f3;sticas, mas a MRPA &#x000e9; melhor tolerada e pode ser um substituto &#x000fa;til onde os recursos s&#x000e3;o limitados. ECR devem ser conduzidos em longo prazo com essas ferramentas diagn&#x000f3;sticas e de acompanhamento para determinar sua import&#x000e2;ncia e signific&#x000e2;ncia em desfechos.</p><p>Hiper e hipotens&#x000e3;o intradial&#x000ed;tica e fora da di&#x000e1;lise s&#x000e3;o mal&#x000e9;ficas e devem ser evitadas.</p><p>Interven&#x000e7;&#x000f5;es n&#x000e3;o farmacol&#x000f3;gicas, como restri&#x000e7;&#x000e3;o diet&#x000e9;tica de s&#x000f3;dio, prolongamento do tempo de di&#x000e1;lise e altera&#x000e7;&#x000e3;o da prescri&#x000e7;&#x000e3;o de di&#x000e1;lise para melhorar a difus&#x000e3;o de s&#x000f3;dio, podem auxiliar no manejo da HA e impactam sintomas, a qualidade de vida e complica&#x000e7;&#x000f5;es cardiovasculares.</p><p>Quando se alcan&#x000e7;a o peso seco, e isso &#x000e9; insuficiente para o controle da HA, a farmacoterapia anti-hipertensiva &#x000e9; recomendada. Embora meta-an&#x000e1;lises evidenciem benef&#x000ed;cio de sobrevida com a terapia, nenhum estudo mostrou cabalmente benef&#x000ed;cio de uma classe de anti-hipertensivos em rela&#x000e7;&#x000e3;o a outra. S&#x000e3;o necess&#x000e1;rios grandes ECR comparativos <italic>head to head</italic> para elucidar o tratamento medicamentoso ideal da HA em di&#x000e1;lise, uma lacuna a ser preenchida pelos pesquisadores do mundo todo.</p><p>Deve-se individualizar o tratamento e as metas press&#x000f3;ricas considerando as melhores pr&#x000e1;ticas, custo/benef&#x000ed;cio, dialis&#x000e2;ncia dos medicamentos, idade, fragilidade, vulnerabilidade, comorbidades, polifarm&#x000e1;cia, al&#x000e9;m das prioridades e prefer&#x000ea;ncias do paciente.</p></sec></body><back><glossary><title>SIGLAS</title><def-list><def-item><term>AMPA:</term><def><p>automedida da press&#x000e3;o arterial</p></def></def-item><def-item><term>AOS:</term><def><p>apneia obstrutiva do sono</p></def></def-item><def-item><term>APR:</term><def><p>atividade plasm&#x000e1;tica de renina</p></def></def-item><def-item><term>ARM:</term><def><p>antagonistas dos receptores mineralocorticoides</p></def></def-item><def-item><term>AVC:</term><def><p>acidente vascular cerebral</p></def></def-item><def-item><term>BB:</term><def><p>betabloqueadores</p></def></def-item><def-item><term>BCC:</term><def><p>bloqueadores dos canais lentos de c&#x000e1;lcio</p></def></def-item><def-item><term>BNP:</term><def><p>pept&#x000ed;deo natriur&#x000e9;tico tipo B</p></def></def-item><def-item><term>BRA:</term><def><p>bloqueadores dos receptores da angiotensina II</p></def></def-item><def-item><term>CV:</term><def><p>cardiovascular</p></def></def-item><def-item><term>DAC:</term><def><p>doen&#x000e7;a arterial coronariana</p></def></def-item><def-item><term>DAOP:</term><def><p>doen&#x000e7;a arterial obstrutiva perif&#x000e9;rica</p></def></def-item><def-item><term>DC:</term><def><p>d&#x000e9;bito card&#x000ed;aco</p></def></def-item><def-item><term>DCV:</term><def><p>doen&#x000e7;a cardiovascular</p></def></def-item><def-item><term>DE:</term><def><p>disfun&#x000e7;&#x000e3;o endotelial</p></def></def-item><def-item><term>DM:</term><def><p>
<italic>diabetes mellitus</italic>
</p></def></def-item><def-item><term>DMAA:</term><def><p>dimetil-arginina-assim&#x000e9;trica</p></def></def-item><def-item><term>DP:</term><def><p>di&#x000e1;lise peritoneal</p></def></def-item><def-item><term>DRC:</term><def><p>doen&#x000e7;a renal cr&#x000f4;nica</p></def></def-item><def-item><term>DRC 5D:</term><def><p>doen&#x000e7;a renal cr&#x000f4;nica com paciente em di&#x000e1;lise</p></def></def-item><def-item><term>ECR:</term><def><p>estudos controlados e randomizados</p></def></def-item><def-item><term>ET1:</term><def><p>endotelina 1</p></def></def-item><def-item><term>EPO:</term><def><p>eritropoetina recombinante humana</p></def></def-item><def-item><term>FA:</term><def><p>fibrila&#x000e7;&#x000e3;o atrial</p></def></def-item><def-item><term>FRR:</term><def><p>fun&#x000e7;&#x000e3;o residual renal</p></def></def-item><def-item><term>GPID:</term><def><p>ganho de peso interdial&#x000ed;tico</p></def></def-item><def-item><term>HA:</term><def><p>hipertens&#x000e3;o arterial</p></def></def-item><def-item><term>HAB:</term><def><p>hipertens&#x000e3;o do avental branco</p></def></def-item><def-item><term>HABNC:</term><def><p>hipertens&#x000e3;o do avental branco n&#x000e3;o controlada</p></def></def-item><def-item><term>HAD:</term><def><p>hipertens&#x000e3;o arterial no paciente em di&#x000e1;lise</p></def></def-item><def-item><term>HAS:</term><def><p>hipertens&#x000e3;o arterial sist&#x000f3;lica</p></def></def-item><def-item><term>HC:</term><def><p>hipertens&#x000e3;o controlada</p></def></def-item><def-item><term>HD:</term><def><p>hemodi&#x000e1;lise</p></def></def-item><def-item><term>HDF:</term><def><p>hemodiafiltra&#x000e7;&#x000e3;o <italic>on-line</italic> de alto volume convectivo</p></def></def-item><def-item><term>HID:</term><def><p>hipertens&#x000e3;o intradial&#x000ed;tica</p></def></def-item><def-item><term>HM:</term><def><p>hipertens&#x000e3;o mascarada</p></def></def-item><def-item><term>HMNC:</term><def><p>hipertens&#x000e3;o mascarada n&#x000e3;o controlada</p></def></def-item><def-item><term>HN:</term><def><p>hipertens&#x000e3;o noturna</p></def></def-item><def-item><term>HS:</term><def><p>hipertens&#x000e3;o sustentada</p></def></def-item><def-item><term>HSNC:</term><def><p>hipertens&#x000e3;o sustentada n&#x000e3;o controlada</p></def></def-item><def-item><term>HVE:</term><def><p>hipertrofia ventricular esquerda</p></def></def-item><def-item><term>IAM:</term><def><p>infarto agudo do mioc&#x000e1;rdio</p></def></def-item><def-item><term>IC:</term><def><p>insufici&#x000ea;ncia card&#x000ed;aca</p></def></def-item><def-item><term>IECA:</term><def><p>inibidores da enzima de convers&#x000e3;o da angiotensina</p></def></def-item><def-item><term>IMC:</term><def><p>&#x000ed;ndice de massa corporal</p></def></def-item><def-item><term>IT:</term><def><p>in&#x000e9;rcia terap&#x000ea;utica</p></def></def-item><def-item><term>KDIGO:</term><def><p>KIDNEY DISEASES IMPROVING GLOBAL OUTCOMES</p></def></def-item><def-item><term>MAPA:</term><def><p>monitoriza&#x000e7;&#x000e3;o ambulatorial da press&#x000e3;o arterial</p></def></def-item><def-item><term>MRPA:</term><def><p>monitoriza&#x000e7;&#x000e3;o residencial da press&#x000e3;o arterial</p></def></def-item><def-item><term>NT-proBNP:</term><def><p>pept&#x000ed;deo natriur&#x000e9;tico N-terminal pro-tipo B</p></def></def-item><def-item><term>NV:</term><def><p>normotens&#x000e3;o verdadeira</p></def></def-item><def-item><term>ON:</term><def><p>&#x000f3;xido n&#x000ed;trico</p></def></def-item><def-item><term>PA:</term><def><p>press&#x000e3;o arterial</p></def></def-item><def-item><term>PAC:</term><def><p>press&#x000e3;o arterial central</p></def></def-item><def-item><term>PAD:</term><def><p>press&#x000e3;o arterial diast&#x000f3;lica</p></def></def-item><def-item><term>PAS:</term><def><p>press&#x000e3;o arterial sist&#x000f3;lica</p></def></def-item><def-item><term>PP:</term><def><p>press&#x000e3;o de pulso</p></def></def-item><def-item><term>PS:</term><def><p>peso seco</p></def></def-item><def-item><term>RA:</term><def><p>rigidez arterial</p></def></def-item><def-item><term>RVP:</term><def><p>resist&#x000ea;ncia vascular perif&#x000e9;rica</p></def></def-item><def-item><term>SBN:</term><def><p>Sociedade Brasileira de Nefrologia</p></def></def-item><def-item><term>SNC:</term><def><p>sistema nervoso central</p></def></def-item><def-item><term>SNS:</term><def><p>sistema nervoso simp&#x000e1;tico</p></def></def-item><def-item><term>SRAA:</term><def><p>sistema renina angiotensina aldosterona</p></def></def-item><def-item><term>TFG:</term><def><p>taxa de filtra&#x000e7;&#x000e3;o glomerular</p></def></def-item><def-item><term>TRS:</term><def><p>terapia renal substitutiva</p></def></def-item><def-item><term>UF:</term><def><p>ultrafiltra&#x000e7;&#x000e3;o</p></def></def-item><def-item><term>VD:</term><def><p>ventr&#x000ed;culo direito</p></def></def-item><def-item><term>VE:</term><def><p>ventr&#x000ed;culo esquerdo</p></def></def-item></def-list></glossary></back></sub-article></article>